Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity

ABSTRACT

Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.

BACKGROUND OF THE INVENTION

Most nucleated eukaryotic cells, whether unicellular organisms orconstituents of multicellular organism including humans, containacidified vacuoles that are critical for cellular maintenance andfunction. In mammalian cells, these vacuoles comprise lysosomes andother endosomal vesicular organelles. The pH of the interior oflysosomes is typically about 4.5 to 5, maintained by vacuolarATP-dependent proton pumps and also by Donnan equilibrium effects.Lysosomes contribute to cytosolic pH buffering, protecting the cell fromacidic environments, and are also primary sites for degrading andrecycling the constituents of aging or damaged organelles such asmitochondria, a process known as autophagy. There are several importantpathological conditions where lysosomal characteristics are altered andcontribute to disease pathogenesis, presenting a potential target forpharmacological therapy.

A growing body of evidence indicates that a common phenotypic change ininvasive cancer cells is a redirection of lysosomes to participate indestruction of surrounding cells via exocytosis of acidic contents,including enzymes. Proteolytic enzymes normally found in lysosomes butsecreted by cancer cells, such as cathepsins, can degrade extracellularmatrix proteins, facilitating tumor invasion and metastasis.Furthermore, lysosomes and other acidic vacuolar organelles are oftenenlarged in cancer cells, which aids pH buffering; many solid tumorsgenerate an acidic extracellular environment, favoring invasion, whichrequires that cancer cells adapt to both produce and tolerate a lowextracellular pH. Cancer cells selected in vitro for invasive potentialhave larger, more acidic lysosomes than do less aggressive cells. Cancercells exposed to ionizing radiation undergo a protective responseinvolving enlargement and acidification of lysosomes. A relatedprotective response through cancer cells acquire survival advantages isactivation of autophagy, which involves fusion of autophagosomescontaining damamged organelles or other cell debris, with lysosomes;disruption of autophagy can impair cancer cell viability. Some cancercells also sequester chemotherapy agents in lysosomes, as a mechanism ofdrug resistance. Chloroquine, an antimalarial drug that accumulates inmammalian lysosomes, potentiates, or restores sensitivity to, anticanceractivity of several classes of chemotherapy agents and targeted smallmolecule and antibody cancer treatments. Lysosomotropic fluorescent dyessuch as acridine orange can be used to visually differentiate tumors insitu from surrounding tissues, indicating a potential sharp distinctionfor specific lysosome-targeting cytotoxic agents to selectively killcancer cells.

Lysosomal alterations are also important features of common inflammatorydiseases, especially those involving activated macrophages, whereexocytosis of lysosomal enzymes, cytokines, and some inflammatorymediators such as HMBG1 that are processed and released via lysosomescan participate in tissue damage and both local and systemicinflammation. Glucocorticoid signaling is also linked to lysosomes, suchthat compromising lysosomal function can enhance anti-inflammatorypathways mediating glucocorticoid effects.

Most fungi have acidic vacuoles similar to lysosomes. These acidicvacuoles are critical for ion and pH homeostasis, storage of aminoacids, autophagy and for processing some proteins. Vacuoles areacidified via a proton pump, the vacuolar H⁺-ATPase, or “V-ATPase”, andit is known that fungi with inactivating mutations of subunits ofV-ATPase that result in impaired vacuole acidification also losevirulence and grow poorly. Ergosterol, a fungal-specific steroidanalogous to cholesterol in mammalian cells as a major membranecomponent, is critical for conformation and activity of the V-ATPase,and V-ATPase dysfunction appears to be a major mechanism of antifungalactivity of ergosterol synthesis inhibitors, which includes severalclasses of existing antifungal agents. Antifungal agents that act viabinding to specific proteins, e.g. enzyme inhibitors, are inherentlyvulnerable to development of drug resistance via single mutations ingenes encoding target proteins. Agents that target fungi via adequatelyspecific targeting and disruption of fungal acidic vacuoles by cationtrapping may be less susceptible to development of resistance throughpoint mutations than are drugs acting by binding to specific proteintargets, due to impaired viability and virulence when vacuolaracidification, is impaired.

Clinically important antimalarial drugs are known that accumulate inacidic vacuoles and lysosomes and their biological activity is largelymediated through their concentration in acidic vacuoles, not only inmalaria but in inflammatory diseases, some cancers and non-malarialinfections by fungi and unicellular and protozoal parasites. Quinolineanalog antimalarial drugs target malaria plasmodia via cation trappingin acidic digestive vacuoles, where they can accumulate toconcentrations several orders of magnitude higher than in extracellularspaces. A large molar fraction of chloroquine, mefloquine, quinacrineand several of their congeners are uncharged at the usual extracellularpH of about 7.4 and the cytoplasmic pH of 7.1, and can thereby passthrough cellular and organelle membranes. In an acidic environment suchas the interior of a lysosome or fungal acidic vacuole, theseantimalarials are predominantly cationic and are thereby restricted fromfree passage through the vacuolar membrane. Antimalarials such aschloroquine impair processing of heme from hemoglobin ingested bymalaria plasmodia after accumulating in the feeding vacuoles, accountingfor much of their specific toxicity to plasmodia. However, chloroquineand similar quinoline-analog antimalarials can accumulate in mammalianlysosomes and fungal acidic vacuoles and impair vacuolar function to adegree sufficient to provide some clinical benefit, if only bypartically deacidifying the vacuoles. Chloroquine is used for treatmentof in chronic autoimmune and inflammatory diseases such as systemiclupus erythematosis or rheumatoid arthritis, with moderate efficacy. Adegree of antifungal activity has been reported for antimalarials suchas chloroquine or quinacrine, both as single agents or in combinationwith other classes of antifungal agents, such as fluconazole, notably inanimal models of systemic cryptococcosis. However, their activity issuboptimal, yielding incomplete fungal growth inhibition. Recent workhas also demonstrated moderate growth inhibitory activity ofchloroquine, mefloquine and other weakly cationic drugs such assiramesine in animal models of cancer. Existing lysosomotropic agentssuch as antimalarial quinolone compounds can thus display sometherapeutically relevant activity in diseases in which acidic vacuolescontribute to pathogenesis. However, the activity and potency ofantimalarials in such diseases are limited, as the target cells cantolerate accumulation of relatively high concentrations of theantimalarials; the specific lethal effect of quinoline compounds inmalaria is largely attributed to disruption of heme processing withinplasmodial feeding vacuoles, a mechanism of cytotoxicity not applicablein the areas of inflammatory disease, cancer or fungal infections.Despite the body of evidence indicating strong potential for targetinglysosomes for treating cancers, existing agents have not shown adequateactivity or therapeutic index for effectively treating cancer in humans.

“Lyosomotropic detergents”, comprising weakly cationic heterocyclicmoieties bearing a single alkyl chain with approximately 10 to 14 carbonatoms, were reported be potently cytotoxic to mammalian cells and todisplay broad spectrum antifungal activity in vitro. This class ofagents accumulate in lysosomes and acidic vacuoles via the same type ofcation trapping process through which antimalarials are concentrated,and when they reach a critical micellar concentration in the vacuole,they behave as detergents, damaging vacuolar membranes. They display acharacteristic sigmoid dose-response curve, as a consequence of theirformation of micellar micro structures. However, there is no informationabout activity or safety of this class of agents in vivo in animalmodels of relevant diseases.

SUMMARY OF THE INVENTION

This invention provides a compound represented by Formula I or apharmaceutically acceptable salt thereof

G-NH-A-Q-X—Y—Z  I

whereinG is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two,or three ring nitrogen atoms. G can be unsubstituted, or it cansubstituted at a ring carbon by amino, dimethylamino, hydroxy, halo,methyl, perfluoromethyl, or alkyl having from 1 to 16 carbon atoms whichalkyl is either unsubstituted or substituted by hydroxy or alkoxy having1 to 12 carbon atoms or acetoxy. Or it can be substituted at a ringnitrogen by alkyl having from 1 to 16 carbon atoms which alkyl is eitherunsubstituted or substituted by hydroxy or alkoxy having from 1 to 8carbon atoms. N is nitrogen, H is hydrogen, and NH is absent or present.A is absent or present and is alkyl having from 1 to 12 carbon atoms,provided that if A has 1 carbon atom Q must be absent;Q is absent or present and is O, NHC(O), or NH, provided that if A isabsent Q must be absent, and if both X and Y are absent Q cannot be O orNH. X is absent or present and is alkyl having from 1 to 5 carbon atoms,provided that if Y is absent and Z is alkoxy or phenoxy X must have morethan 1 carbon atom. Y is absent or present and is phenyl unsubstitutedor substituted by halo, or is a monocyclic or bicyclic aromatic ringhaving one or two nitrogen atoms. Z is absent or present and ishydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted orsubstituted by one phenyl or phenoxy group, alkoxy having from 1 to 12carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, phenyl, phenoxy, or NHC(O)R⁶ or C(O)NHR⁶ or C(O)OR⁶ whereR⁶ is alkyl having from 1 to 6 carbon atoms, provided that if all of A,Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms.

This invention also provides a use or method for treating or preventinga condition in a mammalian subject; the condition being selected fromthe group consisting of an inflammatory disease, a fungal infection, aunicellular parasitic infection, and a neoplastic disease; comprisingadministering to the subject an effective amount of the compound or saltof the invention. It also provides compositions comprising thesecompounds or salt. And it provides a method of inhibiting a fungus exvivo, comprising contacting a surface or the fungus with the compound orsalt.

DETAILED DESCRIPTION OF THE INVENTION

Without wishing to be bound by theory, this invention provides compoundsand their use for treating diseases characterized by pathogenic cellsfeaturing lysosomes or other acidic vacuoles with disease-relatedalterations predisposing them to accumulation of compounds of theinvention, which then selectively inactivate or eliminate suchpathogenic cells. Compounds of the invention, many of which areaminoquinoline and aminoquinazoline derivatives, feature significantimprovements in potency and activity over known aminoquinoline drugssuch as chloroquine, as a consequence of structural moieties thatpotently disrupt lysosomal or vacuolar membrane integrity when thecompounds accumulate in acidic vacuoles in cells. Diseases that are atleast moderately responsive to antimalarial quinoline derivatives andanalogs are in general more effectively treated with compounds of theinvention. Such diseases broadly comprise inflammatory diseases,neoplastic diseases, including both hematologic cancers and solidtumors, and infections by eukaryotic pathogens, including fungi andseveral classes of protozoal or other unicellular parasites.

DEFINITIONS

As used herein the term “alkyl” means a linear or branched-chain orcyclic alkyl group. An alkyl group identified as having a certain numberof carbon atoms means any alkyl group having the specified number ofcarbons. For example, an alkyl having three carbon atoms can be propylor isopropyl; and alkyl having four carbon atoms can be n-butyl,1-methylpropyl, 2-methylpropyl or t-butyl.

As used herein the term “halo” refers to one or more of fluoro, chloro,bromo, and iodo.

As used herein the term “perfluoro” as in perfluoromethyl, means thatthe group in question has fluorine atoms in place of all of the hydrogenatoms.

Certain chemical compounds are referred to herein by their chemical nameor by the two-letter code shown below. The following are compounds ofthis invention.

-   CH N-[8-(Hexyloxy)octyl]quinolin-4-amine-   CI N-(8-Butoxyoctyl)quinolin-4-amine-   CJ N-(8-Methoxyoctyl)quinolin-4-amine-   CK N-[6-(Hexyloxy)hexyl]quinolin-4-amine-   CL N-(6-Butoxyhexyl)quinolin-4-amine-   AL N-[10-(Hexyloxy)decyl]quinolin-4-amine-   AM N-(10-Butoxydecyl)quinolin-4-amine-   CM N-(5-Methoxypentyl)quinolin-4-amine-   AV N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine-   AW 7-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine-   AX 8-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine-   AY N-[8-(Hexyloxy)octyl]-7-(trifluoromethyl)quinolin-4-amine-   CN N-[8-(Hexyloxy)octyl]-8-(trifluoromethyl)quinolin-4-amine-   BB N-{5-[3-(Hexyloxy)propoxy]pentyl}quinolin-4-amine-   BC N-{3-[5-(Hexyloxy)pentyloxy]propyl}quinolin-4-amine-   AJ N-[8-(3-Ethoxypropoxyl)octyl]quinolin-4-amine-   BD N-[8-(2-Propoxyethoxyl)octyl]quinolin-4-amine-   CO N-[8-(Benzyloxy)octyl]quinolin-4-amine-   AR N-(6-Phenoxyhexyl)quinolin-4-amine-   AN N-(8-Phenoxyoctyl)quinolin-4-amine-   CP N-{2-[2-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine-   CQ N-{3-[2-(Hexyloxy)phenoxy]propyl}quinolin-4-amine-   CR N-{4-[2-(Hexyloxy)phenoxy]butyl}quinolin-4-amine-   CS N-[3-(2-Ethoxyphenoxyl)propyl]quinolin-4-amine-   CT N-[3-(2-Methoxyphenoxyl)propyl]quinolin-4-amine-   CU N-{3-[2-(Benyloxy)phenoxy]propyl}quinolin-4-amine-   BH N-[8-(3-Methoxyphenoxyl)octyl]quinolin-4-amine-   CV N-{4-[3-(Hexyloxy)phenoxy]butyl}quinolin-4-amine-   AZ N-{3-[3-(Hexyloxy)phenoxy]propyl}quinolin-4-amine-   CW N-{2-[3-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine-   AD N-[8-(4-Methoxyphenoxyl)octyl]quinolin-4-amine-   CX N-[6-(4-Methoxyphenoxyl)hexyl]quinolin-4-amine-   BA N-{2-[4-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine-   CY N-{3-[4-(Hexyloxy)phenoxy]propyl}quinolin-4-amine-   CZ N-{4-[4-(Hexyloxy)phenoxy]butyl}quinolin-4-amine-   BE N-[8-(m-Tolyloxy)octyl]quinolin-4-amine-   BF N-[8-(p-Tolyloxy)octyl]quinolin-4-amine-   BG N-[8-(o-Tolyloxy)octyl]quinolin-4-amine-   DA N-[8-(4-tert-Butylphenoxy)octyl]quinolin-4-amine-   BJ N-[8-(4-Fluorophenoxyl)octyl]quinolin-4-amine-   BI N-[8-(3-Fluorophenoxyl)octyl]quinolin-4-amine-   DB N-[8-(2-Fluorophenoxyl)octyl]quinolin-4-amine-   DC N-(Biphenyl-4-yl)quinolin-4-amine-   AO N-(4-Hexylphenyl)quinolin-4-amine-   AP Hexyl 4-(quinolin-4-ylamino)benzoate-   DD N-(4-Phenoxyphenyl)quinolin-4-amine-   DE N-(3-Phenoxyphenyl)quinolin-4-amine-   DF N-(2-Phenoxyphenyl)quinolin-4-amine-   DG N-[4-(Quinolin-4-ylamino)phenyl]hexanamide-   DH N-[3-(Quinolin-4-ylamino)phenyl]hexanamide-   AQ N-Hexyl-4-(quinolin-4-ylamino)benzamide-   BV N-Hexyl-3-(quinolin-4-ylamino)benzamide-   DI N-(4-Methoxyphenyl)quinolin-4-amine-   DJ N-[4-(Benzyloxy)phenyl]quinolin-4-amine-   DK N-(4-Butoxyphenyl)quinolin-4-amine-   DL N-[4-(Hexyloxy)phenyl]quinolin-4-amine-   DM N-[3-(Benzyloxy)phenyl]quinolin-4-amine-   DN N-[3-(Hexyloxy)phenyl]quinolin-4-amine-   DO N-[2-(Benzyloxy)phenyl]quinolin-4-amine-   DP N-[2-(Hexyloxy)phenyl]quinolin-4-amine-   BL N-[2-Fluoro-4-(hexyloxy)phenyl]quinolin-4-amine-   DQ N-Benzylquinolin-4-amine-   DR N-Phenethylquinolin-4-amine-   AA N-[4-(Hexyloxy)benzyl]quinolin-4-amine-   AC N-[3-(Hexyloxy)benzyl]quinolin-4-amine-   DS N-[2-(Hexyloxy)benzyl]quinolin-4-amine-   BK N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4-amine-   DT N-[4-(Decyloxy)benzyl]quinolin-4-amine-   DU N-[3-(Decyloxy)benzyl]quinolin-4-amine-   AF N-(3-Phenoxybenzyl)quinolin-4-amine-   BU N-[3-(Benzyloxy)benzyl]quinolin-4-amine-   DV N-(3-Phenethoxybenzyl)quinolin-4-amine-   DW N-[4-(Quinolin-4-ylamino)butyl]benzamide-   DX N-[6-(Quinolin-4-ylamino)hexyl]benzamide-   DY N-[8-(Quinolin-4-ylamino)octyl]benzamide-   DZ 3-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide-   EA 4-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide-   EB 2-(Hexyloxy)-N-[2-(quinolin-4-ylamino)ethyl]benzamide-   EC 2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide-   ED 2-(Hexyloxy)-N-[4-(quinolin-4-ylamino)butyl]benzamide-   EE N-[8-(Quinolin-4-ylamino)octyl]picolinamide-   EF N-[8-(Quinolin-4-ylamino)octyl]nicotinamide-   EG N-[8-(Quinolin-4-ylamino)octyl]isonicotinamide-   BZ N-(Pyridin-4-ylmethyl)quinolin-4-amine-   BY N-(Pyridin-3-ylmethyl)quinolin-4-amine-   EH N-(Pyridin-2-ylmethyl)quinolin-4-amine-   EI N-Hexylquinolin-4-amine-   AG N-(Decyl)quinolin-4-amine-   EJ N-(Dodecyl)quinolin-4-amine-   AI N¹,N⁸-Di(quinolin-4-yl)octane-1,8-diamine-   EK N-[8-(Hexyloxy)octyl]quinolin-6-amine-   EL N-[8-(Hexyloxy)octyl]quinolin-3-amine-   EM N-[8-(Hexyloxy)octyl]quinolin-8-amine-   EN N-[8-(Hexyloxy)octyl]-2-(trifluoromethyl)quinolin-4-amine-   EO 7-Chloro-N-decylquinolin-4-amine-   EP 7-Chloro-N-dodecylquinolin-4-amine-   AH N-(Decyl)quinazolin-4-amine-   EQ N-Dodecylquinazolin-4-amine-   ER N-Decyl-7-fluoroquinazolin-4-amine-   ES N-Dodecyl-7-fluoroquinazolin-4-amine-   ET 7-Chloro-N-decylquinazolin-4-amine-   EU 7-Chloro-N-dodecylquinazolin-4-amine-   EV N-(6-Butoxyhexyl)quinazolin-4-amine-   EW N-[8-(Hexyloxy)octyl]quinazolin-4-amine-   AE N-[8-(4-Methoxyphenoxyl)octyl]quinazolin-4-amine-   EX N-{2-[2-(Hexyloxy)phenoxy]ethyl}quinazolin-4-amine-   EY N-{3-[2-(Hexyloxy)phenoxy]propyl}quinazolin-4-amine-   EZ N-{4-[2-(Hexyloxy)phenoxy]butyl}quinazolin-4-amine-   FA N-[8-(Quinazolin-4-ylamino)octyl]nicotinamide-   AK N-[3-(Hexyloxy)benzyl]quinazolin-4-amine-   CG N-[3-(Decyloxy)benzyl]quinazolin-4-amine-   BM N-(3-Phenoxybenzyl)quinazolin-4-amine-   BN N-[4-(Decyloxy)benzyl]quinazolin-4-amine-   AB N-[4-(Hexyloxy)benzyl]quinazolin-4-amine-   FB    1-[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol-   FC 1-(4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentyl    acetate-   FD 1-Isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-ol-   BP 1-Octyl-1H-imidazo[4,5-c]quinoline-   FE 1-Hexadecyl-1H-imidazo[4,5-c]quinoline-   FF 1-Hexadecyl-1H-imidazo[4,5-c]quinolin-4-amine-   FG 1-[2-(Dodecyloxy)ethyl]-1H-imidazo[4,5-c]quinoline-   FH    1-[2-(Dodecyloxy)ethyl]-N,N-dimethyl-1H-imidazo[4,5-c]quinolin-4-amine-   FI 1-[6-(Octyloxy)hexyl]-1H-imidazo[4,5-c]quinoline-   CD 1-(8-Ethoxyoctyl)-1H-imidazo[4,5-c]quinoline-   CE 1-(8-Methoxyoctyl)-1H-imidazo[4,5-c]quinoline-   BQ 1-(8-Butoxyoctyl)-1H-imidazo[4,5-c]quinoline-   FJ 1-[9-(Hexyloxy)nonyl]-1H-imidazo[4,5-c]quinoline-   FK 1-(10-Butoxydecyl)-1H-imidazo[4,5-c]quinoline-   BO 4-Amino-1-[8-(hexyloxy)octyl]pyridinium salts-   FL 4-(8-Methoxyoctylamino)-1-methylpyridinium iodide-   AS 1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine-   FM 1-Hexadecyl-1H-imidazo[4,5-c]pyridine-   AT 1-(10-Butoxydecyl)-1H-imidazo[4,5-c]pyridine-   FN N-(8-Methoxyoctyl)pyridin-4-amine-   FO N-[8-(Hexyloxy)octyl]pyridin-3-amine-   FP N-[8-(Hexyloxy)octyl]pyridin-2-amine-   AU N-[8-(Hexyloxy)octyl]pyrimidin-4-amine-   FQ N-[8-Hexyloxy)octyl)pyrimidin-2-amine-   FR 1-[8-(Hexyloxy)octyl]-4-phenyl-1H-imidazole-   FS N-[8-(Hexyloxy)octyl]isoquinolin-1-amine-   FT N-[8-(Hexyloxy)octyl]isoquinolin-5-amine-   FU N-[8-(Hexyloxy)octyl]quinoxalin-2-amine-   CC 1-[8-(Hexyloxy)octyl]-1H-benzimidazole-   FV N-[8-(Hexyloxy)octyl]pyrazin-2-amine-   FW 1-[8-(Hexyloxy)octyl]-1H-indole-   FX 3-[8-(Hexyloxy)octyl]-3H-imidazo[4,5-b]pyridine-   FY 1-Dodecyl-1H-imidazo[4,5-c]quinoline-   FZ 1-[3-(Decyloxy)propyl]-1H-imidazo[4,5-c]quinoline-   GA 1-[4-(Decyloxy)butyl]-1H-imidazo[4,5-c]quinoline-   GB 1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]quinoline-   GC 1-{5-[3-(Hexyloxy)propoxy]pentyl}-1H-imidazo[4,5-c]quinoline-   GD 1-{3-[3-(Hexyloxy)phenoxy]propyl}-1H-imidazo[4,5-c]quinoline

The following compounds were less active in the biological activityexample(s) in which they were tested.

-   BR N-(2-Methoxyethyl)quinolin-4-amine-   BS N-[2-(Morpholin-4-yl)ethyl]quinolin-4-amine-   BT N-[3-(Quinolin-4-ylamino)propyl]benzamide-   BW N-(2-Diethylaminoethyl)-4-(quinolin-4-ylamino)benzamide-   BX N-(4-Dimethylaminobenzyl)quinolin-4-amine-   CA N-(Pyridin-4-ylmethyl)-8-(hexyloxy)octanamide-   CB N-(Quinolin-6-yl)-8-(hexyloxy)octanamide-   CF 1-{3-[(5-(Hexyloxy)pentoxy]propyl}1H-imidazo[4,5-c]quinoline

As used herein the transitional term “comprising” is open-ended. A claimutilizing this term can contain elements in addition to those recited insuch claim.

As used in the claims the word “or” means “and/or” unless such readingdoes not make sense in context. So for example, when it is stated inconnection with Formula I that variable G can be substituted at a ringcarbon “or” at a ring nitrogen, it may be substituted at a ring carbon,at a ring nitrogen, or at both a ring carbon and a ring nitrogen.

The following abbreviations are used in the chemical synthesis examplesand elsewhere in this description:

-   DCM dichloromethane-   DIEA N,N-diisopropylethylamine-   DMA N,N-dimethylacetamide-   DMAP 4-(N,N-dimethylamino)pyridine-   DME 1,2-dimethoxyethane-   DMF N,N-dimethylformamide-   DMSO dimethyl sulfoxide-   EA ethyl acetate-   Et₂O diethyl ether-   EtOH ethanol-   FC flash chromatography-   Hex hexanes-   IPA 2-propanol-   LAH lithium tetrahydridoaluminate-   MeOH methanol-   mp melting point-   NMP N-methylpyrrolidinone-   NMR nuclear magnetic resonance spectrometry-   SPE solid phase extraction-   TEA triethylamine-   THF tetrahydrofuran-   TLC thin layer chromatography

Compounds

In an embodiment of the compound or salt of Formula I, G is selectedfrom the group consisting of substituted or unsubstituted quinolyl,substituted or unsubstituted quinazolyl, unsubstituted isoquinolyl,unsubstituted quinoxalyl, unsubstituted benzimidazolyl, unsubstitutedpyridyl, unsubstituted pyrazinyl, unsubstituted indolyl, substituted orunsubstituted imidazoquinolyl, substituted pyridinium, unsubstitutedimidazopyridine, unsubstituted pyrimidyl, and substituted imidazolyl. Inanother embodiment of the compound or salt of Formula I A-Q-X—Y—Z isselected from the group consisting of alkoxyphenylalkyl, alkoxyphenyl,alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, phenoxyphenyl,phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl,phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl,biphenyl, alkylphenyl, alkoxycarbonylphenyl, N-alkylcarbamoylphenyl,alkoxy(halophenyl), phenylalkyl, alkoxy(halophenyl)alkyl,(alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl,isonicotinamidoalkyl, N-(quinolylamino)alkyl, N-(quinazolylamino)alkyl,phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl, phenylalkoxyphenyl,pyridylalkyl and hydroxyalkyl.

Some of the compounds of this invention in which G is unsubstituted orsubstituted quinolyl can be represented by Formula IA

wherein A is absent or present and is alkyl having from 1 to 12 carbonatoms, provided that if A has 1 carbon atom Q must be absent. Q isabsent or present and is O, NHC(O), or NH, provided that if A is absentQ must be absent, and if both X and Y are absent Q cannot be O or NH. Xis absent or present and is alkyl having from 1 to 5 carbon atoms,provided that if Y is absent and Z is alkoxy or phenoxy X must have morethan 1 carbon atom. Y is absent or present and is phenyl unsubstitutedor substituted by halo, or is a monocyclic or bicyclic aromatic ringhaving one or two nitrogen atoms. Z is absent or present and ishydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted orsubstituted by one phenyl or phenoxy group, alkoxy having from 1 to 12carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, phenyl, phenoxy, or NHC(O)R⁶ or C(O)NHR⁶ or C(O)OR⁶ whereR⁶ is alkyl having from 1 to 6 carbon atoms, provided that if all of A,Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms.One of R¹ and R² is hydrogen and the other is selected from the groupconsisting of hydrogen, halo, methyl, and perfluoromethyl. In anembodiment of this invention both R¹ and R² are hydrogen. In anembodiment of Formula IA, A-Q-X—Y—Z is selected from the groupconsisting of alkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl,alkoxyalkyl, alkoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl,phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl,alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl,alkoxycarbonylphenyl, N-alkylcarbamoylphenyl, alkoxy(halophenyl),phenylalkyl, alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl,picolinamidoalkyl, nicotinamidoalkyl, isonicotinamidoalkyl,phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl, phenylalkoxyphenyl,pyridylalkyl and N-(quinolylamino)alkyl.

A more specific embodiment of compounds in which G quinolyl can berepresented by Formula IA1

wherein n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, provided thatif p is 1 then n must not be 0 or 1. p is 0 or 1; and q is 0 or 1. Oneof R¹ and R² is hydrogen and the other is selected from the groupconsisting of hydrogen, halo, methyl, and perfluoromethyl. R³ can bealkyl having from 1 to 10 carbon atoms either unsubstituted orsubstituted by: a) a phenyl or monocyclic or bicyclic aromatic ringhaving one or two nitrogen atoms or phenoxy either unsubstituted orsubstituted by phenoxy or alkoxy having from 1 to 6 carbon atoms, or b)alkoxy having from 1 to 6 carbon atoms, provided that if R³ is alkylsubstituted by alkoxy then alkyl must have more than 1 carbon atom.Alternatively R³ can be phenyl unsubstituted or substituted by halo andunsubstituted or substituted by: a) alkyl having from 1 to 6 carbonatoms unsubstituted or substituted by phenyl or phenoxy, b) alkoxyhaving from 1 to 10 carbon atoms unsubstituted or substituted by phenylor phenoxy, provided that when substituted by phenoxy the alkoxy musthave more than one carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR⁶,C(O)NHR⁶, or NHC(O)R⁶, wherein R⁶ is alkyl having from 1 to 6 carbonatoms.

In an embodiment of the compounds of Formula IA1, R¹ is hydrogen and R²is hydrogen. In a more specific embodiment n is 2, 3, 4, 5, 6, 7, 8, 9,or 10; p is 1; and R³ is alkyl having from 1 to 6 carbon atoms. Examplesof such compounds include N-[8-(Hexyloxy)octyl]quinolin-4-amine,N-(8-Butoxyoctyl)quinolin-4-amine, N-(8-Methoxyoctyl)quinolin-4-amine,N-[6-(Hexyloxy)hexyl]quinolin-4-amine,N-(6-Butoxyhexyl)quinolin-4-amine,N-[10-(Hexyloxy)decyl]quinolin-4-amine,N-(10-Butoxydecyl)quinolin-4-amine, N-(5-Methoxypentyl)quinolin-4-amine.

In another embodiment of the compounds of Formula IA1, n is 2, 3, 4, 5,6, 7, 8, 9, or 10; p is 1; one of R¹ and R² is hydrogen and the other isselected from the group consisting of halo, methyl, and perfluoromethyl;and R³ is alkyl having from 1 to 6 carbon atoms. Examples of suchcompounds include N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine,7-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine,8-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine,N-[8-(Hexyloxy)octyl]-7-(trifluoromethyl)quinolin-4-amine,N-[8-(Hexyloxy)octyl]-8-(trifluoromethyl)quinolin-4-amine.

In another embodiment of the compounds of Formula IA1 in which R¹ ishydrogen and R² is hydrogen: n is 2, 3, 4, 5, 6, 7, 8, 9, or 10; p is 1;R³ is alkyl having from 2 to 5 carbon atoms substituted by alkoxy havingfrom 1 to 6 carbon atoms. Examples of such compounds includeN-{5-[3-(Hexyloxy)propoxy]pentyl}quinolin-4-amine,N-{3-[5-(Hexyloxy)pentyloxy]propyl}quinolin-4-amine,N-[8-(3-Ethoxypropoxyl)octyl]quinolin-4-amine,N-[8-(2-Propoxyethoxy)octyl]quinolin-4-amine.

A subset of compounds of Formula IA1 can be represented by Formula IA1a

wherein n is 0, 1, 2, 3, 4, 5, 6, 7, or 8; p is 0 or 1; q is 0 or 1,provided that if p is 1 then n must not be 0 or 1. One of R¹ and R² ishydrogen and the other is selected from the group consisting ofhydrogen, halo, methyl, and perfluoromethyl. R⁴ is hydrogen or halo. R⁵is selected from the group consisting of hydrogen; halo; unbranched orbranched alkyl having from 1 to 6 carbon atoms unsubstituted orsubstituted by phenyl or phenoxy; alkoxy having from 1 to 10 carbonatoms unsubstituted or substituted by phenyl or phenoxy, provided thatwhen substituted by phenoxy the alkoxy must have more than one carbonatom; phenyl; phenoxy; C(O)OR⁶; C(O)NHR⁶; or NHC(O)R⁶, wherein R⁶ isalkyl having from 1 to 6 carbon atoms. In embodiment of Formula IA1a R¹is hydrogen and R² is hydrogen. In a more specific embodiment p is 1 andR⁴ is hydrogen. In a still more specific embodiment R⁵ is hydrogen.Examples of such compounds includeN-[8-(Benzyloxy)octyl]quinolin-4-amine,N-(6-Phenoxyhexyl)quinolin-4-amine, N-(8-Phenoxyoctyl)quinolin-4-amine.

In another embodiment of Formula IA1a, both R¹ and R² are hydrogen, q is0, and R⁵ is alkoxy having from 1 to 6 carbon atoms unsubstituted orsubstituted by phenyl. In a more specific embodiment R⁵ is in the orthoposition. Examples of such compounds includeN-{2-[2-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine,N-{3-[2-(Hexyloxy)phenoxy]propyl}quinolin-4-amine,N-{4-[2-(Hexyloxy)phenoxy]butyl}quinolin-4-amine,N-[3-(2-Ethoxyphenoxy)propyl]quinolin-4-amine,N-[3-(2-Methoxyphenoxyl)propyl]quinolin-4-amine,N-{3-[2-(Benyloxy)phenoxy]propyl}quinolin-4-amine. Alternatively R⁵ isin the meta position. Examples of such compounds includeN-[8-(3-Methoxyphenoxyl)octyl]quinolin-4-amine,N-{4-[3-(Hexyloxy)phenoxy]butyl}quinolin-4-amine,N-{3-[3-(Hexyloxy)phenoxy]propyl}quinolin-4-amine,N-{2-[3-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine. Alternatively R⁵ is inthe para position. Examples of such compounds includeN-[8-(4-Methoxyphenoxyl)octyl]quinolin-4-amine,N-[6-(4-Methoxyphenoxyl)hexyl]quinolin-4-amine,N-{2-[4-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine,N-{3-[4-(Hexyloxy)phenoxy]propyl}quinolin-4-amine,N-{4-[4-(Hexyloxy)phenoxy]butyl}quinolin-4-amine.

In another embodiment of Formula IA1a, R¹ is hydrogen and R² ishydrogen, p is 1, R⁴ is hydrogen, and R⁵ is unbranched or branched alkylhaving from 1 to 6 carbon atoms. Examples of such compounds includeN-[8-(m-Tolyloxy)octyl]quinolin-4-amine,N-[8-(p-Tolyloxy)octyl]quinolin-4-amine,N-[8-(o-Tolyloxy)octyl]quinolin-4-amine,N-[8-(4-tert-Butylphenoxy)octyl]quinolin-4-amine. Alternatively R⁵ isfluoro. Examples of such compounds includeN-[8-(4-Fluorophenoxyl)octyl]quinolin-4-amine,N-[8-(3-Fluorophenoxyl)octyl]quinolin-4-amine,N-[8-(2-Fluorophenoxyl)octyl]quinolin-4-amine.

In another embodiment of Formula IA1a, R¹ is hydrogen and R² ishydrogen, and p is 0. In a more specific embodiment q is 0. In a stillmore specific embodiment n is 0. Examples of such compound includeN-(Biphenyl-4-yl)quinolin-4-amine, N-(4-Hexylphenyl)quinolin-4-amine,Hexyl 4-(quinolin-4-ylamino)benzoate,N-(4-Phenoxyphenyl)quinolin-4-amine,N-(3-Phenoxyphenyl)quinolin-4-amine,N-(2-Phenoxyphenyl)quinolin-4-amine,N-[4-(Quinolin-4-ylamino)phenyl]hexanamide,N-[3-(Quinolin-4-ylamino)phenyl]hexanamide,N-Hexyl-4-(quinolin-4-ylamino)benzamide,N-Hexyl-3-(quinolin-4-ylamino)benzamide. Alternatively R⁵ is alkoxyhaving from 1 to 10 carbon atoms unsubstituted or substituted by phenyl.Examples of such compounds include N-(4-Methoxyphenyl)quinolin-4-amine,N-[4-(Benzyloxy)phenyl]quinolin-4-amine,N-(4-Butoxyphenyl)quinolin-4-amine,N-[4-(Hexyloxy)phenyl]quinolin-4-amine,N-[3-(Benzyloxy)phenyl]quinolin-4-amine,N-[3-(Hexyloxy)phenyl]quinolin-4-amine,N-[2-(Benzyloxy)phenyl]quinolin-4-amine,N-[2-(Hexyloxy)phenyl]quinolin-4-amine,N-[2-Fluoro-4-(hexyloxy)phenyl]quinolin-4-amine. In another embodimentof Formula IA1a, R¹ is hydrogen and R² is hydrogen, p is 0, q is 0, andn is 1 or 2. Examples of such compounds includeN-Benzylquinolin-4-amine, and N-Phenethylquinolin-4-amine.

In another embodiment of Formula IA1a, R¹ is hydrogen and R² ishydrogen, p is 0, and q is 1. In a more specific embodiment R⁵ is alkoxyhaving from 1 to 10 carbon atoms. Examples of such compounds includeN-[4-(Hexyloxy)benzyl]quinolin-4-amine,N-[3-(Hexyloxy)benzyl]quinolin-4-amine,N-[2-(Hexyloxy)benzyl]quinolin-4-amine,N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4-amine,N-[4-(Decyloxy)benzyl]quinolin-4-amine,N-[3-(Decyloxy)benzyl]quinolin-4-amine. Alternatively R⁵ is phenoxy, oralkoxy having from 1 to 10 carbon atoms substituted by phenyl. Examplesof such compounds include N-(3-Phenoxybenzyl)quinolin-4-amine,N-[3-(Benzyloxy)benzyl]quinolin-4-amine,N-(3-Phenethoxybenzyl)quinolin-4-amine.

Another more specific embodiment of compounds in which G quinolyl can berepresented by Formula IA2

wherein n is 2, 3, 4, 5, 6, 7, or 8. R¹³ is phenyl unsubstituted orsubstituted by alkoxy having from 1 to 6 carbon atoms; or 2-, 3-, or4-pyridyl. In one embodiment R¹³ is unsubstituted phenyl. Examples ofsuch compounds include N-[4-(Quinolin-4-ylamino)butyl]benzamide,

N-[6-(Quinolin-4-ylamino)hexyl]benzamide,N-[8-(Quinolin-4-ylamino)octyl]benzamide. In another embodiment R¹³ isphenyl substituted by alkoxy having from 1 to 6 carbon atoms. Examplesof such compounds include3-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide,4-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide,2-(Hexyloxy)-N-[2-(quinolin-4-ylamino)ethyl]benzamide,2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide,2-(Hexyloxy)-N-[4-(quinolin-4-ylamino)butyl]benzamide. Alternatively R¹³is 2-pyridyl, 3-pyridyl, or 4-pyridyl. Examples of such compoundsinclude N-[8-(Quinolin-4-ylamino)octyl]picolinamide,N-[8-(Quinolin-4-ylamino)octyl]nicotinamide,N-[8-(Quinolin-4-ylamino)octyl]isonicotinamide.

Other examples of compounds of Formula IA includeN-(Pyridin-4-ylmethyl)quinolin-4-amine,N-(Pyridin-3-ylmethyl)quinolin-4-amine,N-(Pyridin-2-ylmethyl)quinolin-4-amine, N-Hexylquinolin-4-amine,N-(Decyl)quinolin-4-amine, N-(Dodecyl)quinolin-4-amine,N¹,N⁸-Di(quinolin-4-yl)octane-1,8-diamine. Other examples of compoundsof Formula I in which G is quinolyl includeN-[8-(Hexyloxy)octyl]quinolin-6-amine,N-[8-(Hexyloxy)octyl]quinolin-3-amine,N-[8-(Hexyloxy)octyl]quinolin-8-amine,N-[8-(Hexyloxy)octyl]-2-(trifluoromethyl)quinolin-4-amine,7-Chloro-N-decylquinolin-4-amine, 7-Chloro-N-dodecylquinolin-4-amine.

Some of the compounds of this invention in which G is unsubstituted orsubstituted quinazolyl can be represented by Formula IB

wherein A is absent or present and is alkyl having from 1 to 12 carbonatoms, provided that if A has 1 carbon atom Q must be absent. Q isabsent or present and is O, NHC(O), or NH, provided that if A is absentQ must be absent, and if both X and Y are absent Q cannot be O or NH. Xis absent or present and is alkyl having from 1 to 5 carbon atoms,provided that if Y is absent and Z is alkoxy or phenoxy X must have morethan 1 carbon atom. Y is absent or present and is phenyl unsubstitutedor substituted by halo, or is a monocyclic or bicyclic aromatic ringhaving one or two nitrogen atoms. Z is absent or present and ishydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted orsubstituted by one phenyl or phenoxy group, alkoxy having from 1 to 12carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, phenyl, phenoxy, or NHC(O)R⁶ or C(O)NHR⁶ or C(O)OR⁶ whereR⁶ is alkyl having from 1 to 6 carbon atoms, provided that if all of A,Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms.R¹ is selected from the group consisting of hydrogen, halo, methyl, andperfluoromethyl.

In an embodiment of Formula IB, R¹ is hydrogen. In another embodiment,A-Q-X—Y—Z is selected from the group consisting of alkoxyphenylalkyl,alkoxyphenyl, alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl,phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl,phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl,(halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl,N-alkylcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl,alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl,nicotinamidoalkyl, isonicotinamidoalkyl, phenylalkoxyphenoxyalkyl,alkylalkoxyphenyl, phenylalkoxyphenyl, pyridylalkyl,N-(quinazolylamino)alkyl, and N-(quinolylamino)alkyl.

A subset of compounds of Formula IB can be represented by Formula IB 1

wherein n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; Q is absent orpresent and is O or NHC(O), provided that if Q is present n cannot be 0or 1; and provided that if Q is absent, then (CH₂)—R⁷ must have morethan 5 carbon atoms. R¹ is hydrogen or halo. R⁷ is selected from thegroup consisting of: hydrogen; alkyl having from 1 to 6 carbon atoms;and phenyl or monocyclic aromatic ring having one nitrogen atom,unsubstituted or substituted by alkyl having from 1 to 6 carbon atoms oralkoxy having from 1 to 10 carbon atoms or phenyl or phenoxy. In anembodiment Q is absent. Examples of such compounds includeN-(Decyl)quinazolin-4-amine, N-Dodecylquinazolin-4-amine,N-Decyl-7-fluoroquinazolin-4-amine,N-Dodecyl-7-fluoroquinazolin-4-amine,7-Chloro-N-decylquinazolin-4-amine,7-Chloro-N-dodecylquinazolin-4-amine. In another embodiment Q is O orNHC(O). Examples of such compounds includeN-(6-Butoxyhexyl)quinazolin-4-amine,N-[8-(Hexyloxy)octyl]quinazolin-4-amine,N-[8-(4-Methoxyphenoxyl)octyl]quinazolin-4-amine,N-{2-[2-(Hexyloxy)phenoxy]ethyl}quinazolin-4-amine,N-{3-[2-(Hexyloxy)phenoxy]propyl}quinazolin-4-amine,N-{4-[2-(Hexyloxy)phenoxy]butyl}quinazolin-4-amine,N-[8-(Quinazolin-4-ylamino)octyl]nicotinamide. In an embodiment ofFormula IB 1, n is 1, Q is absent, and R⁷ is phenyl substituted byalkoxy having from 1 to 10 carbon atoms or phenoxy. Examples of suchcompounds include N-[3-(Hexyloxy)benzyl]quinazolin-4-amine,N-[3-(Decyloxy)benzyl]quinazolin-4-amine,N-(3-Phenoxybenzyl)quinazolin-4-amine,N-[4-(Decyloxy)benzyl]quinazolin-4-amine,N-[4-(Hexyloxy)benzyl]quinazolin-4-amine.

Some of the compounds of this invention in which G is unsubstituted orsubstituted imidazoquinolyl can be represented by Formula IC

Wherein R¹ is hydrogen, OH, NH₂, or N(CH₃)₂; R² is selected from thegroup consisting of hydrogen, halo, methyl, and perfluoromethyl; R⁸ ishydrogen, or alkyl having from 1 to 15 carbon atoms unsubstituted orsubstituted by alkoxy having 1 or 2 carbon atoms or acetoxy; and R⁹ is abranched or unbranched alkyl having from 1 to 16 carbon atoms,unsubstituted or substituted by hydroxy, or alkoxy having from 1 to 12carbon atoms, provided that if substituted by hydroxy or alkoxy R⁹ musthave more than 1 carbon atom. In an embodiment R² is hydrogen. Examplesof such compounds include1-[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol,1-(4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentyl acetate,1-Isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-ol,1-Octyl-1H-imidazo[4,5-c]quinoline,1-Hexadecyl-1H-imidazo[4,5-c]quinoline,1-Hexadecyl-1H-imidazo[4,5-c]quinolin-4-amine,1-Dodecyl-1H-imidazo[4,5-c]quinoline,1-{5-[3-(Hexyloxy)propoxy]pentyl}-1H-imidazo[4,5-c]quinoline,1-{3-[3-(Hexyloxy)phenoxy]propyl}-1H-imidazo[4,5-c]quinoline. In anotherembodiment of Formula IC, R² is hydrogen, and R⁹ is an unbranched alkylhaving from 2 to 10 carbon atoms, substituted by alkoxy having from 1 to12 carbon atoms. Examples of such compounds include1-[2-(Dodecyloxy)ethyl]-1H-imidazo[4,5-c]quinoline,1-[2-(Dodecyloxy)ethyl]-N,N-dimethyl-1H-imidazo[4,5-c]quinolin-4-amine,1-[6-(Octyloxy)hexyl]-1H-imidazo[4,5-c]quinoline,1-(8-Ethoxyoctyl)-1H-imidazo[4,5-c]quinoline,1-(8-Methoxyoctyl)-1H-imidazo[4,5-c]quinoline,1-(8-Butoxyoctyl)-1H-imidazo[4,5-c]quinoline,1-[9-(Hexyloxy)nonyl]-1H-imidazo[4,5-c]quinoline,1-(10-Butoxydecyl)-1H-imidazo[4,5-c]quinoline,1-[3-(Decyloxy)propyl]-1H-imidazo[4,5-c]quinoline,1-[4-(Decyloxy)butyl]-1H-imidazo[4,5-c]quinoline,1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]quinoline.

Some of the compounds of this invention in which G is substitutedpyridinium can be represented by Formula ID

wherein R¹⁰ is alkyl having from 1 to 8 carbon atoms, unsubstituted orsubstituted by alkoxy having from 1 to 6 carbon atoms, provided that ifsubstituted by alkoxy R¹⁰ must have more than 1 carbon atom. R¹¹ ishydrogen; or alkyl having from 1 to 8 carbon atoms, unsubstituted orsubstituted by alkoxy having from 1 to 3 carbon atoms, provided that ifsubstituted by alkoxy R¹¹ must have more than 1 carbon atom. X⁻ is acounterion. Examples of such compounds include a4-Amino-1-[8-(hexyloxy)octyl]pyridinium salt, and4-(8-Methoxyoctylamino)-1-methylpyridinium iodide.

In an embodiment of this invention G is 1H-imidazo[4,5-c]pyridine. Someof those compounds can be represented by Formula IE

wherein R¹² is alkyl having from 2 to 16 carbon atoms, unsubstituted orsubstituted by alkoxy having from 4 to 6 carbon atoms. Examples of suchcompounds include 1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine,1-Hexadecyl-1H-imidazo[4,5-c]pyridine,1-(10-Butoxydecyl)-1H-imidazo[4,5-c]pyridine.

Examples of this invention in which G is pyridyl includeN-(8-Methoxyoctyl)pyridine-4-amine,N-[8-(Hexyloxy)octyl]pyridin-3-amine, andN-[8-(Hexyloxy)octyl]pyridin-2-amine.

Examples of this invention in which G is pyrimidyl includeN-[8-(Hexyloxy)octyl]pyrimidin-4-amine, andN-[8-Hexyloxy)octyl]pyrimidin-2-amine. In an embodiment of thisinvention G is 5-aryl 1H-imidazolyl. Examples of such compounds include1-[8-(Hexyloxy)octyl]-4-phenyl-1H-imidazole. Examples of compounds ofthis invention in which G is isoquinolyl includeN-[8-(Hexyloxy)octyl]isoquinolin-1-amine,N-[8-(Hexyloxy)octyl]isoquinolin-5-amine. Examples of compounds in whichG is quinoxalyl include N-[8-(Hexyloxy)octyl]quinoxalin-2-amine.Examples of compounds in which G is benzimidazolyl include1-[8-(Hexyloxy)octyl]-1H-benzimidazole. Examples of compounds in which Gis pyrazinyl include N-[8-(Hexyloxy)octyl]pyrazin-2-amine. Examples ofcompounds in which G is indolyl include 1-[8-(Hexyloxy)octyl]-1H-indole.In an embodiment of this invention G is 3H-imidazo[4,5-b]pyridine.Examples of such compounds include3-[8-(Hexyloxy)octyl]-3H-imidazo[4,5-b]pyridine.

In certain embodiments of this invention, one or more of the followingcompounds are excluded: imiquimod; 4-(n-decylamino)quinoline[58911-14-1]; 4-decylaminoquinazoline [22754-12-7].

In an embodiment of the compound of this invention, the compound is insubstantially (at least 98%) pure form. This invention provides prodrugsof the compounds and salts described above, and their uses as describedherein. Whenever a phenyl ring is substituted, the substitution may beat the ortho-, meta-, or para-position.

Reaction Schemes

The compounds of the present invention can be made in accordance withthe following reaction schemes.

The compound of formula I wherein G is a monocyclic or bicyclic aromaticring having one or two ring nitrogen atoms, either unsubstituted orsubstituted at a ring carbon by halo, methyl, or perfluoromethyl;

N is nitrogen, H is hydrogen;

A is absent or present and is alkyl having from 1 to 12 carbon atoms,provided that if A has 1 carbon atom Q must be absent;

Q is absent or present and is O, NHC(O), or NH, provided that if A isabsent Q must be absent, and if both X and Y are absent Q cannot be O orNH;

X is absent or present and is alkyl having from 1 to 5 carbon atoms,provided that if Y is absent and Z is alkoxy or phenoxy X must have morethan 1 carbon atom;

Y is absent or present and is phenyl unsubstituted or substituted byhalo, or is a monocyclic or bicyclic aromatic ring having one nitrogenatom;

Z is absent or present and is: a) hydrogen, b) alkyl having from 1 to 12carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, c) alkoxy having from 1 to 10 carbon atoms eitherunsubstituted or substituted by one phenyl or phenoxy group, d) phenyl,e) phenoxy, or f) NHC(O)R⁶ or C(O)NHR⁶ or C(O)OR⁶ where R⁶ is alkyl with1 to 6 carbon atoms except if both X and Y are absent, provided that ifall of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12carbon atoms, can be prepared from the reaction of the compound offormula 1 with the compound of formula 2 where LG is a leaving groupsuch as a halogen, a sulfonyloxy, a siloxy, or a borate via the reactionscheme in Scheme 1. If LG is located in a position on the aromatic ringthat is activated by a nitrogen atom, the reaction of step (a) canproceed thermally without the use of a catalyst, and LG is halo ispreferred, and LG is chloro is most preferred. G is preferably selectedfrom the group of compounds consisting of unsubstituted or substituted4-quinolyl, 4-quinazolyl, 2-quinolyl, 2-quinazolyl, 1-isoquinolyl,3-isoquinolyl, 2-quinoxalyl, 1-phthalazyl, 2-pyridyl, 4-pyridyl,2-pyrimidyl, 4-pyrimidyl, and 2-pyrazinyl. The compound of formula 1 andthe compound of formula 2 and a suitable base such as triethylamine,tripropylamine, N-methylmorpholine, or diisopropylethylamine are heatedin a suitable solvent such as 1-pentanol, 1-butanol, 2-propanol,dimethylformamide, N-methylpyrrolidinone, or a mixture of suitablesolvents. If LG is not located in a position on the aromatic ring thatis activated by a nitrogen atom, the reaction can proceed with the useof a catalyst such as a transition metal complex catalyst such as apalladium complex or a nickel complex.

The compound of formula 7 where T is CH and R² is present or T is N andR² is absent and where either: a) n is 2-12 and p is 1; or b) n is 0 or1 and p is 0; and where q is 0 or 1, and one of R¹ and R² is hydrogenand the other is selected from the group consisting of hydrogen, halo,methyl, and perfluoromethyl, and R³ is alkyl having from 1 to 10 carbonatoms either unsubstituted or substituted by: a) a monocyclic orbicyclic aromatic ring having one or two nitrogen atoms or phenyl eitherunsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms,or b) alkoxy having from 1 to 6 carbons, provided that if R³ is alkylsubstituted by alkoxy then alkyl cannot have 1 carbon atom; phenylunsubstituted or substituted by halo and unsubstituted or substitutedby: a) alkyl having from 1 to 6 carbon atoms, b) alkoxy having from 1 to10 carbon atoms unsubstituted or substituted by phenyl or phenoxyprovided that when substituted by phenoxy the alkoxy must have more thanone carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR⁶, C(O)NHR⁶, orNHC(O)R⁶ wherein R⁶ is alkyl having from 1 to 6 carbon atoms can beprepared starting from the compound of formula 3 or starting from thecompound of formula 6 via the reaction scheme in Scheme 2.

Some compounds of the formula 3 and some compounds of the formula 6 arecommercially available. The compound of formula 3 is reacted with thecompound of formula 4 to give the compound of formula 5 via reaction ofstep (a): the compound of formula 3 is treated with a suitable base andthen is reacted with the compound of formula 4. The selectivity of thereaction for substitution of only one of the bromides of the compound offormula 4 can be increased by using a stoichiometric excess of thecompound of formula 3. If n is 1, any base that is commonly used toconvert an alcohol to an alkoxide is suitable, such as sodium hydride ora hindered alkali metal alkoxide such as sodium isopropoxide. If n is 1,the base must be completely reacted with the compound of formula 3before the addition of the compound of formula 4 is performed. If n is0, any base that is commonly used to convert a phenol to a phenoxide issuitable, such as potassium carbonate or sodium carbonate. If n is 0,the compound of formula 4 may be present when the base is reacted withthe compound of formula 3.

The compound of formula 5 is converted to the compound of formula 6 viareactions of step (b), the Gabriel synthesis of primary amines. Thecompound of formula 5 is reacted with potassium phthalimide underconventionally used conditions to give the phthalimide intermediate,which is converted to the compound of formula 6 under conventionallyused conditions such as hydrazine monohydrate in ethanol at reflux. Anymethod for the cleavage of phthalimides may be used.

The compound of formula 6 is converted to the compound of formula 7 viastep (c): the compound of formula 6 reacts with the compound of formula7 in the presence of a tertiary amine base such as triethylamine,diisopropylethylamine, or tripropylamine at elevated temperature in asuitable solvent, such as 2-propanol heated at reflux if T is N or1-pentanol heated at reflux or dimethylformamide orN-methylpyrrolidinone at 130-150° C. if T is CH.

The compound of formula 3 where q is 0 or 1 and R³ is alkyl having from1 to 10 carbon atoms substituted by alkoxy having from 1 to 12 carbonatoms, provided that if R³ is alkyl substituted by alkoxy then alkylcannot have one carbon, can be prepared via the reaction scheme inScheme 3. In step (a), the compound of formula 9 where n is 2-11 istreated with any base that is commonly used to convert an alcohol to analkoxide, such as sodium hydride or a hindered alkali metal alkoxidesuch as sodium isopropoxide. Then, the compound of formula 10 where R⁶is alkyl having from 1 to 12 carbon atoms is added. The selectivity ofthe reaction for alkylation of only one of the hydroxyls of the compoundof formula 9 can be increased by using a stoichiometric excess of thecompound of formula 9.

The compound of formula 3 where q is 0 or 1 and R³ is phenyl substitutedby halo, alkoxy having from 1 to 10 carbon atoms unsubstituted orsubstituted by phenyl or phenoxy, can be prepared from the compound offormula 11 where q is 0 or 1 and R⁴ is hydrogen or halo via the reactionscheme in Scheme 4. The compound of formula 11 is treated with asuitable base such as potassium carbonate or sodium carbonate andreacted with the compound of formula 10, where R⁶ is alkyl having from 1to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy.When using carbonate bases with the compound of formula 11 wherein q is1, the aromatic hydroxyl will react selectively with the compound offormula 10, despite the presence of the aliphatic hydroxyl. If n is 0,the use of a stoichiometric excess of the compound of formula 11 willminimize the quantity of the dialkylated side product.

The compound of formula 6 where n is 0, p is 0, q is 0, and R³ is phenylunsubstituted or substituted by halo, C(O)OR⁶ wherein R⁶ is alkyl havingfrom 1 to 6 carbon atoms can be prepared starting from the compound offormula 12 where R⁴ is hydrogen or halo and the compound of formula 13where R⁶ is alkyl having from 1 to 6 carbon atoms via the reactionscheme in Scheme 5. The compound of formula 12 may be commerciallyavailable or can be prepared from the carboxylic acid using conventionalmethods. The compound of formula 14 where R⁴ is hydrogen or halo and R⁵is C(O)OR⁶ wherein R⁶ is alkyl having from 1 to 6 carbon atoms isprepared from the reaction of the compound of formula 12 with thecompound of formula 13 in the presence of a base such as pyridine ortriethylamine via step (a). Any of the conventional methods for thepreparation of carboxylic esters from carboxylic acids or theirderivatives and alcohols may be used to prepare the compound of formula14. If the compound of formula 13 is replaced by the amine analog, thereaction scheme will produce the compound of formula 6 where R³ issubstituted by C(O)NHR⁶. The compound of formula 14 is reduced to formthe compound of formula 6 by catalytic reduction using hydrogen and apalladium on charcoal catalyst via step (b). Any of the conventionalmethods for selective reduction of nitro groups to amino groups in thepresence of carboxylic ester groups can be used in step (b).

The compound of formula 6 where n is 0, p is 0, q is 0, and R³ is phenylunsubstituted or substituted by halo, NHC(O)R⁶ wherein R⁶ is alkylhaving from 1 to 6 carbon atoms can be prepared starting from thecompound of formula 15 where R⁴ is hydrogen or halo and the compound offormula 16 where R⁶ is alkyl having from 1 to 6 carbon atoms via thereaction scheme in Scheme 5. The compound of formula 15 and the compoundof formula 16 can react to produce the compound of formula 14 where R⁴is hydrogen or halo and R⁵ is NHC(O)R⁶ wherein R⁶ is alkyl having from 1to 6 carbon atoms via the reaction of step (a) under any conventionalconditions for preparing carboxamides from the reaction of amines withcarboxylic acid chlorides. The compound of formula 14 is reduced to formthe compound of formula 6 by catalytic reduction using hydrogen and apalladium on charcoal catalyst via step (b). Any of the conventionalmethods for reduction of nitro groups to amino groups can be used instep (b).

The compound of formula 6 where n is 0, p is 0, q is 0, and R³ is phenylunsubstituted or substituted by halo, alkoxy having from 1 to 12 carbonatoms either unsubstituted or substituted by one phenyl or phenoxygroup, can be prepared starting from the compound of formula 17 where R⁴is hydrogen or halo and the compound of formula 10 where R⁶ is alkylhaving from 1 to 12 carbon atoms either unsubstituted or substituted byphenyl or phenoxy via the reaction scheme in Scheme 7. A mixture ofcompound of formula 17 and compound of formula 10 is reacted in thepresence of a suitable base such as potassium carbonate or sodiumcarbonate and a suitable solvent such as dimethylformamide to givecompound of formula 14 where R⁴ is hydrogen or halo and R⁵ is alkoxyhaving from 1 to 12 carbon atoms either unsubstituted or substituted byone phenyl or phenoxy group. The compound of formula 14 is reduced toform the compound of formula 6 by catalytic reduction using hydrogen anda palladium on charcoal catalyst via step (b). Any of the conventionalmethods for reduction of nitro groups to amino groups can be used instep (b).

The compound of formula 6 where n is 0, p is 0, q is 1 and R³ is eitherphenyl or a monocyclic or bicyclic aromatic ring having one or twonitrogen atoms, that is unsubstituted or substituted by halo and by: a)alkyl having from 1 to 12 carbon atoms, b) alkoxy having from 1 to 10carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, c) phenyl, d) phenoxy, or e) NHC(O)R⁶ or C(O)NHR⁶ orC(O)OR⁶ where R⁶ is alkyl having from 1 to 6 carbon atoms can beprepared starting from the compound of formula 3 where q is 1 and R³ iseither phenyl or a monocyclic or bicyclic aromatic ring having one ortwo nitrogen atoms, that is unsubstituted or substituted by halo and by:a) alkyl having from 1 to 12 carbon atoms, b) alkoxy having from 1 to 10carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, c) phenyl, d) phenoxy, or e) NHC(O)R⁶ or C(O)NHR⁶ orC(O)OR⁶ where R⁶ is alkyl having from 1 to 6 carbon atoms via thereaction scheme in Scheme 8. The compound of formula 3 is converted tothe compound of formula 18 via the reaction of step (a) by treatmentwith thionyl chloride. Any of the reagents and reactions that are usedconventionally to convert an alcohol and particularly a benzylic alcoholto a halide and particularly a benzylic halide can be used in step (a).Alternatively, the compound of formula 3 is converted to the compound offormula 19 via the reaction of step (b) by treatment withmethanesulfonyl chloride and triethylamine. In step (b), anysulfonylation reagent that is conventionally used to convert a hydroxylto a leaving group can be substituted for methanesulfonyl chloride, andany suitable base can be used in place of triethylamine. The compound offormula 18 or the compound of formula 19 is converted to the compound offormula 6 via reactions of step (c), the Gabriel synthesis of primaryamines. The compound of formula 18 or the compound of formula 19 isreacted with potassium phthalimide under conventionally used conditionsto give the phthalimide intermediate, which is converted to the compoundof formula 6 under conventionally used conditions such as hydrazinemonohydrate in ethanol at reflux. Any method for the cleavage ofphthalimides may be used.

The compound of formula 24 where T is CH and R² is present or T is N andR² is absent and wherein n is 2, 3, 4, 5, 6, 7, or 8; R¹ and R² arehydrogen; and R¹³ is phenyl, 2-, 3-, or 4-pyridyl unsubstituted orsubstituted by: a) alkyl having from 1 to 12 carbon atoms eitherunsubstituted or substituted by one phenyl or phenoxy group, b) alkoxyhaving from 1 to 12 carbon atoms either unsubstituted or substituted byone phenyl or phenoxy group, c) phenyl, or d) phenoxy can be preparedstarting from the compound of formula 20 where R⁶ is alkyl of 1 to 6carbon atoms or, if commercially available, starting from the compoundof formula 21 where R⁶ is alkyl of 1 to 6 carbon atoms and R¹³ isphenyl, 2-, 3-, or 4-pyridyl unsubstituted or substituted by: a) alkylhaving from 1 to 12 carbon atoms either unsubstituted or substituted byone phenyl or phenoxy group, b) alkoxy having from 1 to 12 carbon atomseither unsubstituted or substituted by one phenyl or phenoxy group, c)phenyl, or d) phenoxy via the reaction scheme in Scheme 9. The compoundof formula 20 is reacted with the compound of formula 10 where R⁶ isalkyl having from 1 to 6 carbon atoms in the presence of a suitable basesuch as potassium carbonate via the reaction of step (a). The benzoicacid derivative of the compound of formula 20 can be used as thestarting material, as well, if two equivalents of the compound offormula 10 and two equivalents of a suitable base are used. The compoundof formula 21 can be reacted with the compound of formula 22 where n is2-8 to produce the compound of formula 23 via the reaction of step (b).Step (b) can be carried out in the absence of solvent at a temperatureof 100-130° C. The selectivity of acylation of only one of the aminogroups of the compound of formula 22 can be increased by using astoichiometric excess of the compound of formula 22. The compound offormula 23 can be reacted with the compound of formula 8 to give thecompound of formula 24 via the reaction of step (c). A mixture of thecompound of formula 23 and the compound of formula 7 where T is CH andR¹ and R² are hydrogen is heated in 1-pentanol at reflux ordimethylformamide or N-methylpyrrolidinone or a mixture thereof at130-160° C. in the presence of a suitable base such as triethylamine,tripropylamine, N-methylmorpholine, or diisopropylethylamine to give thecompound of formula 24 where T is CH. A mixture of the compound offormula 23 and the compound of formula 7 where T is N and R¹ and R² arehydrogen is heated in 2-propanol at reflux in the presence of a suitablebase such as triethylamine or diisopropylethylamine to give the compoundof formula 24 where T is N. As an alternative preparation of thecompound of formula 24, compound of formula 8 where T is CH and R² ispresent or T is N and R² is absent can be reacted with the compound offormula 22 to give the compound of formula 25 where T is CH and R² ispresent or T is N and R² is absent via the reaction of step (d). Step(d) is performed using the same solvent, temperature, and base asdescribed for step (c). The compound of formula 21 can be converted tothe compound of formula 26 via the reactions of step (e). Anyconventional method for the conversion of a carboxylic ester to acarboxylic acid chloride can be used for step (e); e.g., basicsaponification and then reaction with thionyl chloride, oxalyl chloride,phosphoryl chloride, or phosphorus(V) chloride. The compound of formula25 where T is CH or N and where R¹ and R² are hydrogen and the compoundof formula 26 can be reacted to give the compound of formula 24 where Tis CH or N via the reaction of step (f) using any of the conventionalmethods for the formation of carboxamides from carboxylic acid chloridesand amines.

The compound of formula I wherein G is imidazoquinolyl unsubstituted orsubstituted at a ring carbon by halo, methyl, or perfluoromethyl; NH isabsent; R¹ is hydrogen, OH, NH₂, or N(CH₃)₂; and either: a) AQXYZ isrepresented by R⁸, and R⁹ is a branched or unbranched alkyl having from1 to 16 carbon atoms, unsubstituted or substituted by hydroxy or alkoxyhaving from 1 to 12 carbon atoms, provided that if substituted byhydroxy or alkoxy R⁹ cannot have 1 carbon atom, or b) AQXYZ isrepresented by R⁹, and R⁸ is hydrogen or alkyl having from 1 to 15carbon atoms unsubstituted or substituted by alkoxy having 1 or 2 carbonatoms or acetoxy can be prepared starting from the compound of formula27 where R¹ is hydrogen or hydroxy and R² is hydrogen, halo, methyl, orperfluoromethyl via the reaction scheme in Scheme 10. In step (a),compound of the formula 27 where R¹ is hydrogen or hydroxy is nitratedto produce the compound of the formula 28 using nitric acid in hotacetic acid or propionic acid. In step (b), the compound of formula 28is treated with a chlorinating agent such as phosphoryl chloride, aloneor in combination with phosphorus(V) chloride, or with phenylphosphonicdichloride to produce the compound of formula 29, where R¹ is chloro ifthe compound of formula 28 had hydroxy as R¹. In step (c), the compoundof formula 29 is reacted with the compound of formula 30 in the presenceof a tertiary amine base such as triethylamine in an inert solvent suchas dichoromethane, aided by gentle warming to produce the compound offormula 31. It is well-established in the literature that the 4-chloroof the compound of formula 29 where R¹ is chloro is the more reactivewith amines. Any of the amines described in the invention can be used instep (c). It was discovered that if compound of formula 29 where R¹ ischloro is stirred with the compound of formula 30 in a mixture ofdimethylformamide and dichloromethane initially, and then thedichloromethane is replaced with toluene and the mixture is heated atreflux, the compound of formula 31 where R¹ is N(CH₃)₂ is produced. Instep (d), the nitro group of the compound of formula 31 is reduced byany of a number of methods. If R¹ is hydrogen or chloro, hydrogenationusing 5% or 10% Pd-C or reduction using zinc dust and hydrochloric acidwill produce the compound of formula 32 where R¹ is hydrogen. If R¹ ischloro, hydrogenation using 10% Pt-C will produce the compound offormula 32 where R¹ is chloro. If R¹ is dimethylamino, all these methodsleave R¹ unchanged. In step (e), the ortho-diamine of the compound offormula 32 is heated with the carboxylic acid compound of formula 33 orthe compound of formula 34, the ortho ester of the compound of 33, toproduce the compound of formula 35. Any ortho ester analog of thecompound of formula 33 may be used. In step (f), if the compound offormula 35 where R¹ is chloro is treated with hydrolytic conditions, thecompound of formula 36 where R¹ is hydroxy is produced. In step (f), ifthe compound of formula 35 where R¹ is chloro is treated with ammonia ora primary amine, the R¹-amino derivative of the compound of formula 36is produced. In step (f), if the compound of formula 35 where R¹ ischloro is treated with zinc dust and hydrochloric acid, the compound offormula 36 where R¹ is hydrogen is produced. The compound of formula 35where R¹ and R² and R⁸ are hydrogen and R⁹ is stable to organolithiumbases can be reacted with an organolithium base and then alkylated by anorganohalide or aldehyde to give the compound of formula 36 where R⁸contains the derivative of the alkylation reagent.

If the compound of formula 33, or the compound of formula 34, or thecompound of formula 37 wherein n is 0-12, provided that if p is 1 then nmust not be 0 or 1; p is 0 or 1; q is 0 or 1; R³ is selected from thegroup consisting of: alkyl having from 1 to 10 carbon atoms eitherunsubstituted or substituted by: a) a monocyclic or bicyclic aromaticring having one or two nitrogen atoms either unsubstituted orsubstituted by alkoxy having from 1 to 6 carbon atoms, or b) alkoxyhaving from 1 to 6 carbon atoms, provided that if R³ is alkylsubstituted by alkoxy then alkyl must have more than 1 carbon atom; andphenyl unsubstituted or substituted by halo and unsubstituted orsubstituted by: a) alkyl having from 1 to 6 carbon atoms, b) alkoxyhaving from 1 to 10 carbon atoms unsubstituted or substituted by phenylor phenoxy, provided that when substituted by phenoxy the alkoxy musthave more than one carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR⁶,C(O)NHR⁶, or NHC(O)R⁶, wherein R⁶ is alkyl having from 1 to 6 carbonatoms is not available commercially or as a synthetic intermediate, thecompound of formula 5 can be converted to the compound of formula 37 andhence to the compound of formula 33, or the compound of formula 5 can beconverted to the compound of formula 34 via the Pinner reaction by thescheme shown in Scheme 11. In step (a), the compound of formula 5 isreacted with the alkali metal salt of acetic acid, such as potassiumacetate or sodium acetate or lithium acetate, in a suitable solvent suchas dimethylformamide. Then, the acetate ester is hydrolyzed atmoderately basic pH to produce the compound of formula 37. The compoundof formula 37, a primary alcohol, can be oxidized to the carboxylic acidcompound of the formula 33 via the reaction of step (b) using any of thenumerous suitable methods for the oxidation of alcohols to acids, suchas the Jones oxidation. Alternatively, the compound of formula 5 isreacted with an alkali metal cyanide such as sodium cyanide or potassiumcyanide in a suitable solvent such as dimethylformamide to produce thecompound of formula 38 via the reaction of step (c). In step (d), thecompound of formula 38 is treated with an alcohol such as methanol andan acid catalyst such as hydrochloric acid to form the compound offormula 34.

The compound of formula ID wherein R¹⁰ is alkyl having from 1 to 8carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 6carbon atoms, provided that if substituted by alkoxy R¹⁰ must have morethan 1 carbon atom; R¹¹ is hydrogen, or alkyl having from 1 to 8 carbonatoms, unsubstituted or substituted by alkoxy having from 1 to 3 carbonatoms, provided that if substituted by alkoxy R¹¹ must have more than 1carbon atom; and X⁻ is a counterion can be prepared by the scheme shownin Scheme 12. If the compound of formula 41 is not commerciallyavailable, compound 39, 4-chloropyridine hydrochloride, can be used toprepare it via the reaction of step (a). Compound 39 is heated at130-140° C. in a hindered alcohol such as 2-propanol in the presence ofa tertiary amine base such as triethylamine with the compound of formula40 to give the compound of formula 41. Via the reaction of step (b), thecompound of formula 41 is reacted with an alkyl sulfonate such as thecompound of formula 42 in a suitable solvent such as acetone to give thecompound of formula ID, where X⁻ is a counterion such asmethanesulfonate, iodide, bromide, or chloride. Any alkyl iodide oralkyl bromide or alkyl sulfonate derivative of R¹⁰ can be used in thereaction of step (b).

The compound of formula 48, where R¹² is alkyl having from 2 to 16carbon atoms, unsubstituted or substituted by alkoxy having from 4 to 6carbons, can be prepared starting from compound 43,4-hydroxy-3-nitropyridine, by the scheme shown in Scheme 13. Compound 43is reacted with a suitable halogenating agent such as phenylphosphonicdichloride to give compound 44, 4-chloro-3-nitropyridine via thereaction of step (a). Compound 44 is reacted with the compound offormula 45 in the presence of a suitable base such as triethylamine in asuitable solvent such as pyridine to produce the compound of formula 46via the reaction of step (b). Any of the amines described in theinvention can be used in step (b). The nitro group of the compound offormula 46 is reduced to the amino group of the compound of formula 47by catalytic hydrogenation via the reaction of step (c). The compound offormula 47 is heated in triethyl orthoformate to produce the compound offormula 48 via the reaction of step (d). Using the same steps (b), (c),and (d), but starting from commercially available compound 49,2-chloro-3-nitropyridine, the compound of formula 52 is prepared.

Any compound of formula 53 where G is a monocyclic, bicyclic, ortricyclic aromatic ring having one, two, or three ring nitrogen atomswhere a ring nitrogen atom is bonded to hydrogen can react with thecompound of formula 55 where Br-AQXYZ is a primary alkyl bromide toproduce the compound of the formula 54, where AQXYZ is given by claim 1for the compound of formula I, by the scheme shown in Scheme 14. Thecompound of the formula 53 is treated with a strong base such as sodiumtert-butoxide in a suitable solvent such as dimethylformamide, and theresulting amide anion is treated with the compound of formula 55 toproduce the compound of formula 54 via the reaction of step (a). If theamide anion is in resonance with a neighboring nitrogen, the alkylationby the compound of formula 55 occurs at the less hindered nitrogenselectively. The primary alkyl iodide, chloride, alkanesulfonate, orarylsulfonate of AQXYZ can be used in place of the compound of formula55 for the reaction of step (a).

Any compound of formula 58 where G is a monocyclic, bicyclic, ortricyclic aromatic ring having one, two, or three ring nitrogen atoms asdefined in claim 1, where a ring carbon atom is bonded to an NH₂ group,can undergo an alkylation procedure to produce a compound with theformula 59, where A, Q, X, Y, and Z are as defined in claim 1, startingfrom the compound of formula 56, where (AQXYZ) is a radical that isterminated by a primary alcohol group, by the scheme shown in Scheme 15.Many compounds of the formula 58 are available commercially. Thecompound of the formula 56, where the radical (AQXYZ) is terminated by aprimary alcohol function and where (AQXYZ) does not contain anotheralcohol group or an amino group, can undergo oxidation by any of avariety of conventional methods such as the Swern oxidation or oxidationby tetrapropylammonium perruthenate/N-methylmorpholine N-oxide toproduce the compound of formula 57 via the reaction of step (a). Thecompound of formula 58 can undergo reductive alkylation by the compoundof formula 57 via the reaction of step (b) using any conventional methodfor amine reductive alkylation such as by sodium cyanoborohydride intetrahydrofuran. Alternatively, the compound of formula 58 can undergoacylation by the carboxylic acid radical of (AQXYZ) via the reaction ofstep (d) using any conventional method for amide formation such as acarbodiimide condensation or a mixed anhydride acylation using isopropylchloroformate. Also, step (d) can be carried out using the acid chloridederivative of the compound of formula 60, which can be produced usingany conventional reagent for the preparation of acid chlorides such asthionyl chloride or oxalyl chloride. The compound of formula 60 can beproduced from the compound of formula 56 via the reaction of step (c)using any suitable conventional reagent for the oxidation of alcoholssuch as the Jones reagent. The amide group of the compound of formula61, where (AQXYZ) does not contain an ester or another amide group, canbe reduced to the amino group of the compound of formula 59 via thereaction of step (e) using a suitable reducing agent such as lithiumaluminum hydride.

Any compound of formula 58 where G is a monocyclic, bicyclic, ortricyclic aromatic ring having one, two, or three ring nitrogen atoms asdefined in claim 1, where a ring carbon atom is bonded to an NH₂ group,can undergo an alkylation procedure to produce a compound with theformula 59, where A, Q, X, Y, and Z are as defined in claim 1, startingfrom the compound of formula 56, where (AQXYZ) is a radical that isterminated by a primary alcohol group, by the scheme shown in Scheme 16.Many compounds of the formula 58 are available commercially. Thecompound of the formula 56, where the radical (AQXYZ) is terminated by aprimary alcohol function and where (AQXYZ) does not contain anotheralcohol or amino group, can undergo a sulfonylation reaction usingmethanesulfonyl chloride and an amine base such as pyridine ortriethylamine to produce the compound of formula 62 via the reaction ofstep (a). The compound of formula 58 can undergo substitutive alkylationby the compound of formula 62 to produce the compound of formula 59 viathe reaction of step (b) using any conventional method for aminealkylation, such as heating the mixture in tetrahydrofuran ordimethylformamide in the absence or presence of a base such astriethylamine, diisopropylamine, or N-methylmorpholine. Analogs of thecompound of formula 62 where the methanesulfonate group is replaced by aconventional good leaving group such as iodide, bromide, chloride, or adifferent sulfonate group can be used in step (b).

Uses and Methods of Treatment

This invention provides certain compounds, described below, for treatingdiseases characterized by pathogenic cells featuring lysosomes or otheracidic vacuoles with disease-related alterations predisposing them toaccumulation of compounds of the invention, which then selectivelyinactivate or eliminate such pathogenic cells. Compounds of theinvention, many of which are aminoquinoline and aminoquinazolinederivatives, feature significant improvements in potency and activityover known aminoquinoline drugs such as chloroquine, as a consequence ofstructural moieties that potently disrupt lysosomal or vacuolar membraneintegrity when the compounds accumulate in acidic vacuoles in cells.Diseases that are at least moderately responsive to antimalarialquinoline derivatives and analogs are in general more effectivelytreated with compounds of the invention. Such diseases broadly compriseinflammatory diseases, neoplastic diseases, including both hematologiccancers and solid tumors, and infections by eukaryotic pathogens,including fungi and several classes of protozoal or other unicellularparasites.

Anti-Inflammatory Use

An important action of compounds of the invention is anti-inflammatoryactivity, providing utility for treating or preventing diseases orsymptoms related to excessive tissue inflammation. This invention alsoprovides compositions containing a compound of this invention as well asthe use of a compound of this invention for the manufacture of amedicament for treatment or prevention of inflammatory diseases.Compounds of the invention display selectivity for suppressing orinactivating macrophages that have been stimulated into apro-inflammatory state, with less of an effect on non-stimulatedmacrophages. Activated pro-inflammatory macrophages contribute topathogenesis of a large variety of inflammatory and autoimmune diseases.Macrophages are both antigen presenting cells and effectors for tissuedamage directed by autoreactive T cells, and participate in tissuedamage and dysfunction in diseases including but not limited torheumatoid arthritis, systemic lupus erythematosis, psoriasis,inflammatory bowel disease, and atopic dermatitis. Inflammatorymacrophages participate in many systemic diseases, including autoimmunediseases, cardiovascular and metabolic diseases, and neurodegenerativeconditions. Activated macrophages play a primary role in tissue damagein instability of atherosclerotic plaques, with consequent risk ofrupture and thrombotic vessel occlusion. Activated macrophages inadipose tissue contribute to metabolic abnormalities including insulinresistance, type 2 diabetes and other consequences of obesity.Osteoclasts are macrophage-like cells that mediate bone degeneration inosteoporosis and in participate in bone destruction and “bone pain” incancers arising in or metastasized to bones. Compositions of theinvention are useful for treating these and other disorders in whichactivated macrophages contribute to inflammatory disease pathogenesis.

Several classes of topical agents are used for treatment of inflammatorydiseases of the skin, such as atopic dermatitis, eczema or psoriasis.Corticosteroids are widely used, but have the potential for both localand systemic toxicities, particularly with prolonged use. They can causelocal skin atrophy or thinning, which may lead to disruption of theskin, as well as telangiectasia. Furthermore, topical corticosteroidscan be absorbed systemically in amounts sufficient to cause systemicside effects. A second class of agents for treatment of atopicdermatitis is T cell immunosuppressants, such as the calcineurininhibitors tacrolimus and pimecrolimus. Their local and systemicimmunosuppressive effects have led to concerns about depressingimmunosurveillance of cancers, including melanomas and lymphomas.

Vitamin D analogs, notably calcipotriene, are known for topicaltreatment of psoriasis. Calciptoriene acts by inhibiting excessiveproliferation of keratinocytes. Application to normal skin iscontra-indicated due to a bleaching effect and there is also apossibility of adverse events from systemic absorption. Dermalirritation or itching is known as a side effect of calcipotriene.Compounds of the invention are particularly active against macrophageprecursors that have been activated by exposure to vitamin D3. It ispossible that psoriasis treatment with calcipotriene, while providingsome improvements by inhibiting keratinocyte proliferation, may alsodirect local macrophages toward a pro-inflammatory state, contributingto known side effects such as irritation, and limiting the nettherapeutic effect. The ability of compounds of the invention toinactivate pro-inflammatory vitamin D3-primed macrophage precursors asshown in several Examples below indicates that combination topicaltreatment with compounds of the invention and vitamin D analogs mayprovide unexpected benefits in psoriasis and psoriatic dermatitis, bothin treating the inflammatory epidermal hyperproliferation and inreducing irritation or itching as side effects of vitamin D analogs.

Compounds of the invention are useful for treating ocular inflammation,including keratitis, whether caused by infection (fungal, bacterial,amoebic) or by non-infectious triggers such as corneal injury or contactlenses. Compounds of the invention are especially suitable for fungalkeratitis, counteracting both infectious fungi and concurrentinflammatory damage. Compounds of the invention inhibit cornealangiogenesis and other inflammatory changes in response to mechanical orchemical injury.

Compounds of the invention are useful for treating a variety ofinflammatory or hyperproliferative skin conditions or lesions, includingbut not limited to eczema, atopic dermatitis, psoriasis, and impetigo.Impetigo is a superficial bacterial skin infection with inflammatorydamage to the epidermia; compounds of the invention both suppressinflammation and have direct inhibitory or bactericidal effects on grampositive bacteria, including but not limited to Staphylococcus aureusand Staphylococcus pyogenes, the primary organisms responsible forimpetigo. Compounds of the invention also inhibit pre-neoplastic andneoplastic skin alterations, which often exhibit characteristics of bothinflammation and neoplasia, including but not limited to actinickeratosis, seborrheic keratoses and warts.

Examples E and F demonstrate efficacy of compounds of the invention fortreating skin inflammation and psoriatic dermatitis in established mousemodels of human skin disorders.

Macrophages and related cells types contribute to pathogenesis ofautoimmune diseases involving the adaptive immune system both as antigenpresenting cells and as effectors damaging tissues after inappropriatestimulation by T cells, which secrete interferon gamma and otherinflammatory mediators that recruit and activate macrophages. Compoundsof the invention disrupt antigen presentation by macrophages anddendritic cells, and also inactivate pro-inflammatory effectormacrophages that damage tissues. A general guidance is that compounds ofthe invention are useful for treating chronic or episodic autoimmunediseases where chloroquine, hydroxychloroquine or other antimalarialquinoline analogs display activity in humans or relevant animal models,and are generally more potent and active than the antimalarials ininflammatory and non-malaria infectious diseases. Such diseases includebut are not limited to rheumatoid arthritis, systemic and discoid lupuserythematosis, psoriatic arthritis, vasculitis, Sjogrens syndrome,scleroderma, autoimmune hepatitis, and multiple sclerosis.

Macrophage activation syndrome (MAS) is an acute complication of severalautoimmune diseases, especially in childhood-onset conditions such asidiopathic juvenile arthritis where it affects more than 10% ofpatients, and also in inflammatory bowel diseases. In MAS, macrophagesare over-activated, causing damage to the hematopoietic system andsystemic inflammation; MAS is sometimes lethal. Compounds of theinvention are useful for treatment of MAS, and are optionally deliveredorally or by intravenous injection or infusion.

Example G shows beneficial activity of compounds of the invention whenadministered orally to mice in a model of multiple sclerosis, anautoimmune disease.

For treatment of chronic autoimmune disorders, compounds of theinvention are administered systemically, preferably orally. Fortreatment of acute inflammatory conditions, or flares of autoimmunediseases, intravenous treatment with compounds of the invention is anoptional suitable delivery route.

For oral or intravenous treatment of autoimmune or inflammatorydiseases, compounds of the invention are typically administered in dosesranging from 1 to 1000 milligrams per day, advantageously 100 to 600milligrams per day, in single doses or divided into two or three dosesper day.

Antifungal and Antiparasitic Uses

The compounds of this invention are useful in inhibiting fungal growth,both in vivo and ex vivo. Accordingly this invention also providesmethods and uses for inhibiting the growth of a fungus in a mammaliansubject, for example a human. These methods can be used to treat and toprevent fungal infection. Ex vivo, it is useful to treat surfaces with acompound of this invention to inhibit or prevent fungal growth, or inagriculture or horticulture to prevent or treat fungi that affectvaluable plants. This invention also provides compositions containing acompound of this invention as well as the use of a compound of thisinvention for the manufacture of a medicament for inhibiting the growthof a fungus.

This invention is based, in part, on the finding that the compounds ofthis invention are effective in inhibiting the growth of a variety offungal species, as shown in the biological activity examples below.Without wishing to be bound by theory, it is believed that compounds ofthis disclosure exploit the vulnerability of the fungal acidic vacuole.They are believed to accumulate in acidic vacuoles via cation trapping,and furthermore exert antifungal activity by disrupting the structureand function of the acidic vacuoles.

In accordance with this invention, the growth of fungi generally isinhibited. Examples of fungi that can be inhibited include but are notlimited to Candida, Saccharomyces, Trichophyton, Cryptococcus,Aspergillus, and Rhizopus. In more specific embodiments of thisinvention the fungus is Candida albicans; Candida glabrata;Saccharomyces cerevisiae; Trichophyton rubrum; Cryptococcus neoformans,for example Cryptococcus neoformans serotypes D and A; and Aspergillusfumigatus.

This invention also provides methods of treating and preventingparasitic infections. Due to the capability of compounds of theinvention to enter and accumulate within acidic vacuoles in cells, theyare useful for treating infections due to parasitic microorganisms thatreside within acidic vacuoles in macrophages and other cell types.Tuberculosis (mycobacteria), listeria or staphylococcus (gram positivebacteria), cryptococcus (fungus), and leishmania and trypanosomes(amoebae), Coxiella burnetii (gram negative bacteria), and Plasmodium(some of which cause malaria) are nonlimiting examples of important suchinfectious organisms, in which residence within macrophages can protectthe organisms from cellular or humoral immunity, or reduce the efficacyof drug treatments.

Compounds of the invention, which bear lipophilic moieties and aregenerally partially neutral at physiological pH (7.3), can pass freelyinto acidic vacuoles harboring parasites, and are concentrated andtrapped there due to ionization in the acidic environment (pH 4-6.5).These compounds disrupt the structure and function of acidic vacuoles ashospitable sites for parasites and also have direct antiparasiticactivity, clue to acidic vacuoles within many parasitic organisms.

Parasites whose viability or virulence is dependent on integrity andfunction of an acidic vacuole are also vulnerable to compounds of theinvention, similar to the basis for their antifungal activity. Theacidic vacuole of malaria plasmodia provides an environment forconcentration of compounds of the invention. Similarly, trypanosomeshave a large acidic vacuole which is necessary for utilization ofenvironmental nutrients. Compounds of the invention are useful fortreatment or prevention of malaria and trypanosome infections. Morebroadly, protozoal parasites in general use acidified digestive vacuolesfor acquisition and digestion of food, and are therefore susceptible toantiparasitic actions of compounds of the invention.

The antimalarial drug chloroquine is reported to have antiparasiticactivity against a variety of organisms harbored in acidic vacuoles inhost cells, or which have acidic vacuoles themselves, including but notlimited to tuberculosis mycobacteria, cryptosporidium, leishmania andcryptococcus. In general, chloroquine acts by accumulating in acidicvacuoles via cation trapping. Activity of chloroquine is thus anindicator of likely activity of compounds of the inventions (many ofwhich comprise an aminoquinoline or other heterocycle similar to that ofchloroquine for the purpose of targeting acidic vacuoles), with thedifference that compounds of the invention are substantially more potentand active than is chloroquine, as demonstrated in Cryptococcusneoformans in Example K, where chloroquine produced less than 50% growthinhibition at a concentration of 100 micromolar, whereas many compoundsof the invention produced 100% growth inhibition at much lowerconcentrations. Chloroquine, despite published reports showing that itcan improve survival in animal models of cryptococcosis, displays aceiling of about 40% inhibition of C. neoformans growth in vitro,whereas compounds of the invention are substantially more potent thanchloroquine and can cause 100% inhibition of Cryptococcus growth, due tosuperior disruption of the membranes of acidic vacuoles in which therespective drugs are accumulated.

For treatment of fungal or parasitic infections, compounds of theinvention are administered in vehicles and by routes of administrationappropriate for the nature and location of the infection. For dermal ornail infections, compound of the invention are applied in a topicalformulation which is optionally a lotion, ointment, solution,suspension, or spray. For ocular fungal infections, compounds of theinvention are formulated in eyedrops. For systemic infections, compoundsof the invention are administered orally in tablets, capsules, dragees,solutions or suspensions, or administered systemically by injection insaline, lipid emulsions, liposomes or other standard parenteralvehicles. Lung infections, especially involving organisms residing inalveolar macrophages, are optionally treated via inhalational deliveryof compounds of the invention and suitable excipients known to beacceptable for inhalational drug delivery. For intravenous or oraladministration to treat systemic infections, compounds of the inventionare administered in doses ranging from 10 to 2000 milligrams per day,advantageously 200 to 1000 milligrams per day.

Other classes of antifungal agents in clinical use include inhibitors ofergosterol synthesis (“azole” antifungals including but not limited tofluconazole, ketoconazole, voriconazole, and allylamines including butnot limited to terbinafine), polyene antifungals which act by binding tofungal membrane constituents, especially ergosterol (including but notlimited to amphotericin B or nystatin), echinocandin inhibtors of gluoansynthesis (including but not limited to caspofungin), and other agentsknown as active antifungals in medical practice. Compounds of theinvention act via a distinct mechanism of action versus existingclinically important antifungals and are optionally coadministered withone or more other antifungal agent to improve overall antifungaltreatment. Compounds of the invention are coadministered as separatepharmaceutical formulations, or are optionally formulated into a singlecombined-drug product. A combination of compounds of the inventions withazole antifungals is particularly advantageous as a completely oralregimen for use against cyptoccoccosis, which otherwise generallyrequires amphotericin B injections or infusions for initial induction.Compounds of the invention are also optionally coadministered withamphotericin B. One formulation of amphotericin B involves itsincorporation into lipids comprising the membranes of liposomes. Becausemany of the compounds of the invention bear lipophilic moieties thatinsert into lipid membranes, they are advantageously incorporated intoliposomes, either as single agents or in combination with amphotericin Bor other known polyene antifungal agents.

Anticancer Uses

This invention provides compounds that are useful for systemic treatmentof cancer, based on consistent lysosomal changes characterizing invasivecancers. Lysosomal changes in cancer, including their enlargement andacidification, facilitates survival of cancer cells in acidicextracellular environments and also increase the ability of cancer cellsto invade surrounding tissues, through exocytosis of lysosomal contents,including proteases and polysaccharidases which can degradeextracellular matrix components. However, these stereotyped changes inlysosomal properties can render cancer cells vulnerable tolysosome-disrupting agents with appropriate physicochemical propertiesfor selectively accumulating in and damaging lysosomes in cancer cellsversus normal tissues.

Compounds of the invention accumulate in lysosomes in cancer cells anddisrupt their integrity, thereby displaying potent selective cytotoxicactivity against cancer cells in vivo and in vitro.

Because one major mechanism for cancer cell resistance to a variety ofchemotherapy agents is to sequester them in lysosomes and other acidicvesicular compartments, compounds of the invention are able to restoreor enhance sensitivity of cancer cells to a variety of classes ofanticancer agents, including antimetabolites, tyrosine kinaseinhibitors, anticancer antibodies against growth factor receptors,anthracyclines, platinum compounds, alkylating agents, and antibodies.Compounds of the invention typically do not display toxicitiesoverlapping dose limiting toxicities of most anticancer agents,permitting combination of compounds of the invention with other classesof antineoplastic drugs with a net improvement in efficacy andtherapeutic index.

Cancer cells exposed to sublethal doses of ionizing radiation undergo aprotective response that increases their resistance to subsequentirradiation. A component of this protective response is formation ofenlarged lysosomes or other acidified vacuolar organelles; inhibition ofthe vacuolar ATPase responsible for acidifying lysosomes withbafilomycin A prevents the protective response in sublethally irradiatedcells and sensitizes cancer cells to ionizing radiation Lysosomal damageis a significant mediator of radiation-induced death in cancer cells. Bydisrupting the integrity of lysosomal membranes, compounds of theinvention are useful for reducing resistance of cancer cells totherapeutic ionizing radiation and for potentiating anticancereffectiveness of ionizing radiation therapy. Compounds of the inventionare optionally administered prior to ionizing radiation therapy ofcancer (whether with external irradiation or administration ofantibody-targeted radioisotopes) as radiosensitizers, or they may begiven after irradiation to attack surviving cancer cells undergoingprotective responses to nonlethal irradiation involving production orenlargement of acidic vacuoles.

One mechanism imparting selective survival and proliferation advantagesin some cancers is upregulation of autophagy, a process through whichdamaged organelles or other cell debris are engulfed by autophagosomes,which fuse with lysosomes to digest and recycle constituent molecules.By concentrating in and disrupting lysosomes, compounds of the inventionimpair autophagy in cancer cells, thereby reducing their viability andresistance to other anticancer treatments.

For treatment of cancer, compounds of the invention are administered byoral or intravenous administration in doses of 10 to 2000 milligrams perday. Compounds of the invention are administered as single agents or incombination with other cancer treatments appropriate for a particulartype of cancer, and generally in doses when such agents are used alone,as compounds of the invention will generally not have overlappingtoxicities with other classes of anticancer agents that wouldnecessitate substantial dose reduction.

Pharmaceutical Compositions

This invention provides a pharmaceutical composition comprising abiologically active agent as described herein and a pharmaceuticallyacceptable carrier. Further embodiments of the pharmaceuticalcomposition of this invention comprise any one of the embodiments of thebiologically active agents described above. In the interest of avoidingunnecessary redundancy, each such agent and group of agents is not beingrepeated, but they are incorporated into this description ofpharmaceutical compositions as if they were repeated.

Preferably the composition is adapted for oral administration, e.g. inthe form of a tablet, coated tablet, dragee, hard or soft gelatincapsule, solution, emulsion or suspension. In general the oralcomposition will comprise from 10 to 1000 mg of the compound of thisinvention. It is convenient for the subject to swallow one or twotablets, coated tablets, dragees, or gelatin capsules per day. Howeverthe composition can also be adapted for administration by any otherconventional means of systemic administration including rectally, e.g.in the form of suppositories, parenterally, e.g. in the form ofinjection solutions, or nasally.

The biologically active compounds can be processed with pharmaceuticallyinert, inorganic or organic carriers for the production ofpharmaceutical compositions. Lactose, corn starch or derivativesthereof, talc, stearic acid or its salts and the like can be used, forexample, as such carriers for tablets, coated tablets, dragees and hardgelatin capsules. Suitable carriers for soft gelatin capsules are, forexample, vegetable oils, waxes, fats, semi-solid and liquid polyols andthe like. Depending on the nature of the active ingredient no carriersare, however, usually required in the case of soft gelatin capsules,other than the soft gelatin itself. Suitable carriers for the productionof solutions and syrups are, for example, water, polyols, glycerol,vegetable oils and the like. Suitable carriers for suppositories are,for example, natural or hardened oils, waxes, fats, semi-liquid orliquid polyols and the like.

The pharmaceutical compositions can, moreover, contain preservatives,solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners,colorants, flavorants, salts for varying the osmotic pressure, buffers,coating agents or antioxidants. They can also contain still othertherapeutically valuable substances, particularly anti-inflammatory orantifungal agents (depending on whether an inflammatory disease or afungal infection or cancer are being addressed in a patient) that actthrough mechanisms other than those underlying the effects of thecompounds of the invention.

For treatment of cancer, preferred additional drugs that canadvantageously be coadministered or coformulated with a compound of theinvention comprise orally active anticancer agents. Because compounds ofthe invention act through a unique mechanism not shared by otheranticancer drugs, they are compatible with a large variety of concurrenttherapies, including antimetabolites, anthracyclines, tyrosine kinaseinhibitors, platinum drugs, or alkylating agents. Such agents, whenorally active, are administered or coformulated to deliver quantities ofdrugs determined in previous clinical trials to be effective andadequately tolerated.

For systemic treatment of diseases, including some cancers, inflammatoryconditions and fungal or protozoal infections, compounds of theinvention are optionally administered by intravenous injection orinfusion. For intravenous administration, compounds of the invention aredissolved in suitable intravenous formulations as solutions or in lipidemulsions, using standard excipients known in the art as well-toleratedintravenous formulation ingredients and compositions. Suitable volumesand concentrations are selected for delivery of 10 to 2000 miligrams ofcompounds of the invention per day, depending on the specificrequirements for a compound, and a disease condition as determined inclinical trials.

Compounds of the invention are optionally incorporated into liposomalformulations. The lipophilic moieties of compounds of the inventionpermit their direct incorporation into lipid layers of lipososomes.Liposomes are advantageous in some conditions for intravenousadministration due to improved efficacy and milder infusion reactionsversus nonliposomal formulations. Liposomes are also suitable forinhalational delivery to treat fungal or parasitic infections of thelungs, or inflammation of the lungs and airways. In some embodiments,compounds of the invention are incorporated into liposomal deliveryformulations with other drugs, including but not limited to antifungalagents such as liposomal amphotericin B, or anticancer agents such asliposomal doxorubicin.

For treatment of inflammatory skin conditions or fungal infections ofthe skin or nails, or of nasal passages, compounds of the invention areapplied topically in a pharmaceutically acceptable formulation. Thetopical composition can be in various forms, including, but not limitedto, a solution, spray, gel, hydrogel, lotion, cream, ointment, paste, oran emulsion in the form of liquid suspension, lotion, or cream. Thecomposition can also be applied via a dermal patch, or bandage which canbe applied on the affected area as needed, to provide an extendedexposure of the skin to the medication; in such formulations,appropriate standard topical medicament excipients and vehicles aresuitable for delivering compounds of the invention. Standardconstituents for topical formulations are known in the art and aresuitable as vehciles for compounds of the invention. Ointment bases cancomprise one or more of hydrocarbons (paraffin wax, soft paraffin,microcrystalline wax, or ceresine), absorption bases (wool fat orbeeswax), macrogois (polyethylene glycol), or vegetable oils. Lotionsand creams are water in oil or oil in water emulsions; the oilcomponents can comprise long chain fatty acids, alcohols or esters, andoptional contain biocompatible nonionic surfactants, Compounds of theinvention are incorporated into topical vehicles in concentrationsranging from 0.01% to 5%, preferably 0.02 to 1%. Compounds of theinvention are applied to skin lesions once to three times per day fordurations dependent on the rate of resolution of the condition.

For treatment of some lung infections, including fungal infections orparasites residing in alveolar macrophages, inhalational formulas ofcompounds of the invention are suitable. Excipients and inhalationaldrug delivery devices are known in the art and are useful for deliveringcompounds of the invention to treat lung infections, includingcryptococcus and tuberculosis.

Compounds of the invention are advantageously coformulated with otherantifungal or anti-inflammatory agents for topical or systemicadministration, particularly when both drugs are appropriatelyadministered via the same route and schedule. Compounds of the inventionare compatible with standard formulations and excipients used for othertopical or systemic antifungal or anti-inflammatory agents, includingbut not limited to ointments and tablets or capsules. Advantageous drugcategories for combination in topical anti-inflammatory formulationsinclude corticosteroids, calcineurin inhibitors and vitamin D analogues,and other agents known to have independent therapeutic activity ininflammatory skin conditions.

The invention will be better understood by reference to the followingexamples, which illustrate but do not limit the invention describedherein.

EXAMPLES Chemical Synthesis Examples Example 1N-[8-(Hexyloxy)octyl]quinolin-4-amine

A mixture of 4-chloroquinoline (300 mg, 1.84 mmol),8-(hexyloxy)octan-1-amine (558 mg, 2.44 mmol), and DMAP (260 mg, 2.13mmol) was heated at 135° C. for 3 hr. The mixture was cooled andpartitioned between DCM and 5% Na₂CO₃. The organic phase was dried overNa₂SO₄ and concentrated. FC (10%, 12%, 14% MeOH/DCM step gradient) gave279 mg of product as a solid. Rf 0.26 (10% MeOH/DCM); mp 64.0-65.5° C.(from EA/Hex); ¹H NMR (CDCl₃) δ 8.51 (d, 1H, J=5.2 Hz), 7.94 (d, 1H,J=8.4 Hz), 7.74 (d, 1H, J=8.4 Hz), 7.57 (m, 1H), 7.37 (m, 1H), 6.37 (d,1H, J=5.5 Hz), 5.24 (br s, 1H, NH), 3.39-3.34 (m, 4H), 3.25 (m, 2H),1.73-1.26 (m, 20H), 0.84 (m, 3H).

Example 2 N-(8-Butoxyoctyl)quinolin-4-amine

8-Butoxyoctan-1-ol 60% Sodium hydride in mineral oil (3.5 g, 87.5 mmol)was washed twice with 20 mL of hexanes. Anhydrous DMF (300 mL) wasadded, the mixture was cooled with an ice bath, and 1,8-octanediol (51.2g, 351 mmol) was added. After 1.5 hr, 1-bromobutane (6 g, 43.8 mmol) wasadded slowly. The mixture was warmed to room temperature. After 24 hr,the mixture was concentrated. The residue was taken up in Et₂O (500 mL)and washed with saturated NaHCO₃ and H₂O (400 mL each). The aqueousphases were extracted with Et₂O (3×400 mL). The combined organic phaseswere dried over Na₂SO₄, filtered, and concentrated to give 3.9 gcolorless oil. Rf 0.4 (30% EA/Hex); ¹H NMR (CDCl₃) δ 3.6 (t, 2H),3.4-3.3 (m, 4H), 1.6-1.4 (m, 6H), 1.4-1.2 (m, 10H), 0.9 (t, 3H).

8-Butoxyoctyl methanesulfonate A mixture of 8-butoxyoctan-1-ol (3.99 g,20.2 mmol) and TEA (3.4 mL, 24.2 mmol) in 70 mL of DCM was cooled usingan ice bath. Then, methanesulfonyl chloride (1.87 mL, 24.1 mmol) wasadded. After 2 hr, the mixture was washed with H₂O, saturated NaHCO₃,H₂O, 1M HCl, and H₂O (50 mL each). The organic phase was dried overNa₂SO₄, filtered through a pad of silica gel, and concentrated to give1.3 g of colorless oil.

1-Butoxy-8-iodooctane A mixture of 8-butoxyoctyl methanesulfonate (1.3g, 6.6 mmol) and sodium iodide (1.0 g, 6.7 mmol) in 100 ml of acetonewas heated at reflux for 2 hr. The mixture was cooled, filtered, andconcentrated. The residue was taken up in EA (400 mL) and washed withsaturated NaHCO₃ and brine (100 mL each). The organic phase was driedover Na₂SO₄, filtered, and concentrated to give 1.3 g of yellow liquid.

N-(8-Butoxyoctyl)phthalimide 1-Butoxy-8-iodooctane (6.2 g, 20.2 mmol)and potassium phthalimide (3.73 g, 20.2 mmol) in 50 mL of DMF were mixedat 60-80° C. for 12 hr. The cooled mixture was concentrated, and theresidue was partitioned between EA (3×300 mL) and 5% Na₂S₂O₃, H₂O, andbrine (100 mL each). The combined organic phases were dried over Na₂SO₄,filtered, and concentrated to give 5.2 g of solid. ¹H NMR (CDCl₃) δ 7.8and 7.7 (m, 4H, AA′BB′), 3.6 (t, 2H), 3.4-3.3 (m, 4H), 1.7-1.2 (m, 16H),0.9 (t, 3H).

8-Butoxyoctan-1-amine Hydrazine monohydrate (0.92 mL, 19 mmol) was addedto a mixture of N-(8-butoxyoctyl)phthalimide (5.2 g, 15.9 mmol) and 80mL of EtOH. The mixture was heated at reflux for 2 hr. Then, the mixturewas cooled with an ice bath and stirred vigourously while 200 mL of Et₂Owere added. The precipitate was filtered and washed with Et₂O, and theorganic phases were concentrated to give 3.9 g of amber oil. ¹H NMR(CD₃OD) 3.5-3.4 (m, 4H), 2.9 (t, 2H), 1.7-1.3 (m, 16H), 0.9 (t, 3H).

N-(8-Butoxyoctyl)quinolin-4-amine A mixture of 8-butoxyoctan-1-amine(0.569 mg, 2.89 mmol), 4-chloroquinoline (710 mg, 4.33 mmol), TEA (5 mL,36 mmol), and 0.5 mL of NMP was sealed in a heavy walled glass tube andmixed at 130° C. for 4 days. The mixture was cooled and partitionedbetween EA and 5% Na₂CO₃ and brine, dried over Na₂SO₄, filtered, andconcentrated. Purification by FC (60% EA/Hex+2% TEA) gave 244 mg of oil.¹H NMR (CDCl₃) δ 8.9 (m, 1H, NH), 8.7 (d, 1H), 8.2-8.1 (m, 2H), 7.6 (m,1H), 7.4 (m, 1H), 6.4 (d, 1H), 3.5 (m, 2H), 3.4-3.3 (m, 4H), 1.8 (m,2H), 1.7-1.3 (m, 14H), 0.9 (t, 3H).

Example 3 N-(8-Methoxyoctyl)quinolin-4-amine

8-(Benzyloxy)octan-1-ol A 60% dispersion of sodium hydride in mineraloil (5.38 g, 134 mmol) was washed with hexanes to remove the oil. Whilecooling with an ice bath, a mixture of 1,8-octanediol (24.49 g, 168mmol) in 300 mL of DMF was added slowly. The mixture was allowed to warmto room temperature. After 1 hr, a mixture of benzyl chloride (7.70 mL,66.7 mmol) in 30 mL of DME was added dropwise. After 2 hr, additionalbenzyl chloride (1.00 mL, 8.7 mmol) was added, and the mixture wasstirred overnight. Then, 2 mL of concentrated NH₄OH was added. After 1hr, the volatile components were evaporated. The residue was taken up inEt₂O and thrice washed with 1M HCl and once with brine. The organicphase was dried over anhydrous MgSO₄ and evaporated onto silica gel.SPE, washing with 5% EA/Hex and then eluting with 20% EA/Hex gave 12.19g of the product as a colorless oil. (Eluting with EA gave 12.19 g ofrecovered 1,8-octanediol after recrystallization from EA/Hex.) Rf 0.55(20% EA/Hex).

[(8-Methoxyoctyloxy)methyl]benzene A 60% dispersion of sodium hydride inmineral oil (2.1 g, 52 mmol) was washed with hexanes to remove the oil.While cooling with an ice bath, a mixture of 8-(benzyloxy)octan-1-ol(9.9 g, 42 mmol) in 25 mL of DMF was added slowly. The mixture wasallowed to warm to room temperature. After 1 hr, dimethyl sulfate (4.0mL, 42 mmol) was added, and the mixture was stirred overnight. Themixture was diluted with Et₂O, washed with 1 M HCl, twice with 0.1 MHCl, and brine, dried over MgSO₄, and concentrated. SPE, washing with 1%EA/Hex and then eluting with 10% Et₂O/Hex gave 8.63 g of the product asan oil. Rf 0.62 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.36-7.24 (m, 5H), 4.49(s, 2H), 3.45 (t, 2H, J=6.7 Hz), 3.35 (t, 2H, J=6.7 Hz), 3.32 (s, 3H),1.62-1.50 (m, 4H), 1.40-1.25 (m, 8H).

8-Methoxyoctan-1-ol A mixture of [(8-methoxyoctyloxy)methyl]benzene(8.60 g, 34.4 mmol) and 860 mg of 5% Pd-C in 80 mL of THF was stirredunder an atmosphere of hydrogen for 40 hr. The mixture was placed underan atmosphere of argon and filtered through a pad of Celite, washingwith additional THF. An aliquot was evaporated to dryness forspectroscopy. Rf 0.26 (30% EA/Hex); ¹H NMR (CDCl₃) δ 3.59 (t, 2H, J=6.7Hz), 3.33 (t, 2H, J=6.4 Hz), 3.29 (s, 3H), 1.84 (s, 1H, OH), 1.60-1.45(m, 4H), 1.40-1.25 (m, 8H).

8-Methoxyoctyl methanesulfonate A mixture of 8-methoxyoctan-1-ol (34.3mmol) in 100 mL of THF was cooled by an ice bath. Methanesulfonylchloride (4.50 mL, 57.5 mmol) and TEA (8.30 mL, 59.2 mmol) were added,and a white precipitate formed quickly. After 2 hr, the mixture wasdiluted with EA and washed with H₂O, saturated NaHCO₃, brine, 1M HCl,and brine, and the organic phase was dried over MgSO₄ and concentrated.SPE, washing with 10% EA/Hex and then eluting with 30% EA/Hex gave 7.34g of oil containing 8-methoxyoctyl methanesulfonate and8-methoxyoctan-1-ol in a 9:1 mole ratio, as determined by NMR.8-Methoxyoctyl methanesulfonate had Rf 0.31 (30% EA/Hex); ¹H NMR (CDCl₃)δ 4.19 (t, 2H, J=6.7 Hz), 3.34 (t, 2H, J=6.5 Hz), 3.30 (s, 3H), 2.98 (s,3H), 1.72 (m, 2H), 1.52 (m, 2H), 1.40-1.25 (m, 8H).

N-(8-Methoxyoctyl)phthalimide A 9:1 mixture of 8-methoxyoctylmethanesulfonate and 8-methoxyoctan-1-ol (4.10 g) was taken up in 80 mLof DMF and potassium phthalimide (4.4 g, 24 mmol) was added. The mixturewas heated at 80-100° C. for 4 hr. Then, the mixture was cooled, dilutedwith EA, and washed with H₂O, twice with 0.1M HCl, and brine. Theorganic phase was dried over MgSO₄ and concentrated onto silica gel.SPE, eluting with 30% EA/Hex, gave 4.32 g of the product as a solid. Rf0.50 (30% EA/Hex); ¹H NMR (CDCl₃) δ 7.81 and 7.67 (m, 4H, AA′BB′), 3.64(t, 2H, J=7.3 Hz), 3.32 (t, 2H, J=6.7 Hz), 3.29 (s, 3H), 1.62 (m, 2H),1.50 (m, 2H), 1.40-1.20 (m, 8H).

8-Methoxyoctan-1-amine Hydrazine monohydrate (1.00 mL, 20.6 mmol) wasadded to a mixture of N-(8-methoxyoctyl)phthalimide (4.32 g, 14.9 mmol)in 100 mL of EtOH, and the mixture was heated at reflux for 6 hr, duringwhich a white precipitate formed. Then, the mixture was cooled, 4 mL of6M HCl were added, most of the volatile components were evaporated, 100mL of 0.1M HCl were added, and the mixture was allowed to stand for 30min. The precipitate was filtered and washed twice with 50 mL of 0.1MHCl. The combined filtrate was washed thrice with 50 mL of Et₂O. The pHof the filtrate was adjusted to greater than 10 by adding solid NaOHwhile cooling with an ice bath. The filtrate was extracted with DCM (150mL, 2×100 mL). The organic phases were dried over anhydrous Na₂SO₄ andconcentrated to give 2.17 g of oil. ¹H NMR (CDCl₃) δ 3.30 (t, 2H, J=6.6Hz), 3.27 (s, 3H), 2.62 (m, 2H), 1.53-1.24 (m, 12H), 1.41 (s, 2H, NH ₂).

N-(8-Methoxyoctyl)quinolin-4-amine A mixture of 4-chloroquinoline (3.00mmol), 8-methoxyoctan-1-amine (233 mg, 1.46 mmol), DIEA (0.52 mL, 3.00),and 4 mL of IPA was heated at 135° C. for 16 hr in a sealed tube. Themixture was treated with additional 8-methoxyoctan-1-amine (343 mg, 2.16mmol) and heated for an additional 64 hr. Then, the mixture was treatedwith additional 8-methoxyoctan-1-amine (140 mg, 0.88 mmol) and heatedfor an additional 48 hr. The mixture was cooled and the volatilecomponents were evaporated. The residue was partitioned between EA and5% Na₂CO₃, and the organic phases were washed with brine, dried overanhydrous Na₂SO₄, and concentrated. The product was purified using FC,eluting with 10% and then 15% MeOH/DCM. The product-containing fractionswere concentrated, and the residue was taken up in DCM, washed with 5%Na₂CO₃, dried over anhydrous Na₂SO₄ and evaporated to give 694 mg of theproduct as a solid. Rf 0.26 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.41 (d,1H, J=5.7 Hz), 7.93 (m, 1H), 7.52 (m, 1H), 7.30 (m, 1H), 6.33 (d, 1H,J=5.7 Hz), 6.09 (br s, 1H, NH), 3.31-3.23 (m, 7H), 1.65, (m, 2H), 1.48(m, 2H), 1.33-1.25 (m, 8H).

Example 4 N-[6-(Hexyloxy)hexyl]quinolin-4-amine

6-(Hexyloxy)hexan-1-amine was made starting from 1,6-hexanediolfollowing the method for the preparation of 10-(hexyloxy)decan-1-amine.

6-(Hexyloxy)hexan-1-ol Rf 0.16 (10% EA/Hex); ¹H NMR (CDCl₃) δ 3.59 (m,2H), 3.36 (t, 2H, J=6.7 Hz), 3.35 (t, 2H, J=6.8 Hz), 1.87 (s, 1H, OH),1.56-1.47 (m, 6H), 1.36-1.25 (m, 10H), 0.85 (m, 3H).

6-(Hexyloxy)hexyl methanesulfonate Rf 0.16 (20% EA/Hex); ¹H NMR (CDCl₃)δ 4.21 (t, 2H, J=6.6 Hz), 3.38 (t, 2H, 6.4 Hz), 3.37 (t, 2H, J=6.7 Hz),2.98 (s, 3H), 1.74 (m, 2H), 1.61-1.46 (m, 4H), 1.40-1.37 (m, 4H),1.35-1.24 (m, 6H), 0.87 (t, 3H, J=6.8 Hz).

N-[6-(Hexyloxy)hexyl]phthalimide Rf 0.40 (20% EA/Hex).

6-(Hexyloxy)hexan-1-amine ¹H NMR (CDCl₃) δ 3.36 (m, 2H), 3.35 (t, 2H,J=6.8 Hz), 2.67 (m, 2H), 2.10 (br s, 2H, NH ₂), 1.78-1.19 (m, 16H), 0.85(t, 3H, J=6.8 Hz).

A mixture of 6-(hexyloxy)hexan-1-amine (234 mg, 1.16 mmol),4-chloroquinoline (235 mg, 1.44 mmol) and TEA (0.50 mL, 3.56 mmol) in 1mL of NMP was heated at 160° C. for 16 hr. The mixture was cooled andpartitioned between EA and 5% Na₂CO₃. The organic phases were washedwith brine, dried over Na₂SO₄, and concentrated. SPE, washing with 40%EA/Hex and 4% MeOH/DCM and eluting with 8% MeOH/DCM, gave 137 mg ofproduct as a solid. Rf 0.42 (7.5% MeOH/DCM); mp 41-44° C. (from EA/Hex);¹H NMR (CDCl₃) δ 8.45 (d, 1H, J=5.5 Hz), 7.92 (d, 1H, J=8.4 Hz), 7.86(d, 1H, J=8.4 Hz), 7.55 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.33 (ddd, 1H,J=1.2, 6.9, 8.4 Hz), 6.35 (br s, 1H, NH), 3.37-3.22 (m, 6H), 1.72-1.19(m, 16H), 0.83 (m, 3H).

Example 5 N-(6-Butoxyhexyl)quinolin-4-amine

6-Butoxyhexan-1-ol 60% Sodium hydride in mineral oil (3.56 g, 89 mmol)was washed twice with 20 mL of hexanes. Anhydrous DMF (250 mL) wasadded, the mixture was cooled with an ice bath, and 1,6-hexanediol (41.4g, 351 mmol) was added. After 1.5 hr, 1-bromobutane (4.71 mL, 43.7 mmol)was added slowly. The mixture was warmed to room temperature. After 24hr, the mixture was concentrated. The residue was taken up in Et₂O (500mL) and washed with saturated NaHCO₃ and H₂O (400 mL each). The aqueousphases were extracted with Et₂O (3×400 mL). The combined organic phaseswere dried over Na₂SO₄, filtered, and concentrated to give 6.55 gcolorless oil. Rf 0.4 (30% EA/Hex); ¹H NMR (CDCl₃) δ 3.6 (t, 2H),3.4-3.3 (m, 4H), 1.6-1.4 (m, 6H), 1.4-1.2 (m, 6H), 0.8 (t, 3H).

6-Butoxyhexyl methanesulfonate A mixture of 6-butoxyhexan-1-ol (6.55 g,37.6 mmol) and TEA (5.51 mL, 39.5 mmol) in 100 mL of DCM was cooledusing an ice bath. Then, methanesulfonyl chloride (3.06 mL, 39.5 mmol)was added. After 1.5 hr, the mixture was washed with H₂O, saturatedNaHCO₃, H₂O, 1M HCl, and H₂O (50 mL each). The organic phase was driedover Na₂SO₄, filtered through a pad of silica gel, and concentrated togive 9.24 g of colorless oil. ¹H NMR (CDCl₃) δ 4.2 (t, 2H), 3.4-3.3 (m,4H), 2.9 (s, 3H), 1.7 (m, 2H), 1.6-1.2 (m, 10H), 0.8 (t, 3H).

1-Butoxy-6-iodohexane A mixture of 6-butoxyhexyl methanesulfonate (9.23g, 36.6 mmol) and sodium iodide (5.5 g, 36.6 mmol) in 300 ml of acetonewas heated at reflux for 3 hr. The mixture was cooled, filtered, andconcentrated. The residue was taken up in EA (400 mL) and washed withsaturated NaHCO₃ and brine (100 mL each). The organic phase was driedover Na₂SO₄, filtered, and concentrated to give 10.4 g of yellow liquid.

N-(6-Butoxyhexyl)phthalimide 1-Butoxy-6-iodohexane (10.4 g, 36.6 mmol)and potassium phthalimide (6.78 g, 36.6 mmol) in 300 mL of DMF weremixed at 60-80° C. for 12 hr. The cooled mixture was concentrated, andthe residue was partitioned between EA (3×300 mL) and 5% Na₂S₂O₃, H₂O,and brine (100 mL each). The combined organic phases were dried overNa₂SO₄, filtered, and concentrated to give 7.2 g of solid. ¹H NMR(CDCl₃) δ 7.8 and 7.7 (m, 4H, AA′BB′), 3.6 (t, 2H), 3.4-3.3 (m, 4H),1.7-1.2 (m, 12H), 0.8 (t, 3H).

6-Butoxyhexan-1-amine Hydrazine monohydrate (1.3 mL, 27 mmol) was addedto a mixture of N-(6-butoxyhexyl)phthalimide (6.72 g, 22.2 mmol) and 100mL of EtOH. The mixture was heated at reflux for 16 hr. Then, themixture was cooled with an ice bath and stirred vigourously while 200 mLof Et₂O were added. The precipitate was filtered and washed with Et₂O,and the organic phases were concentrated to give 4.2 g of amber oil. ¹HNMR (CD₃OD) 3.5-3.4 (m, 4H), 2.9 (t, 2H), 1.7-1.3 (m, 12H), 0.9 (t, 3H).

N-(6-Butoxyhexyl)quinolin-4-amine A mixture of 6-butoxyhexan-1-amine(0.5 g, 2.9 mmol), 4-chloroquinoline (711 mg, 4.4 mmol), TEA (5 mL, 36mmol), and 0.5 mL of NMP was sealed in a heavy walled glass tube andmixed at 130° C. for 4 days. The mixture was cooled and partitionedbetween EA and 5% Na₂CO₃ and brine, dried over Na₂SO₄, filtered, andconcentrated. Purification by FC (60% EA/Hex+2% TEA) gave 220 mg ofamber oil. ¹H NMR (CDCl₃) δ 8.4 (d, 1H), 8.3-8.1 (m, 3H), 7.6 (m, 1H),7.4 (m, 1H), 6.4 (d, 1H), 3.5 (m, 2H), 3.4-3.3 (m, 4H), 1.8 (m, 2H),1.7-1.3 (m, 10H), 0.9 (t, 3H).

Alternative Synthesis

6-Butoxyhexan-1-ol 60% Dispersion of sodium hydride in mineral oil (14g, 350 mmol) was washed with two 50 mL portions of Hex, and then driedin vacuo. While cooling with an ice bath, IPA (50 mL) and 1,6-hexanediol(200 g, 1700 mmol) were added cautiously, with gas evolution observable.The mixture was allowed to warm to room temperature, and 1-bromobutane(25.0 mL, 234 mmol) was added. The mixture was warmed at 45° C. for 3days. Then, 6.6 mL of acetic acid were added, and distillation ofvolatile components was carried out until by 90° C. was attained. Theresidue was loaded onto silica gel. Two rounds of SPE (50% EA/Hex) gave36.7 g of pale yellow liquid. Rf 0.40 (50% EA/Hex).

6-Butoxyhexyl methanesulfonate 6-Butoxyhexan-1-ol (36.7 g, 211 mmol) wastaken up in 600 mL of Et₂O cooled by an ice bath. Methanesulfonylchloride (19.8 mL, 253 mmol) and TEA (35.5 mL, 253 mmol) were added,accompanied by immediate precipitate formation. After 1.5 hr, 100 mL ofH₂O were added, and the phases were separated. The aqueous phase wasextracted with EA (2×150 mL), and the organic phases were washed withsaturated NaHCO₃, H₂O, 1M HCl, H₂O, and brine (100 mL each). The organicphases were dried over anhydrous Na₂SO₄, filtered through a pad ofsilica gel, and concentrated to 52.2 g of pale yellow liquid. Rf 0.55;¹H NMR (CDCl₃) δ 4.19 (m, 2H), 3.65-3.34 (m, 4H), 2.97 (s, 3H), 1.72 (m,2H), 1.56-1.50 (m, 4H), 1.50-1.30 (m, 6H), 0.88 (t, 3H); ¹³C NMR (CDCl₃)δ 70.8, 70.7, 70.2, 37.4, 32.0, 29.7, 29.2, 25.8, 25.4, 19.5, 14.0.

1-Butoxy-6-iodohexane A mixture of 6-butoxyhexyl methanesulfonate (52.2g, 207 mmol) and sodium iodide (40 g, 267 mmol) in 400 ml of acetone washeated at reflux for 1 hr. The mixture was cooled, concentrated, andpartitioned between EA (3×300 mL) and H₂O, 5% Na₂S₂O₃, H₂O, and brine(150 mL each). The organic phases were dried over Na₂SO₄ andconcentrated to give the product as a yellow liquid that contained 13mol % of the starting material. ¹H NMR (CDCl₃) δ 3.38-3.35 (m, 4H), 3.16(t, 2H, J=7.0 Hz), 1.80 (m, 2H), 1.58-1.48 (m, 4H), 1.40-1.30 (m, 6H),0.88 (t, 3H, J=7.3 Hz); ¹³C NMR (CDCl₃) δ 70.8, 70.7, 33.6, 32.0, 30.5,29.7, 25.3, 19.5, 14.1, 7.2.

N-(6-Butoxyhexyl)phthalimide Crude 1-butoxy-6-iodohexane and potassiumphthalimide (46 g, 249 mmol) in 300 mL of DMF were mixed at roomtemperature for 41 hr and at 60-80° C. for 24 hr. The cooled mixture wasconcentrated, and the residue was partitioned between EA (3×350 mL) andH₂O, 5% Na₂S₂O₃, H₂O, and brine (100 mL each). The combined organicphases were dried over Na₂SO₄, filtered through a pad of silica gel, andconcentrated. SPE (10% EA/Hex) gave 51.6 g of colorless liquid. Rf 0.38(20% EA/Hex); ¹H NMR (CDCl₃) δ 7.77 and 7.65 (m, 4H, AA′BB′), 3.62 (t,2H, J=7.3 Hz), 3.34-3.31 (m, 4H), 1.63 (m, 2H), 1.52-1.44 (m, 4H),1.35-1.25 (m, 6H), 0.85 (m, 3H); ¹³C NMR (CDCl₃) δ 168.5, 133.9, 132.3,123.2, 70.8, 70.7, 38.0, 31.9, 29.7, 28.7, 26.8, 25.9, 19.4, 14.0.

6-Butoxyhexan-1-amine Hydrazine monohydrate (9.1 mL, 187 mmol) was addedto a mixture of N-(6-butoxyhexyl)phthalimide (51.6 g, 170 mmol) and 900mL of EtOH. The mixture was heated at reflux for 12 hr, and allowed tostand at room temperature for 3 days. Then, 250 mL of volatile materialwas removed by distillation. 1M HCl (200 mL) was added to the still-warmpot residue. After cooling to room temperature, the precipitate wasremoved by filtration, washing with three 200 mL portions of 50% aqueousEtOH. The filtrate was adjusted to pH 10 by adding NaOH pellets,concentrated, and taken up in 800 mL of DCM. The aqueous phase wasseparated, and the organic phase was dried over anhydrous Na₂SO₄ andconcentrated. SPE, washing with DCM and 5% MeOH/DCM and eluting with 8%MeOH/DCM+3% NH₄OH, gave ninhydrin (+) product fractions. The productfractions were concentrated and taken up in DCM. The organic phase wasseparated, dried over anhydrous Na₂SO₄, and concentrated to give 29.1 gof yellow liquid. Rf 0.09 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 3.26 (t, 2H,J=6.6 Hz), 3.25 (t, 2H, J=6.6 Hz), 2.55 (t, 2H, J=6.9 Hz), 1.46-1.38 (m,4H), 1.32 (m, 2H), 1.34 (br s, 2H, NH ₂), 1.26-1.20 (m, 6H), 0.78 (t,3H, J=7.4 Hz); ¹³C NMR (CDCl₃) δ 70.7, 70.6, 42.1, 33.6, 31.8, 29.7,26.7, 26.0, 19.3, 13.8.

N-(6-Butoxyhexyl)quinolin-4-amine 6-Butoxyhexan-1-amine (6.05 g, 34.6mmol) was taken up in 150 mL of 1-pentanol, and 15 mL was removed bydistillation. Tripropylamine (15.8 mL, 82.9 mmol) and 4-chloroquinoline(8.20 g, 50.3 mmol) were added, and the mixture was heated at reflux for25 hr and allowed to stand at room temperature for 2 days. Then, most ofthe volatile components were evaporated, and 30 mL of 1N NaOH and 60 mLof 5% Na₂CO₃ were added. The mixture was extracted with DCM (3×150 mL),and the organic phases were dried over Na₂SO₄ and evaporated onto silicagel. SPE, washing with 50% EA/Hex and eluting with 5% MeOH/DCM+2% TEA,gave a brown oil. Upon cooling below 0° C., the oil solidified. Thesolid was washed with cold 10% EA/Hex and dried in vacuo to give 6.62 gof colorless solid. Rf 0.07 (50% EA/Hex) 0.35 (10% MeOH/DCM); mp62.5-65.0° C.; ¹H NMR (CDCl₃) δ 8.52 (d, 1H, J=5.5 Hz), 7.99 (dd, 1H,J=0.7, 8.4 Hz), 7.77 (dd, 1H, J=0.7, 8.4 Hz), 7.62 (ddd, 1H, J=1.5, 7.0,8.4 Hz), 7.42 (ddd, 1H, J=1.4, 6.9, 8.4 Hz), 6.42 (d, 1H, J=5.5 Hz),5.26 (br s, 1H, NH), 3.41 (t, 2H, J=6.6 Hz), 3.40 (t, 2H, J=6.6 Hz),3.33 (m, 2H), 1.78 (m, 2H), 1.64-1.31 (m, 10H), 0.91 (t, 3H, J=7.3 Hz);¹³C NMR (CDCl₃) δ 150.5, 150.3, 147.8, 129.5, 129.4, 124.9, 119.6,118.8, 98.9, 70.9, 70.8, 43.4, 32.0, 29.9, 29.1, 27.2, 26.2, 19.6, 14.1.

Example 6 N-[10-(Hexyloxy)decyl]quinolin-4-amine

10-(Hexyloxy)decan-1-ol 60% Sodium hydride dispersion in mineral oil(1.08 g, 27 mmol) was washed with hexane. 2-Propanol (150 mL) was added,slowly at first. Then, 1,10-decanediol (31.3 g, 180 mmol) was added, andthe mixture was warmed slightly to attain homogeneity. 1-Bromohexane(2.50 mL, 17.9 mmol) was added dropwise. After being stirred at roomtemperature overnight, the mixture was heated at reflux for 2 hr andthen 100 mL of volatile components were removed by distillation. 1M HCl(10 mL) was added, and then the remainder of the solvent was removed bydistillation. Purification by solid phase extraction, eluting with 12%EA/Hex, gave 1.20 g of 10-(hexyloxy)decan-1-ol as a colorless liquid. Rf0.22 (20% EA/Hex); ¹H NMR (CDCl₃) δ 3.63 (m, 2H), 3.40-3.35 (m, 4H),1.65-1.55 (m, 6H), 1.40-1.20 (m, 18H), 0.87 (m, 3H).

10-(Hexyloxy)decan-1-amine Methanesulfonyl chloride (0.50 mL, 6.39 mmol)was added to a mixture of 10-(hexyloxy)decan-1-ol (1.20 g, 4.65 mmol)and triethylamine (0.98 mL, 6.99 mmol) in 100 mL of DME cooled by an icebath. After 1 hr, the mixture was partitioned between EA (3×100 mL) andH₂O, saturated NaHCO₃, H₂O, 0.1M HCl, and brine (50 mL each), and theorganic phases were dried over Na₂SO₄, filtered through a pad of silicagel, and concentrated. The residue was taken up in 150 mL of acetone,sodium iodide (1.27 g, 8.47 mmol) was added, and the mixture was heatedat reflux for 3 hr. Then, the mixture was cooled, the solvent wasevaporated, and the residue was partitioned between EA (3×100 mL) and 5%Na₂S₂O₃ and H₂O (50 mL of each), and the organic phases were dried overNa₂SO₄, filtered through a pad of silica gel, and concentrated. Theresidue was taken up in 20 mL of NMP and potassium phthalimide (1.66 g,8.97 mmol) was added. After the iodide was consumed, as observed by TLC,the mixture was partitioned between EA (3×100 mL) and 0.1M HCl and brine(50 mL of each), and the organic phases were dried over Na₂SO₄, filteredthrough a pad of silica gel, and concentrated. The residue was taken upin 30 mL of ethanol, hydrazine monohydrate (0.60 mL, 12.5 mmol) wasadded, and the mixture was heated at reflux for 8 hr. Then, the volatilecomponents were evaporated, the residue was partitioned between DCM(3×60 mL) and 5% Na₂CO₃ (50 mL), and the organic phases were dried overNa₂SO₄ and concentrated to give 964 mg of 10-(hexyloxy)decan-1-amine asan oil that solidified upon standing. ¹H NMR (CD₃OD) δ 3.45-3.36 (m,4H), 2.72 (m, 2H), 1.65-1.45 (m, 6H), 1.45-1.25 (m, 18H), 0.89 (m, 3H).

N-[10-(Hexyloxy)decyl]quinolin-4-amine A mixture of10-(hexyloxy)decan-1-amine (256 mg, 1.00 mmol), 4-chloroquinoline (240mg, 1.47 mmol), and a particle of prilled DMAP in 1.5 mL of DIEA wereheated at 150° C. in a sealed tube for 24 hr. The cooled mixture waspartitioned between DCM (3×60 mL) and 5% Na₂CO₃ (50 mL), and the organicphases were dried over Na₂SO₄ and concentrated. Purification by solidphase extraction, washing with 50% EA/Hex and then eluting the productwith 50% EA/Hex+2% TEA, gave 175 mg of the product as a solid. Rf 0.42(50% EA/Hex+0.5% TEA); ¹H NMR (CDCl₃) δ 8.51 (d, 1H, J=5.2 Hz), 7.94(dd, 1H, J=1.0, 8.4 Hz), 7.74 (d, 1H, J=8.2 Hz), 7.57 (ddd, 1H, J=1.5,6.9, 8.4 Hz), 7.36 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 6.37 (d, 1H, J=5.4Hz), 5.23 (br s, 1H, NH), 3.36 (t, 4H, J=6.7 Hz), 3.25 (m, 2H), 1.70 (m,2H), 1.56-1.26 (m, 22H), 0.85 (m, 3H).

Example 7 N-(10-Butoxydecyl)quinolin-4-amine

1-Bromo-10-butoxydecane 60% Sodium hydride dispersion in mineral oil(1.7 g, 42 mmol) was washed with hexane. While cooling with an ice bath,a mixture of 1-butanol (10 mL, 109 mmol) and DMF (40 mL) was added,slowly at first. After gas evolution ceased, a mixture of1,10-dibromodecane (47.1 g, 157 mmol) and 100 mL of DCM and 40 mL of DMFwere added in one portion. The mixture was allowed to come to roomtemperature overnight. Then, the DCM was evaporated, and the residue waspartitioned between EA (3×250 mL) and 0.1M HCl and brine (100 mL each),and the organic phases were dried over Na₂SO₄ and concentrated.Purification by SPE, washing with Hex to recover excess dibromide andthen eluting with 10% EA/Hex gave 10.7 g of 1-bromo-10-butoxydecanecontaminated with 1,10-dibutoxydecane. Rf 0.39 (10% EA/Hex); ¹H NMR(CDCl₃) δ 3.40-3.36 (m, 6H), 1.82 (m, 2H), 1.57-1.47 (m, 4H), 1.41-1.26(m, 14H), 0.89 (m, 3H).

10-Butoxydecan-1-amine A mixture of 1-bromo-10-butoxydecane (21.1 g, 72mmol) and sodium azide (5.1 g, 78 mmol) in 30 mL of DMF was stirred atroom temperature until the bromide was consumed, as observed by TLC. Themixture was partitioned between EA (3×350 mL) and H₂O (3×100 mL) andbrine (100 mL), and the organic phases were dried over Na₂SO₄ andconcentrated. Purification by SPE using 10% EA/Hex gave 19.6 g of theazide product. The azide was taken up in 40 mL of EA and 40 mL of MeOHunder a blanket of argon, 2.0 g of 5% Pd/C were added, and the mixturewas stirred under an atmosphere of hydrogen until the azide wasconsumed, as observed by TLC. The catalyst was removed by filtration andthe volatile components were evaporated. Purification by SPE, washingwith 50% EA/Hex and then eluting with 15% MeOH/DCM+2% TEA, gave 7.0 g of10-butoxydecan-1-amine as a colorless solid. ¹H NMR (CDCl₃) δ 3.40-3.34(m, 4H), 2.55 (m, 2H), 2.1 (br s, 2H, NH ₂), 1.58-1.26 (m, 20H), 0.90(m, 3H).

N-(10-Butoxydecyl)quinolin-4-amine A mixture of 10-butoxydecan-1-amine(312 mg, 1.36 mmol), 4-chloroquinoline (375 mg, 2.30 mmol) and DIEA(0.50 mL, 2.87 mmol) in 3 mL of 2-propanol was heated at 130° C. for 3days and the 160° C. for 1 day. The volatile components were evaporated.The mixture was partitioned between DCM (3×60 mL) and 5% Na₂CO₃ (50 mL),and the organic phases were dried over Na₂SO₄ and concentrated.Purification by long-column FC (10% MeOH/DCM) gaveN-(10-butoxydecyl)quinolin-4-amine. Rf 0.34 (10% MeOH/DCM); ¹H NMR(CDCl₃) δ 8.52 (d, 1H, J=5.4 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.75 (d, 1H,J=8.4 Hz), 7.60 (dd, 1H, J=7.0, 8.2 Hz), 7.39 (dd, 1H, J=6.9, 8.4 Hz),6.39 (d, 1H, J=5.2 Hz), 5.20 (br s, 1H, NH), 3.41-3.35 (m, 4H), 3.28 (m,2H), 1.73 (m, 2H), 1.59-1.28 (m, 18H), 0.89 (m, 3H).

Example 8 N-(5-Methoxypentyl)quinolin-4-amine

1-Bromo-5-methoxypentane MeOH (20 mL) was added drop-wise tohexane-washed sodium hydride (61.8 mmol) while cooling with an ice bath.The mixture was added drop-wise to a mixture of 1,5-dibromopentane(99.44 g, 0.432 mol) and 100 mL of 1:1 MeOH and THF. After 42 hr, mostof the solvent was removed by distillation at room pressure. Then,gentle vacuum distillation gave approximately 20 mL of liquid, which wascomprised of a 1:1 mixture of 1,5-dibromopentane and1-bromo-5-methoxypentane. The pot was partitioned between DCM and H₂O,and the organic phase was dried over MgSO₄ and concentrated bydistillation at room pressure to leave 96 g of a 2.1:1 mixture of1,5-dibromopentane and DCM. The dibromide was retreated with sodiummethoxide. The crude 1-bromo-5-methoxypentane mixtures were combined andseparated by SPE, washing with pentane to recover 1,5-dibromopentane andeluting with 10% Et₂O/pentane to get 8.40 g of colorless liquid afterconcentration by distillation. Rf 0.53 (5% EA/Hex) 0.44 (10% Et₂O/Hex);¹H NMR (CDCl₃) δ 3.4-3.3 (m, 4H), 3.31 (s, 3H), 1.86 (m, 2H), 1.6 (m,2H), 1.3 (m, 2H).

1-Azido-5-methoxypentane A mixture of 1-bromo-5-methoxypentane 2.76 g,15.2 mmol) and sodium azide (1.14 g, 17.5 mmol) in 10 mL of DMF wasstirred at room temperature for 16 hr. Then, the mixture was partitionedbetween Et₂O (3×70 mL) and H₂O (3×50 mL) and brine. The organic phaseswere dried over Na₂SO₄ and the mixture was carried on. Rf 0.36 (10%Et₂O/Hex).

5-Methoxypentan-1-amine A mixture of 1-azido-5-methoxypentane in Et₂Oand 286 mg of 5% Pd-C was stirred under a blanket of hydrogen for 24 hr.The mixture was blanketed with argon and filtered through a pad ofCelite. Most of the Et₂O was removed by distillation at atmosphericpressure. ¹H NMR (CDCl₃) δ 3.35 (t, 2H), 3.3 (s, 3H), 2.6 (m, 2H),1.6-1.3 (m, 6H).

N-(5-Methoxypentyl)quinolin-4-amine A mixture of5-methoxypentan-1-amine, 4-chloroquinoline (900 mg, 5.52 mmol), and DIEA(0.50 mL, 2.87 mmol) was heated at 130° C. in a sealed tube for 24 hr.The mixture was cooled and partitioned between EA and 5% Na₂CO₃ andbrine. The organic phases were dried over anhydrous Na₂SO₄ andconcentrated. SPE, washing with 40% EA/Hex+2% TEA and eluting with 80%EA/Hex+2% TEA, gave a solid. Rf 0.20 (80% EA/Hex+2% TEA); ¹H NMR (CDCl₃)δ 8.46 (d, 1H, J=5.2 Hz), 7.90 (dd, 1H, J=1.0, 8.4 Hz), 7.77 (m, 1H),7.51 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.28 (ddd, 1H, J=1.2, 6.9, 8.1 Hz),6.31 (d, 1H, J=5.4 Hz), 5.55 (m, 1H, NH), 3.30 (t, 2H, J=6.2 Hz), 3.25(s, 3H), 3.20 (m, 2H), 1.65 (p, 2H, J=7 Hz), 1.57-1.42 (m, 4H).

Example 9 N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine

N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine A mixture of8-(hexyloxy)octan-1-amine (479 mg, 2.09 mmol), 4-chloroquinaldine (575mg, 3.25 mmol), and DIEA (1.00 mL, 5.74 mmol) was heated at 140° C. in asealed tube for 4 days. Then, the volatile material was evaporated, andthe residue was purified by FC (7% MeOH/DCM) to give 217 mg ofN-[8-(hexyloxy)octyl]-2-methylquinolin-4-amine. ¹H NMR (CDCl₃) δ 7.87(d, 1H, J=8.4 Hz), 7.67 (d, 1H, J=8.0 Hz), 7.53 (m, 1H), 7.29 (m, 1H),6.26 (s, 1H), 5.10 (m, 1H, NH), 3.35 (t, 4H, J=6.5 Hz), 3.21 (m, 2H),2.57 (s, 3H), 1.73-1.21 (m, 20H), 0.85 (m, 3H).

Example 10 7-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine

7-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine A mixture of8-(hexyloxy)octan-1-amine (537 mg, 2.34 mmol), 4,7-dichloroquinoline(565 mg, 2.85 mmol), DIEA (0.50 mL, 2.87 mmol), and 1 mL of NMP washeated at 140° C. in a sealed tube for 24 hr. Then, the volatilematerial was evaporated, and the residue was purified by SPE (5%MeOH/DCM and then 30% EA/Hex+2% TEA) to give 358 mg of7-chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine. Rf 0.20 (5% MeOH/DCM),0.31 (30% EA/Hex+2% TEA); ¹H NMR (CDCl₃) δ 8.43 (d, 1H, J=5.4 Hz), 7.87(d, 1H, J=2.0 Hz), 7.68 (d, 1H, J=8.9 Hz), 7.22 (dd, 1H, J=2.2, 8.9 Hz),6.30 d, 1H, J=5.4 Hz), 5.46 (t, 1H, J=4.8 Hz, NH), 3.33 (t, 4H, J=6.7Hz), 3.19 (m, 2H), 1.70-1.23 (m, 20H), 0.82 (m, 3H).

Example 11 8-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine

8-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine A mixture of8-(hexyloxy)octan-1-amine (456 mg, 1.99 mmol), 4,8-dichloroquinoline(480 mg, 2.42 mmol), DIEA (0.43 mL, 2.47 mmol), and 1 mL of NMP washeated at 140° C. in a sealed tube for 24 hr. Then, the volatilematerial was evaporated, and the residue was purified by SPE (5%MeOH/DCM and then 30% EA/Hex+2% TEA) to give 338 mg of8-chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine. Rf 0.28 (5% MeOH/DCM),0.38 (30% EA/Hex+2% TEA); ¹H NMR (CDCl₃) δ 8.61 (d, 1H, J=5.5 Hz),7.72-7.64 (m, 2H), 7.26 (m, 1H), 6.41 (d, 1H, J=5.4 Hz), 5.19 (t, 2H,J=4.7 Hz, NH), 3.38-3.33 (m, 4H), 3.26 (m, 2H), 1.76 (m, 20H), 0.85 (m,3H).

Example 12 N-[8-(Hexyloxy)octyl]-7-(trifluoromethyl)quinolin-4-amine

A mixture of 8-(hexyloxy)octan-1-amine (546 mg, 2.38 mmol),4-chloro-7-trifluoromethylquinoline (711 mg, 3.06 mmol), DIEA (0.50 mL,2.87 mmol), and 1 mL of NMP was heated at 140-150° C. in a sealed tubefor 24 hr. Then, the residue was partitioned between EA and 5% Na₂CO₃and brine, and the organic phases were dried over Na₂SO₄ andconcentrated. Purification by SPE failed, but FC (25% EA/Hex) gave 626mg of a yellow oil that solidified upon standing. Rf 0.10 (20% EA/Hex);¹H NMR (CDCl₃) δ 8.53 (d, 1, J=5.4 Hz), 8.19 (s, 1), 7.87 (d, 1, J=8.9Hz), 7.47 (dd, 1, J=1.7, 8.9 Hz), 6.42 (d, 1, J=5.5 Hz), 5.47 (m, 1),3.36-3.32 (m, 4), 3.25 (m, 2), 1.81-1.17 (m, 20), 0.83 (m, 3).

Example 13 N-[8-(Hexyloxy)octyl]-8-(trifluoromethyl)quinolin-4-amine

N-[8-(Hexyloxy)octyl]-8-(trifluoromethyl)quinolin-4-amine A mixture of8-(hexyloxy)octan-1-amine (590 mg, 2.58 mmol),4-chloro-8-(trifluoromethyl)quinoline (780 mg, 3.36 mmol), and DIEA(0.50 mL, 2.86 mmol) in 1 mL of NMP was heated in a heavy walled sealedtube at 140-150° C. for 48 hr. Then, the residue was partitioned betweenEA and 5% Na₂CO₃ and brine, and the organic phases were dried overNa₂SO₄ and concentrated. FC (20% EA/Hex) gave 793 mg of yellow oil. Rf0.28 (20% EA/Hex); ¹H NMR (CDCl₃) δ 8.60 (d, 1, J=5.4 Hz), 7.94 (d, 1,J=8.6 Hz), 7.91 (d, 1, J=7.4 Hz), 7.35 (m, 1), 6.42 (d, 1, J=5.4 Hz),5.23 (m, 1, NH), 3.36 (t, 4, J=6.6 Hz), 3.23 (m, 2), 1.74-1.25 (m, 20),0.85 (m, 3).

Example 14 N-{5-[3-(Hexyloxy)propoxy]pentyl}quinolin-4-amine

3-(Hexyloxy)propan-1-ol One mole of sodium metal was added in portionsto 250 g of 1,3-propanediol cooled by an ice bath and blanketed withargon. After the metal had dissolved, 0.466 mole of 1-iodohexane mixedin 100 mL of DMF was added dropwise. The mixture was allowed to warm toroom temperature overnight. Then, the mixture was warmed to 60° C. for 2hr. Then, the mixture was cooled to room temperature and treated with 10mL of concentrated NH₄OH for 1 hr. Then, the mixture was partitionedbetween EA (3×250 mL) and 1.5 L H₂O+H₃PO₄ (pH ˜10), H₂O, 1M HCl, 2×0.1MHCl, and brine. The organic phases were dried over MgSO₄ andconcentrated. Purification by SPE, washing with 10% EA/Hex and elutingwith 30% EA/Hex, gave 44.2 g of 3-(hexyloxy)propan-1-ol as a pale yellowliquid. Rf 0.28 (30% EA/Hex); ¹H NMR (CDCl₃) δ 3.74 (t, 2H), 3.60 (t,2H, J=5.7 Hz), 3.39 (t, 2H), 2.66 (s, 1H, OH), 1.80 (m, 2H), 1.53 (m,2H), 1.56-1.20 (m, 6H), 0.85 (m, 3H).

3-(Hexyloxy)propyl methanesulfonate was prepared by the method used forthe preparation of 3-phenoxybenzyl methanesulfonate, using 44.2 g of3-(hexyloxy)propan-1-ol, 43 mL of TEA, and 24 mL of methanesulfonylchloride in 540 mL of DCM. The crude material was taken up in 450 mL ofacetone and reacted with 55.7 g of sodium iodide at reflux for 4 hr.Then, the mixture was cooled and diluted with 1 volume of hexanes. Thesolid was filtered, and the filtrate was concentrated. The residue wastaken up in 350 mL of DCM and washed with 5% Na₂S₂O₃ (to remove color)and H₂O. The organic phase was dried over Na₂SO₄ and concentrated togive crude 1-(3-iodopropoxyl)hexane.

1,5-Pentanediol (230 mL) was blanketed with argon, and 22.6 g ofpotassium metal was added in portions. The exothermic evolution of gaswas moderated by cooling with an ice bath. Then, at room temperature, amixture of the crude 1-(3-iodopropoxyl)hexane and 100 mL of DMA wasadded dropwise. After being stirred overnight, unreacted iodide wasobserved by TLC. Sodium hydride (7.4 g) was added in 2-gram portionswith cooling by an ice bath. The mixture was allowed to stir at roomtemperature for 60 hr. Then, the mixture was cooled with an ice bath andneutralized by the addition of concentrated HCl. The mixture waspartitioned between EA and H₂O, and the organic phases were washed with5% Na₂S₂O₃ (to remove color) and brine, dried over Na₂SO₄, andconcentrated. Purification by SPE, washing with 5% EA/Hex and theneluting with 30% EA/Hex, gave 39.0 g of5-[3-(hexyloxy)propoxy]pentan-1-ol as a colorless oil. Rf 0.19 (30%EA/Hex), 0.31 (40% EA/Hex); ¹H NMR (CDCl₃) δ 3.60 (t, 2H, J=6.6 Hz),3.48-3.34 (m, 8H), 1.8 (m, 2H), 1.6-1.5 (m, 4H), 1.5-1.2 (m, 10H), 0.85(t, 3H, J=6.7 Hz).

5-[3-(Hexyloxy)propoxy]pentyl methanesulfonate (51.0 g) was prepared bythe method used for 3-(hexyloxy)propyl methanesulfonate, using 39.0 g of5-[3-(hexyloxy)propoxy]pentan-1-ol, 24.4 mL of TEA, 13.6 mL ofmethanesulfonyl chloride, and 420 mL of DCM. Rf 0.38 (40% EA/Hex); ¹HNMR (CDCl₃) δ 4.23 (t, 2H, J=6.4 Hz), 3.5-3.3 (m, 8H), 2.98 (s, 3H),1.8-1.7 (m, 4H), 1.7-1.4 (m, 6H), 1.4-1.2 (m, 6H), 0.9 (t, 3H).

5-Azidopentyl 3-(hexyloxy)propyl ether (29.3 g) was produced from thereaction of 5-[3-(hexyloxy)propoxy]pentyl methanesulfonate (51 g) andsodium azide (11.3 g) in 80 mL of DMF at room temperature following themethod used for 8-(3-ethoxypropoxyl)octan-1-amine. Rf 0.20 (5% EA/Hex);¹H NMR (CDCl₃) δ 3.4-3.3 (m, 8H), 3.22 (t, 2H), 1.7 (m, 2H), 1.6-1.2 (m,14H), 0.84 (t, 3H).

5-[3-(Hexyloxy)propoxy]pentan-1-amine (26.4 g) was prepared from5-azidopentyl 3-(hexyloxy)propyl ether using LAH by the method used toprepare [4-(hexyloxy)phenyl]methanamine. ¹H NMR (CDCl₃) δ 3.5-3.3 (m,8H), 2.65 (t, 2H, J=6.4 Hz), 1.8 (m, 2H), 1.7-1.2 (m, 14H), 0.84 (t, 3,J=6.8 Hz).

N-{5-[3-(Hexyloxy)propoxy]pentyl}quinolin-4-amine A mixture of5-[3-(hexyloxy)propoxy]pentan-1-amine (482 mg, 1.97 mmol),4-chloroquinoline (345 mg, 2.12 mmol), DIEA (0.80 mL, 4.59 mmol), and 2mL of NMP were heated at 160° C. for 3 days in a sealed tube. Then, themixture was cooled, the volatile material was evaporated, the residuewas partitioned between DCM and 5% Na₂CO₃, and the organic phase wasdried over Na₂SO₄ and concentrated. SPE, washing with 50% EA/Hex andthen eluting with 60% EA/Hex+2% TEA, gave 502 mg ofN-{5-[3-(hexyloxy)propoxy]pentyl}quinolin-4-amine as an amber oil. Rf0.20 (60% EA/Hex+2% TEA); ¹H NMR (CDCl₃) δ 8.48 (d, 1H, J=5.4 Hz), 7.91(dd, 1H, 1.2, 8.4 Hz), 7.76 (m, 1H), 7.54 (ddd, 1H, J=1.2, 6.9, 8.4 Hz),7.32 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 6.34 (d, 1H, J=5.4 Hz), 5.42 (t, 1H,J=5.0 Hz), 3.46-3.20 (m, 10H), 1.83-1.39 (m, 10H), 1.31-1.15 (m, 6H),0.81 (m, 3H).

Example 15 N-{3-[5-(Hexyloxy)pentyloxy]propyl}quinolin-4-amine

N-{3-[5-(Hexyloxy)pentyloxy]propyl}quinolin-4-amine (426 mg) was made bya method analogous to that used for the preparation ofN-{5-[3-(hexyloxy)propoxy]pentyl}quinolin-4-amine, but the two diolswere reacted in the reverse sequence. Rf 0.18 (60% EA/Hex+2% TEA); ¹HNMR (CDCl₃) δ 8.47 (d, 1H, J=5.5 Hz), 7.90 (dd, 1H, J=0.7, 8.4 Hz), 7.70(m, 1H), 7.54 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.32 (ddd, 1H, J=1.2, 6.9,8.4 Hz), 6.30 (d, 1H, J=5.4 Hz), 6.19 (m, 1H), 3.57 (m, 2H), 3.44-3.24(m, 8H), 1.96 (m, 2H), 1.86-1.16 (m, 14H), 0.81 (m, 3H).

Example 16 N-[8-(3-Ethoxypropoxyl)octyl]quinolin-4-amine

1-Bromo-8-(3-ethoxypropoxy)octane 60% Dispersion of sodium hydride inmineral oil (1.4 g, 35 mmol) was washed twice with 20 mL of hexane.Anhydrous NMP (50 mL) and DME (50 mL) were added, the mixture was cooledwith an ice bath, and 3-ethoxy-1-propanol (2.00 mL, 17.4 mmol) wasadded. After evolution of gas ceased, 1,8-dibromooctane (25.7 mL, 139mmol) was added in one portion. After 16 hr at room temperature, themixture was heated at reflux for 1.5 hr. Then, the volatile componentswere evaporated, and the residue was diluted with 150 mL of H₂O andextracted with DCM (2×25 mL). The combined organic phases were washedwith 0.05M HCl, dried over anhydrous MgSO₄, and concentrated. SPE,washing with hexane to recover 1,8-dibromooctane and then eluting with10% EA/Hex, gave 4.15 g of 1-bromo-8-(3-ethoxypropoxyl)octane. Rf 0.28(10% EA/Hex); ¹H NMR (CDCl₃) δ 3.50-3.31 (m, 10H), 1.88-1.77 (m, 4H),1.56-1.38 (m, 10H), 1.17 (t, 3H, J=6.9 Hz).

1-Azido-8-(3-ethoxypropoxyl)octane 1-Bromo-8-(3-ethoxypropoxyl)octane(4.15 g, 14.1 mmol) was taken up in 50 mL of DMF, and sodium azide (1.09g, 16.8 mmol) and catalytic sodium iodide were added. After 88 hr, themixture was partitioned between EA (150 mL) and H₂O (50 mL), and theorganic phase was washed with brine (50 mL), dried over Na₂SO₄, andconcentrated. FC (5% EA/Hex) gave 2.55 g of colorless liquid. Rf 0.37(10% EA/Hex); ¹H NMR (CDCl₃) δ 3.50-3.42 (m, 6H), 3.38 (t, 2H, J=6.7Hz), 3.24 (t, 2H, J=6.9 Hz), 1.82 (m, 2H), 1.64-1.49 (m, 4H), 1.31 (brm, 8H), 1.18 (t, 3H, J=6.9 Hz).

8-(3-Ethoxypropoxyl)octan-1-amine 1-Azido-8-(3-ethoxypropoxyl)octane(2.55 g, 9.84 mmol) was taken up in 100 mL of EA. The mixture was placedunder an atmosphere of argon, 10% Pd/C (200 mg) was added, and the argonwas replaced by hydrogen. When the starting material was consumed, asobserved by TLC, the hydrogen was replaced by argon, and the mixture wasfiltered through Celite, washing with EA. The filtrate was concentratedto give 1.0 g of yellow oil. ¹H NMR (CDCl₃) δ 3.6-3.3 (m, 8H), 2.6 (m,1H), 2.4 (m, 1H), 1.8 (m, 2H), 1.7-1.1 (m, 15H).

N-[8-(3-Ethoxypropoxy)octyl]quinolin-4-amine A mixture of8-(3-ethoxypropoxyl)octan-1-amine (1.0 g, 4.4 mmol), 4-chloroquinoline(1.46 g, 9.0 mmol), TEA (4.0 mL, 28 mmol), and 0.2 mL of NMP was sealedin a heavy walled glass tube and mixed at 130° C. for 4 days. Themixture was cooled and partitioned between EA and 5% Na₂CO₃ and brine,dried over Na₂SO₄, filtered, and concentrated. Purification by FC (60%EA/Hex+2% TEA) gave 147 mg of amber oil. ¹H NMR (CDCl₃) δ 8.4 (d, 1H),8.1-7.9 (m, 2H), 7.6 (m, 1H), 7.4 (m, 1H), 6.4 (d, 1H), 6.2 (br s, 1H,NH), 3.6-3.3 (m, 10H), 1.9-1.7 (m, 6H), 1.6-1.2 (m, 8H), 1.2 (m, 3H).

Example 17 N-[8-(2-Propoxyethoxyl)octyl]quinolin-4-amine

N-[8-(2-Propoxyethoxyl)octyl]quinolin-4-amine (550 mg) was made usingethylene glycol monopropyl ether (2.00 mL, 17.5 mmol), 1,8-dibromooctane(25.7 mL, 139 mmol), and 4-chloroquinoline (1.42 g) using the method forthe preparation of N-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine.

1-Bromo-8-(2-propoxyethoxyl)octane: Rf 0.29 (10% EA/Hex); 3.55 (br s,4H, A₂B₂), 3.46-3.34 (m, 6H), 1.81 (m, 2H), 1.65-1.52 (m, 4H), 1.42-1.30(m, 8H), 0.88 (t, 3H, J=7.4 Hz).

1-Azido-8-(2-propoxyethoxyl)octane: Rf 0.37 (10% EA/Hex); 3.55 (br s,4H, A₂B₂), 3.43 (t, 2H, J=6.7 Hz), 3.40 (t, 2H, J=6.8 Hz), 3.22 (m, 2H,J=6.9 Hz), 1.65-1.52 (m, 6H), 1.29-1.20 (m, 8H), 0.88 (t, 3H, J=7.4 Hz).

N-[8-(2-Propoxyethoxyl)octyl]quinolin-4-amine: ¹H NMR (CDCl₃) δ 8.3 (m,2H), 8.1 (d, 1H), 7.6 (m, 1H), 7.4 (m, 2H), 6.4 (d, 1H), 3.55 (br s, 4H,A₂B₂), 3.45-3.35 (m, 6H), 1.8 (m, 2H), 1.6-1.2 (m, 12H), 0.9 (t, 3H).

Example 18 N-[8-(Benzyloxy)octyl]quinolin-4-amine

8-(Benzyloxy)octan-1-amine (880 mg) was prepared from8-(benzyloxy)octan-1-ol (4.23 g) following the method used in thepreparation of 10-(hexyloxy)decan-1-amine.

A mixture of 8-(benzyloxy)octan-1-amine (235 mg, 1.00 mmol),4-chloroquinoline (201 mg, 1.23 mmol), DIEA (0.50 mL, 2.87 mmol), and 2mL of IPA was heated in a heavy walled glass tube at 150° C. for 4 days.The mixture was cooled and partitioned between DCM and 5% Na₂CO₃, andthe organic phase was dried over Na₂SO₄, and concentrated. SPE, washingwith 3% MeOH/DCM and eluting with 8% MeOH/DCM, gave 150 mg of theproduct as a yellow oil. Rf 0.13 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.49(d, 1H, J=5.4 Hz), 7.97 (d, 1H, J=8.4 Hz), 7.86 (d, 1H, J=8.4 Hz), 7.58(ddd, 1H, J=1.2, 7.0, 8.5 Hz), 7.40-7.21 (m, 6H), 6.38 (d, 1H, J=5.4Hz), 5.68 (m, 1H), 4.48 (s, 2H), 3.44 (t, 2H, J=6 Hz), 3.27 (m, 2H),1.75-1.52 (m, 4H), 1.37-1.32 (m, 8H).

Example 19 N-(6-Phenoxyhexyl)quinolin-4-amine

N-(6-Phenoxyhexyl)quinolin-4-amine (188 mg) was prepared starting from1,6-dibromohexane (4.25 mL) and phenol (326 mg) following the methodused for the preparation of N-(8-phenoxyoctyl)quinolin-4-amine.

(6-Bromohexyloxy)benzene (409 mg): Rf 0.46 (5% EA/Hex); ¹H NMR (CDCl₃) δ7.3 (m, 2H), 6.9 (m, 3H), 4.0 (m, 2H), 3.4 (m, 2H), 2.0-1.7 (m, 4H),1.6-1.4 (m, 4H).

(6-Azidohexyloxy)benzene (344 mg): ¹H NMR (CDCl₃) δ 7.3 (m, 2H), 6.9 (m,3H), 4.0 (m, 2H), 3.28 (t, 2H, J=6.8 Hz), 1.8 (m, 2H), 1.7-1.4 (m, 6H).

6-Phenoxyhexan-1-amine (224 mg): ¹H NMR (CDCl₃) δ 7.3 (m, 2H), 6.9 (m,3H), 3.91 (t, 2H, J=6.4 Hz), 2.6 (m, 2H), 1.8-1.3 (m, 8H).

N-(6-Phenoxyhexyl)quinolin-4-amine: Rf 0.15 (50% EA/Hex+2% TEA); ¹H NMR(CDCl₃) δ 8.53 (d, 1H, J=5.2 Hz), 7.97 (m, 1H), 7.75 (m, 1H), 7.60 (ddd,1H, J=1.2, 6.9, 8.2 Hz), 7.38 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.30-7.22(m, 2H), 6.95-6.86 (m, 3H), 6.39 (d, 1H, J=5.5 Hz), 5.22 (t, 1H, J=4.7Hz), 3.94 (t, 2H, J=6 Hz), 3.29 (m, 2H), 1.81-1.44 (m, 8H).

Example 20 N-(8-Phenoxyoctyl)quinolin-4-amine

(8-Bromooctyloxy)benzene A mixture of phenol (321 mg, 3.41 mmol),1,8-dibromooctane (5.00 mL, 27.0 mmol), and K₂CO₃ (1.41 g, 10.2 mmol) in6 mL of DMF and 6 mL of 1,2-dimethoxyethane was heated at 90° C. for 24hr. The mixture was cooled and partitioned between ether (3×175 mL) and0.1N NaOH (75 mL) and 1:1 0.1M HCl/brine (75 mL). The organic phaseswere dried over MgSO₄ and concentrated. Purification by FC (5% EA/Hex)gave 533 mg of (8-bromooctyloxy)benzene as a colorless oil. Rf 0.50 (5%EA/Hex); ¹H NMR (CDCl₃) δ 7.31-7.24 (m, 2H), 6.95-6.88 (m, 3H), 3.95 (t,2H, J=6.5 Hz), 3.41 (t, 2H, J=6.8 Hz), 1.91-1.73 (m, 4H), 1.47-1.27 (m,8H).

(8-Azidooctyloxy)benzene (460 mg of a colorless oil) and then8-phenoxyoctan-1-amine (339 mg of a colorless solid) were preparedfollowing the method for 10-butoxydecan-1-amine using 533 mg of(8-bromooctyloxy)benzene and 170 mg of sodium azide.

(8-Azidooctyloxy)benzene: ¹H NMR (CDCl₃) δ 7.33-7.25 (m, 2H), 6.97-6.88(m, 3H), 3.96 (m, 2H), 3.26 (t, 2H, J=7.0 Hz), 1.80 (m, 2H), 1.60 (m,2H), 1.50-1.38 (m, 8H).

8-Phenoxyoctan-1-amine: ¹H NMR (CDCl₃) δ 7.26-7.20 (m, 2H), 6.91-6.84(m, 3H), 3.90 (t, 2H, J=6.4 Hz), 2.63 (m, 2H), 1.74 (m, 2H), 1.5-1.2 (m,10H).

N-(8-Phenoxyoctyl)quinolin-4-amine A mixture of 8-phenoxyoctan-1-amine(339 mg, 1.53 mmol), 4-chloroquinoline (328 mg, 2.01 mmol) and TEA (0.50mL, 3.56 mmol) in 1 mL of NMP was heated at 160° C. for 24 hr. Themixture was cooled and partitioned between EA and 5% Na₂CO₃. The organicphases were washed with brine, dried over Na₂SO₄, and concentrated.Purification by FC (50% EA/Hex+2% TEA) gave 431 mg ofN-(8-phenoxyoctyl)quinolin-4-amine. Rf 0.18 (50% EA/Hex+2% TEA); ¹H NMR(CDCl₃) δ 8.53 (d, 1H, J=5.4 Hz), 7.97 (dd, 1H, J=1.0, 8.4 Hz), 7.74 (m,1H), 7.60 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.39 (ddd, 1H, J=1.5, 6.9, 8.4Hz), 7.30-7.22 (m, 2H), 6.95-6.86 (m, 3H), 6.39 (d, 1H, J=5.4 Hz), 5.17(br s, 1H, NH), 3.93 (t, 2H, J=6.5 Hz), 3.27 (m, 2H), 1.82-1.68 (m, 4H),1.47-1.40 (m, 8H).

Example 21 N-{2-[2-(Hexyloxy)phenoxyl]ethyl}quinolin-4-amine

2-[2-(Hexyloxy)phenoxy]ethanol A mixture of 2-(hexyloxy)phenol (9.10 g,46.9 mmol), ethylene carbonate (6.4 g, 72.7 mmol), and K₂CO₃ (10.0 g,72.5 mmol) in 50 mL of DMF was heated at 70-75° C. for 17 hr and then90° C. for 6 hr. The mixture was cooled, partly neutralized with 1M HCl,and partitioned between EA and 1M HCl, H₂O (2×), and brine. The organicphases were dried over MgSO₄, filtered through a pad of silica gel, andconcentrated to a brown oil. SPE, washing with 10% EA/Hex and theneluting with 37% EA/Hex, gave 10.73 g of pale yellow liquid. Rf 0.15(20% EA/Hex); ¹H NMR (CDCl₃) δ 6.99-6.94 (m, 2H), 6.92-6.87 (m, 2H),4.12 (m, 2H), 4.00 (t, 2H), 3.88 (m, 2H), 2.80 (s, 1H, OH), 1.82 (m,2H), 1.46 (m, 2H), 1.38-1.31 (m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ150.2, 148.6, 122.8, 121.3, 117.2, 113.9, 72.5, 69.3, 61.5, 31.8, 29.4,25.9, 22.8, 14.2.

2-[2-(Hexyloxy)phenoxy]ethyl methanesulfonate The crude2-[2-(hexyloxy)phenoxy]ethanol (10.73 g, 45.1 mmol) was taken up in 170mL of 1,2-dimethoxyethane and cooled by an ice bath. Methanesulfonylchloride (4.90 mL, 62.6 mmol) and then TEA (9.40 mL 67.0 mmol) wereadded. After 2 hr, 5 mL of H₂O were added, and the volatile componentswere evaporated. The residue was partitioned between EA and H₂O,saturated NaHCO₃, H₂O, 1M HCl, H₂O (2×), and brine. The organic phaseswere dried over MgSO₄ and concentrated to give 13.67 g of colorlesssolid. Rf 0.37 (30% EA/Hex); ¹H NMR (CDCl₃) δ 6.99-6.86 (m, 4H), 4.60(m, 2H), 4.25 (m, 2H), 3.98 (m, 2H), 3.16 (s, 3H), 1.78 (m, 2H), 1.46(m, 2H), 1.38-1.30 (m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 149.7,147.9, 122.8, 121.1, 115.5, 113.7, 69.1, 69.0, 67.6, 38.1, 31.8, 29.5,25.9, 22.8, 14.2.

-[2-(Hexyloxy)ethyl]phthalimide A mixture of2-[2-(hexyloxy)phenoxy]ethyl methanesulfonate (13.67 g, 43.2 mmol),potassium phthalimide (15.5 g, 84 mmol), and sodium iodide (610 mg) in50 mL of DMF was heated at 90° C. for 24 hr. The cooled mixture waspartitioned between EA and 5% Na₂CO₃ and brine. The organic phases weredried over Na₂SO₄ and concentrated, and the residue was filtered througha pad of silica gel in 30% EA/Hex and evaporated to give a solid.Recrystallization from EtOH gave 10.4 g of colorless solid. ¹H NMR(CDCl₃) δ 7.85 and 7.72 (m, 4H, AA′BB′), 6.94-6.82 (m, 4H), 4.26 and4.12 (m, 4H, A₂B₂), 3.88 (t, 2H), 1.71 (m, 2H), 1.42-1.27 (m, 6H), 0.90(m, 3H); ¹³C NMR (CDCl₃) δ 168.3, 149.8, 148.6, 134.1, 132.4, 123.5,122.3, 121.1, 115.6, 114.3, 69.3, 66.4, 37.7, 31.8, 29.4, 25.8, 22.8,14.2.

2-[2-(Hexyloxy)phenoxy]ethanamineN-[2-(Hexyloxy)ethyl]phthalimide (10.4g, 28.3 mmol) was taken up in 130 mL of EtOH, and hydrazine monohydrate(2.0 mL, 41 mmol) was added. The mixture was heated at reflux for 16 hr.After heating was halted, 140 mL of 1M HCl was added to the still-warmmixture, and the mixture was stirred vigorously during cooling. Theprecipitate was filtered and washed with EtOH. The filtrate wasconcentrated. SPE, washing with 7% MeOH/DCM and then 7% MeOH/DCM+2% TEAgave fractions containing 6.80 g of oily-solid ninhydrin (+) product. Rf0.40 (5% MeOH/DCM+2% TEA); ¹H NMR (CDCl₃) δ 6.94-6.82 (m, 4H), 4.00 (t,2H, J=5.2 Hz), 3.97 (t, 2H, J=6.7 Hz), 3.05 (t, 2H, J=5.2 Hz), 1.80 (m,2H), 1.54 (br s, 2H, NH ₂), 1.50-1.28 (m, 6H), 0.89 (m, 3H).

N-{2-[2-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine Crude2-[2-(hexyloxy)phenoxy]ethanamine (6.8 g, 28.7 mmol) was taken up in 30mL of DMA, and 25 mL was evaporated in vacuo. The residue was dilutedwith 5 mL of NMP, and 4-chloroquinoline (4.20 g, 25.8 mmol) and DIEA(10.0 mL, mmol) were added. The mixture was heated in a sealed tube at160° C. for 24 hr. Then, the mixture was cooled, partitioned between EAand 5% Na₂CO₃ (3×) and brine. The organic phase was dried over Na₂SO₄and concentrated to give a solid. Trituration with Et₂O and drying gave3.11 g of colorless solid. Rf 0.31 (10% MeOH/DCM); mp 104.5-106.0° C.;¹H NMR (CDCl₃) δ 8.55 (d, 1H, J=5.5 Hz), 8.04 (m, 1H), 7.85 (d, 1H,J=8.4 Hz), 7.66 (ddd, 1H, J=1.4, 6.9, 8.4 Hz), 7.44 (m, 1H), 7.02-6.97(m, 2H), 6.95-6.89 (m, 2H), 6.50 (d, 1H, J=5.5 Hz), 6.00 (br s, 1H, NH),4.37 (t, 2H, J=5.1 Hz), 4.02 (t, 2H, J=6.9 Hz), 3.71 (m, 2H), 1.79 (m,2H), 1.40 (m, 2H), 1.28-1.20 (m, 4H), 0.83 (m, 3H).

Example 22 N-{3-[2-(Hexyloxy)phenoxy]propyl}quinolin-4-amine

2-(Hexyloxy)phenol A mixture of catechol (28.9 g, 263 mmol), K₂CO₃ (37g, 268 mmol), and 1-bromohexane (29.0 mL, 207 mmol) in 130 mL of DMAreacted at room temperature for 20 hr with the aid of mechanicalstirring. TLC of an aliquot showed the presence of a substantial amountof catechol. The mixture was heated at 80° C., and TLC of an aliquotshowed good reaction progress. 1-Bromohexane (5.9 mL, 42 mmol) and K₂CO₃(6 g, 43 mmol) were added, and heating continued for 10 hr. Then, themixture was cooled, and most of the volatile components were evaporated.The residue was partitioned between EA (3×250 mL) and H₂O, 5% Na₂CO₃(2×), H₂O, 0.1M HCl, and brine (200 mL each). The combined organicphases were dried over MgSO₄ and concentrated. SPE (5% EA/Hex) gave 34.8g of a 4:1 mixture of 2-(hexyloxy)phenol and 1,2-bis(hexyloxy)benzene asdetermined by ¹H NMR. A sample was purified by SPE, washing with Hex toobtain the diether, and then eluting 2-(hexyloxy)phenol using 5% EA/Hex.Rf 0.38 (5% EA/Hex); ¹H NMR (CDCl₃) δ 7.0-6.8 (m, 4H), 5.7 (s, 1H), 4.0(t, 2H), 1.9 (m, 2H), 1.5 (m, 2H), 1.4-1.3 (m, 4H), 1.9 (t, 3H).

N-{3-[2-(Hexyloxy)phenoxy]propyl}phthalimide A mixture of2-(hexyloxy)phenol that contained 1,2-bis(hexyloxy)benzene (90 mol %pure, 61.8 g), K₂CO₃ (43.6 g, 316 mmol), andN-(3-bromopropyl)phthalimide (76.9 g, 287 mmol) in 150 mL of DMF washeated at 60° C. for 24 hr with the aid of mechanical stirring. TLC (5%EA, 45% toluene, 50% Hex) of an aliquot showed that substantial bromidestarting material remained, so the temperature was raised to 100° C.After 16 hr, the reaction was completed, as shown by TLC. Then, themixture was cooled, and most of the volatile components were evaporated.The residue was partitioned between EA (3×250 mL) and H₂O neutralizedusing H₃PO₄, 0.1M HCl, H₂O, and brine (200 mL each). The combinedorganic phases were dried over MgSO₄ and concentrated to give 83 g ofthe product as a light tan solid that contained 2-(hexyloxy)phenol and1,2-bis(hexyloxy)benzene, as shown by ¹H NMR. Rf 0.21 (1:9:10EA/toluene/Hex) 0.19 (10% EA/Hex); ¹H NMR (CDCl₃) δ 7.82 and 7.71 (m,4H, AA′BB′), 6.93-6.82 (m, 4H), 4.06 (t, 2H), 3.96-3.88 (m, 4H), 2.19(m, 2H), 1.76 (m, 2H), 1.46-1.24 (m, 6H), 0.87 (m, 3H).

3-[2-(Hexyloxy)phenoxy]propan-1-amine CrudeN-{3-[2-(hexyloxy)phenoxy]propyl}phthalimide was dissolved in 450 mL ofwarm IPA, and hydrazine monohydrate (24.8 mL, 327 mmol) was added. Themixture was heated at 80° C. for 12 hr with the aid of mechanicalstirring, and then the mixture was allowed to stand at room temperaturefor 48 hr. The solid was broken up, diluted with 400 mL of Et₂O, andstirred for 1 hr. The precipitate was filtered and washed with 50%MeOH/Et₂O (2×200 mL). The combined filtrates were concentrated to give73 g of amber liquid. The liquid was taken up in 400 mL of DCM andwashed with 1N NaOH and H₂O (100 mL each). The organic phase wasconcentrated. The mixture was separated by SPE. Elution with 1% MeOH/DCMgave 20 g of a mixture of 2-(hexyloxy)phenol and1,2-bis(hexyloxy)benzene. Then, elution with 7% MeOH/DCM+2% NH₄OH gavethe product. The partially concentrated fractions were washed with 200mL of H₂O, the water phase was extracted with 150 mL of DCM, and thecombined organic phases were dried over Na₂SO₄, filtered, andconcentrated to give 33.6 g of an amber liquid. Rf 0.06 (5% MeOH/DCM,ninhydrin (+)); ¹H NMR (CDCl₃) δ 6.91-6.87 (m, 4H), 4.09 (t, 2H), 3.98(t, 2H, J=6.6 Hz), 2.93 (t, 2H), 1.95 (q, 2H), 1.80 (m, 2H), 1.50-1.31(m, 6H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 121.5, 121.2, 114.4, 114.1,69.3, 67.9, 40.0, 33.4, 31.8, 29.5, 25.9, 22.8, 14.2.

N-{3-[2-(Hexyloxy)phenoxy]propyl}quinolin-4-amine3-[2-(Hexyloxy)phenoxy]propan-1-amine (28.4 g, 113 mmol) was taken up in230 mL of 1-pentanol, and 70 mL of volatile material was removed bydistillation in order to ensure anhydrous conditions. The mixture wasallowed to cool below reflux temperature, and tripropylamine (43 mL, 226mmol) and 4-chloroquinoline (23.9 g, 147 mmol) were added. Heating atreflux was resumed. After 15 hr, TLC of an aliquot indicated noninhydrin (+) starting material remained. After stifling at roomtemperature for 48 hr, 120 mL of volatile material was removed bydistillation. The cooled mixture was diluted with 350 mL of DCM andwashed with 2N NaOH, H₂O, and 5% Na₂CO₃ (100 mL each). The aqueousphases were extracted in turn with 350 mL of DCM. The combined organicphases were dried over Na₂SO₄, filtered, and concentrated. Purificationby FC, eluting with a step gradient of 40, 50, and 60% EA/Hex+2% TEA,gave pure product fractions, as shown by TLC and NMR. The productmixture was concentrated, taken up in EA, washed with 5% Na₂CO₃ andbrine, dried over Na₂SO₄, filtered, and concentrated to give a yellowoil. Standing under Et₂O and cooling using an ice bath gave a colorlessprecipitate. The precipitate was collected by filtration and washed withice-cold Et₂O to give 33.9 g of the product after drying in vacuo. mp61.0-62.0° C.; ¹H NMR (CDCl₃) δ 8.55 (d, 1H, J=5.1 Hz), 7.95 (dd, 1H,J=0.8, 8.5 Hz), 7.84 (dd, 1H, J=1.1, 8.4 Hz), 7.60 (m, 1H), 7.35 (m,1H), 6.98-6.87 (m, 4H), 6.44 (d, 1H, J=5.5 Hz), 5.98 (t, 1H, J=4.4 Hz,NH), 4.21 (t, 1H, J=5.5 Hz), 4.02 (t, 2H), 3.58 (m, 2H), 2.27 (m, 2H),1.75 (m, 2H), 1.40 (m, 2H), 1.27-1.21 (m, 4H), 0.84 (m, 3H); ¹³C NMR(CDCl₃) δ 151.2, 150.1, 149.6, 148.7, 148.6, 130.0, 129.0, 124.5, 122.3,121.1, 120.2, 119.2, 115.2, 113.8, 98.7, 69.2, 69.2, 42.1, 31.6, 29.3,28.5, 25.8, 22.7, 14.1.

Example 23 N-{4-[2-(Hexyloxy)phenoxy]butyl}quinolin-4-amine

N-(4-Bromobutyl)phthalimide A mixture of 1,4-dibromobutane (22 mL, 185mmol) and potassium phthalimide (11.35 g, 61.4 mmol) in 60 mL of DMF wasmixed at room temperature for 1 day. Then, the reaction mixture wasextracted with hexane (3×150 mL). The hexane fractions were dried overMgSO₄, filtered, and concentrated to give 30 g of a 1:2.2 molar mixtureof recovered 1,4-dibromobutane and DMF. This mixture was diluted with 30mL of DMF and retreated with potassium phthalimide (4.80 g, 26 mmol) atroom temperature for 1 day. The two reaction mixtures in DMF werepartitioned between 1:1 EA/Hex (3×150 mL) and H₂O (2×100 mL), 0.1M HCl(100 mL), and brine (100 mL). The organic phases were dried over MgSO₄and concentrated. SPE, eluting with 0% and 10% EA/Hex, gave 17.3 g ofcolorless solid. Rf 0.55 (40% EA/Hex); ¹H NMR (CDCl₃) δ 7.86-7.81 (m,2H), 7.73-7.69 (m, 2H), 3.71 (t, 2H), 3.43 (t, 2H), 1.94-1.80 (m, 4H);¹³C NMR (CDCl₃) δ 168.5, 134.2, 132.3, 123.5, 37.2, 32.9, 30.1, 27.4.

N-{4-[2-(Hexyloxy)phenoxy]butyl}phthalimide A mixture ofN-(4-bromobutyl)phthalimide (17.3 g, 61.3 mmol), 2-(hexyloxy)phenol(14.9 g, 61 mmol), and K₂CO₃ (9.5 g, 69 mmol) in 80 mL of DMF was heatedat 80° C. for 20 hr. Then, the mixture was cooled, partitioned between40% EA/Hex (3×300 mL) and 0.25M HCl (340 mL), H₂O, 0.1M HCl, and brine(150 mL each), dried over MgSO₄, concentrated, filtered through a pad ofsilica gel with 40% EA/Hex, and concentrated to give 25.7 g of paleyellow solid.

4-[2-(Hexyloxy)phenoxy]butan-1-amine CrudeN-{4-[2-(hexyloxy)phenoxy]butyl}phthalimide was taken up in 400 mL ofIPA, and hydrazine monohydrate (4.40 mL, 91 mmol) was added. The mixturewas heated at 80° C. for 12 hr. Then, the mixture was cooled, resultingin precipitation. Et₂O (400 mL) was added, and the heterogeneous mixturewas stirred vigorously. The precipitate was removed by filtrationthrough Celite, and the precipitate was washed with Et₂O (4×150 mL). Thevolatile components were evaporated to leave 14.2 g of colorless solid.¹H NMR (CDCl₃) δ 6.88-6.83 (m, 4H), 3.98 (t, 2H, J=6.2 Hz), 3.96 (t, 2H,J=6.7 Hz), 2.77 (t, 2H, J=6.9 Hz), 2.17 (br s, 2H), 1.89-1.74 (m, 4H),1.64 (m, 2H), 1.50-1.23 (m, 6H), 0.89 (m, 3H).

N-[4-{2-(Hexyloxy)phenoxy]butyl}quinolin-4-amine Crude4-[2-(hexyloxy)phenoxy]butan-1-amine (14.2 g, 53.6 mmol) was taken up in400 mL of 1-pentanol, and 100 mL was removed by distillation. Themixture was cooled below boiling, and tripropylamine (15 mL, 78.7 mmol)and 4-chloroquinoline (8.75 g, 53.7 mmol) were added. Heating at refluxwas resumed for 18 hr. Then, the mixture was concentrated bydistillation. SPE, washing with 50% EA/Hex and then eluting with 10%MeOH/DCM gave a brown oil after concentration. The oil was taken up inDCM and washed with 5% Na₂CO₃, dried over Na₂SO₄, and concentrated.Purification by FC (60% EA/Hex+2% TEA), evaporation of solvents from theproduct fractions, and then evaporation of MeOH and drying gave 3.7 g ofthe product as a colorless solid. ¹H NMR (CDCl₃) δ 8.53 (d, 1H, J=5.5Hz), 7.95 (dd, 1H, J=0.7, 8.4 Hz), 7.74 (m, 1H), 7.59 (ddd, 1H, J=1.1,7.0, 8.1 Hz), 7.33 (m, 1H), 6.97-6.88 (m, 4H), 6.43 (d, 1H, J=5.2 Hz),5.63 (t, 1H, NH), 4.11 (t, 1H), 4.00 (t, 2H), 3.49 (m, 2H), 2.01-1.94(m, 4H), 1.74 (m, 2H), 1.39 (m, 2H), 1.23-1.16 (m, 4H), 0.80 (m, 3H);¹³C NMR (CDCl₃) δ 151.3, 150.0, 149.5, 148.8, 148.8, 130.1, 129.1,124.6, 121.8, 121.1, 119.8, 119.1, 114.4, 113.7, 98.8, 69.2, 69.2, 42.8,31.7, 29.4, 26.8, 25.9, 25.8, 22.8, 14.1.

Example 24 N-[3-(2-Ethoxyphenoxyl)propyl]quinolin-4-amine

N-[3-(2-Ethoxyphenoxyl)propyl]quinolin-4-amine (217 mg) was preparedfollowing the method for the preparation ofN-{3-[4-(hexyloxy)phenoxy]propyl}quinolin-4-amine, starting with2-ethoxyphenol (1.5 g) and N-(3-bromopropyl)phthalimide (2.91 g).

N-[3-(2-Ethoxyphenoxy)propyl]phthalimide (2.57 g): ¹H NMR (CDCl₃) δ 7.85and 7.75 (m, 4H, AA′BB′), 6.95-6.80 (m, 4H), 4.1-4.0 (m, 4H), 3.9 (t,2H), 2.2 (m, 2H), 1.4 (t, 3H).

3-(2-Ethoxyphenoxyl)propan-1-amine (0.76 g): ¹H NMR (CDCl₃) δ 6.9 (m,4H), 4.1-4.0 (m, 4H), 2.95 (t, 2H), 1.95 (m, 2H), 1.5 (br s, 2H, NH ₂),1.4 (t, 3H).

N-[3-(2-Ethoxyphenoxyl)propyl]quinolin-4-amine: ¹H NMR (CDCl₃) δ 8.8 (brs, 1H, NH), 8.5 (m, 1H), 8.4 (m, 1H), 8.2 (d, 1H), 7.7 (m, 1H), 7.5 (m,1H), 7.0-6.8 (m, 4H), 6.6 (d, 1H), 4.2 (m, 2H), 4.1 (m, 2H), 3.8 (q,2H), 2.4 (m, 2H), 1.4 (t, 3H).

Example 25 N-[3-(2-Methoxyphenoxyl)propyl]quinolin-4-amine

3-(2-Methoxyphenoxyl)propan-1-amine was prepared following the methodfor the preparation of 3-[4-(Hexyloxy)phenoxy]propan-1-amine, startingwith 2-methoxyphenol (1.5 g) and N-(3-bromopropyl)phthalimide (3.2 g).

N-[3-(2-Methoxyphenoxy)propyl]phthalimide (3.19 g): ¹H NMR (CDCl₃) δ 7.8and 7.7 (m, 4H, AA′BB′), 6.9-6.8 (m, 4H), 4.1 (t, 2H), 3.9 (t, 2H), 3.7(s, 3H), 2.2 (m, 2H).

3-(2-Methoxyphenoxyl)propan-1-amine (770 mg): ¹H NMR (CDCl₃) δ 6.9-6.8(m, 4H), 4.1 (t, 2H), 3.8 (s, 3H), 2.9 (t, 2H), 2.0 (m, 2H), 1.5 (br s,2H, NH ₂).

N-[3-(2-Methoxyphenoxy)propyl]quinolin-4-amine A mixture of3-(2-methoxyphenoxyl)propan-1-amine (770 mg, 3.95 mmol),4-chloroquinoline (777 mg, 4.77 mmol), 0.15 mL of NMP and 2 mL of TEAwere heated at 130° C. in a sealed tube for 5 days. Then, the mixturewas cooled and concentrated in vacuo. Purification by preparative TLC(5% MeOH/DCM) gave the product. ¹H NMR (CDCl₃) δ 8.4 (d, 1H), 8.2 (d,1H), 8.1 (d, 1H), 7.7 (m, 1H), 7.4 (m, 1H), 7.1 (br s, 1H, NH), 7.0-6.9(m, 4H), 6.5 (d, 1H), 4.3 (t, 2H), 3.9 (s, 3H), 3.7 (m, 2H), 2.3 (m,2H).

Example 26 N-{3-[2-(Benyloxy)phenoxy]propyl}quinolin-4-amine

N-{3-[2-(Benyloxy)phenoxy]propyl}quinolin-4-amine was prepared followingthe method for the preparation ofN-{3-[4-(hexyloxy)phenoxy]propyl}quinolin-4-amine, starting with2-(benzyloxy)phenol (2.0 g) and N-(3-bromopropyl)phthalimide (2.68 g).

N-{3-[2-(Benzyloxy)phenoxy]propyl}phthalimide (3.6 g): ¹H NMR (CDCl₃) δ7.8 and 7.7 (m, 4H, AA′BB′), 7.5-7.3 (m, 4H), 7.0-6.8 (m, 5H), 5.1 (s,2H), 4.1 (t, 2H), 3.9 (t, 2H), 2.2 (m, 2H).

3-[2-(Benzyloxy)phenoxy]propan-1-amine (1.92 g): ¹H NMR (CDCl₃) δ7.5-7.3 (m, 5H), 6.9-6.8 (m, 4H), 5.1 (s, 2H), 4.1 (t, 2H), 2.9 (t, 2H),2.0 (m, 2H).

N-{3-[2-(Benyloxy)phenoxy]propyl}quinolin-4-amine: ¹H NMR (CDCl₃) δ 8.5(d, 1H), 7.9 (d, 1H), 7.8 (d, 1H), 7.5 (m, 1H), 7.4-7.2 (m, 6H), 7.0-6.9(m, 4H), 6.4 (d, 1H), 6.0 (br s, 1H, NH), 5.1 (s, 2H), 4.2 (t, 2H), 3.6(m, 2H), 2.3 (m, 2H).

Example 27 N-[8-(3-Methoxyphenoxyl)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-3-methoxybenzene (1.28 g) was prepared by the samemethod used for 1-(8-bromooctyloxy)-3-methylbenzene using3-methoxyphenol (638 mg, 5.14 mmol), 1,8-dibromooctane (14.3 g, 53mmol), and K₂CO₃ (852 mg, 6.17 mmol) in 14 mL of NMP and 7 mL of DMEheated for 24 hr. ¹H NMR (CDCl₃) δ 7.2 (m, 1H), 6.46 (m, 3H), 3.9 (t,2H), 3.4 (t, 2H, J=6.9 Hz), 1.9-1.7 (m, 4H), 1.6-1.2 (m, 8H).

1-(8-Iodooctyloxy)-3-methoxybenzene (1.47 g) was prepared from1-(8-bromooctyloxy)-3-methoxybenzene (1.28 g, 6.78 mmol) and sodiumiodide (601 mg) in 50 mL of acetone following the method used in thepreparation of 10-(hexyloxy)decan-1-amine.

N-[8-(3-Methoxyphenoxy)octyl]phthalimide (1.0 g) was prepared from1-(8-iodooctyloxy)-3-methoxybenzene (1.47 g, 4.06 mmol) and potassiumphthalimide (1.13 g) in 50 mL of DMF at 60-80° C. for 12 hr followingthe method for N-[8-(hexyloxy)octyl]phthalimide. ¹H NMR (CDCl₃) δ 7.85(m, 2H), 7.7 (m, 2H), 7.2 (m, 1H), 6.7-6.5 (m, 3H), 3.9 (m, 2H), 3.8 (s,3H), 3.65 (m, 2H), 1.8-1.6 (m, 4H), 1.5-1.3 (m, 8H).

8-(3-Methoxyphenoxyl)octan-1-amine (438 mg, 1.74 mmol) was prepared fromN-[8-(3-methoxyphenoxy)octyl]phthalimide (1.0 g, 2.6 mmol) usinghydrazine monohydrate (0.20 mL) in EtOH (50 mL) following the method for[3-(hexyloxy)phenyl]methanamine. ¹H NMR (CD₃OD) δ 7.1 (m, 1H), 6.5-6.4(m, 3H), 3.9 (t, 2H), 3.7 (s, 3H), 2.7 (t, 2H), 1.8 (m, 2H), 1.6-1.4 (m,10H).

N-[8-(3-Methoxyphenoxyl)octyl]quinolin-4-amine (200 mg) was preparedfrom 8-(3-methoxyphenoxyl)octan-1-amine (438 mg, 1.74 mmol),4-chloroquinoline (572 mg), TEA (2 mL), and NMP (0.2 mL) following themethod for N-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃)δ 8.5 (d, 1H), 8.0 (d, 1H), 7.75 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.15(m, 1H), 6.5-6.4 (m, 4H), 5.1 (br s, 1H, NH), 3.9 (t, 2H), 3.3 (m, 2H),1.8 (m, 4H), 1.6-1.3 (m, 8H).

Example 28 N-{4-[3-(Hexyloxy)phenoxy]butyl}quinolin-4-amine

1-(4-Bromobutoxy)-3-(hexyloxy)benzene A mixture of 3-(hexyloxy)phenol(1.21 g, 6.26 mmol), 1,4-dibromobutane (7.00 mL, 59 mmol), and K₂CO₃(950 mg, 6.88 mmol) in 14 mL of 1:1 NMP/1,2-dimethoxyethane was heatedat gentle reflux for 40 hr. The mixture was cooled and partitionedbetween DCM and 1M HCl. The organic phase was dried over MgSO₄ andconcentrated in vacuo with warming to remove excess dibromide. Theresidue was separated by SPE, washing with Hex and then eluting theproduct with 5% EA/Hex to give 1-(4-bromobutoxy)-3-(hexyloxy)benzene(1.42 g). Rf 0.40 (5% EA/Hex); ¹H NMR (CDCl₃) δ 7.15 (m, 1H), 6.51-6.43(m, 3H), 3.99-3.90 (m, 4H), 3.48 (t, 2H, J=6.6 Hz), 2.11 (m, 2H), 1.93(m, 2H), 1.81 (m, 2H), 1.50-1.29 (m, 6H), 0.92 (m, 3H).

N-{4-[3-(Hexyloxy)phenoxy]butyl}phthalimide1-(4-Bromobutoxy)-3-(hexyloxy)benzene (1.40 g, 4.26 mmol), potassiumphthalimide (1.18 g, 6.38 mmol), and DMF (5 mL) were mixed at roomtemperature until the bromide was consumed, as observed by TLC of analiquot. The mixture was partitioned between EA and H₂O and brine, andthe organic phase was dried over MgSO₄ and concentrated. SPE (15%EA/Hex) gave 1.60 g of the product. Rf 0.40 (20% EA/Hex); ¹H NMR (CDCl₃)δ 7.83 and 7.70 (m, 4H, AA′BB′), 7.12 (m, 1H), 6.48-6.42 (m, 3H),3.98-3.88 (m, 4H), 3.76 (t, 2H, J=6.8 Hz), 1.92-1.70 (m, 6H), 1.49-1.25(m, 6H), 0.89 (m, 3H).

4-[3-(Hexyloxy)phenoxy]butan-1-amine A mixture of theN-{4-[3-(hexyloxy)phenoxy]butyl}phthalimide (1.60 g, 4.05 mmol),hydrazine monohydrate (0.30 mL, 6.3 mmol), and 15 mL of EtOH were heatedat reflux for 8 hr. The mixture was cooled and partitioned between EAand 5% K₂CO₃ and brine, and the organic phases were dried over Na₂SO₄and concentrated. SPE, washing with 5% MeOH/DCM and eluting with 10%MeOH/DCM+2% TEA gave 1.05 g of the amine as a colorless solid. ¹H NMR(CD₃OD+CDCl₃) δ 7.01 (t, 1H, J=7.8 Hz), 6.37-6.32 (m, 3H), 3.83-3.76 (m,4H), 2.66 (t, 2H), 1.74-1.50 (m, 6H), 1.34-1.17 (m, 6H), 0.77 (m, 3H).

N-{4-[3-(Hexyloxy)phenoxy]butyl}quinolin-4-amine A mixture of the4-[3-(hexyloxy)phenoxy]butan-1-amine (300 mg, 1.20 mmol),4-chloroquinoline (283 mg, 1.74 mmol), DIEA (0.50 mL, 2.87 mmol), and1.5 mL of IPA was sealed in a heavy walled glass tube and mixed at 180°C. for 3 days. The mixture was cooled and partitioned between EA and 5%Na₂CO₃ and brine, dried over Na₂SO₄, and concentrated. SPE, washing with3% MeOH/DCM and eluting with 10% MeOH/DCM, gave 293 mg of the product asa solid. Rf 0.26 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.52 (d, 1, J=5.2 Hz),7.97 (d, 1, J=8.4 Hz), 7.72 (d, 1, J=8.4 Hz), 7.61 (m, 1H), 7.37 (m,1H), 7.17 (t, 1, J=8 Hz), 6.53-6.47 (m, 3), 6.42 (d, 1, J=5.5 Hz), 5.35(br s, 1H, NH), 4.03 (m, 2H), 3.91 (m, 2H), 3.40 (m, 2H), 1.96-1.95 (m,4), 1.75 (m, 2H), 1.46-1.31 (m, 6), 0.89 (m, 3).

Example 29 N-{3-[3-(Hexyloxy)phenoxy]propyl}quinolin-4-amine

3-(Hexyloxy)phenol A mixture of resorcinol (7.1 g), K₂CO₃ (1.13 g), and1-bromohexane (1.0 mL) in 60 mL of NMP reacted at 50-60° C. for 20 hrwith the aid of mechanical stirring. Then, the mixture was cooled, andmost of the volatile components were evaporated. The residue waspartitioned between EA (3×250 mL) and H₂O, 5% Na₂CO₃ (2×), H₂O, 0.1MHCl, and brine (200 mL each). The combined organic phases were driedover MgSO₄ and concentrated. SPE (5% EA/Hex) gave 1.29 g of3-(hexyloxy)phenol. ¹H NMR (CDCl₃) δ 7.10 (m, 1H), 6.48 (m, 1H),6.42-6.38 (m, 2H), 3.91 (t, 2H, J=6.7 Hz), 1.75 (m, 2H), 1.48-1.31 (m,6H), 0.89 (m, 3H).

N-{3-[3-(Hexyloxy)phenoxy]propyl}phthalimide A mixture of3-(hexyloxy)phenol (9.8 g), K₂CO₃ (9.8 g), andN-(3-bromopropyl)phthalimide (15.5 g) in 150 mL of 2-butanone was heatedat reflux for 24 hr with the aid of mechanical stirring. Then, themixture was cooled, and most of the volatile components were evaporated.The residue was partitioned between EA (3×250 mL) and H₂O neutralizedusing H₃PO₄, 0.1M HCl, H₂O, and brine (200 mL each). The combinedorganic phases were dried over MgSO₄ and concentrated to give 7.58 g ofthe product. ¹H NMR (CDCl₃) δ 7.81 and 7.68 (m, 4H, AA′BB′), 7.09 (t,1H, J=8.2 Hz), 6.45 (ddd, 1H, J=1.0, 2.5, 8.4 Hz), 6.39-6.32 (m, 2H),3.99 (t, 2H, J=6.0 Hz), 3.91-3.83 (m, 4H), 2.16 (m, 2H), 1.73 (m, 2H),1.45-1.21 (m, 6H), 0.90 (m, 3H).

3-[3-(Hexyloxy)phenoxy]propan-1-amine CrudeN-{3-[3-(hexyloxy)phenoxy]propyl}phthalimide (1.20 g) was dissolved in50 mL of EtOH, and hydrazine monohydrate (0.22 mL) was added. Themixture was heated at reflux for 12 hr, and then the mixture was allowedto stand at room temperature for 48 hr. The solid was broken up, dilutedwith 50 mL of ether, and stirred for 1 hr. The precipitate was filteredand washed with 50% MeOH/ether (2×40 mL). The combined filtrates wereconcentrated. The liquid was taken up in 100 mL of DCM and washed with1N NaOH and H₂O (10 mL each). The organic phase was concentrated. SPE,washing with 1% MeOH/DCM and then eluting with 7% MeOH/DCM+2% NH₄OH,gave the product. The partially concentrated fractions were washed with20 mL of H₂O, the water phase was extracted with 40 mL of DCM, and thecombined organic phases were dried over Na₂SO₄ and concentrated to give763 mg of an amber liquid. ¹H NMR (CDCl₃) δ 7.13 (m, 1H), 6.49-6.43 (m,3H), 4.00 (t, 2H, J=6.1 Hz), 3.90 (t, 2H), 2.89 (t, 2H, J=6.7 Hz),1.96-1.84 (m, 4H), 1.74 (m, 2H), 1.48-1.28 (m, 6H), 0.89 (m, 3H).

N-{3-[3-(Hexyloxy)phenoxy]propyl}quinolin-4-amine A mixture of3-[3-(hexyloxy)phenoxy]propan-1-amine (763 mg, 3.04 mmol),4-chloroquinoline (746 mg, 4.58 mmol), DIEA (1.0 mL, 5.74 mmol), and 0.1mL of DMF was sealed in a heavy walled glass tube and heated at 130° C.for 4 days. The mixture was cooled. SPE, washing with 50% EA/Hex andeluting with 10% MeOH/DCM, gave the product contaminated by ninhydrin(+) material. FC (8% to 9% MeOH/DCM) resulted in partial purification.SPE (60% EA/Hex+1% TEA) gave 389 mg of product as an oil that solidifiedupon standing. Rf 0.25 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.52 (d, 1H,J=5.2 Hz), 7.96 (dd, 1H, J=0.8, 8.4 Hz), 7.77 (dd, 1H, J=1.0, 8.4 Hz),7.61 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.40 (ddd, 1H, J=1.2, 6.9, 8.4 Hz),7.17 (m, 1H), 6.53-6.48 (m, 3), 6.42 (d, 1H, J=5.4 Hz), 5.74 (br s, 1H,NH), 4.14 (m, 2H), 3.90 (m, 2H), 3.54 (m, 2H), 2.23 (m, 2H), 1.76 (m,2H), 1.49-1.24 (m, 6), 0.89 (m, 3).

Example 30 N-{2-[3-(Hexyloxy)phenoxyl]ethyl}quinolin-4-amine

3-(Hexyloxy)phenol (2.5 g), N-(2-bromoethyl)phthalimide (3.27 g), andK₂CO₃ (1.95 g) in acetone (50 mL) at reflux and subsequent treatmentwith hydrazine monohydrate (3.5 mL) in EtOH (24 mL) at reflux gave 226mg of ninhydrin (+) 2-[3-(hexyloxy)phenoxy]ethan-1-amine. ¹H NMR (CDCl₃)δ 7.10 (m, 1H), 6.55-6.40 (m, 3H), 4.00-3.80 (m, 4H), 3.00 (br s, 2H),1.90-1.70 (m, 4H), 1.50-1.30 (m, 6H), 0.90 (m, 3H).

N-{2-[3-(Hexyloxy)phenoxyl]ethyl}quinolin-4-amine A mixture of2-[3-(hexyloxy)phenoxy]ethan-1-amine (226 mg, 0.95 mmol),4-chloroquinoline (233 mg, 1.43 mmol), DIEA (1.0 mL, 5.74 mmol), and0.15 mL of DMF was sealed in a heavy walled glass tube and stirred at140° C. and mixed for 5 days. The cooled mixture was concentrated andseparated by FC (7% MeOH/DCM) to give 150 mg of product as a pink solid.Rf 0.32 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.50 (d, 1H, J=5.5 Hz), 7.99(d, 1H, J=8.2 Hz), 7.93 (d, 1H, J=8.1 Hz), 7.62 (m, 1H), 7.42 (m, 1H),7.16 (m, 1H), 6.54-6.47 (m, 4), 6.21 (br s, 1H, NH), 4.28 (t, 2H, J=5.2Hz), 3.92 (m, 2H), 3.75 (m, 2H), 1.75 (m, 2H), 1.48-1.24 (m, 6), 0.88(t, 3, J=6.7 Hz).

Example 31 N-[8-(4-Methoxyphenoxyl)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-4-methoxybenzene A mixture of 4-methoxyphenol (5.08g, 41.0 mmol) and K₂CO₃ (6.12 g, 44.3 mmol) in 40 mL of DMF was stirredfor 1.25 hr. Then, a mixture of 1,8-dibromooctane (86.0 g, 316 mmol) in40 mL of DMF was added. The mixture was stirred for 24 hr and then itwas allowed to stand for 6 days. The mixture was partitioned between 1:1EA/Hex and H₂O (3×), 0.1M HCl, and brine, and the organic phases weredried over Na₂SO₄, filtered, and concentrated. The residue in 10% EA/Hexwas filtered through a pad of silica gel, and then most of the solventswere evaporated. Vacuum distillation was performed to remove most of theexcess dibromide, and the pot residue consisted of almost colorlesssolid and a small amount of liquid. The pot was rinsed twice with Hexand the solid was dried in vacuo. Rf 0.42 (10% EA/Hex); ¹H NMR (CDCl₃) δ6.82 (s, 4H), 3.89 (t, 2H), 3.76 (s, 3H), 3.40 (t, 2H, J=6.8 Hz),1.90-1.70 (m, 4H), 1.48-1.33 (m, 8H).

N-[8-(4-Methoxyphenoxy)octyl]phthalimide A mixture of crude1-(8-bromooctyloxy)-4-methoxybenzene and potassium phthalimide (7.59 g,41.0 mmol) in 60 mL of NMP was stirred at room temperature until thebromide was consumed, as shown by TLC analysis of an aliquot. Then, 30mL of H₂O was added, and much of the volatile material was evaporated invacuo. The residue was partitioned between 1:1 EA/Hex and H₂O and brine.The organic phases were dried over Na₂SO₄, filtered, and concentrated togive 14.88 g of a colorless solid. Rf 0.11 (10% EA/Hex).

8-(4-Methoxyphenoxyl)octan-1-amine Hydrazine monohydrate (4.00 mL, 84mmol) was added to a mixture of N-[8-(4-methoxyphenoxy)octyl]phthalimide(14.8 g, 38.8 mmol) and 125 mL of denatured EtOH using mechanicalstifling. The mixture was heated at reflux for 15 hr, during which timea colorless precipitate formed. The mixture was concentrated byevaporation, and the residue was partitioned between isopropyl acetate(300, 2×125 mL) and 5% Na₂CO₃ (200, 3×100 mL) and brine (100 mL). Thecombined organic phases were dried over Na₂SO₄, filtered, andconcentrated to give 8.63 g of white solid after drying in vacuo. ¹H NMR(CDCl₃) δ 6.79 (s, 4H), 4.66 (s, 3H), 3.86 (t, 2H, J=6.4 Hz), 3.72 (s,3H), 2.72 (t, 2H, J=7.4 Hz), 1.71 (m, 2H), 1.55-1.33 (m, 10H).

N-[8-(4-Methoxyphenoxy)octyl]quinolin-4-amine8-(4-Methoxyphenoxyl)octan-1-amine (4.60 g, 18.3 mmol) was taken up in100 mL of 1-pentanol, and 30 mL of volatile material was removed bydistillation. The mixture was cooled below boiling, and tripropylamine(7.00 mL, 36.7 mmol) and 4-chloroquinoline (3.28 g, 20.1 mmol) wereadded. Heating at reflux was resumed. After 26.25 hr, the mixture wascooled, and 20 mL of 1N NaOH was added. Volatile material was removed byevaporation. The mixture was diluted with DCM (350 mL) and washed with5% Na₂CO₃ (50 mL). The aqueous phase was extracted with DCM (100 mL).The combined organic phases were dried over Na₂SO₄, filtered, andconcentrated. SPE, washing with 50% EA/Hex and then eluting with 50%EA/Hex+2% TEA, gave product fractions that were combined andconcentrated. The residue was partitioned between DCM and 5% Na₂CO₃. Thecombined organic phases were dried over Na₂SO₄, filtered, andconcentrated to afford a yellow solid. The solid was triturated withice-cold 20% Et₂O/Hex and dried in vacuo. The solid had mp 141.0-144.0°C. The solid was dissolved in minimal hot butanone and then the mixturewas allowed to cool to room temperature. After chilling in an ice bathfor 2 hr, the precipitate was collected and washed with ice-coldbutanone to give 3.98 g of a tan solid. Rf 0.23 (5% MeOH/DCM+2% TEA); mp143.0-145.5° C.; ¹H NMR (CDCl₃) δ 8.56 (d, 1H, J=5.1 Hz), 7.98 (dd, 1H,J=0.7, 8.5 Hz), 7.72 (m, 1H), 7.62 (m, 1H), 7.42 (m, 1H), 6.85-6.80 (m,4H, AA′BB′), 6.42 (d, 1H, J=5.5 Hz), 4.97 (br s, 1H, NH), 3.90 (t, 2H,J=6.6 Hz), 3.76 (s, 3H), 3.31 (m, 2H), 1.80-1.73 (m, 4H), 1.48-1.39 (m,8H); ¹³C NMR (CDCl₃) δ 153.9, 153.5, 151.3, 149.8, 148.7, 130.3, 129.1,124.8, 119.3, 118.9, 115.6, 114.8, 99.0, 68.8, 56.0, 43.4, 29.6, 29.5,29.5, 29.2, 27.3, 26.2.

Example 32 N-[6-(4-Methoxyphenoxyl)hexyl]quinolin-4-amine

1-(6-Bromohexyloxy)-4-methoxybenzene A mixture of 1,6-dibromohexane (2.4mL, 15.7 mmol), 4-methoxyphenol (243 mg, 1.96 mmol), and K₂CO₃ (550 mg,3.99 mmol) in 4 mL of DMF and 3 mL of DME was stirred 16 hr at roomtemperature, 4 hr at 80° C., and 64 hr at room temperature. The mixturewas diluted with EA and washed with H₂O, 5% Na₂CO₃, H₂O, 0.1M HCl, andbrine. The organic phase was dried over anhydrous Na₂SO₄, filteredthrough a pad of silica gel, and concentrated. SPE, washing with Hex andthen eluting with 15% EA/Hex, gave 623 mg of the product as a colorlesssolid. Rf 0.29 (5% EA/Hex); ¹H NMR (CDCl₃) δ 6.82 (s, 4H, AA′BB′), 3.90(t, 2H, J=6.3 Hz), 3.76 (s, 3H), 3.41 (m, 2H, AB), 1.88 (m, 2H), 1.76(m, 2H), 1.56-1.39 (m, 4H).

1-(6-Azidohexyloxy)-4-methoxybenzene A mixture of1-(6-bromohexyloxy)-4-methoxybenzene 623 mg, 2.17 mmol) and sodium azide(210 mg, 3.23 mmol) in 5 mL of DMF was stirred at room temperature for48 hr. Then, the mixture was diluted with EA and washed with H₂O andbrine. The organic phase was dried over MgSO₄ and concentrated to give500 mg of oily solid. Rf 0.50 (15% Et₂O/Hex); ¹H NMR (CDCl₃) δ 6.82 (s,4H, AA′BB′), 3.89 (t, 2H, J=6.5 Hz), 3.74 (s, 3H), 3.25 (t, 2H, J=6.9Hz), 1.76 (m, 2H), 1.62 (m, 2H), 1.55-1.36 (m, 4H).

6-(4-Methoxyphenoxyl)hexan-1-amine A mixture of1-(6-azidohexyloxy)-4-methoxybenzene (500 mg) and 65 mg of 5% Pd-C in 25mL of MeOH was stirred under a blanket of hydrogen for 16 hr. Themixture was blanketed with argon and filtered through a pad of Celite.The filtrate was concentrated to give 448 mg of oil. ¹H NMR (CDCl₃) δ6.77 (s, 4H, AA′BB′), 3.84 (m, 2H), 3.70 (s, 3H), 2.64 and 2.56 (m, 2H,AB), 1.71 (m, 2H), 1.51-1.31 (m, 6H).

N-[6-(4-Methoxyphenoxy)hexyl]quinolin-4-amine Four mL of pyridine wasevaporated from 6-(4-methoxyphenoxyl)hexan-1-amine (448 mg, 2.01 mmol).Then, a mixture of the amine, 4-chloroquinoline (424 mg, 2.60 mmol),DIEA (0.80 mL, 4.59 mmol), and 1.5 mL of NMP was heated at 160° C. in asealed tube for 24 hr. The mixture was cooled and partitioned betweenDCM and 5% Na₂CO₃. The organic phase was dried over anhydrous Na₂SO₄ andconcentrated. FC (50% EA/Hex+2% TEA) gave an oil that contained residualNMP, as observed by NMR. Dilution with EtOH and evaporation under highvacuum was repeated until NMP was undetectable by NMR. Rf 0.12 (50%EA/Hex+2% TEA); ¹H NMR (CDCl₃) δ 8.52 (d, 1H, J=5.2 Hz), 7.96 (d, 1H,J=8.4 Hz), 7.74 (d, 1H, J=8.4 Hz), 7.59 (ddd, 1H, J=1.2, 6.9, 8.4 Hz),7.37 (ddd, 1H, J=1.2, 6.9, 8.2 Hz), 6.82-6.80 (m, 4H), 6.39 (d, 1H,J=5.4 Hz), 5.20 (m, 1H, NH), 3.89 (t, 2H, J=6.3 Hz), 3.74 (s, 3H), 3.31(m, 2H), 1.78-1.75 (m, 4H), 1.52-1.49 (m, 4H).

Example 33 N-{2-[4-(Hexyloxy)phenoxyl]ethyl}quinolin-4-amine

4-(Hexyloxy)phenol was prepared by methods similar to that used for thepreparation of 3-(hexyloxy)phenol. 4-(Benzyloxy)phenol (11.45 g), K₂CO₃(8.68 g), 1-bromohexane (10.4 mL), and DMF (50 mL) at 80-100° C. gave1-(benzyloxy)-4-(hexyloxy)benzene (12.97 g). Rf 0.68 (20% EA/Hex); ¹HNMR (CDCl₃) δ 7.44-7.28 (m, 5H), 6.91-6.76 (m, 4H), 5.00 (s, 2H), 3.89(t, 2H, J=6.6 Hz), 1.74 (m, 2H), 1.49-1.24 (m, 6H), 0.89 (m, 3H).

4-(Hexyloxy)phenol A mixture of 1-(benzyloxy)-4-(hexyloxy)benzene (12.97g) and 5% Pd/C (1.2 g) in 200 mL of 1:1 MeOH/EA was stirred underhydrogen for 16 hr. Starting material was consumed, as seen by TLCanalysis. The reaction mixture was filtered through Celite, the solventswere exchanged to 12% EA/Hex, and the mixture was filtered through a padof silica gel and concentrated to give 8.84 g of 4-(hexyloxy)phenol. Rf0.21 (10% EA/Hex); ¹H NMR (CDCl₃) δ 6.80-6.72 (m, 4H), 3.88 (t, 2H,J=6.7 Hz), 1.79-1.68 (m, 2H), 1.48-1.30 (m, 6H), 0.91-0.86 (m, 3H).

2-[4-(Hexyloxy)phenoxy]ethanol A mixture of 4-(hexyloxy)phenol (11.0 g,56.7 mmol), ethylene carbonate (7.5 g, 85 mmol), and K₂CO₃ (11.7 g, 85mmol) in 60 mL of DMF was heated at 60° C. for 16 hr. The mixture waspartitioned between EA and H₂O, 0.1M HCl, H₂O, and brine. The organicphases were dried over MgSO₄ and concentrated. SPE, washing with 10%EA/Hex (which gave 5.8 g of recovered starting phenol) and eluting with37% EA/Hex, gave the product as colorless solid. The recovered startingmaterial was retreated with the reagents. The combined product yield was11.4 g of colorless solid. Rf 0.20 (20% EA/Hex); ¹H NMR (CDCl₃) δ6.83-6.81 (m, 4H, AA′BB′), 4.03 and 3.93 (m, 4H, A₂B₂), 3.90 (t, 2H,J=6.6 Hz), 1.79-1.72 (m, 2H), 1.45 (m, 2H), 1.36-1.30 (m, 4H), 0.90 (m,3H); ¹³C NMR (CDCl₃) δ 153.9, 152.9, 115.8, 115.7, 70.2, 68.9, 61.8,31.8, 29.6, 25.9, 22.8, 14.2.

2-[4-(Hexyloxy)phenoxy]ethanamine was prepared by the method used forthe preparation of [3-(hexyloxy)phenyl]methanamine.

2-[4-(Hexyloxy)phenoxy]ethanol (11.4 g), methanesulfonyl chloride (5.60mL), TEA (11.0 mL), and DCM (150 mL) at 0° C. gave2-[4-(hexyloxy)phenoxy]ethyl methanesulfonate (13.9 g). ¹H NMR (CDCl₃) δ6.85-6.81 (m, 4H, AA′BB′), 4.54 and 4.19 (m, 4H, A₂B₂), 3.90 (t, 2H,J=6.6 Hz), 3.08 (s, 3H), 1.76 (m, 2H), 1.44 (m, 2H), 1.36-1.30 (m, 4H),0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 154.3, 152.2, 116.0, 115.8, 68.9, 68.4,66.9, 38.0, 31.8, 29.5, 25.9, 22.8, 14.2.

2-[4-(Hexyloxy)phenoxy]ethyl methanesulfonate (13.9 g), potassiumphthalimide (8.57 g), and DMF (40 mL) at 60° C. gaveN-{2-[4-(hexyloxy)phenoxy]ethyl}phthalimide (11.58 g afterrecrystallization from EtOH/H₂O). Rf 0.40 (30% EA/Hex); ¹H NMR (CDCl₃) δ7.85 and 7.71 (m, 4H, AA′BB′), 6.79 (m, 4H, AA′BB′), 4.18 and 4.08 (m,4H, A₂B₂), 3.86 (t, 2H, J=6.6 Hz), 1.73 (m, 2H), 1.42 (m, 2H), 1.34-1.28(m, 4H), 0.89 (m, 3H); ¹³C NMR (CDCl₃) δ 168.4, 153.9, 152.6, 134.2,132.3, 123.5, 115.9, 115.6, 68.8, 65.7, 37.7, 31.8, 29.5 25.9, 22.8,14.2.

2-[4-(Hexyloxy)phenoxy]ethanamineN-{2-[4-(Hexyloxy)phenoxy]ethyl}phthalimide (11.6 g), hydrazinemonohydrate (2.25 mL), IPA (125 mL), and EtOH (50 mL) at reflux gave acolorless solid (7.50 g). ¹H NMR (CDCl₃) δ 6.73 (s, 4H, AA′BB′), 3.80(t, 2H, J=5.2 Hz), 3.79 (t, 2H, J=6.7 Hz), 2.93 (t, 2H), 1.66 (m, 2H),1.41-1.21 (m, 6H), 0.85-0.80 (m, 3H).

N-{2-[4-(Hexyloxy)phenoxyl]ethyl}quinolin-4-amine Crude2-[4-(hexyloxy)phenoxy]ethanamine (7.40 g, 31.2 mmol) was taken up in 30mL of DMA, and then 25 mL was evaporated. The residue was transferred toa heavy-walled sealed tube, and 5 mL of NMP, 4-chloroquinoline (5.09 g,31.2 mmol), and DIEA (10.8 mL, 62 mmol) were added. The mixture washeated at 160° C. for 16 hr. After cooling, dilution of the mixture with5% Na₂CO₃ resulted in the formation of a precipitate. The precipitatewas filtered and washed with H₂O. The precipitate was recrystallizedfrom MeOH/H₂O and then from MeOH to give 7.50 g of colorless solid. Rf0.20 (5% MeOH/DCM); mp 131.5-132.0° C.; ¹H NMR (CDCl₃) δ 8.58 (d, 1H,J=5.2 Hz), 8.00 (dd, 1H, J=0.8, 8.4 Hz), 7.79 (dd, 1H, J=0.8, 8.4 Hz),7.66-7.62 (m, 1H), 7.44 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 6.86 (m, 4H,AA′BB′), 6.49 (d, 1H, J=5.5 Hz), 5.60 (br s, 1H, NH), 4.25 (t, 2H), 3.90(t, 2H, J=6.6 Hz), 3.70 (m, 2H), 1.74 (m, 2H), 1.45 (m, 2H), 1.36-1.30(m, 4H), 0.90 (m, 3H); ¹³C NMR (CDCl₃) δ 154.2, 152.6, 151.0, 149.9,148.5, 130.0, 129.4, 125.1, 119.7, 119.1, 115.9, 115.8, 99.2, 68.9,66.9, 42.9, 31.8, 29.5, 25.9, 22.8, 14.2.

Example 34 N-{3-[4-(Hexyloxy)phenoxy]propyl}quinolin-4-amine

N-{3-[4-(Hexyloxy)phenoxy]propyl}phthalimide A mixture of4-(hexyloxy)phenol (1.04 g, 5.36 mmol), N-(3-bromopropyl)phthalimide(1.44 g, 5.37 mmol), K₂CO₃ (1.12 g, 8.12 mmol), and 10 mL of DMF wasreacted for 26 hr. Then, the mixture was diluted with EA and washed withH₂O, 0.1M HCl, and brine, dried over anhydrous Na₂SO₄, and concentrated.The residue was filtered through a pad of silica gel using 20% EA/Hex,and the filtrate was concentrated to give 1.96 g of a pale yellow solid.Rf 0.20 (15% EA/Hex), 0.38 20% EA/Hex+2% DIEA); ¹H NMR (CDCl₃) δ 7.83and 7.69 (m, 4H, AA′BB′), 6.79-6.71 (m, 4H, AA′BB′), 3.96 (t, 2H, J=6.2Hz), 3.91-3.81 (m, 4H), 2.14 (m, 2H), 1.73 (m, 2H), 1.48-1.28 (m, 6H),0.89 (m, 3H).

3-[4-(Hexyloxy)phenoxy]propan-1-amine A mixture ofN-{3-[4-(hexyloxy)phenoxy]propyl}phthalimide (1.96 g) and hydrazinemonohydrate (0.40 mL, 8.24 mmol) in 40 mL of EtOH was heated at refluxfor 20 hr. Then, the volatile components were evaporated. SPE, washingwith 5% MeOH/DCM and then eluting with 5% MeOH/DCM+2% TEA, gave 632 mgof colorless solid. Rf 0.21 (5% MeOH/DCM+25 DIEA); ¹H NMR (CDCl₃) δ 6.75(br s, 4H), 3.92 (t, 2H, J=6.0 Hz), 3.83 (t, 2H, J=6.7 Hz), 3.00 (br m,2H, NH ₂), 2.82 (t, 2H, J=6.8 Hz), 1.87 (m, 2H), 1.68 (m, 2H), 1.43-1.23(m, 6H), 0.83 (m, 3H).

N-{3-[4-(Hexyloxy)phenoxy]propyl}quinolin-4-amine A mixture of3-[4-(hexyloxy)phenoxy]propan-1-amine (476 mg, 1.90 mmol),4-chloroquinoline (416 mg, 2.55 mmol), and DIEA (0.50 mL, 2.86 mmol) in1 mL of NMP was heated at 150° C. in a sealed tube for 18 hr. Then, themixture was cooled and partitioned between EA and 5% Na₂CO₃ and brine.The organic phase was dried over Na₂SO₄ and concentrated. SPE, washingwith 2.5% MeOH/DCM and then eluting with 7% MeOH/DCM, gave 633 mg ofsolid. Rf 0.28 (10% MeOH/DCM); mp 84.5-86.0° C. (from EA/Hex); ¹H NMR(CDCl₃) δ 8.51 (d, 1H, J=5.4 Hz), 7.95 (dd, 1H, J=1.0, 8.5 Hz), 7.79 (m,1H), 7.57 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.35 (ddd, 1H, J=1.2, 6.9, 8.1Hz), 6.82 (br s, 4H, AA′BB′), 6.38 (d, 1H, J=5.4 Hz), 5.97 (m, 1H, NH),4.03 (t, 2H, J=5.4 Hz), 3.86 (t, 2H, J=6.4 Hz), 3.47 (m, 2H), 2.15 (m,2H), 1.73 (m, 2H), 1.47-1.25 (m, 6H), 0.88 (m, 3H).

Example 35 N-{4-[4-(Hexyloxy)phenoxy]butyl}quinolin-4-amine

1-(4-Bromobutoxy)-4-(hexyloxy)benzene 4-(Hexyloxy)phenol (1.52 g, 7.84mmol), 1,4-dibromobutane (7.4 mL, 62 mmol), and K₂CO₃ (1.22 g, 8.84mmol) in 8 mL of DMF was mixed for 16 hr. The mixture was partitionedbetween EA and 0.1M HCl and brine, and the organic phases were driedover MgSO₄, filtered, and concentrated. SPE, washing with 1% EA/Hex andthen eluting with 5% EA/Hex gave 2.36 g of colorless solid. Rf 0.59 (15%EA/Hex); ¹H NMR (CDCl₃) δ 6.80 (br s, 4H, AA′BB′), 3.93 (t, 2H, J=6.0Hz), 3.88 (t, 2H, J=6.7 Hz), 3.48 (m, 2H), 2.05 (m, 2H), 1.90 (m, 2H),1.74 (m, 2H), 1.48-1.28 (m, 6H), 0.89 (m, 3H).

N-{4-[4-(Hexyloxy)phenoxy]butyl}phthalimide1-(4-Bromobutoxy)-4-(hexyloxy)benzene (2.36 g, 7.17 mmol) and potassiumphthalimide (2.0 g, 10.8 mmol) in 12 mL of DMF was mixed for 60 hr. Themixture was partitioned between EA and 0.1M HCl and brine, and theorganic phases were dried over MgSO₄, filtered, and concentrated. SPE,washing with 5% EA/Hex and then eluting with 15% EA/Hex gave 2.64 g ofcolorless solid. Rf 0.31 (15% EA/Hex); ¹H NMR (CDCl₃) δ 7.83 and 7.70(m, 4H, AA′BB′), 6.78 (br s, 4H, AA′BB′), 3.92 (t, 2H, J=6.1 Hz), 3.87(t, 2H, J=6.7 Hz), 3.75 (t, 2H, J=7.0 Hz), 1.92-1.68 (m, 6H), 1.48-1.22(m, 6H), 0.89 (m, 3H).

4-[4-(Hexyloxy)phenoxy]butan-1-amine A mixture ofN-{4-[4-(hexyloxy)phenoxy]butyl}phthalimide (2.64 g, 6.68 mmol) andhydrazine monohydrate (0.65 mL, 13.4 mmol) in 60 mL of EtOH was heatedat reflux for 20 hr. The mixture was cooled, concentrated, andpartitioned between EA and 5% Na₂CO₃ and brine. The organic phases weredried over Na₂SO₄, filtered, and concentrated. SPE, washing with 4%MeOH/DM and then eluting with 6% MeOH/DCM+2% DIEA gaveproduct-containing fractions. These fractions were concentrated, takenup in DCM and washed with 5% Na₂CO₃, dried over Na₂SO₄, filtered, andconcentrated to give 1.69 g of colorless solid. Rf 0.20 (5% MeOH/DCM+2%DIEA, ninhydrin (+)); ¹H NMR (CDCl₃) δ 6.80 (br s, 4H, AA′BB′),3.93-3.85 (m, 4H), 2.75 (t, 2H, J=7 Hz), 1.87-1.26 (m, 14H), 0.89 (m,3H).

N-{4-[4-(Hexyloxy)phenoxy]butyl}quinolin-4-amine A mixture of4-[4-(hexyloxy)phenoxy]butan-1-amine (499 mg, 1.88 mmol),4-chloroquinoline (3999 mg, 2.45 mmol), and DIEA (0.50 mL, 2.86 mmol) in1 mL of NMP was heated at 150° C. in a sealed tube for 18 hr. Then, themixture was cooled and partitioned between EA and 5% Na₂CO₃ and brine.The organic phase was dried over Na₂SO₄ and concentrated. SPE, washingwith 2.5% MeOH/DCM and then eluting with 7% MeOH/DCM, gave 633 mg ofsolid. Rf 0.25 (10% MeOH/DCM); mp 113.0-114.0° C. (from EA/Hex); ¹H NMR(CDCl₃) δ 8.53 (d, 1H, J=5.2 Hz), 7.95 (m, 1H), 7.70 (d, 1H, J=7.6 Hz),7.58 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.34 (ddd, 1H, J=1.2, 6.9, 8.2 Hz),6.82 (br s, 4H, AA′BB′), 6.40 (d, 1H, J=5.4 Hz), 5.38 (br t, 1H, NH),3.96 (t, 2H, J=5.6 Hz), 3.88 (t, 2H, J=6.5 Hz), 3.36 (br m, 2H),1.92-1.90 (m, 4H), 1.74 (m, 2H), 1.48-1.28 (m, 6H), 0.89 (m, 3H).

Example 36 N-[8-(m-Tolyloxy)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-3-methylbenzene A mixture of m-cresol (1.00 mL, 9.54mmol), 1,8-dibromooctane (15.0 mL, 81 mmol), and K₂CO₃ (2.6 g, 18.8mmol) in 20 mL of NMP and 10 mL of DME was heated at reflux for 66 hr.Then, the mixture was cooled, diluted with DCM (20 mL), and extractedwith 0.05N NaOH (150, 100 mL) and 1M HCl (100 mL). The aqueous phaseswere extracted with DCM (20 mL), and the combined organic phases weredried over MgSO₄ and concentrated. SPE, washing with Hex to recoverdibromide and then eluting with 3% EA/Hex, gave 1.7 g of1-(8-bromooctyloxy)-3-methylbenzene. Rf 0.39 (5% EA/Hex); ¹H NMR (CDCl₃)δ 7.15 (t, 1H), 6.8-6.65 (m, 3H), 3.95 (t, 2H), 3.4 (t, 2H), 3.3 (s,3H), 1.9-1.7 (m, 4H), 1.5-1.2 (m, 8H).

1-(8-Azidoocyloxy)-3-methylbenzene (1.7 g) was prepared from1-(8-bromooctyloxy)-3-methylbenzene (1.7 g, 5.69 mmol) and sodium azide(740 mg, 11.4 mmol) in 50 mL of DMF following the method for thepreparation of 10-butoxydecan-1-amine.

8-(m-Tolyloxy)octan-1-amine (0.6 g) was prepared from1-(8-azidoocyloxy)-3-methylbenzene (1.7 g) by the method used for thepreparation of 10-butoxydecan-1-amine. ¹H NMR (CDCl₃) δ 7.1 (m, 1H), 6.6(m, 3H), 3.9 (m, 2H), 2.7 (t, 1H), 2.3 (m, 4H), 1.8-1.6 (m, 4H), 1.5-1.3(m, 8H).

N-[8-(m-Tolyloxy)octyl]quinolin-4-amine (166 mg) was prepared from8-(m-tolyloxy)octan-1-amine (0.6 g), 4-chloroquinoline (840 mg), TEA (2mL), and NMP (0.2 mL) following the method forN-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.6 (m,2H), 8.05 (m, 2H), 7.6 (t, 1H), 7.4 (t, 1H), 7.1 (t, 1H), 6.8-6.6 (m,3H), 6.4 (d, 1H), 3.9 (t, 2H), 3.5 (m, 2H), 2.3 (s, 3H), 1.9-1.7 (m,4H), 1.5-1.3 (m, 8H).

Example 37 N-[8-(p-Tolyloxy)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-4-methylbenzene (1.9 g) was prepared by the samemethod used for 1-(8-bromooctyloxy)-3-methylbenzene using p-cresol (1.00mL, 9.54 mmol), 1,8-dibromooctane (15.0 mL, 51 mmol), and K₂CO₃ (2.6 g,18.8 mmol) in 20 mL of NMP and 10 mL of DME heated for 66 hr. ¹H NMR(CDCl₃) δ 7.0 (d, 2H), 6.8 (d, 2H), 3.9 (t, 2H), 3.4 (t, 2H), 2.3 (s,3H), 1.9-1.7 (m, 4H), 1.5-1.2 (m, 8H).

1-(8-Azidooctyloxy)-4-methylbenzene (1.9 g) was prepared from1-(8-bromooctyloxy)-4-methylbenzene (1.9 g, 6.36 mmol) and sodium azide(830 mg, 12.7 mmol) in 50 mL of DMF following the method for thepreparation of 10-butoxydecan-1-amine.

8-(p-Tolyloxy)octan-1-amine (0.6 g) was prepared1-(8-azidooctyloxy)-4-methylbenzene (1.9 g) by the method used for thepreparation of 10-butoxydecan-1-amine. ¹H NMR (CDCl₃) δ 7.05 (d, 2H),6.75 (d, 2H), 3.9 (m, 2H), 2.7 (m, 1H), 2.35 (t, 1H), 2.3 (s, 3H),1.8-1.2 (m, 12H).

N-[8-(p-Tolyloxy)octyl]quinolin-4-amine (161 mg) was prepared from8-(p-tolyloxy)octan-1-amine (0.6 g), 4-chloroquinoline (840 mg), TEA (2mL), and NMP (0.2 mL) following the method forN-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.5 (d,1H), 8.0 (d, 1H), 7.85 (d, 1H), 7.6 (t, 1H), 7.4 (t, 1H), 7.1 (m, 3H),6.8 (m, 3H), 6.4 (d, 1H), 3.9 (t, 2H), 3.4 (m, 2H), 2.3 (s, 3H), 1.9-1.7(m, 4H), 1.5-1.3 (m, 8H).

Example 38 N-[8-(o-Tolyloxy)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-2-methylbenzene (1.3 g) was prepared by the samemethod used for 1-(8-bromooctyloxy)-3-methylbenzene using o-cresol (696mg, 6.44 mmol), 1,8-dibromooctane (14 g, 81 mmol), and K₂CO₃ (1.00 g,7.25 mmol) in 12 mL of NMP and 12 mL of DME heated for 16 hr.

1-(8-Iodooctyloxy)-2-methylbenzene (1.3 g) was prepared from1-(8-bromooctyloxy)-2-methylbenzene (1.3 g, 4.35 mmol) and sodium iodide(652 mg, 4.35 mmol) in 50 mL of acetone following the method used in thepreparation of 10-(hexyloxy)decan-1-amine.

N-[8-(o-Tolyloxy)octyl]phthalimide (1.3 g) was prepared from1-(8-iodooctyloxy)-2-methylbenzene (1.3 g) and potassium phthalimide(1.0 g, 5.4 mmol) in 50 mL of DMF following the method forN-[8-(hexyloxy)octyl]phthalimide. ¹H NMR (CDCl₃) δ 7.85 (m, 2H), 7.7 (m,2H), 7.15 (m, 2H), 6.8 (m, 2H), 3.95 (m, 2H), 3.7 (m, 2H), 2.2 (m, 3H),1.9-1.6 (m, 4H), 1.6-1.25 (m, 8H).

8-(o-Tolyloxy)octan-1-amine (390 mg) was prepared fromN-[8-(o-tolyloxy)octyl]phthalimide (1.0 g, 2.74 mmol) using hydrazinemonohydrate (0.2 mL) in EtOH (50 mL) following the method for[3-(hexyloxy)phenyl]methanamine. ¹H NMR (DMSO-d₆) δ 7.1 (m, 2H),6.9-6.75 (m, 2H), 3.9 (t, 2H), 2.5 (m, 2H), 2.15 (s, 3H), 1.75 (m, 2H),1.5-1.2 (m, 10H).

N-[8-(o-Tolyloxy)octyl]quinolin-4-amine (300 mg) was prepared from8-(o-tolyloxy)octan-1-amine (390 mg), 4-chloroquinoline (544 mg), TEA (2mL), and NMP (0.2 mL) following the method forN-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.55 (d,1H), 8.0 (d, 1H), 7.75 (d, 1H), 7.65 (m, 1H), 7.45 (m, 1H), 7.15 (m,2H), 6.8 (m, 2H), 6.4 (d, 1H), 3.95 (t, 2H), 3.35 (m, 2H), 2.3 (s, 3H),1.8 (m, 4H), 1.6-1.3 (m, 8H).

Example 39 N-[8-(4-tert-Butylphenoxy)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-4-tert-butylbenzene (900 mg) was prepared by thesame method used for 1-(8-bromooctyloxy)-3-methylbenzene using4-tert-butylphenol (647 mg, 4.31 mmol), 1,8-dibromooctane (11.7 g, 43mmol), and K₂CO₃ (714 mg, 5.17 mmol) in 12 mL of NMP and 6 mL of DMEheated for 24 hr. ¹H NMR (CDCl₃) δ 7.28 and 6.82 (m, 4H, AA′BB′), 3.93(m, 2H), 3.40 (t, 2H, J=6.8 Hz), 1.90-1.71 (m, 4H), 1.46-1.22 (m, 8H),1.29 (s, 9H).

1-tert-Butyl-4-(8-iodooctyloxyl)benzene (900 mg) was prepared from1-(8-bromooctyloxy)-4-tert-butylbenzene (900 mg) and sodium iodide (400mg) in 50 mL of acetone following the method for the preparation of10-(hexyloxy)decan-1-amine.

N-[8-(4-tert-Butylphenoxy)octyl]phthalimide (1.3 g) was prepared from1-tert-butyl-4-(8-iodooctyloxyl)benzene (900 mg) and potassiumphthalimide (860 mg) in 50 mL of DMF following the method for thepreparation of N-[8-(hexyloxy)octyl]phthalimide. ¹H NMR (CDCl₃) δ 7.85and 7.70 (m, 4H, AA′BB′), 7.3 and 6.8 (m, 4H, AA′BB′), 3.9 (t, 2H), 3.65(m, 2H), 1.8-1.6 (m, 4H), 1.6-1.3 (m, 17H).

8-(4-tert-Butylphenoxy)octan-1-amine (590 mg) was prepared fromN-[8-(4-tert-butylphenoxy)octyl]phthalimide (900 mg) and hydrazinemonohydrate (0.17 mL) in 50 mL of EtOH following the method for thepreparation of [3-(hexyloxy)phenyl]methanamine. ¹H NMR (DMSO-d₆) δ 7.25and 6.80 (m, 4H, AA′BB′), 3.9 (t, 2H), 2.5 (m, 2H), 1.68 (m, 2H),1.5-1.2 (m, 19H).

N-[8-(4-tert-Butylphenoxy)octyl]quinolin-4-amine A mixture of8-(4-tert-butylphenoxy)octan-1-amine (510 mg, 1.84 mmol),4-chloroquinoline (604 mg, 3.70 mmol), TEA (4.0 mL, 28 mmol), and 0.4 mLof NMP was heated in a heavy walled glass tube at 130° C. for 4 days.The mixture was cooled and partitioned between EA and 5% Na₂CO₃ andbrine, dried over Na₂SO₄, filtered, and concentrated. Purification by FC(60% EA/Hex+2% TEA) gave 320 mg of solid. Mp 108-110° C. (from MeOH); ¹HNMR (CDCl₃) δ 8.4 (d, 1H), 8.0 (d, 1H), 7.8 (d, 1H), 7.6 (m, 1H), 7.4(m, 1H), 7.3 and 6.8 (m, 4H, AA′BB′), 6.4 (d, 1H), 5.2 (br s, 1H, NH),3.9 (m, 2H), 3.3 (m, 2H), 1.8-1.6 (m, 4H), 1.6-1.3 (m, 8H), 1.3 (s, 9H).

Example 40 N-[8-(4-Fluorophenoxyl)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-4-fluorobenzene (2.75 g) was prepared by the samemethod used for 1-(8-bromooctyloxy)-3-methylbenzene using 4-fluorophenol(1.33 g, 12.1 mmol), 1,8-dibromooctane (20 mL, 108 mmol), and K₂CO₃(1.77 g, 14.3 mmol) in 20 mL of NMP and 10 mL of DME heated for 24 hr.¹H NMR (CDCl₃) δ 7.0-6.9 (m, 2H), 6.8 (m, 2H), 3.89 (t, 2H, J=6.4 Hz),3.40 (t, 2H, J=6.8 Hz), 1.9-1.7 (m, 4H), 1.6-1.2 (m, 8H).

1-Fluoro-4-(8-iodooctyloxyl)benzene was prepared from1(8-bromooctyloxy)-4-fluorobenzene (2.75 g, 9.08 mmol) and sodium iodide(1.63 g, 10.9 mmol) in 70 mL of acetone following the method used in thepreparation of 10-(hexyloxy)decan-1-amine.

N-[8-(4-Fluorophenoxy)octyl]phthalimide (2.19 g) was prepared from1-fluoro-4-(8-iodooctyloxyl)benzene and potassium phthalimide (2.52 g,13.6 mmol) in 50 mL of DMF at 60-80° C. for 12 hr following the methodfor N-[8-(hexyloxy)octyl]phthalimide. ¹H NMR (CDCl₃) δ 7.85 (m, 2H), 7.7(m, 2H), 6.9 (m, 2H), 6.8 (m, 2H), 3.9 (t, 2H), 3.7 (t, 2H), 1.8-1.6 (m,4H), 1.5-1.3 (m, 8H).

8-(4-Fluorophenoxyl)octan-1-amine (657 mg, 2.75 mmol) was prepared fromN-[8-(4-fluorophenoxy)octyl]phthalimide (2.19 g, 5.94 mmol) usinghydrazine monohydrate (0.43 mL) in EtOH (50 mL) following the method for[3-(hexyloxy)phenyl]methanamine. ¹H NMR (CD₃OD) δ 7.0-6.8 (m, 4H), 3.9(t, 2H), 2.7 (t, 2H), 1.75 (m, 2H), 1.6-1.3 (m, 10H).

N-[8-(4-Fluorophenoxyl)octyl]quinolin-4-amine was prepared from8-(4-fluorophenoxyl)octan-1-amine (657 mg, 2.75 mmol), 4-chloroquinoline(676 mg), TEA (2 mL), and NMP (0.2 mL) at 130° C. in a sealed tube for 5days following the method forN-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.5 (d,1H), 8.0 (d, 1H), 7.9 (d, 1H), 7.65 (m, 1H), 7.4 (m, 1H), 7.1-6.8 (m,4H), 6.4 (d, 1H), 5.6 (br s, 1H, NH), 4.0 (t, 2H), 3.35 (m, 2H), 1.8 (m,2H), 1.7-1.2 (m, 10H).

Example 41 N-[8-(3-Fluorophenoxyl)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-3-fluorobenzene (2.06 g) was prepared by the samemethod used for 1-(8-bromooctyloxy)-3-methylbenzene using 3-fluorophenol(1.60 g, 14.3 mmol), 1,8-dibromooctane (25 mL, 135 mmol), and K₂CO₃(2.56 g, 18.5 mmol) in 25 mL of NMP and 12 mL of DME heated for 24 hr.Rf 0.42 (5% EA/Hex); ¹H NMR (CDCl₃) δ 7.2 (m, 1H), 6.7-6.6 (m, 3H), 3.9(t, 2H), 3.4 (t, 2H), 1.9-1.7 (m, 4H), 1.6-1.2 (m, 8H).

1-Fluoro-3-(8-iodooctyloxyl)benzene was prepared from1-(8-bromooctyloxy)-3-fluorobenzene (2.06 g, 6.78 mmol) and sodiumiodide (1.22 g, 8.13 mmol) in 60 mL of acetone following the method usedin the preparation of 10-(hexyloxy)decan-1-amine.

N-[8-(3-Fluorophenoxy)octyl]phthalimide (1.85 g) was prepared from1-fluoro-3-(8-iodooctyloxyl)benzene and potassium phthalimide (1.9 g,10.3 mmol) in 50 mL of DMF at 60-80° C. for 12 hr following the methodfor N-[8-(hexyloxy)octyl]phthalimide. ¹H NMR (CDCl₃) δ 7.85 (m, 2H), 7.7(m, 2H), 7.2 (m, 1H), 6.7-6.5 (m, 3H), 3.9 (t, 2H), 3.7 (t, 2H), 1.8-1.6(m, 4H), 1.5-1.3 (m, 8H).

8-(3-Fluorophenoxyl)octan-1-amine (874 mg, 3.66 mmol) was prepared fromN-[8-(3-fluorophenoxy)octyl]phthalimide (1.85 g, 5.01 mmol) usinghydrazine monohydrate (0.36 mL) in EtOH (50 mL) following the method for[3-(hexyloxy)phenyl]methanamine. ¹H NMR (CD₃OD) δ 7.25 (m, 1H), 6.8-6.6(m, 3H), 3.9 (t, 2H), 2.7 (t, 2H), 1.8 (m, 2H), 1.6-1.3 (m, 10H).

N-[8-(3-Fluorophenoxyl)octyl]quinolin-4-amine was prepared from8-(3-fluorophenoxyl)octan-1-amine (874 mg, 3.66 mmol), 4-chloroquinoline(900 mg), TEA (2 mL), and NMP (1 mL) at 130° C. in a sealed tube for 5days following the method forN-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.5 (d,1H), 8.0 (d, 1H), 7.85 (d, 1H), 7.65 (m, 1H), 7.4 (m, 1H), 7.15 (m, 1H),6.7-6.5 (m, 3H), 6.5 (d, 1H), 5.6 (br s, 1H, NH), 3.9 (t, 2H), 3.35 (m,2H), 1.8 (m, 4H), 1.6-1.3 (m, 8H).

Example 42 N-[8-(2-Fluorophenoxyl)octyl]quinolin-4-amine

1-(8-Bromooctyloxy)-2-fluorobenzene (2.97 g) was prepared by the samemethod used for 1-(8-bromooctyloxy)-3-methylbenzene using 2-fluorophenol(1.69 g, 15.1 mmol), 1,8-dibromooctane (38.3 g, 141 mmol), and K₂CO₃(2.76 g, 20 mmol) in 25 mL of NMP and 20 mL of DME heated for 24 hr. Rf0.33 (5% EA/Hex); ¹H NMR (CDCl₃) δ 7.10-6.83 (m, 4H), 4.0 (m, 2H), 3.38(t, 2H, J=6.9 Hz), 1.91-1.76 (m, 4H), 1.47-1.32 (m, 8H).

1-Fluoro-2-(8-iodooctyloxyl)benzene (3.43 g) was prepared from1-(8-bromooctyloxy)-2-fluorobenzene (2.97 g, 9.80 mmol) and sodiumiodide (1.76 g, 11.7 mmol) in 70 mL of acetone following the method usedin the preparation of 10-(hexyloxy)decan-1-amine.

N-[8-(2-Fluorophenoxy)octyl]phthalimide (2.84 g) was prepared from1-fluoro-2-(8-iodooctyloxyl)benzene (3.43 g) and potassium phthalimide(2.72 g, 14.7 mmol) in DMF at 60-80° C. for 12 hr following the methodfor N-[8-(hexyloxy)octyl]phthalimide. ¹H NMR (CDCl₃) δ 7.85 and 7.70 (m,4H, AA′BB′), 7.10-6.80 (m, 4H), 4.00 (t, 2H), 3.70 (t, 2H), 1.90-1.60(m, 4H), 1.55-1.25 (m, 8H).

8-(2-Fluorophenoxyl)octan-1-amine (1.27 g, 5.32 mmol) was prepared fromN-[8-(2-fluorophenoxy)octyl]phthalimide (2.84 g, 7.70 mmol) usinghydrazine monohydrate (0.50 mL) in EtOH (50 mL) following the method for[3-(hexyloxy)phenyl]methanamine.

N-[8-(2-Fluorophenoxyl)octyl]quinolin-4-amine (100 mg) was prepared from8-(2-fluorophenoxyl)octan-1-amine (1.27 g, 5.32 mmol), 4-chloroquinoline(1.3 g, 7.98 mmol), TEA (2 mL), and NMP (1 mL) at 130° C. in a sealedtube for 5 days following the method forN-[8-(3-ethoxypropoxy)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.4 (d,1H), 8.0 (d, 1H), 7.9 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.0-6.7 (m,4H), 6.4 (d, 1H), 5.9 (br s, 1H, NH), 3.9 (t, 2H), 3.3 (m, 2H), 1.9-1.2(m, 12H).

Example 43 N-(Biphenyl-4-yl)quinolin-4-amine

A mixture of 4-biphenylamine (200 mg, 1.18 mmol), 4-chloroquinoline (228mg), and DIEA (0.25 mL, 1.43 mmol) in 1 mL of NMP was heated at 150° C.in a sealed tube for 24 hr. The cooled mixture was diluted with EA,washed with 5% Na₂CO₃ (2×) and brine, dried over anhydrous Na₂SO₄, andconcentrated. SPE, eluting with a step gradient of 1%, 3%, and 5%MeOH/DCM, gave fractions that were concentrated to give a brown solid.The solid was washed with MeOH and dried in vacuo. Rf 0.21 (5%MeOH/DCM); mp 222-226° C.; ¹H NMR (20% CD₃OD/CDCl₃) δ 8.38 (d, 1H, J=5.7Hz), 8.06 (m, 1H), 7.91 (m, 1H), 7.67-7.26 (m, 11H), 6.98 (d, 1H, J=5.5Hz).

Example 44 N-(4-Hexylphenyl)quinolin-4-amine

A mixture of 4-hexylaniline (197 mg, 1.11 mmol), 4-chloroquinoline (210mg) and DIEA (0.24 mL) in 1 mL of NMP was heated at 150° C. in a sealedtube for 24 hr. The mixture was cooled and partitioned between EA and 5%Na₂CO₃. The organic phases were washed with brine, dried over Na₂SO₄,and concentrated. Purification by SPE (step gradient 1, 2, 3, 5, 6%MeOH/DCM) gave fractions yielding a yellow solid. Recrystallization fromMeOH gave 229 mg of a colorless solid. Rf 0.14 (5% MeOH/DCM); mp132.5-133.0° C.; ¹H NMR (CDCl₃) δ 8.52 (d, 1H, J=5.7 Hz), 8.03 (dd, 1H,J=0.7, 8.4 Hz), 7.85 (d, 1H, J=7.6 Hz), 7.64 (ddd, 1H, J=1.5, 6.9, 8.4Hz), 7.44 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 6.88-6.81 (m, 4H), 6.50 (d, 1H,J=5.7 Hz), 5.92 (br s, 1H, NH), 4.26 (t, 2H, J=5 Hz), 3.89 (t, 2H, J=6Hz), 3.73 (q, 2H, J=5.2 Hz), 1.74 (m, 2H), 1.48-1.28 (m, 6H), 0.89 (m,3H).

Example 45 Hexyl 4-(quinolin-4-ylamino)benzoate

Hexyl 4-aminobenzoate (282 mg), prepared from 1-hexanol and4-nitrobenzoyl chloride in two unremarkable steps, was reacted with4-chloroquinoline (322 mg) and DIEA (0.50 mL) in 2 mL of NMP heated at160° C. in a sealed tube for 16 hr. The mixture was cooled andpartitioned between EA and 5% Na₂CO₃. The organic phases were washedwith brine, dried over Na₂SO₄, and concentrated. Purification by SPE,washing with 20% EA/Hex and then eluting with 55% EA/Hex, gave a yellowsolid. Recrystallization from EA/Hex gave a colorless solid. Rf 0.14(50% EA/Hex); ¹H NMR (CDCl₃) δ 8.61 (d, 1H, J=5.2 Hz), 8.09-8.03 (m,4H), 7.70 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.52 (ddd, 1H, J=1.2, 6.9, 8.4Hz), 7.34-7.31 (m, 2H), 7.19 (d, 1H, J=5.2 Hz), 4.30 (t, 2H, J=6.6 Hz),1.76 (m, 2H), 1.47-1.24 (m, 6H), 0.89 (m, 3H).

Example 46 N-(4-Phenoxyphenyl)quinolin-4-amine

A mixture of 4-phenoxyaniline (182 mg, 0.98 mmol), 4-chloroquinoline(175 mg, 1.07 mmol), and DIEA (0.50 mL, 2.87 mmol) in 1 mL of NMP washeated at 140-150° C. in a sealed tube for 24 hr. Then, the mixture wascooled and partitioned between DCM and 5% Na₂CO₃. The organic phase wasdried over Na₂SO₄ and concentrated. SPE, washing with 50% EA/Hex andeluting with 5% MeOH/DCM, gave a solid. Recrystallization from EA/Hexgave 111 mg of tan solid. A second crop of 111 mg light tan solid wasobtained from MeOH. The two crops had comparable NMR spectra. Rf 0.19(5% MeOH/DCM); mp 170-172° C. (from MeOH); ¹H NMR (CDCl₃) δ 8.51 (d, 1H,J=5.5 Hz), 8.05 (d, 1H, J=8.7 Hz), 7.99 (d, 1H, J=8.4 Hz), 7.68 (ddd,1H, J=1.3, 6.9, 8.2 Hz), 7.50 (ddd, 1H, J=1.3, 6.9, 8.2 Hz), 7.40-7.25(m, 5H), 7.22-6.99 (m, 5H), 6.83 (d, 1H, J=5.4 Hz).

Example 47 N-(3-Phenoxyphenyl)quinolin-4-amine

A mixture of 3-phenoxyaniline (307 mg, 1.66 mmol), 4-chloroquinoline(296 mg, 1.82 mmol), and DIEA (0.32 mL, 1.84 mmol) in 1 mL of NMP washeated at 140-150° C. in a sealed tube for 24 hr. Then, the mixture wascooled and partitioned between DCM and 5% Na₂CO₃. The organic phase wasdried over Na₂SO₄ and concentrated. SPE, washing with 20% EA/Hex, 20%EA/Hex+2% TEA, and 35% EA/Hex+2% TEA, then eluting with 50% EA/Hex+2%TEA, gave 208 mg of yellow solid. Rf 0.26 (7.5% MeOH/DCM); mp 189-192°C. (from MeOH); ¹H NMR (CDCl₃) δ 8.40 (d, 1H, J=5.2 Hz), 7.98-7.91 (m,2H), 7.62 (m, 1H), 7.45 (m, 1H), 7.34-7.26 (m, 3H), 7.10-6.98 (m, 6H),6.90 (t, 1H, J=2.2 Hz), 6.75 (dd, 1H, J=2.5, 8.1 Hz).

Example 48 N-(2-Phenoxyphenyl)quinolin-4-amine

A mixture of 2-phenoxyaniline (286 mg, 1.54 mmol), 4-chloroquinoline(278 mg, 1.70 mmol), and 4-methylmorpholine (0.19 mL, 1.73 mmol) in 0.5mL of NMP was heated in a heavy walled sealed tube at 130° C. for 20 hr.The mixture was cooled and partitioned between EA and 5% Na₂CO₃ andbrine. The organic phases were dried over Na₂SO₄ and concentrated. FC(7.5% MeOH/DCM) gave a dark oil that contained residual4-methylmorpholine. The oil was filtered through a pad of silica gelusing 30% EA/Hex+2% TEA to give 402 mg of solid. Rf 0.10 (5% MeOH/DCM);¹H NMR (CDCl₃) δ 8.61 (d, 1H, J=5.2 Hz), 8.03 (dd, 1H, J=0.7, 8.4 Hz),7.85-7.81 (m, 1H), 7.64 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.59 (m, 1H),7.43 (m, 1H), 7.34-7.24 (m, 2H), 7.19-6.98 (m, 8H).

Example 49 N-[4-(Quinolin-4-ylamino)phenyl]hexanamide

N-(4-Nitrophenyl)hexanamide Hexanoyl chloride ((0.81 mL, 5.8 mmol) wasadded slowly to a mixture of 4-nitroaniline ((800 mg, 5.79 mmol) in 5 mLof pyridine and 15 mL of DMF cooled by an ice bath. After 30 min, themixture was warmed to room temperature. After an additional 2 hr, thevolatile components were evaporated. The residue was taken up in EA (100mL) and washed with saturated NaHCO₃ (2×75 mL), H₂O (2×50 mL), 0.1N HCl(2×25 mL), and H₂O. The organic phase was concentrated in vacuo to give1.50 g product. ¹H NMR (CDCl₃) δ 8.2 (m, 2H), 7.7 (m, 2H), 7.4 (br s,1H, NH), 2.4 (m, 2H), 1.8 (m, 2H), 1.4-1.3 (m, 4H), 0.9 (m, 3H).

N-(4-Aminophenyl)hexanamide A mixture of N-(4-nitrophenyl)hexanamide(1.50 g), 10% Pd-C (200 mg), and 75 mL of MeOH was stirred under ablanket of hydrogen until the starting material was consumed, asobserved by analytical TLC. Then, the atmosphere was purged with argon,and the mixture was filtered through a pad of Celite. Evaporation of thesolvent gave 1.22 g of product. ¹H NMR (CDCl₃) δ 7.2 (m, 3H), 7.0 (br s,1H, NH), 6.6 (m, 2H), 3.6 (br s, 2H, NH ₂), 2.3 (m, 2H), 1.7 (m, 2H),1.4-1.2 (m, 4H), 0.9 (m, 3H).

N-[4-(Quinolin-4-ylamino)phenyl]hexanamide A mixture of4-chloroquinoline (358 mg, 2.20 mmol), N-(4-aminophenyl)hexanamide (300mg, 1.46 mmol), and TEA (1 mL) was heated at 130° C. in a sealed tubefor 5 days. Then the volatile components were evaporated. The residuewas purified by preparative TLC (10% MeOH/DCM) to give 329 mg ofproduct. Rf 0.3 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.56 (d, 1H, J=5.5 Hz),8.04 (d, 2H, J=8.9 Hz), 8.05-7.99 (m, 2H), 7.69 (ddd, 1H, J=1.2, 6.9,8.2 Hz), 7.51 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.30 (d, 2H, J=8.9 Hz),7.18 (d, 1H, J=5.4 Hz), 4.35 (q, 2H, J=7 Hz), 1.38 (t, 3H, J=7 Hz).

Example 50 N-[3-(Quinolin-4-ylamino)phenyl]hexanamide

N-[3-(Quinolin-4-ylamino)phenyl]hexanamide was prepared following themethod for N-[4-(quinolin-4-ylamino)phenyl]hexanamide, starting with3-nitroaniline (800 mg) and hexanoyl chloride (0.81 mL) and using4-chloroquinoline (358 mg).

N-(4-Nitrophenyl)hexanamide (1.50 g): ¹H NMR (CDCl₃) δ 8.4 (m, 1H),8.0-7.9 (m, 2H), 7.8 (br s, 1H, NH), 7.5 (m, 1H), 2.4 (m, 2H), 1.8 (m,2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).

N-(4-Aminophenyl)hexanamide (1.34 g): ¹H NMR (CDCl₃) δ 7.4 (br s, 1H,NH), 7.2 (br s, 1H), 7.0 (t, 1H), 6.7 (d, 1H), 6.4 (d, 1H), 3.5 (br s,2H, NH ₂), 2.3 (t, 2H), 1.7 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).

N-[3-(Quinolin-4-ylamino)phenyl]hexanamide: Rf 0.2 (10% MeOH/DCM); ¹HNMR (CD₃OD) δ 8.5 (d, 1H), 8.4 (d, 1H), 8.0-7.8 (m, 3H), 7.7 (m, 1H),7.5-7.3 (m, 2H), 7.1 (m, 1H), 7.0 (d, 1H), 2.4 (t, 2H), 1.7 (m, 2H),1.4-1.2 (m, 4H), 0.9 (m, 3H).

Example 51 N-Hexyl-4-(quinolin-4-ylamino)benzamide

N-Hexyl-4-(quinolin-4-ylamino)benzamide 4-Amino-N-hexylbenzamide (220mg), prepared from 1-aminohexane (0.70 mL) and 4-nitrobenzoyl chloride(450 mg) in two unremarkable steps, was reacted with 4-chloroquinoline(239 mg) and DIEA (0.50 mL) in 1 mL of IPA heated at 130-180° C. in asealed tube for 8 days. The mixture was cooled and partitioned betweenDCM and 5% Na₂CO₃. The organic phases were dried over Na₂SO₄, andconcentrated. Purification by SPE, washing with 3% MeOH/DCM and theneluting with 15% MeOH/DCM, gave 105 mg of a solid. Rf 0.08 (5%MeOH/DCM); ¹H NMR (20% CD₃OD/CDCl₃) δ 8.39 (d, 1H, J=5.4 Hz), 8.15 (dd,1H, J=0.7, 8.4 Hz), 7.89 (dd, 1H, J=0.7, 8.4 Hz), 7.80-7.75 (m, 2H),7.65 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.47 (ddd, 1H, J=1.2, 6.9, 8.4 Hz),7.36-7.30 (m, 2H), 7.07 (d, 1H, J=5.5 Hz), 3.35 (m, 2H, AB), 1.57 (m,2H), 1.32-1.21 (m, 6H), 0.84 (t, 3H, J=6 Hz).

N-Hexyl-4-nitrobenzamide (467 mg): ¹H NMR (CDCl₃) δ 8.17 (d, 2H, J=8.7Hz), 7.91 (d, 2H, J=8.7 Hz), 7.00 (br s, 1H, NH), 3.39 (m, 2H), 1.56 (m,2H), 1.4-1.1 (m, 6H), 0.81 (m, 3H).

4-Amino-N-hexylbenzamide: Rf 0.22 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ 7.56(m, 2H), 6.58 (m, 2H), 6.56 (br s, 1H, NH), 4.12 (br s, 2H, NH ₂), 3.57(m, 2H), 1.53 (m, 2H), 1.47-1.22 (m, 6H), 0.84 (m, 3H).

Example 52 N-Hexyl-3-(quinolin-4-ylamino)benzamide

N-Hexyl-3-(quinolin-4-ylamino)benzamide (117 mg) was prepared followingthe method for N-hexyl-4-(quinolin-4-ylamino)benzamide, starting from3-nitrobenzoic acid (1.17 g) and 1-hexylamine (1.02 mL) and using4-chloroquinoline (225 mg).

N-Hexyl-3-nitrobenzamide: ¹H NMR (CDCl₃) δ 8.56 (m, 1H), 8.28 (m, 1H),8.13 (ddd, 1H, J=1.2, 1.7, 7.7 Hz), 7.58 (t, 1H, J=7.9 Hz), 6.84 (br s,1H, NH), 3.44 (m, 2H), 1.60 (m, 2H), 1.39-1.23 (m, 6H), 0.84 (t, 3H,J=7.0 Hz).

3-Amino-N-hexylbenzamide (1.47 g): Rf 0.25 (5% MeOH/DCM); ¹H NMR (CDCl₃)δ 7.14-7.00 (m, 3H), 6.71 (m, 1H), 6.42 (br s, 1H, NH), 3.80 (br s, 2H,NH ₂), 3.34 (m, 2H), 1.53 (m, 2H), 1.48-1.21 (m, 6H), 0.84 (m, 3H).

N-Hexyl-3-(quinolin-4-ylamino)benzamide: Rf 0.05 (5% MeOH/DCM); ¹H NMR(20% CD₃OD/CDCl₃) δ 8.34 (d, 1H, J=5.6 Hz), 8.18 (dd, 1H, J=0.7, 8.4Hz), 7.91-7.88 (m, 1H), 7.70-7.64 (m, 2H), 7.53-7.38 (m, 4H), 6.93 (d,1H, J=5.7 Hz), 3.35 (m, 2H), 1.57 (m, 2H), 1.32-1.20 (m, 6H), 0.84 (m,3H).

Example 53 N-(4-Methoxyphenyl)quinolin-4-amine

A mixture of p-anisidine (138 mg, 1.12 mmol), 4-chloroquinoline (235 mg,1.44 mmol), and DIEA (0.50 mL, mmol) was heated at 130° C. in a sealedtube for 40 hr. The cooled mixture was partitioned between EA (3×) and5% Na₂CO₃ (3×) and brine, and the organic phases were dried overanhydrous Na₂SO₄ and concentrated to give 385 mg of brown oil.Purification by preparative TLC (10% MeOH/DCM) gave 294 mg of brown oilthat solidified upon standing. ¹H NMR (CDCl₃) δ 8.48 (d, 1H, J=5.4 Hz),7.99 (d, 1H, J=8.4 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.64 (ddd, 1H, J=1.3,7.0, 8.5 Hz), 7.45 (m, 1H), 7.21 (m, 2H), 6.93 (m, 2H), 6.68 (d, 1H,J=5.2 Hz), 3.82 (s, 3H).

Example 54 N-[4-(Benzyloxy)phenyl]quinolin-4-amine

A mixture of 4-(benzyloxy)aniline (197 mg, 0.99 mmol), 4-chloroquinoline(169 mg, 1.04 mmol), and DIEA (0.18 mL, 1.03 mmol) in 1 mL of NMP washeated at 150° C. in a sealed tube for 24 hr. Then, the mixture wascooled and partitioned between EA (2×) and 5% Na₂CO₃ (2×) and brine. Theorganic phase was dried over Na₂SO₄ and concentrated. SPE, washing with1% MeOH/DCM and eluting with 5% MeOH/DCM while cutting fractions, gave152 mg of colorless solid. Rf 0.18 (5% MeOH/DCM); mp 201-202° C. (fromMeOH); ¹H NMR (CDCl₃) δ 8.49 (d, 1H, J=5.4 Hz), 8.02 (dd, 1H, J=1.0, 8.6Hz), 7.91 (dd, 1H, J=0.7, 8.4 Hz), 7.66 (ddd, 1H, J=1.2, 6.9, 8.4 Hz),7.51-7.31 (m, 6H), 7.26-7.20 (m, 2H), 7.06-6.98 (m, 2H), 6.71 (d, 2H,J=5.2 Hz), 5.09 (s, 2H).

Example 55 N-(4-Butoxyphenyl)quinolin-4-amine

A mixture of 4-butoxyaniline (236 mg, 1.43 mmol), 4-chloroquinoline (236mg, 1.45 mmol), and DIEA (0.26 mL, 1.49 mmol) in 1 mL of NMP was heatedat 150° C. in a sealed tube for 24 hr. The cooled mixture waspartitioned between EA (2×) and 5% Na₂CO₃ (2×) and brine, and theorganic phases were dried over anhydrous Na₂SO₄ and concentrated to givea solid. SPE, washing with 1% MeOH/DCM and eluting with 5% MeOH/DCM,gave fractions affording a solid after concentration. Recrystallizationfrom MeOH gave 177 mg. Rf 0.18 (5% MeOH/DCM); mp 181-185° C.; ¹H NMR(CDCl₃) δ 8.45 (d, 1H, J=5.4 Hz), 8.03 (dd, 1H, J=1.0, 8.7 Hz), 7.97 (d,1H, J=8.4 Hz), 7.67 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.48 (ddd, 1H, J=1.5,6.9, 8.4 Hz), 7.22 and 6.95 (m, 4H, AA′BB′), 6.67 (d, 1H, J=5.4 Hz),3.98 (t, 2H, J=6.5 Hz), 1.79 (m, 2H), 1.51 (m, 2H), 0.99 (t, 3H, J=7.3Hz).

Example 56 N-[4-(Hexyloxy)phenyl]quinolin-4-amine

1-(Hexyloxy)-4-nitrobenzene A mixture of 4-nitrophenol (480 mg, 3.45mmol), 1-bromohexane (0.43 mL, 3.08 mmol), K₂CO₃ (481 mg, 3.57 mmol),and 20 mg sodium iodide in 5 mL of DMF was heated at 60° C. for 18 hr.The cooled mixture was diluted with Et₂O and washed with 5% Na₂CO₃ andbrine, repetitively, until the aqueous phase was colorless. The organicphase was dried over MgSO₄ and concentrated to obtain 532 mg of yellowoil. Rf 0.21 (5% EA/Hex); ¹H NMR (CDCl₃) δ 8.19-8.13 (m, 2H, AA′BB′),6.94-6.88 (m, 2H, AA′BB′), 4.02 (t, 2H), 1.80 (m, 2H), 1.50-1.29 (m,6H), 0.89 (m, 3H).

4-(Hexyloxy)aniline A mixture of 1-(hexyloxy)-4-nitrobenzene (532 mg,2.38 mmol) and 5% Pd/C (60 mg) in 20 mL of MeOH was stirred under ahydrogen atmosphere for 3 hr. Then, the mixture was filtered through apad of Celite and concentrated to give 458 mg of oil. ¹H NMR (CDCl₃) δ6.78-6.72 (m, 2H, AA′BB′), 6.65-6.59 (m, 2H, AA′BB′), 3.88 (t, 2H), 3.44(br s, 2H, NH ₂), 1.75 (m, 2H), 1.50-1.28 (m, 6H), 0.92 (m, 3H).

N-[4-(Hexyloxy)phenyl]quinolin-4-amine A mixture of 4-(hexyloxy)aniline(430 mg, 2.23 mmol), 4-chloroquinoline (431 mg, 2.64 mmol), and DIEA(1.0 mL, 5.74 mmol) in 1 mL of NMP was heated in a heavy walled sealedtube at 160° C. for 24 hr. The mixture was cooled and partitionedbetween EA and 5% Na₂CO₃ and brine. The organic phases were dried overNa₂SO₄ and concentrated to give a solid that was recrystallized fromEtOH to give a colorless solid. ¹H NMR (CDCl₃) δ 8.49 (d, 1, J=5.2 Hz),8.02 (dd, 1, J=0.7, 8.4 Hz), 7.91 (d, 1, J=8.4 Hz), 7.67 (ddd, 1, J=1.5,6.9, 8.4 Hz), 7.48 (ddd, 1, J=1.5, 6.9, 8.4 Hz), 7.25-7.18 (m, 2H),6.98-6.92 (m, 2H), 6.69 (d, 1, J=5.5 Hz), 6.64 (br s, 1H), 3.97 (t, 2H,J=6 Hz), 1.80 (m, 2H), 1.50-1.30 (m, 6), 0.92 (m, 3).

Example 57 N-[4-(Benzyloxy)phenyl]quinolin-4-amine

A mixture of 3-(benzyloxy)aniline (312 mg, 1.57 mmol), 4-chloroquinoline(280 mg, 1.72 mmol), and DIEA (0.30 mL, 1.72 mmol) in 1 mL of NMP washeated at 150° C. in a sealed tube for 24 hr. Then, the mixture wascooled and partitioned between DCM and 5% Na₂CO₃. The organic phase wasdried over Na₂SO₄ and concentrated. SPE, washing with 20% EA/Hex, 20%EA/Hex+2% TEA, and 35% EA/Hex+2% TEA, then eluting with 50% EA/Hex+2%TEA, gave 528 mg of yellow solid. Recrystallization from MeOH gave 390mg of pale yellow solid. Rf 0.26 (7.5% MeOH/DCM); mp 77-80° C. (fromMeOH); ¹H NMR (CDCl₃) δ 8.45 (d, 1H, J=5.5 Hz), 8.04 (d, 1H, J=8.4 Hz),7.98 (d, 1H, J=8.4 Hz), 7.67 (m, 1H), 7.53-7.24 (m, 8H), 6.94-6.79 (m,4H), 5.08 (s, 2H).

Example 58 N-[3-(Hexyloxy)phenyl]quinolin-4-amine

1-(Hexyloxy)-3-nitrobenzene A mixture of 3-nitrophenol (553 mg, 3.98mmol), 1-bromohexane (0.50 mL, 3.58 mmol), and K₂CO₃ (618 mg, 4.48 mmol)in 5 mL of DMF was heated at 60-80° C. for 12 hr. The cooled mixture wasdiluted with Et₂O and washed with 5% Na₂CO₃ and brine, repetitively,until the aqueous phase was colorless, and then with 0.1M HCl and brine.The organic phase was dried over MgSO₄ and concentrated to obtain 756 mgof oil. ¹H NMR (CDCl₃) δ 7.78 (ddd, 1H, J=1.0, 2.0, 7.9 Hz), 7.70 (m,1H), 7.39 (m, 1H), 7.19 (ddd, 1H, J=1.0, 2.4, 8.1 Hz), 4.01 (t, 2H,J=6.6 Hz), 1.80 (m, 2H), 1.58-1.30 (m, 6H), 0.89 (m, 3H).

3-(Hexyloxy)aniline A mixture of 1-(hexyloxy)-3-nitrobenzene (756 mg,3.39 mmol) and 5% Pd/C (90 mg) in 20 mL of MeOH was stirred under ahydrogen atmosphere for 3 hr. Then, the mixture was filtered through apad of Celite and concentrated to give 660 mg of light orange oil. ¹HNMR (CDCl₃) δ 7.04 (m, 1H), 6.34-6.23 (m, 3H), 3.90 (t, 2H), 3.62 (br s,2H, NH ₂), 1.75 (m, 2H), 1.49-1.26 (m, 6H), 0.90 (m, 3H).

N-[3-(Hexyloxy)phenyl]quinolin-4-amine Anhydrous pyridine (4 mL) wasevaporated from the crude 3-(hexyloxy)aniline (406 mg, 2.10 mmol), then4-chloroquinoline (420 mg, 2.58 mmol), DIEA (0.80 mL, 4.59 mmol), and1.5 mL of NMP were added, and the mixture was heated at 160° C. in aheavy walled sealed tube for 24 hr. The mixture was cooled andpartitioned between EA and 5% Na₂CO₃ and brine. The organic phases weredried over Na₂SO₄ and concentrated. SPE, washing with 20% EA/Hex andthen eluting with 50% EA/Hex+2% TEA, gave the product as a brown oilthat contained residual NMP. Crystallization from EA/Hex gave 410 mg oflight tan solid. Rf 0.32 (50% 50% EA/Hex+2% TEA); ¹H NMR (CDCl₃) δ 8.55(d, 1, J=5.2 Hz), 8.03-7.96 (m, 2H), 7.63 (ddd, 1, J=1.2, 6.9, 8.4 Hz),7.43 (ddd, 1, J=1.2, 6.7, 8.2 Hz), 7.26 (m, 1H), 7.14 (br s, 1H), 7.04(d, 1, J=5.5 Hz), 6.87-6.83 (m, 2H), 6.69 (m, 1H), 3.90 (t, 2H, J=6 Hz),1.75 (m, 2H), 1.45-1.30 (m, 6), 0.89 (m, 3).

Example 59 N-[4-(Benzyloxy)phenyl]quinolin-4-amine

A mixture of 2-(benzyloxy)aniline (301 mg, 1.51 mmol), 4-chloroquinoline(268 mg, 1.64 mmol), and 4-methylmorpholine (0.18 mL, 1.64 mmol) in 0.5mL of NMP was heated in a heavy walled sealed tube at 130° C. for 20 hr.The mixture was cooled and partitioned between EA and 5% Na₂CO₃ andbrine. The organic phases were dried over Na₂SO₄ and concentrated. FC(7.5% MeOH/DCM) gave a dark oil that contained residual4-methylmorpholine. The oil was filtered through a pad of silica gelusing 30% EA/Hex+2% TEA to give 268 mg of tan solid. Rf 0.12 (5%MeOH/DCM); ¹H NMR (CDCl₃) δ 8.60 (d, 1H, J=5.4 Hz), 8.05 (dd, 1H, 1.0,8.4 Hz), 7.88 (dd, 1H, J=0.8, 8.4 Hz), 7.66 (ddd, 1H, J=1.2, 6.9, 8.4Hz), 7.53-7.40 (m, 2H), 7.37-7.29 (m, 5H), 7.15 (d, 1H, J=5.2 Hz),7.07-6.98 (m, 3H), 5.17-5.10 (m, 2H, AB).

Example 60 N-[4-(Hexyloxy)phenyl]quinolin-4-amine

1-(Hexyloxy)-2-nitrobenzene 2-Nitrophenol (1.38 g, 9.93 mmol),1-bromohexane (1.30 mL, 9.30 mmol), and K₂CO₃ (1.38 g, 10.0 mmol) in 6mL of DMF was mixed at room temperature for 3 days. The mixture wasdiluted with Et₂O and washed with 0.25N NaOH until the aqueous phase wascolorless, and then with brine. The organic phase was dried over MgSO₄and concentrated. Rf 0.39 (5% EA/Hex); ¹H NMR (CDCl₃) δ 7.78 (dd, 1H,J=1.7, 8.2 Hz), 7.48 (ddd, 1H, J=1.8, 7.3, 8.9 Hz), 7.04 (dd, 1H, J=1.0,8.5 Hz), 6.97 (ddd, 1H, 1.2, 7.4, 8.2 Hz), 4.07 (t, 2H, J=6.4 Hz), 1.80(m, 2H), 1.51-1.28 (m, 6H), 0.90 (m, 3H).

2-(Hexyloxy)aniline A mixture of the 1-(hexyloxy)-2-nitrobenzene and 5%Pd/C (94 mg) in 15 mL of MeOH and 15 mL of EA was stirred under ahydrogen atmosphere for 5 hr. Then, the mixture was filtered through apad of Celite and concentrated. The residue was filtered through silicagel using 30% EA/Hex to give 1.51 g of brown oil that contained residual1-bromohexane, as shown by NMR analysis. SPE, washing with hexane andeluting with 30% EA/Hex gave 1.38 g of red-brown oil. Rf 0.26 (5%EA/Hex); ¹H NMR (CDCl₃) δ 6.81-6.68 (m, 4H), 3.98 (t, 2H, J=6.4 Hz),3.76 (br s, 2H, NH ₂), 1.81 (m, 2H), 1.53-1.23 (m, 6H), 0.91 (m, 3H).

N-[2-(Hexyloxy)phenyl]quinolin-4-amine A mixture of 2-(hexyloxy)aniline(282 mg, 1.46 mmol), 4-chloroquinoline (258 mg, 1.58 mmol), and4-methylmorpholine (0.18 mL, 1.64 mmol) in 0.5 mL of NMP was heated in aheavy walled sealed tube at 130° C. for 20 hr. The mixture was cooledand partitioned between EA and 5% Na₂CO₃ and brine. The organic phaseswere dried over Na₂SO₄ and concentrated. FC (7.5% MeOH/DCM) gave a darkoil that contained residual 4-methylmorpholine. The oil was filteredthrough a pad of silica gel using 30% EA/Hex+2% TEA to give 416 mg oftan solid. Rf 0.13 (5% MeOH/DCM) 0.50 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ8.59 (dd, 1H, J=6.3, 11.5 Hz), 8.05 (m, 1H), 7.95 (m, 1H), 7.65 (ddd,1H, J=1.3, 6.7, 9.7 Hz), 7.50-7.44 (m, 2H), 7.19-7.13 (m, 2H), 7.06-6.91(m, 3H), 3.99 (t, 2H, J=6.4 Hz), 1.75 (m, 2H), 1.45-1.17 (m, 6H), 0.83(m, 3H).

Example 61 N-[2-Fluoro-4-(hexyloxy)phenyl]quinolin-4-amine

2-Fluoro-4-(hexyloxy)-1-nitrobenzene (2.6 g) was prepared from3-fluoro-4-nitrophenol (5.0 g, 31.5 mmol), 60% sodium hydride (1.9 g),1-bromohexane (4.75 mL), and 30 mL of DMF following the method for1-(8-bromooctyloxy)-3-methylbenzene. ¹H NMR (CDCl₃) δ 8.05 (t, 1H), 6.7(m, 2H), 4.0 (t, 2H), 1.8 (m, 2H), 1.6-1.3 (m, 6H), 0.9 (m, 3H).

2-Fluoro-4-(hexyloxy)aniline (1.6 g) was prepared from2-fluoro-4-(hexyloxy)-1-nitrobenzene (2.6 g) following the method for8-(3-ethoxypropoxyl)octan-1-amine. ¹H NMR (CDCl₃) δ 6.75-6.5 (m, 3H),3.85 (t, 2H), 3.4 (br s, 2H, NH ₂), 1.75 (m, 2H), 1.5-1.2 (m, 6H), 0.9(m, 3H).

N-[2-Fluoro-4-(hexyloxy)phenyl]quinolin-4-amine (114 mg) was preparedfrom 2-fluoro-4-(hexyloxy)aniline (1.6 g), 4-chloroquinoline (1.33 g),TEA (5 mL), and NMP (0.5 mL) at 130° C. in a sealed tube for 5 daysfollowing the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4-amine.¹H NMR (CDCl₃) δ 8.55 (d, 1H), 8.05 (d, 1H), 7.95 (d, 1H), 7.7 (m, 1H),7.5 (m, 1H), 7.3 (m, 1H), 6.75 (m, 2H), 6.65 (d, 1H), 6.4 (br s, 1H,NH), 3.95 (t, 2H), 1.8 (m, 2H), 1.6-1.3 (m, 6H), 0.9 (m, 3H).

Example 62 N-Benzylquinolin-4-amine

A mixture of benzylamine (166 mg, 1.55 mmol), 4-chloroquinoline (268 mg,1.64 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated in a heavy walledsealed tube at 130° C. for 40 hr. The mixture was cooled, a mixture ofEtOH and H₂O was added, and the sealed mixture was heated for 16 hr.Then, the mixture was cooled and partitioned between EA (3×) and 5%Na₂CO₃ (3×) and brine. The organic phases were dried over Na₂SO₄ andconcentrated to give 385 mg of oil. Purification by preparative TLC (10%MeOH/DCM) gave 294 mg of brown oil. Rf 0.33 (10% MeOH/DCM); ¹H NMR(CDCl₃) δ 8.49 (d, 1H, J=5.2 Hz), 7.98 (dd, 1H, J=0.8, 8.4 Hz), 7.82 (d,1H, J=8.4 Hz), 7.61 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.42-7.27 (m, 6H),6.41 (d, 1H, J=5.4 Hz), 5.76 (br s, 1H), 4.51 (m, 2H, AB).

Example 63 N-Phenethylquinolin-4-amine

A mixture of 2-phenethylamine (177 mg, 1.46 mmol), 4-chloroquinoline(258 mg, 1.58 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated at 130° C.in a sealed tube for 40 hr. The cooled mixture was partitioned betweenEA (3×) and 5% Na₂CO₃ (3×) and brine, and the organic phases were driedover anhydrous Na₂SO₄ and concentrated to give a solid. Washing withEt₂O gave 230 mg of red solid. ¹H NMR (CDCl₃) δ 8.55 (d, 1H, J=5.4 Hz),7.98 (m, 1H), 7.64-7.58 (m, 2H), 7.42-7.24 (m, 6H), 6.48 (d, 1H, J=5.4Hz), 5.17 (br s, 1H, NH), 3.60 (m, 2H), 3.06 (t, 2H, J=6.9 Hz).

Example 64 N-[4-(Hexyloxy)benzyl]quinolin-4-amine

4-(Hexyloxy)benzonitrile A mixture of 4-cyanophenol (25.2 g, 212 mmol),K₂CO₃ (24.7 g, 233 mmol), and 1-bromohexane (29.6 mL, 212 mmol) in 150mL of DMF was stirred at room temperature for 24 hr and then at 55° C.for 24 hr. 4-Cyanophenol remained, as shown by TLC. Na₂CO₃ (7.0 g, 66mmol), and 1-bromohexane (3.0 mL, 21 mmol) were added, and, after 24 hr,the temperature was lowered to 40° C. and additional Na₂CO₃ (12.4 g, 117mmol) and 1-bromohexane (10.0 mL, 72 mmol) were added. However, after 24hr, no consumption of the remaining 4-cyanophenol was apparent. Themixture was cooled to room temperature and 6 mL of concentrated NH₄OHwas added. After standing for 3 days, the mixture was partitionedbetween EA (3×250 mL) and H₂O (300 and 200 mL), 1M HCl (100 mL), andbrine (150 mL). The combined organic phases were dried over MgSO₄ andconcentrated. SPE (10% EA/Hex) gave 35.8 g of colorless oil thatsolidified upon standing. Rf 0.63 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.55and 6.92 (m, 4H, AA′BB′), 3.98 (t, 2H, J=6.6 Hz), 1.78 (m, 2H), 1.43 (m,2H), 1.35-1.30 (m, 4H), 0.89 (m, 3H); ¹³C NMR (CDCl₃) δ 162.6, 134.1,119.5, 115.4, 103.8, 68.6, 31.7, 29.1, 25.8, 22.7, 14.2.

[4-(Hexyloxy)phenyl]methanamine 4-(Hexyloxy)benzonitrile (35.8 g, 176mmol) was taken up in 350 mL of THF, and the mixture was cooled by anice bath. LAH (7 g, 184 mmol) was added cautiously in portions. After 1hr, the mixture was heated at reflux. After 15 hr, the mixture wascooled with an ice bath. Cautiously, with thorough stirring, in portionsand in sequence, 7 mL of H₂O, 7 mL of 15% NaOH, and 21 mL of H₂O wereadded to the ice-cold mixture. The resultant heterogenous mixture wasdiluted with 350 mL of IPA. The mixture was filtered through a bed ofCelite, and the solids were washed with 200 mL of IPA. The filtrate wasconcentrated to give 34.4 g of the product that contained residual IPA.Rf 0.25 (5% MeOH/DCM+2% TEA, ninhydrin (+)); ¹H NMR (CDCl₃) δ 7.17 and6.83 (m, 4H, AA′BB′), 3.90 (t, 2H, J=6.7 Hz), 3.74 (s, 2H), 2.00 (br s,2H, NH ₂), 1.78 (m, 2H), 1.48-1.27 (m, 6H), 0.88 (m, 3H).

N-[4-(Hexyloxy)benzyl]quinolin-4-amine [4-(Hexyloxy)phenyl]methanamine(166 mmol) was taken up in 400 mL of 1-pentanol, and 150 mL of volatilematerial was removed by distillation in order to ensure anhydrousconditions. The mixture was allowed to cool to 70° C., andtripropylamine (63 mL, 330 mmol) and 4-chloroquinoline (28 g, 172 mmol)were added. Heating at reflux was resumed. After 16 hr, TLC of analiquot indicated very little ninhydrin (+) starting material remained.Volatile material was removed by distillation and evaporation. Thecooled mixture was diluted with 1:2 DCM/EA and washed with 3N NaOH (60mL), H₂O, and brine. The combined organic phases were dried over Na₂SO₄,filtered, and concentrated. SPE, eluting with 50% EA/Hex and then 15%EtOH/DCM, gave a brown oil. The oil was taken up in EA and washed with5% Na₂CO₃ and brine. The organic phase was dried over Na₂SO₄, filtered,and concentrated. EA (10 mL) and then hexanes (20 mL) were added to theresidue. A precipitate was obtained. The colorless precipitate wascollected by filtration and washed with 100 mL of 50% EA/Hex and then 50mL of 30% EA/Hex. A second crop was obtained from the combinedfiltrates. The crops were combined and dried in vacuo to give 38.4 g. Rf0.25 (5% MeOH/DCM); mp 103.5-104.0° C.; ¹H NMR (CDCl₃) δ 8.55 (d, 1H,J=5.5 Hz) 8.00 (d, 1H, J=0.7 Hz), 7.98 (d, 1H, J=0.7 Hz), 7.74 (m, 1H),7.65-7.61 (m, 1H), 7.41 (m, 1H), 7.30 and 6.90 (m, 4H, AA′BB′), 6.46 (d,1H, J=5.1 Hz), 5.33 (m, 1H), 4.43 (m, 2H, AB), 3.96 (t, 2H, J=6.6 Hz),1.79 (m, 2H), 1.46 (m, 2H), 1.39-1.30 (m, 4H), 0.90 (m, 3H); ¹³C NMR(CDCl₃) δ 159.2, 151.4, 149.6, 148.7, 130.3, 129.5, 129.2, 129.1, 124.9,119.5, 119.0, 115.2, 99.5, 68.4, 47.4, 31.8, 29.4, 25.9, 22.8, 14.2.

Example 65 N-[3-(Hexyloxy)benzyl]quinolin-4-amine

3-(Hexyloxy)benzaldehyde A mixture of 3-hydroxybenzaldehyde (10.3 g,84.4 mmol), K₂CO₃ (13.9 g, 100.7 mmol), and 1-bromohexane (11.2 mL, 80.0mmol) in 90 mL of DMF was heated at 60° C. for 12 hr. The mixture wascooled to room temperature, poured into 30% EA/Hex, and washed with H₂O,5% Na₂CO₃, H₂O, 0.1M HCl, and brine. The organic phases were dried overNa₂SO₄, filtered through a pad of silica gel, and concentrated to give15.8 g of brown oil. Rf 0.56 (20% EA/Hex), ¹H NMR (CDCl₃) δ 9.94 (s,1H), 7.43-7.36 (m, 3H), 7.14 (m, 1H), 3.99 (t, 2H, J=6.6 Hz), 1.79 (m,2H), 1.45 (m, 2H), 1.37-1.28 (m, 4H), 0.89 (m, 3H); ¹³C NMR (CDCl₃) δ192.4, 159.9, 137.9, 130.1, 123.4, 122.1, 113.0, 68.4, 31.7, 29.2, 25.8,22.7, 14.2.

[3-(Hexyloxy)phenyl]methanol 3-(Hexyloxy)benzaldehyde was taken up in160 mL of MeOH, and the mixture was cooled using an ice bath. NaBH₄(3.17 g, 83 mmol) was added in three portions, during which gas wasevolved from the mixture. Three hours after the final addition, 10 mL ofacetone was added, and the mixture was allowed to stand for 3 days.Then, the volatile material was evaporated, and the residue waspartitioned between 1:1 EA/Hex and H₂O, 5% Na₂CO₃ (2×), H₂O, 0.1M HCl(2×), and brine. The organic phases were dried over Na₂SO₄, filteredthrough a pad of silica gel, and concentrated to give 15.3 g of lightbrown oil. Rf 0.28 (20% EA/Hex); ¹H NMR (CDCl₃) δ 8.16 (m, 1H),7.83-7.81 (m, 2H), 7.73 (m, 1H), 5.55 (s, 2H), 4.86 (t, 2H, J=6.6 Hz),2.86 (br s, 1H, OH), 2.69 (m, 2H), 2.37 (m, 2H), 2.27-2.23 (m, 4H), 1.82(t, 3H, J=7.0 Hz); ¹³C NMR (CDCl₃) δ 159.6, 142.7, 129.7, 119.1, 114.0,113.1, 69.2, 65.4, 31.8, 29.4, 25.9, 22.8, 14.2.

3-(Hexyloxy)benzyl methanesulfonate [3-(Hexyloxy)phenyl]methanol wastaken up in 180 mL of THF and 100 mL of EA and cooled using an ice bath.TEA (12.4 mL, 88 mmol) and then methanesulfonyl chloride (6.30 mL, 80mmol) were added. A white precipitate formed rapidly. After 2 hr, 5 mLof H₂O were added, and the volatile components were evaporated. Theresidue was partitioned between EA (3×300 mL) and H₂O, saturated NaHCO₃,H₂O, 0.1M HCl, and brine (100 mL each). The combined organic phases weredried over Na₂SO₄, filtered through a pad of silica gel, andconcentrated to give 20.75 g of light brown oil. Rf 0.50 (30% EA/Hex);¹H NMR (CDCl₃) δ 7.3 (m, 1H), 6.9-6.8 (m, 3H), 5.2 (s, 2H), 4.0 (t, 2H,J=6.6 Hz), 2.9 (2s, 3H), 1.8 (m, 2H), 1.4 (m, 2H), 1.4-1.3 (m, 4H), 0.9(m, 3H); ¹³C NMR (CDCl₃) δ 159.7, 134.9, 130.1, 120.9, 115.7, 114.9,71.7, 68.3, 38.6, 31.7, 29.4, 25.9, 22.8, 14.2.

N-[3-(Hexyloxy)benzyl]phthalimide A mixture of 3-(hexyloxy)benzylmethanesulfonate and potassium phthalimide (15.4 g, 83.2 mmol) in 200 mLof DMF was stirred using a mechanical stirrer at room temperature for 4hr and then at 50° C. for 4 hr. Then, H₂O (100 mL) was added, and thevolatile material was evaporated. The residue was partitioned between EAand 5% Na₂CO₃ (2×), H₂O, 0.1M HCl, and brine. The organic phases weredried over Na₂SO₄, filtered through a pad of silica gel, andconcentrated. Crystallization from IPA gave 20.74 g of colorless solid.Rf 0.56 (30% EA/Hex); ¹H NMR (CDCl₃) δ 7.9 and 7.7 (m, 4H, AA′BB′), 7.2(m, 1H), 7.0-6.9 (m, 2H), 6.8 (m, 1H), 4.8 (s, 2H), 3.9 (t, 2H, J=6.6Hz), 1.8 (m, 2H), 1.5 (m, 2H), 1.3-1.2 (m, 4H), 0.9 (m, 3H); ¹³C NMR(CDCl₃) δ 168.2, 159.6, 138.0, 134.2, 132.3, 129.8, 123.6, 120.8, 114.8,114.1, 68.1, 41.8, 31.8, 29.4, 25.9, 22.8, 14.2.

[3-(Hexyloxy)phenyl]methanamine Hydrazine monohydrate (2.20 mL, 45.3mmol) was added to a mixture of N-[3-(hexyloxy)benzyl]phthalimide (10.1g, 30.0 mmol) and 90 mL of denatured EtOH with mechanical stifling. Themixture was heated at reflux for 15 hr, during which time a colorlessprecipitate formed. The mixture was concentrated by evaporation, and theresidue was partitioned between DCM (150, 2×80 mL) and 5% Na₂CO₃ (2×100mL). The combined organic phases were dried over Na₂SO₄, filtered, andconcentrated. SPE, washing with 50% isopropyl acetate/Hex and theneluting with 3% MeOH/DCM+2% TEA gave 4.40 g of the product as a paleyellow liquid, which was carried on without additional drying. Rf 0.26(10% MeOH/DCM, ninhydrin (+)); ¹H NMR (CDCl₃) δ 7.22 (m, 1H), 6.87-6.84(m, 2H), 6.76 (dd, 1H, J=2.4, 8.0 Hz), 3.94 (t, 2H, J=6.6 Hz), 3.82 (brs, 2H, AB), 1.76 (m, 2H), 1.59 (br s, 2H, NH ₂), 1.47-1.29 (m, 6H), 0.89(t, 3H, J=6.8 Hz).

N-[3-(Hexyloxy)benzyl]quinolin-4-amine [3-(Hexyloxy)phenyl]methanamine(7.20 g, 34.8 mmol) was taken up in 100 mL of 1-pentanol, and then 25 mLof volatile material was removed by distillation. The mixture was cooledbelow boiling, and tripropylamine (10.0 mL, 52.4 mmol) and4-chloroquinoline (5.67 g, 34.8 mmol) were added. Heating at reflux wasresumed. After 26 hr, volatile material was removed by evaporation. Themixture was diluted with DCM (350 mL) and washed with 1N NaOH (50 mL)and 5% Na₂CO₃ (50 mL). The aqueous phases were extracted with DCM (100mL). The combined organic phases were dried over Na₂SO₄, filtered, andconcentrated. SPE, washing with 50% EA/Hex and then eluting with 50%EA/Hex+2% TEA, gave product fractions that were combined andconcentrated. The residue was partitioned between EA (400, 175 mL) and5% Na₂CO₃ and brine (50 mL each). The combined organic phases were driedover Na₂SO₄, filtered, and concentrated to approximately 50 mL,whereupon substantial precipitate formed. The precipitate wasrecrystallized by heating and cooling, at the end of which 20 mL ofhexanes was added. After standing overnight, the colorless precipitatewas collected by filtration and washed with 30% EA/Hex. (The motherliquor contained approximately 2.4 g of material, but it was not treatedfurther.) Drying in vacuo gave 4.05 g. Rf 0.20 (10% MeOH/DCM); mp109.5-110.0° C.; ¹H NMR (CDCl₃) δ 8.55 (d, 1H, J=5.1 Hz), 8.00 (dd, 1H,J=0.7, 8.4 Hz), 7.76 (dd, 1H, J=1.1, 8.5 Hz), 7.65 (ddd, 1H, J=1.4, 6.9,8.4 Hz), 7.44 (m, 1H), 7.29 (t, 1H), 6.98-6.94 (m, 2H), 6.86 (dd, 1H,J=1.8, 8.1 Hz), 6.46 (d, 1H, J=5.2 Hz), 5.34 (t, 1H, NH), 4.50 (m, 2H,AB), 3.94 (t, 2H, J=6.6 Hz), 1.80-1.73 (m, 2H), 1.46-1.40 (m, 2H),1.35-1.30 (m, 4H), 0.91-0.87 (m, 3H); ¹³C NMR (CDCl₃) δ 160.0, 151.4,149.6, 148.8, 139.4, 130.4, 130.2, 129.2, 125.0, 119.8, 119.5, 119.1,114.2, 113.9, 99.7, 68.3, 47.9, 31.8, 29.5, 25.9, 22.8, 14.2.

Example 66 N-[2-(Hexyloxy)benzyl]quinolin-4-amine

[2-(Hexyloxy)phenyl]methanol A mixture of 3-hydroxybenzyl alcohol (3.06g, 24.7 mmol), 1-bromohexane (3.20 mL, 22.9 mmol), K₂CO₃ (3.50 g, 25.4mmol), and 10 mL of DMF was reacted for 40 hr. The mixture waspartitioned between EA and H₂O, 5% Na₂CO₃, H₂O, 0.1M HCl, and brine. Theorganic phases were dried over anhydrous Na₂SO₄ and concentrated. SPE,washing with 5% EA/Hex and eluting with 15% EA/Hex, gave 2.86 g ofproduct. Rf 0.31 (15% EA/Hex); ¹H NMR (CDCl₃) δ 7.27-7.22 (m, 2H),6.95-6.85 (m, 2H), 4.69 (s, 2H), 4.01 (t, 2H, J=6.5 Hz), 2.45 (br s, 1H,OH), 1.81 (m, 2H), 1.52-1.32 (m, 6H), 0.91 (m, 3H).

N-[2-(Hexyloxy)benzyl]phthalimide DIEA (4.90 mL, 28.1 mmol) was added toa mixture of [2-(hexyloxy)phenyl]methanol (2.86 g, 13.8 mmol) andmethanesulfonyl chloride (2.10 mL, 26.8 mmol) in 25 mL of dioxane and 10mL of EA cooled by an ice bath. After 2 hr, the mixture was partitionedbetween EA and H₂O, saturated NaHCO₃, H₂O, 0.1M HCl, and brine. Theorganic phases were dried over anhydrous Na₂SO₄ and concentrated. Theresidue was filtered through a pad of silica gel using 50% EA/Hex andthe filtrate was concentrated to give crude 2-(hexyloxy)benzylmethanesulfonate. The crude 2-(hexyloxy)benzyl methanesulfonate wastaken up in 150 mL of acetone, sodium iodide (3.1 g, 21 mmol) was added,and the mixture was heated at reflux for 1.5 hr. Then, the solvent wasevaporated, and the solid residue was partitioned between EA and H₂O.The organic phase was decolorized with aqueous Na₂S₂O₃ and washed withH₂O and brine, dried over anhydrous MgSO₄, and concentrated. The residuewas filtered through a pad of silica gel using 25% EA/Hex and thefiltrate was concentrated to give crude1-(hexyloxy)-2-(iodomethyl)benzene. A mixture of the crude1-(hexyloxy)-2-(iodomethyl)benzene and potassium phthalimide (3.8 g, 20mmol) in 12 mL of DMF was reacted at room temperature for 24 hr. Themixture was partitioned between EA and H₂O, aqueous Na₂S₂O₃, H₂O, 5%Na₂CO₃, H₂O, 0.1M HCl, and brine, and the organic phases were dried overanhydrous MgSO₄ and concentrated. SPE, washing with 5% EA/Hex andeluting with 15% EA/Hex, gave 2.30 g of oil. Careful TLC (avoidingoverloading and using a longer plate) showed that the product containeda nearly co-migratory impurity. Rf 0.37 (15% EA/Hex); ¹H NMR (CDCl₃) δ7.84 and 7.71 (m, 4H, AA′BB′), 7.27-7.14 (m, 2H), 6.88-6.81 (m, 2H),4.91 (s, 2H), 3.96 (t, 2H, J=6.5 Hz), 1.77 (p, 2H, J=6.7 Hz), 1.46-1.22(m, 6H), 0.88 (m, 3H).

[2-(Hexyloxy)phenyl]methanamine Hydrazine monohydrate was added to amixture of N-[2-(hexyloxy)benzyl]phthalimide and 80 mL of EtOH, and themixture was heated at reflux for 20 hr. The mixture was cooled, and thevolatile components were evaporated. The residue was partitioned betweenEA and 5% Na₂CO₃ and brine, dried over anhydrous Na₂SO₄, andconcentrated. SPE, washing with 18% EA/Hex followed by 4% MeOH/DCM andeluting with 6% MeOH/DCM+2% TEA, gave the ninhydrin (+) product. Rf 0.61(5% MeOH/DCM+2% TEA).

N-[2-(Hexyloxy)benzyl]quinolin-4-amine A mixture of[2-(hexyloxy)phenyl]methanamine (417 mg, 2.01 mmol), 4-chloroquinoline(430 mg, 2.64 mmol), and DIEA (0.50 mL, 2.86 mmol) in 1 mL of NMP washeated at 150° C. in a sealed tube for 18 hr. Then, the mixture wascooled and partitioned between EA and 5% Na₂CO₃ and brine. The organicphase was dried over Na₂SO₄ and concentrated. SPE, washing with 2.5%MeOH/DCM and then eluting with 7% MeOH/DCM, gave 545 mg of solid. Rf0.20 (10% MeOH/DCM); mp 90-91° C. (from EA/Hex); ¹H NMR (CDCl₃) δ ¹H NMR(CDCl₃) δ 8.52 (d, 1H, J=5.5 Hz), 7.98 (dd, 1H, J=0.7, 8.4 Hz), 7.77(dd, 1H, J=1.0, 8.4 Hz), 7.61 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.39 (ddd,1H, J=1.2, 6.9, 8.1 Hz), 7.31-7.23 (m, 2H), 6.92-6.87 (m, 2H), 6.48 (d,1H, J=5.2 Hz), 5.71 (bt, 1H, J=5.2 Hz, NH), 4.54 (m, 2H, AB), 4.02 (t,2H, J=6.4 Hz), 1.84-1.74 (m, 2H), 1.50-1.17 (m, 6H), 0.87-0.81 (m, 3H).

Example 67 N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4-amine

3-Fluoro-4-(hexyloxy)benzonitrile (721 mg) was prepared from3-fluoro-4-hydroxybenzonitrile (1.5 g, 10.9 mmol), 60% sodium hydride(654 mg), 1-bromohexane (1.30 mL), and 10 mL of DMF following the methodfor 1-(8-bromooctyloxy)-3-methylbenzene. ¹H NMR (CDCl₃) δ 7.5 (t, 1H),6.8-6.6 (m, 2H), 3.95 (t, 2H), 1.8 (m, 2H), 1.5-1.2 (m, 6H), 0.9 (m,3H).

[3-Fluoro-4-(hexyloxy)phenyl]methanamine (212 mg, 0.9 mmol) was preparedfrom 3-fluoro-(4-hexyloxyl)benzonitrile (721 mg, 3.3 mmol) and LAH (6.6mmol) in THF (50 mL) at 0° C. for 4 hr and room temperature for 12 hrfollowing the method for [4-(hexyloxy)phenyl]methanamine. ¹H NMR (CDCl₃)δ 7.15 (t, 1H), 6.7-6.5 (m, 2H), 3.9 (t, 2H), 3.75 (s, 2H), 1.75 (m,2H), 1.6-1.2 (m, 8H), 0.9 (m, 3H).

N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4-amine (325 mg) was preparedfrom [3-fluoro-4-(hexyloxy)phenyl]methanamine (486 mg, 2.2 mmol),4-chloroquinoline (541 mg, 3.3 mmol), TEA (4 mL), and NMP (0.5 mL) at130° C. in a sealed tube for 5 days following the method forN-[8-(3-ethoxypropoxyl)octyl]quinolin-4-amine. ¹H NMR (CDCl₃) δ 8.5 (d,1H), 8.0 (d, 1H), 7.8 (d, 1H), 7.6 (m, 1H), 7.4 (m, 1H), 7.25 (t, 1H),6.6 (m, 2H), 6.45 (d, 1H), 5.8 (br s, 1H, NH), 4.5 (m, 2H, AB), 3.9 (t,2H), 1.8 (m, 2H), 1.6-1.2 (m, 6H), 0.9 (m, 3H).

Example 68 N-[4-(Decyloxy)benzyl]quinolin-4-amine

4-(Decyloxy)benzonitrile A mixture of 4-hydroxybenzonitrile (4.32 g,36.3 mmol), 1-bromodecane (6.80 mL, 32.9 mmol), and K₂CO₃ (6.61 g, 47.8mmol) in 20 mL of DMF was reacted for 2 days. The solvent was evaporatedin vacuo. The residue was partitioned between 50% EA/Hex (3×150 mL) and5% Na₂CO₃ (3×80 mL), H₂O (40 mL), 0.1M HCl (40 mL), and brine (80 mL).The organic phases were dried over anhydrous Na₂SO₄ and concentrated togive 8.30 g of colorless oil that solidified upon standing. ¹H NMR(CDCl₃) δ 7.54 and 6.90 (m, 4H, AA′BB′), 3.97 (t, 2H, J=6.6 Hz), 1.78(m, 2H), 1.42 (m, 2H), 1.34-1.25 (m, 12H), 0.86 (m, 3H); ¹³C NMR (CDCl₃)δ 162.6, 134.0, 119.4, 115.3, 103.7, 68.5, 32.0, 29.6, 29.4, 29.4, 29.1,26.0, 22.8, 14.2.

[4-(Decyloxy)phenyl]methanamine Lithium aluminum hydride (2.0 g, 53mmol) was added in portions to a mixture of 4-(decyloxy)benzonitrile(8.30 g, 32.0 mmol) and 80 mL of THF cooled by an ice bath. Then, themixture was allowed to warm to room temperature. After 2 hr, the mixturewas cooled by an ice bath, and 2 mL H₂O, 2 mL 15% NaOH, and 6 mL H₂Owere added sequentially and cautiously. The resulting solids werefiltered, and the solids were washed with 5% MeOH/DCM+1% TEA. Thefiltrate was concentrated, then taken up in DCM and washed with 5%Na₂CO₃. The organic phase was dried over anhydrous Na₂SO₄ andconcentrated. SPE, washing with 40% isopropyl acetate/Hex and elutingwith 3% MeOH/DCM+2% TEA, gave ninhydrin (+) fractions. These fractionswere concentrated, and the residue was taken up in DCM, washed with 5%Na₂CO₃, dried over anhydrous Na₂SO₄, and concentrated to give 7.61 g ofcolorless solid. Rf 0.11 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 7.18 and 6.83(m, 4H, AA′BB′), 3.90 (t, 2H, J=6.6 Hz), 3.76 (s, 2H), 1.75 (m, 2H),1.56 (br s, 2H, NH ₂), 1.43 (m, 2H), 1.39-1.26 (m, 12H), 0.87 (t, 3H,J=6.9 Hz); ¹³C NMR (CDCl₃) δ 158.1, 135.4, 128.2, 114.5, 68.0, 46.0,32.0, 29.6, 29.6, 29.5, 29.4, 26.1, 22.7, 14.2.

N-[4-(Decyloxy)benzyl]quinolin-4-amine [4-(Decyloxy)phenyl]methanamine(5.90 g, 22.4 mmol) was taken up in 100 mL of 1-pentanol, and 25 mL wasremoved by distillation. The mixture was cooled slightly, andtripropylamine (6.50 mL, 34.1 mmol) and 4-chloroquinoline (3.63 g, 22.3mmol) were added. Heating at reflux was continued for 24 hr. Then, thevolatile components were evaporated, and the residue was partitionedbetween DCM and 5% Na₂CO₃. The organic phase was dried over anhydrousNa₂SO₄ and concentrated onto silica gel. SPE, washing with 50% EA/Hexand then eluting with 10% MeOH/DCM, gave a solid. The solid was taken upin DCM, washed with 5% Na₂CO₃, dried over anhydrous Na₂SO₄, andconcentrated to give a solid. Recrystallization from EA/Hex gave 3.70 gcolorless solid. Rf 0.13 (10% MeOH/DCM); mp 96.5-97.0° C.; ¹H NMR(CDCl₃) δ 8.55 (d, 1H, J=5.2 Hz), 7.99 (d, 1H, J=8.5 Hz), 7.74 (d, 1H,J=8.4 Hz), 7.63 (m, 1H), 7.42 (m, 1H), 7.30 and 6.90 (m, 4H, AA′BB′),6.47 (d, 1H, J=5.1 Hz), 5.30 (br s, 1H, NH), 4.44 (m, 2H, AB), 3.95 (m,2H), 1.79 (m, 2H), 1.46 (m, 2H), 1.32-1.27 (m, 10H), 0.88 (m, 3H); ¹³CNMR (CDCl₃) δ 159.1, 151.3, 149.6, 148.7, 130.2, 129.4, 129.2, 129.2,124.9, 119.5, 118.9, 115.1, 99.5, 68.3, 47.3, 32.1, 29.8, 29.8, 29.6,29.5, 29.5, 26.2, 22.9, 14.3.

Example 69 N-[3-(Decyloxy)benzyl]quinolin-4-amine

3-(Decyloxy)benzaldehyde 1-Bromodecane (15.0 mL, 72.6 mmol) was added toa mixture of 3-hydroxybenzaldehyde (9.75 g, 79.9 mmol) and K₂CO₃ (12.2g, 88.4 mmol) in 80 mL of DMF heated at 50° C. using mechanicalstirring. After 22 hr, the mixture was diluted with H₂O (100 mL) andextracted with EA (3×100 mL), and the organic phases were washed with 5%Na₂CO₃ and H₂O (100 mL each), 0.1M HCl (2×100 mL), and brine (100 mL),and dried over anhydrous Na₂SO₄. Evaporation of the volatile componentsyielded 18.74 g of product as a brown oil. Rf 0.54 (10% EA/Hex); ¹H NMR(CDCl₃) δ 9.96 (s, 1H), 7.44-7.37 (m, 3H), 7.18 (m, 1H), 4.00 (t, 2H,J=6.6 Hz), 1.80 (m, 2H), 1.46 (m, 2H), 1.36-1.23 (m, 12H), 0.88 (m, 3H);¹³C NMR (CDCl₃) δ 192.4, 159.9, 138.0, 130.2, 123.5, 122.2, 113.0, 68.5,32.1, 29.8, 29.7, 29.6, 29.5, 29.3, 26.2, 22.9, 14.3.

[3-(Decyloxy)phenyl]methanol Sodium borohydride (2.63 g, 69.2 mmol) wasadded to a mixture of 3-(decyloxy)benzaldehyde (18.74 g) and 160 mL ofMeOH cooled by an ice bath. After 1 hr, residual hydride was quenched byadding H₂O, and 80 mL of 1M HCl was added slowly, resulting inprecipitation. The volatile components were evaporated, and the residuewas partitioned between 50% EA/Hex and H₂O, 5% Na₂CO₃ (2×), H₂O, andbrine. The organic phases were dried over anhydrous Na₂SO₄, filteredthrough a pad of silica gel, and concentrated to give 21.05 g of productas a light brown solid. Rf 0.11 (10% EA/Hex) 0.28 (1:4:5EA/toluene/Hex); ¹H NMR (CDCl₃) δ 7.24 (m, 1H), 6.90-6.88 (m, 2H), 6.81(m, 1H), 4.60 (br s, 2H, AB), 3.94 (t, 2H, J=6.6 Hz), 2.55 (br s, 1H,OH), 1.78 (m, 2H), 1.46 (m, 2H), 1.38-1.24 (m, 12H), 0.91 (m, 3H); ¹³CNMR (CDCl₃) δ 159.5, 142.7, 129.6, 119.0, 113.8, 113.0, 68.1, 65.2,32.0, 29.8, 29.7, 29.6, 29.5, 29.4, 26.2, 22.8, 14.3.

3-(Decyloxy)benzyl methanesulfonate Triethylamine (11.8 mL, 84.4 mmol)was added to a mixture of [3-(Decyloxy)phenyl]methanamine (21.05 g,mmol) and methanesulfonyl chloride (6.60 mL, 84.4 mmol) in 120 mL of THFcooled by an ice bath. A precipitate formed rapidly. After 1 hr, 5 mL ofH₂O was added, and the volatile components were evaporated. The residuewas partitioned between EA and H₂O, saturated NaHCO₃, H₂O, 0.1M HCl, andbrine. The organic phases were dried over anhydrous Na₂SO₄, filteredthrough a pad of silica gel, and concentrated to give 23.53 g of3-(decyloxy)benzyl methanesulfonate as an amber oil that solidified uponstanding. Rf 0.45 (1:4:5 EA/toluene/Hex) 0.35 (20% EA/Hex); ¹H NMR(CDCl₃) δ 7.29 (m, 1H), 6.98-6.90 (m, 3H), 5.19 (m, 2H, AB), 3.95 (t,2H, J=6.6 Hz), 2.90 (s, 3H), 1.78 (m, 2H), 1.43 (m, 2H), 1.36-1.28 (m,12H), 0.88 (m, 3H); ¹³C NMR (CDCl₃) δ 159.6, 134.9, 130.1, 120.8, 115.6,114.8, 71.7, 68.2, 38.4, 32.0, 29.7, 29.7, 29.5, 29.4, 29.4, 26.2, 22.8,14.3.

N-[3-(Decyloxy)benzyl]phthalimide A mixture of 3-(decyloxy)benzylmethanesulfonate (23.53 g, 68.8 mmol) and potassium phthalimide (14.00g, 75.7 mmol) in 90 mL of DMF was reacted at room temperature for 16 hrand at 50-60° C. for 3 hr. The mixture was cooled, diluted with 350 mLH₂O, and extracted with EA (3×400 mL). The organic phases were washedwith H₂O (3×200 mL) and brine (2×200 mL), dried over anhydrous Na₂SO₄,and concentrated to give a colorless solid. The solid was broken up andwashed with 10% EA/Hex to give 11.40 g of solid as a colorless solid.The washes were partially concentrated to give an additional 6.95 g ofcolorless solid. Rf 0.50 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.84 and 7.70(m, 4H, AA′BB′), 7.21 (m, 1H), 7.00-6.96 (m, 2H), 6.79 (m, 1H), 4.81 (s,2H, AB), 3.92 (t, 2H, J=6.6 Hz), 1.74 (m, 2H), 1.43 (m, 2H), 1.30-1.26(m, 12H), 0.88 (m, 3H); ¹³C NMR (CDCl₃) δ 168.2, 159.6, 137.9, 134.2,132.4, 129.9, 123.6, 120.8, 114.8, 114.1, 68.2, 41.8, 32.1, 29.8, 29.8,29.6, 29.5, 29.5, 29.5, 26.2, 22.9, 14.3.

[3-(Decyloxy)phenyl]methanamine Hydrazine monohydrate (3.90 mL, 80.3mmol) was added in three portions to a mixture ofN-[3-(decyloxy)benzyl]phthalimide (5.12 g, 13.0 mmol) and IPA heated atreflux. After the starting material was consumed as observed by TLC (30hr), the mixture was cooled and concentrated. The residue waspartitioned between isopropyl acetate and 5% Na₂CO₃ and brine, and theorganic phases were dried over anhydrous Na₂SO₄ and concentrated. SPE,washing with 50% isopropyl acetate/Hex and then eluting with 3%MeOH/DCM+2% TEA, gave ninhydrin (+) material. Partial concentration andwashing of the filtrate with 5% Na₂CO₃ and drying over Na₂SO₄ gave 3.25g of yellow oil after drying in vacuo.

N-[3-(Decyloxy)benzyl]quinolin-4-amine A mixture of[3-(decyloxy)phenyl]methanamine (2.54 g, 9.66 mmol), 4-chloroquinoline(1.73 g, 10.62 mmol), and tripropylamine (4.00 mL, 21.0 mmol) in 65 mLof 1-pentanol was heated at reflux for 16 hr. Analytical TLC indicated asubstantial quantity of unreacted [3-(decyloxy)phenyl]methanamine.4-Chloroquinoline (0.85 g, 5.21 mmol) and tripropylamine (2.00 mL, 10.5mmol) were added. After 24 hr, the mixture was cooled and 15 mL of 1NNaOH were added. The volatile components were evaporated, the residuewas taken up in DCM and washed with 5% Na₂CO₃, and the organic phase wasdried over anhydrous Na₂SO₄ and evaporated onto silica gel. SPE, washingwith 70% EA/Hex and eluting with 50% EA/Hex+2% TEA, gave 2.62 g of whitesolid after crystallization from IPA. Recrystallization from 30% EA/Hexgave 2.00 g of N-[3-(decyloxy)benzyl]quinolin-4-amine as a white powderysolid. Rf 0.24 (50% EA/Hex+2% TEA) 0.40 (10% MeOH/DCM); mp 71.0-72.0°C.; ¹H NMR (CDCl₃) δ 8.55 (d, 1H, J=5.1 Hz), 8.00 (m, 1H), 7.77 (m, 1H),7.64 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 7.43 (ddd, 1H, J=1.5, 7.0, 8.5 Hz),7.28 (m, 1H), 6.97-6.93 (m, 2H), 6.85 (dd, 1H, J=1.8, 8.1 Hz), 6.45 (d,1H, J=5.5 Hz), 5.38 (m, 1H, NH), 4.49 (m, 2H, AB), 3.94 (m, 2H), 1.77(m, 2H), 1.42 (m, 2H), 1.34-1.26 (m, 10H), 0.87 (m, 3H); 159.9, 151.4,149.6, 148.7, 139.3, 130.3, 130.2, 129.2, 125.0, 119.7, 119.5, 18.95,114.1, 113.8, 99.6, 68.3, 47.8, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5,26.3, 22.9, 14.3.

Example 70 N-(3-Phenoxybenzyl)quinolin-4-amine

3-Phenoxybenzyl methanesulfonate A mixture of 3-phenoxybenzyl alcohol(15.44 g, 77.2 mmol) and TEA (13.1 mL, 93.4 mmol) in 180 mL of THF and100 mL of EA was cooled using an ice bath. Then, methanesulfonylchloride (6.60 mL, 84.4 mmol) was added. A white precipitate formedrapidly. After 2 hr, 5 mL of H₂O were added, and the volatile componentswere evaporated. The residue was partitioned between EA (3×300 mL) andH₂O, saturated NaHCO₃, H₂O, 0.1M HCl, and brine (100 mL each). Thecombined organic phases were dried over Na₂SO₄, filtered through a padof silica gel, and concentrated to give 22.02 g of colorless oil. Rf0.38 (30% EA/Hex); ¹H NMR (CDCl₃) δ 7.4-7.3 (m, 3H), 7.2-7.1 (m, 2H),7.1-7.0 (m, 4H), 5.2 (m, 2H, AB), 2.9 (s, 3H); ¹³C NMR (CDCl₃) δ 158.0,156.7, 135.5, 130.4, 130.1, 124.0, 123.4, 119.5, 119.4, 118.8, 71.0,38.4.

N-(3-Phenoxybenzyl)phthalimide A mixture of 3-phenoxybenzylmethanesulfonate (22.5 g, 80.9 mmol) and potassium phthalimide (16.4 g,88.6 mmol) in 200 mL of NMP was stirred at 50° C. for 17 hr using amechanical stirrer. Then, H₂O (100 mL) was added, and the volatilematerial was evaporated. The residue was partitioned between EA and 5%Na₂CO₃ (2×), H₂O, 0.1M HCl, and brine. The organic phases were driedover Na₂SO₄, filtered through a pad of silica gel, and concentrated.Crystallization from IPA gave 23.55 g of colorless solid. Rf 0.53 (30%EA/Hex); ¹H NMR (CDCl₃) δ 7.85 and 7.73 (m, 4H, AA′BB′), 7.34-7.24 (m,3H), 7.15-7.07 (m, 3H), 6.99-6.97 (m, 2H), 6.88-6.85 (m, 1H), 4.82 (m,2H, AB); ¹³C NMR (CDCl₃) δ 168.1, 157.6, 157.1, 138.4, 134.5, 134.2,132.2, 130.2, 129.9, 123.8, 123.6, 123.6, 123.2, 119.1, 119.1, 118.1,41.4.

(3-Phenoxyphenyl)methanamine Hydrazine monohydrate (3.50 mL, 72.1 mmol)was added to a mixture of N-(3-phenoxybenzyl)phthalimide (6.28 g, 19.1mmol) and 200 mL of IPA while using mechanical stifling. The mixture washeated at reflux for 7 hr. After standing overnight, a precipitate hadformed. The mixture was concentrated by evaporation, and the residue waspartitioned between isopropyl acetate and 5% Na₂CO₃ and brine. Theorganic phases were dried over Na₂SO₄, filtered, and concentrated. SPE,washing with 50% isopropyl acetate/Hex and then eluting with 3%MeOH/DCM+2% TEA gave fractions that contained ninhydrin (+) product. Thecombined product fractions were washed with 5% Na₂CO₃, dried overNa₂SO₄, filtered, and concentrated to give 3.25 g of yellow oil. Rf 0.28(10% MeOH/DCM); ¹H NMR (CDCl₃) δ 7.36-7.25 (m, 3H), 7.12-6.95 (m, 5H),6.87 (ddd, 1H, J=1.0, 2.5, 8.2 Hz), 3.82 (br s, 2H), 2.15 (br s, 2H, NH₂).

N-(3-Phenoxybenzyl)quinolin-4-amine (3-Phenoxyphenyl)methanamine (2.02g, 10.2 mmol) was taken up in 60 mL of 1-pentanol, and then 15 mL ofvolatile material was removed by distillation. The mixture was cooledbelow boiling, and tripropylamine (3.80 mL, 19.9 mmol) and4-chloroquinoline (1.65 g, 10.2 mmol) were added. Heating at reflux wasresumed. After 66 hr, volatile material was removed by evaporation. Themixture was partitioned between DCM (150, 100 mL) and 5% Na₂CO₃ (80 mL).The combined organic phases were dried over Na₂SO₄, filtered, andconcentrated to give a solid. Recrystallization from EA/Hex gave 2.08 gof colorless solid. Rf 0.34 (10% MeOH/DCM); mp 163.0-164.0° C.; ¹H NMR(CDCl₃) δ 8.54 (d, 1H, J=5.5 Hz), 8.00 (m, 1H), 7.76 (d, 1H, J=8.1 Hz),7.64 (m, 1H), 7.43 (m, 1H), 7.34-7.29 (m, 3H), 7.11 (m, 1H), 7.05 (s,1H), 7.02-6.99 (m, 2H), 6.94 (dd, 1H, J=2.2, 8.0 Hz), 6.42 (d, 1H, J=5.5Hz), 5.46 (br s, 1H, NH) 4.51 (m, 2H, AB); ¹³C NMR (CDCl₃) δ 158.2,156.9, 151.3, 149.5, 148.7, 139.9, 130.5, 130.3, 130.0, 129.3, 125.0,123.8, 122.2, 119.5, 119.3, 118.9, 118.0, 117.8, 99.7, 47.4.

Example 71 N-[3-(Benzyloxy)benzyl]quinolin-4-amine

3-(Benzyloxy)benzonitrile A mixture of 3-hydroxybenzonitrile (504 mg,4.24 mmol), benzyl chloride (607 mg, 4.78 mmol), and K₂CO₃ (605 mg, 4.38mmol) in 2 mL of DMF reacted for 42 hr. The mixture was diluted with 50%EA/Hex and washed with 5% Na₂CO₃ (2×) and brine made acidic with 1M HCl.The organic phase was dried over anhydrous MgSO₄ and concentrated. FC(15% EA/Hex) gave 780 mg of colorless oil. Rf 0.50 (20% EA/Hex); ¹H NMR(CDCl₃) δ 7.43-7.31 (m, 6H), 7.26-7.17 (m, 3H), 5.08 (m, 2H, AB).

[3-(Benzyloxy)phenyl]methanamine A mixture of 3-(benzyloxy)benzonitrileand 30 mL of THF was cooled by an ice path. LAH (195 mg and then 190 mg)was added. The mixture was allowed to warm to room temperature. After 24hr, the mixture was cooled by an ice bath, and 0.40 mL H₂O, 0.40 mL 15%NaOH, and 1.2 mL H₂O were added in succession. The heterogeneous mixturewas diluted with 5% MeOH/DCM and preloaded on silica gel. SPE, washingwith 5% MeOH and eluting with 10% MeOH/DCM+2% TEA gave 672 mg ofcolorless oil that solidified upon standing. ¹H NMR (CDCl₃) δ 7.48-7.23(m, 6H), 6.98-6.83 (m, 3H), 5.07 (m, 2H, AB), 3.83 (m, 2H, AB).

N-[3-(Benzyloxy)benzyl]quinolin-4-amine (600 mg) was prepared from[3-(benzyloxy)phenyl]methanamine (670 mg, 3.14 mmol), 4-chloroquinoline(767 mg, 4.70 mmol), and DIEA (1.20 mL, 6.88 mmol) in 0.5 mL DMF heatedin a sealed tube. FC (7% MeOH/DCM) gave 600 mg of product. Rf 0.38 (10%MeOH/DCM); ¹H NMR (CDCl₃) δ 8.43 (d, 1H, J=5.4 Hz), 8.01-7.96 (m, 2H),7.62-7.56 (m, 1H), 7.40-7.22 (m, 7H), 6.99-6.88 (m, 3), 6.53 (br s, 1H,NH), 6.34 (d, 1H, J=5.5 Hz), 4.99 (s, 2H), 4.48 (m, 2H, AB).

Example 72 N-(3-Phenethoxybenzyl)quinolin-4-amine

N-(3-Phenethoxybenzyl)quinolin-4-amine was prepared by the method forN-[3-(benzyloxy)benzyl]quinolin-4-amine starting with3-hydroxybenzonitrile (561 mg, 4.71 mmol), 2-bromoethylbenzene (1.34 g,7.24 mmol), and K₂CO₃ (1.00 g, 7.25 mmol) in 2 mL of DMF heated at 60°C.

3-(Phenethoxy)benzonitrile (454 mg): Rf 0.46 (20% EA/Hex): ¹H NMR(CDCl₃) δ 7.38-7.20 (m, 7H), 7.10 (m, 2H), 4.18 (t, 2H, J=6.9 Hz), 3.11(t, 2H, J=6.9 Hz).

(3-(Phenethoxyphenyl)methanamine (480 mg): ¹H NMR (CDCl₃) δ 7.36-7.20(m, 6H), 6.87 (m, 2H), 6.78 (m, 1H), 4.18 (t, 2H, J=7.2 Hz), 3.82 (m,2H, AB), 3.10 (t, 2H, J=7.2 Hz), 2.16 (br s, 2H, NH ₂).

N-(3-Phenethoxybenzyl)quinolin-4-amine (358 mg): Rf 0.12 (5% MeOH/DCM);¹H NMR (CDCl₃) δ 8.39 (d, 1H, J=5.4 Hz), 7.96 (d, 1H, J=8.4 Hz), 7.91(d, 1H, J=8.4 Hz), 7.59 (m, 1H), 7.38 (m, 1H), 7.31-7.18 (m, 6H),6.94-6.90 (m, 2H), 6.80 (dd, 1H, J=2.4, 8.1 Hz), 6.35 (d, 1H, J=5.5 Hz),6.26 (br s, 1H), 4.48 (m, 2H, AB), 4.12 (t, 2H, J=7.0 Hz), 3.05 (m, 2H).

Example 73 N-[4-(Quinolin-4-ylamino)butyl]benzamide

N¹-(Quinolin-4-yl)butane-1,4-diamine A mixture of 1,4-butanediamine(1.54 g, 17.5 mmol), 4-chloroquinoline (357 mg, 2.19 mmol), and DIEA(0.50 mL, 2.87 mmol) was heated at 130° C. in a sealed tube for 24 hr.The mixture was cooled, taken up in EA, and washed with 5% Na₂CO₃ (3×)and brine. The organic phase was dried over Na₂SO₄ and concentrated. ¹HNMR (20% CD₃OD/CDCl₃) δ 8.33 (d, 1H, J=5.5 Hz), 7.86 (ddd, 1H, J=0.5,1.5, 8.4 Hz), 7.81 (ddd, 1H, J=0.5, 1.2, 8.4 Hz), 7.53 (ddd, 1H, J=1.3,6.7, 8.4 Hz), 7.33 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.29 (d, 1H, J=5.5Hz), 3.20 (m, 2H), 2.66 (t, 2H, J=6.9 Hz), 1.69 (m, 2H), 1.51 (m, 2H).

N-[4-(Quinolin-4-ylamino)butyl]benzamideN¹-(Quinolin-4-yl)butane-1,4-diamine (185 mg, 0.86 mmol) was taken up in5 mL of pyridine, and the mixture was concentrated. The residue wastaken up in 10 mL of DCM, cooled by an ice bath, and TEA (0.49 mL, 3.5mmol) and then benzoyl chloride (0.40 mL, 3.43 mmol) were added. Themixture was allowed to warm to room temperature. After 2 hr, 3.43 mL of1N NaOH were added, and the volatile components were removed bydistillation. The residue was partitioned between EA and 5% Na₂CO₃ andbrine. The organic phases were dried over Na₂SO₄ and concentrated. SPE,washing with 5% MeOH/DCM and eluting with 15% MeOH/DCM, gave an oilysolid. Repurification by preparative TLC (15% MeOH/DCM) gave the productas a solid. Rf 0.21 (15% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.31 (d, 1H, J=5.7Hz), 8.10 (m, 1H), 7.80-7.77 (m, 3H), 7.62 (ddd, 1H, J=1.2, 6.6, 8.4Hz), 7.55-7.39 (m, 4H), 6.51 (d, 1H, J=5.5 Hz), 3.45 (q, 2H, J=7 Hz),1.86-1.76 (m, 4H).

Example 74 N-[6-(Quinolin-4-ylamino)hexyl]benzamide

N¹-(Quinolin-4-yl)hexane-1,6-diamine A mixture of 1,6-hexanediamine(2.05 g, 17.7 mmol) and 4-chloroquinoline (297 mg, 1.82 mmol) was heatedat 130° C. in a sealed tube for 24 hr. The mixture was cooled,partitioned between EA (3×) and 5% Na₂CO₃ (3×) and brine. The organicphases were dried over Na₂SO₄ and concentrated. ¹H NMR (20% CD₃OD/CDCl₃)δ 8.39 (d, 1H, J=5.4 Hz), 7.87 (d, 1H, J=8.1 Hz), 7.75 (d, 1H, J=8.4Hz), 7.56 (ddd, 1H, J=1.3, 6.9, 8.4 Hz), 7.36 (m, 1H), 6.35 (d, 1H,J=5.4 Hz), 3.26 (m, 2H), 2.63 (m, 2H), 1.71 (m, 2H), 1.49-1.38 (m, 6H).

N-[6-(Quinolin-4-ylamino)hexyl]benzamideN¹-(Quinolin-4-yl)hexane-1,6-diamine (230 mg, 0.946 mmol) was taken upin 5 mL of pyridine, and the mixture was concentrated. The residue wastaken up in 10 mL of DCM, cooled by an ice bath, and TEA (0.53 mL, 3.8mmol) and then benzoyl chloride (0.44 mL, 3.78 mmol) were added. Themixture was allowed to warm to room temperature. After 2 hr, 3.78 mL of1N NaOH were added. The mixture was partitioned between DCM and 5%Na₂CO₃. The organic phase was dried over Na₂SO₄ and concentrated.Purification by preparative TLC (15% MeOH/DCM) gave the product. Theresidue from concentration of the eluate was taken up in DCM, washedwith 5% Na₂CO₃, dried over Na₂SO₄ and concentrated to give the product.Rf 0.23 (15% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.30 (d, 1H, J=6.0 Hz), 8.09(d, 1H, J=8.4 Hz), 7.91 (d, 1H, J=8.4 Hz), 7.82-7.78 (m, 2H), 7.55 (m,1H), 7.45-7.30 (m, 4H), 6.94 (t, 1H, J=6 Hz), 6.81 (br s, 1H), 6.24 (d,1H, J=6.2 Hz), 3.40 (m, 2H), 3.25 (m, 2H), 1.68-1.54 (m, 8H).

Example 75 N-[8-(Quinolin-4-ylamino)octyl]benzamide

N-(8-Aminooctyl)benzamide A mixture of 1,8-octanediamine (3.27 g, 22.7mmol) and methyl benzoate (0.40 mL, 3.20 mmol) was heated at 115° C. for24 hr. The mixture was cooled and partitioned between EA and H₂O. Theorganic phase, which contained a 1:1 molar ratio of diamine andmonoamide, was concentrated. Reverse-phase SPE, washing with 20%MeOH/H₂O and eluting with MeOH, gave the product fraction, which wasconcentrated, taken up in DCM, washed with 5% Na₂CO₃, dried over Na₂SO₄,and concentrated to give 698 mg of product. ¹H NMR (20% CD₃OD/CDCl₃) δ7.64-7.59 (m, 2H), 7.43 (br s, 1H, NH), 7.32-7.18 (m, 3H), 3.19 (m, 2H),2.45 (m, 2H), 1.42 (m, 2H), 1.27-1.04 (m, 10H).

N-[8-(Quinolin-4-ylamino)octyl]benzamide A mixture ofN-(8-aminooctyl)benzamide (357 mg, 1.44 mmol), 4-chloroquinoline (312mg, 1.91 mmol), and DIEA (0.50 mL, 2.87 mmol) in 1 mL of NMP was heatedat 160° C. in a sealed tube for 24 hr. The mixture was cooled, dilutedwith DCM, and washed with 5% Na₂CO₃. The organic phase was dried overNa₂SO₄ and concentrated. SPE, washing with 5% MeOH/DCM and eluting with2.5% MeOH/DCM+2% TEA, gave the product as an oil, which was crystallizedfrom EtOH. Rf 0.33 (50% EA/Hex+2% TEA); ¹H NMR (CDCl₃) δ 8.33 (d, 1H,J=5.7 Hz), 7.87 (dd, 1H, J=0.7, 8.4 Hz), 7.80 (d, 1H, J=8.7 Hz),7.74-7.71 (m, 2H), 7.58 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.48-7.34 (m,4H), 6.38 (d, 1H, J=5.7 Hz), 3.38-3.26 (m, 4H), 1.74-1.35 (m, 12H).

Example 76 3-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide

N-(8-Aminooctyl)-3-methoxybenzamide A mixture of methyl3-methoxybenzoate (863 mg, 5.20 mmol) and 1,8-octanediamine (6.90 g) washeated at 110-120° C. for 24 hr. The mixture was cooled and partitionedbetween EA (3×60 mL) and H₂O, 2.5% Na₂CO₃ (3×), and brine (60 mL each).The organic phases were dried over anhydrous Na₂SO₄ and concentrated.NMR showed the residue consisted of 2.3:1 ratio of amide and diamine.Reverse-phase SPE (ODS-silica gel), washing with 20% MeOH/H₂O and theneluting with MeOH, gave 1.43 g yellow oil. NMR showed the oil consistedof 7.3:1 ratio of amide and diamine.

3-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide A mixture ofN-(8-aminooctyl)-3-methoxybenzamide (540 mg, 1.94 mmol),4-chloroquinoline (340 mg, 2.08 mmol), and DIEA (0.80 mL, 4.59 mmol) in2.5 mL of NMP was heated at 160° C. in a sealed tube for 3 days. Themixture was cooled, diluted with EA, washed with 5% Na₂CO₃ and brine,dried over Na₂SO₄, and concentrated. SPE, washing with 1% MeOH/DCM andthen eluting with 7.5% MeOH/DCM+2% TEA, gave the product as a solid. Rf0.19 (EA+2% TEA); mp 162-165° C. (from MeOH); ¹H NMR (20% CD₃OD/CDCl₃) δ8.38 (d, 1H, J=5.7 Hz), 8.04 (d, 1H, J=8.4 Hz), 7.92 (d, 1H, J=8.4 Hz),7.57 (m, 1H), 7.40-7.21 (m, 4H), 6.95 (ddd, 1H, J=1.2, 2.7, 8.1 Hz),6.85 (m, 1H), 6.36 (d, 1H, J=5.7 Hz), 6.31 (br s, 1H, NH), 3.75 (s, 3H),3.41-3.25 (m, 4H), 1.72-1.16 (m, 12H).

Example 77 4-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide

N-(8-Aminooctyl)-4-methoxybenzamide A mixture of methyl4-methoxybenzoate (874 mg, 5.26 mmol) and 1,8-octanediamine (6.18 g) washeated at 110-120° C. for 4 days. The mixture was cooled and partitionedbetween EA (3×60 mL) and H₂O, 2.5% Na₂CO₃ (3×), and brine (60 mL each).The organic phases were dried over anhydrous Na₂SO₄ and concentrated.Reverse-phase SPE (ODS-silica gel), washing with 20% MeOH/H₂O and theneluting with MeOH, gave an oil. The oil was taken up in DCM and washedwith 5% Na₂CO₃, dried over Na₂SO₄, and concentrated to give 533 mg ofsticky yellow solid. ¹H NMR (CD₃OD) δ 7.77 and 6.96 (m, 4H, AA′BB′),4.88 (s, 3H), 3.34 (m, 2H), 3.13 (m, 1H, NH), 2.60 (m, 2H), 1.91 (2×s,2H, NH ₂), 1.62-1.33 (m, 12H).

4-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide A mixture ofN-(8-aminooctyl)-4-methoxybenzamide (533 mg, 1.92 mmol) and 7.5 mL ofanhydrous pyridine was evaporated to dryness. Then, 4-chloroquinoline(335 mg, 2.08 mmol) and DIEA (0.80 mL, 4.59 mmol) in 2.5 mL of NMP wasadded and the mixture was heated at 160° C. in a sealed tube for 3 days.The mixture was cooled, diluted with EA, washed with 5% Na₂CO₃ andbrine, dried over Na₂SO₄, and concentrated. SPE, washing with 1%MeOH/DCM and then eluting with 7.5% MeOH/DCM+2% TEA, gave the product asa solid. Rf 0.00 (5% MeOH/DCM) 0.20 (EA+2% TEA); ¹H NMR (20%CD₃OD/CDCl₃) δ 8.30 (d, 1H, J=5.7), 7.82-7.76 (m, 2H), 7.65 and 6.82 (m,4H, AA′BB′), 7.53 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.33 (ddd, 1H, J=1.2,6.9, 8.4 Hz), 6.32 (d, 1H, J=5.5 Hz), 3.74 (s, 3H), 3.32-3.19 (m, 4H),1.70-1.25 (m, 12H).

Example 78 2-(Hexyloxy)-N-[2-(quinolin-4-ylamino)ethyl]benzamide

Methyl 2-(hexyloxy)benzoate A mixture of methyl salicylate (7.76 g, 51.1mmol), K₂CO₃ (8.8 g, 64 mmol), and 1-bromohexane (8.60 mL, 61.5 mmol) in30 mL of DMF was heated at 50° C. for 20.5 hr. The mixture waspartitioned between 1:1 EA/Hex (3×150 mL) and 0.2M HCl, 0.1M HCl, andbrine (50 mL of each). The organic phases were dried over Na₂SO₄ andconcentrated. SPE, washing with Hex and eluting with 20% EA/Hex, gave11.7 g colorless liquid.

N-(2-Aminoethyl)-2-(hexyloxy)benzamide A mixture of methyl2-(hexyloxy)benzoate (2.11 g, 8.94 mmol) and 1,2-ethanediamine (5.40 mL,81.0 mmol) was heated at 115° C. in a sealed tube for 72 hr. Then, thevolatile components were evaporated in vacuo. The residue was taken upin 10 mL of MeOH and evaporated in vacuo to give 2.34 g amber liquid. ¹HNMR (CD₃OD) δ 7.84 (m, 1H), 7.45 (ddd, 1H, J=1.9, 7.4, 9.2 Hz), 7.09 (d,1H, J=8.1 Hz), 7.02 (m, 1H), 4.13 (t, 2H, J=6.5 Hz), 3.47 (m, 2H), 2.84(m, 2H), 1.86 (m, 2H), 1.49 (m, 2H), 1.39-1.34 (m, 4H), 0.93 (m, 3H);¹³C NMR (CD₃OD) δ 169.0, 158.5, 134.1, 132.0, 123.7, 122.0, 114.0, 70.4,43.5, 42.3, 32.9, 30.4, 27.2, 23.9, 14.6.

2-(Hexyloxy)-N-[2-(quinolin-4-ylamino)ethyl]benzamideN-(2-Aminoethyl)-2-(hexyloxy)benzamide (2.34 g, 8.86 mmol) was taken upin 65 mL of 1-pentanol, and 15 mL was removed by distillation. Themixture was cooled slightly, and tripropylamine 3.40 mL, 17.8 mmol) and4-chloroquinoline (1.60 g, 9.82 mmol) were added. The mixture was heatedat reflux for 63 hr. Then, the mixture was concentrated in vacuo. Theresidue was partitioned between DCM and 5% Na₂CO₃, and the organic phasewas dried over Na₂SO₄ and concentrated. FC (5% MeOH/DCM+2% TEA) gave1.84 g of brown syrup, which solidified upon standing. The solid wasrinsed with 20%, 33%, and 50% Et₂O/Hex and dried in vacuo to give 1.67 gof solid. Rf 0.30 (5% MeOH/DCM+2% TEA); ¹H NMR (CDCl₃) δ 8.56-8.51 (m,2H), 8.28 (dd, 1H, J=1.8, 8.1 Hz), 7.92 (d, 1H, J=8.8 Hz), 7.60 (m, 1H),7.46-7.41 (m, 2H), 7.08 (m, 1H), 6.93 (d, 1H, J=8.0 Hz), 6.77 (br s, 1H,NH), 6.33 (d, 1H, J=5.1 Hz), 4.06 (t, 2H, J=6.6 Hz), 3.90 (m, 2H), 3.50(m, 2H), 1.77 (m, 2H), 1.42-1.23 (m, 6H), 0.87 (t, 3H, J=7 Hz); ¹³C NMR(CDCl₃) δ 168.1, 157.3, 151.2, 150.3, 148.6, 133.5, 132.5, 129.8, 129.1,124.9, 121.5, 120.9, 120.6, 119.1, 112.5, 98.1, 69.3, 46.1, 39.1, 31.5,29.2, 26.0, 22.7, 14.2.

Example 79 2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide

2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide (1.6 g) wasprepared by the method for2-(hexyloxy)-N-[4-(quinolin-4-ylamino)butyl]benzamide, starting withmethyl 2-(hexyloxy)benzoate (2.13 g) and 1,3-diaminopropane (6.00 mL)and using 4-chloroquinoline (1.70 g).

N-(3-Aminopropyl)-2-(hexyloxy)benzamide: ¹H NMR (CDCl₃) δ 7.85 (dd, 1H,J=1.8, 7.7 Hz), 7.44 (ddd, 1H, J=1.8, 7.3, 9.2 Hz), 7.10 (d, 1H, J=8.4Hz), 7.02 (m, 1H), 4.14 (m, 2H), 3.48 (m, 2H), 3.30 (m, 2H), 2.72 (m,2H), 1.86 (m, 2H), 1.75 (m, 2H), 1.40-1.35 (m, 4H), 0.93 (m, 3H); ¹³CNMR (CDCl₃) δ 168.8, 158.5, 134.1, 132.0, 123.6, 122.0, 114.0, 70.4,40.0, 38.2, 33.9, 32.9, 30.4, 27.2, 23.9, 14.6.

2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide: Rf 0.08 (5%MeOH/DCM); ¹H NMR (CDCl₃) δ 8.50 (d, 1H, J=5.5 Hz), 8.25 (dd, 1H, J=1.8,7.7 Hz), 8.24-8.20 (m, 1H), 8.01-7.98 (m, 1H), 7.93 (dd, 1H, J=0.7, 8.4Hz), 7.58 (ddd, 1H, J=1.1, 7.0, 8.1 Hz), 7.44-7.36 (m, 2H), 7.10-7.06(m, 1H), 6.92 (d, 1H, J=8.1 Hz), 6.49-6.46 (t, 1H, J=6 Hz, NH), 6.39 (d,1H, J=5.5 Hz), 4.03 (t, 2H), 3.63-3.59 (m, 2H), 3.46-3.42 (m, 2H), 2.64(br s, 1H, NH), 1.95-1.89 (m, 2H), 1.81-1.74 (m, 2H), 1.45-1.27 (m, 6H),0.89-0.86 (m, 3H); ¹³C NMR (CDCl₃) δ 166.8, 157.2, 151.0, 150.0, 148.7,133.1, 132.4, 129.7, 129.1, 124.7, 121.4, 21.3, 120.4, 119.3, 112.4,98.3, 69.2, 39.6, 39.6, 36.8, 31.6, 29.3, 28.7, 26.0, 22.7, 14.1.

Example 80 2-(Hexyloxy)-N-[4-(quinolin-4-ylamino)butyl]benzamide

N-(4-Aminobutyl)-2-(hexyloxy)benzamide A mixture of 1,4-diaminobutane(5.37 g, 61 mmol) and methyl 2-(hexyloxy)benzoate (1.80 g, 7.63 mmol)was heated at 110° C. in a sealed tube for 48 hr. The mixture waspartitioned between isopropyl acetate (3×125 mL) and H₂O (100 mL), 5%Na₂CO₃ (2×100 mL), and brine (100 mL). The organic phases were driedover anhydrous Na₂SO₄ and concentrated to give 2.10 g of colorlesssyrup. ¹H NMR (CDCl₃) δ 8.15 (dd, 1H, J=7.7, 1.8 Hz), 8.01 (br s, 1H),7.33 (ddd, 1H, J=9.2, 7.3, 1.8 Hz), 6.98 (m, 1H), 6.88 (d, 1H, J=8.4Hz), 4.04 (m, 2H), 3.41 (m, 2H), 2.68 (m, 2H), 1.80 (m, 2H), 1.59 (m,2H), 1.52-1.40 (m, 4H), 1.32-1.25 (m, 4H), 1.12 (br, s, 2H), 0.86 (m,3H); ¹³C NMR (CDCl₃) δ 165.3, 157.0, 132.6, 132.2, 121.6, 121.1, 112.2,69.0, 42.0, 39.6, 31.6, 31.3, 29.3, 27.1, 26.0, 22.6, 14.0.

2-(Hexyloxy)-N-[4-(quinolin-4-ylamino)butyl]benzamideN-(4-Aminobutyl)-2-(hexyloxy)benzamide was taken up in 60 mL of1-pentanol, and 15 mL of volatile liquid was removed by distillation.The mixture was cooled slightly, and tripropylamine (2.70 mL, 14.2 mmol)and 4-chloroquinoline (1.29 g, 7.91 mmol) were added. Heating at refluxwas resumed for 42 hr. The cooled mixture was concentrated andpartitioned between DCM and 5% Na₂CO₃, and the organic phase was driedover anhydrous Na₂SO₄ and concentrated. The residue was taken up in EAand then concentrated again. The resulting oil solidified upon standing.The solid was broken up and washed with 20%, 50%, and 100% Et₂O/Hex.Drying in vacuo gave 1.53 g of yellow-gray solid. Rf 0.21 (5%MeOH/DCM+2% TEA); ¹H NMR (CD₃OD) δ 8.53 (d, 1H, J=5.5 Hz), 8.24 (dd, 1H,J=1.9, 7.7 Hz), 8.16 (m, 1H, NH), 7.95 (d, 1H, J=8.4 Hz), 7.85 (d, 1H,J=8.4 Hz), 7.61 (m, 1H), 7.44-7.38 (m, 2H), 7.07 (m, 1H), 6.94 (d, 1H,J=8.4 Hz), 6.41 (d, 1H, J=5.1 Hz), 5.44 (br s, 1H, NH), 4.08 (m, 2H),3.57 (m, 2H), 3.39 (m, 2H), 1.91-1.75 (m, 6H), 1.44 (m, 2H), 1.34-1.27(m, 4H), 0.86 (m, 3H); ¹³C NMR (CDCl₃) δ 165.9, 157.2, 151.2, 149.9,148.7, 133.0, 132.5, 130.1, 129.1, 124.8, 121.5, 121.4, 119.8, 119.0,112.4, 98.9, 69.2, 43.2, 39.3, 31.7, 29.4, 28.0, 26.2, 26.1, 22.8, 14.2.

Example 81 N-[8-(Quinolin-4-ylamino)octyl]picolinamide

N-(8-Aminooctyl)picolinamide A mixture of 1,8-octanediamine (8.19 g,56.9 mmol) and methyl picolinate (970 mg, 7.08 mmol) was heated at 130°C. for 60 hr. The mixture was cooled, taken up in methanol, andevaporated onto silica gel. The pre-loaded silica gel was loaded on topof a flash column and eluted using 15% MeOH/DCM+2% TEA. Concentration ofthe product-containing fractions gave 1.28 g of liquid. Rf 0.23 (15%MeOH/DCM+2% TEA); ¹H NMR (20% CD₃OD/CDCl₃) δ 8.5 (ddd, 1H, J=1.0, 1.7,4.9 Hz), 8.2 (m, 1H), 8.0 (br s, 1H, NH), 7.8 (m, 1H), 7.4 (ddd, 1H,J=1.5, 4.9, 7.7 Hz), 3.43 (m, 2H), 2.66 (m, 2H), 2.17 (br s, 2H, NH ₂),1.65-1.28 (m, 12H).

N-[8-(Quinolin-4-ylamino)octyl]picolinamide A mixture ofN-(8-aminooctyl)picolinamide (557 mg, 2.24 mmol), 4-chloroquinoline (544mg, 3.34 mmol), DIEA (1 mL, 6 mmol) and 0.5 mL of DMF was heated at 140°C. in a sealed tube for 89 hr. Then, the volatile components wereevaporated, and the residue was purified by FC (8% MeOH/DCM) to give 520mg of product. Rf 0.38 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.6 (d, 1H), 8.4(d, 1H), 8.1 (d, 1H), 8.1-7.9 (m, 3H), 7.7 (m, 1H), 7.5 (m, 1H), 7.30(m, 1H), 6.3 (d, 1H), 3.4-3.3 (m, 4H), 1.7 (m, 2H), 1.5 (m, 2H), 1.3-1.0(m, 8H).

Example 82 N-[8-(Quinolin-4-ylamino)octyl]nicotinamide

N-(8-Aminooctyl)nicotinamide A mixture of 1,8-diaminooctane (9.78 g,67.0 mmol) and methyl nicotinate (1.50 g, 10.9 mmol) was heated at 84°C. for 16 hr and 110-120° C. for an additional 56 hr. The cooled mixturewas separated by SPE, washing with 5% MeOH/DCM+2% TEA to remove theoctane-1,8-bis(amide) and residual methyl nicotinate and then with 15%MeOH/DCM+2% TEA to elute ninhydrin (+) product fractions. The productfractions were concentrated, taken up in DCM, washed with 5% Na₂CO₃,dried over Na₂SO₄, filtered, and dried to give 2.07 g of pale yellowsolid. Rf 0.10 (15% MeOH/DCM+2% TEA); ¹H NMR (CD₃OD) δ 8.95 (dd, 1H,J=0.8, 2.2 Hz), 8.67 (m, 1H), 8.23 (m, 1H), 7.53 (m, 1H), 3.38 (t, 2H,J=7.3 Hz), 2.60 (t, 2H), 1.61 (m, 2H), 1.47-1.33 (m, 10H); ¹³C NMR(CD₃OD) δ 167.8, 152.7, 149.2, 137.1, 132.4, 125.3, 42.8, 41.3, 34.1,30.7, 30.6, 28.2, 28.2, 22.2.

N-[8-(Quinolin-4-ylamino)octyl]nicotinamide N-(8-aminooctyl)nicotinamide(5.66 g, 22.7 mmol) was taken up in 100 mL of 1-pentanol, and then 50 mLof volatile material was removed by distillation. The mixture was cooledbelow boiling, and tripropylamine (9.50 mL, 49.8 mmol) and4-chloroquinoline (4.08 g, 25.0 mmol) were added. Heating at reflux wasresumed. After 22 hr, volatile material was removed by evaporation. Themixture was partitioned between DCM (175, 2×100 mL) and a combination of25 mL of 1N NaOH and 25 mL of 5% Na₂CO₃. The combined organic phaseswere dried over Na₂SO₄, filtered, and concentrated to give a dark syrup.Two crystallizations from MeOH/H₂O and drying in vacuo over P₂O₅ gave2.31 g of tan solid. Rf 0.56 (15% MeOH/DCM+2% TEA); mp 139.5-141.0° C.;¹H NMR (DMSO-d₆) δ 8.97 (m, 1H), 8.66 (m, 1H), 8.61 (t, 1H, J=5.5 Hz),8.35 (d, 1H, J=5.1 Hz), 8.19 (d, 1H, J=8.8 Hz), 8.14 (ddd, 1H, J=1.4,2.2, 7.7 Hz), 7.74 (dd, 1H, J=1.1, 8.5 Hz), 7.57 (m, 1H), 7.46 (m, 1H),7.38 (ddd, 1H, J=1.4, 7.0, 8.4 Hz), 7.16 (t, 1H, J=5 Hz), 6.40 (d, 1H,J=5.5 Hz), 3.27-3.22 (m, 4H), 1.65 (m, 2H), 1.44 (m, 2H), 1.30 (m, 8H);¹³C NMR (DMSO-d₆) δ 164.6, 151.6, 150.4, 150.2, 148.3, 148.0, 134.8,130.1, 128.7, 123.7, 123.4, 121.7, 118.8, 98.0, 42.4, 39.2, 29.0, 28.8,28.7, 27.8, 26.6, 26.4.

Example 83 N-[8-(Quinolin-4-ylamino)octyl]isonicotinamide

N-(8-Aminooctyl)isonicotinamide A mixture of 1,8-diaminooctane (7.66 g,53 mmol) and methyl isonicotinate (910 mg, 6.64 mmol) was heated at 130°C. for 60 hr. The cooled mixture was partitioned between DCM and 5%Na₂CO₃, and the organic phase was dried over anhydrous Na₂SO₄ andconcentrated. FC (15% MeOH/DCM+2% TEA) gave 539 mg of oily solid. Rf0.15 (15% MeOH/DCM+2% TEA); ¹H NMR (20% CD₃OD/CDCl₃) δ 8.59 and 7.66 (m,4H, AA′BB′), 3.33 (m, 2H), 3.10 (m, 1H, NH), 2.78 (m, 2H), 1.85 (s, 2H,NH ₂), 1.57-1.24 (m, 12H).

N-[8-(Quinolin-4-ylamino)octyl]isonicotinamide A mixture ofN-(8-aminooctyl)isonicotinamide (539 mg, 2.16 mmol), 4-chloroquinoline(536 mg, 3.29 mmol), DIEA (2 mL, 12 mmol) and 0.5 mL of DMF was heatedat 140° C. in a sealed tube for 89 hr. Then, the volatile componentswere evaporated, and the residue was purified by FC (8% MeOH/DCM) togive 113 mg of product. Rf 0.13 (10% MeOH/DCM); ¹H NMR (20% CD₃OD/CDCl₃)δ 8.58 and 7.62 (m, 4H, AA′BB′), 8.35 (d, 1H, J=5.4 Hz), 7.83 (dd, 1H,J=0.7, 8.4 Hz), 7.71 (m, 1H), 7.55 (ddd, 1H, J=1.3, 7.0, 8.2 Hz), 7.35(ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.34 (d, 1H, J=5.5 Hz), 3.37-3.21 (m,4H), 1.70-1.22 (m, 12H).

Example 84 N-(Pyridin-4-ylmethyl)quinolin-4-amine

N-(Pyridin-4-ylmethyl)quinolin-4-amine was prepared following the methodfor N-(pyridin-2-ylmethyl)quinolin-4-amine. Rf 0.29 (5% MeOH/DCM+2%TEA); ¹H NMR (CDCl₃) δ 8.51-8.47 (m, 2H), 8.39 (d, 1H, J=5.4 Hz),8.03-8.00 (m, 1H), 7.95 (dd, 1H, J=1.0, 8.4 Hz), 7.59 (ddd, 1, J=1.2,6.9, 8.4 Hz), 7.40 (ddd, 1H, J=1.5, 6.9, 8.4 Hz), 7.28-7.22 (m, 2H),6.61 (br s, 1H), 6.19 (d, 1H, J=5.4 Hz), 4.56 (br s, 2H).

Example 85 N-(Pyridin-3-ylmethyl)quinolin-4-amine

N-(Pyridin-3-ylmethyl)quinolin-4-amine was prepared following the methodfor N-(pyridin-2-ylmethyl)quinolin-4-amine. Rf 0.36 (5% MeOH/DCM+2%TEA); ¹H NMR (CDCl₃) δ 8.56 (d, 1H, J=2.0 Hz), 8.45 (dd, 1H, J=1.7, 5.0Hz), 8.41 (d, 1H, J=5.2 Hz), 7.98 (d, 1H, J=8.4 Hz), 7.91 (dd, 1H,J=1.0, 8.4 Hz), 7.61 (ddd, 1H, J=1.7, 2.0, 7.9 Hz), 7.54 (ddd, 1H,J=1.2, 6.9, 8.2 Hz), 7.33 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 7.17 (dd, 1H,J=5.0, 7.9 Hz), 6.61 (br s, 1H), 6.29 (d, 1H, J=5.5 Hz), 4.50 (m, 2H,AB).

Example 86 N-(Pyridin-2-ylmethyl)quinolin-4-amine

A mixture of 4-chloroquinoline (228 mg, 1.40 mmol),2-(aminomethyl)pyridine (144 mg, 1.33 mmol), and DIEA (0.50 mL) washeated at 130° C. in a sealed tube for 48 hr. Then, the mixture wascooled, partitioned between EA and 5% Na₂CO₃ and brine, dried overNa₂SO₄, and concentrated. FC (3% MeOH/DCM+2% TEA) gaveproduct-containing fractions, which were concentrated. The residue wastaken up in DCM and washed with 5% Na₂CO₃, dried over Na₂SO₄, andconcentrated to give the product. Rf 0.54 (5% MeOH/DCM+2% TEA); ¹H NMR(CDCl₃) δ 8.57-8.54 (m, 1H), 8.46 (d, 1H, J=5.4 Hz), 7.99-7.91 (m, 2H),7.62-7.52 (m, 2H), 7.37 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.26-7.23 (m,1H), 7.18-7.13 (m, 1H), 7.03 (br s, 1H), 6.32 (d, 1H, J=5.4 Hz), 4.52(m, 2H, AB).

Example 87 N-Hexylquinolin-4-amine

A mixture of 4-chloroquinoline (248 mg, 1.52 mmol) and 1-hexylamine (2mL, 15 mmol) was heated in a sealed tube at 100° C. for 2 days, 120-130°C. for 2 days, and 150° C. for 1 day. The mixture was cooled andpartitioned between EA and 5% Na₂CO₃ and brine, and the organic phasewas dried over Na₂SO₄ and concentrated in vacuo. SPE, washing with 25%EA/Hex and eluting with 12% MeOH/DCM, followed by repurification bypreparative TLC (10% MeOH/DCM), gave the product as an oil. Rf 0.16 (5%MeOH/DCM); ¹H NMR (CDCl₃) δ 8.48 (d, 1H, J=5.4 Hz), 7.97 (dd, 1H, J=1.0,8.4 Hz), 7.87 (d, 1H, J=8.4 Hz), 7.60 (ddd, 1H, J=1.5, 6.9, 8.4 Hz),7.40 (ddd, 1H, J=1.2, 6.9, 8.4 Hz), 6.40 (d, 1H, J=5.7 Hz), 5.66 (br s,1H, NH), 3.32 (m, 2H), 1.75 (m, 2H), 1.46-1.26 (m, 6H), 0.89 (m, 3H).

Example 88 N-(Decyl)quinolin-4-amine

A mixture of 1-aminodecane (4.36 g, 27.8 mmol), tripropylamine (8.00 mL,42.0 mmol), and 4-chloroquinoline (4.55 g, 27.9 mmol) in 25 mL of1-pentanol was heated at reflux for 3 days. Then, the volatilecomponents were evaporated. The residue was take up in DCM (150 mL) andwashed with 5% Na₂CO₃ (100 mL). The aqueous phase was extracted with DCM(100 mL), and the combined organic phases were dried over Na₂SO₄,filtered, and concentrated to give a dark liquid. SPE, eluting with 1%and then 5% MeOH/DCM+2% TEA, gave product fractions that wereconcentrated, partitioned between DCM (150, 100 mL) and 5% Na₂CO₃ (100mL), dried over Na₂SO₄, filtered, and concentrated. Recrystallizationfrom EA/Hex gave 4.14 g colorless solid. Rf 0.30 (5% MeOH/DCM+2% TEA);mp 79.0-80.0° C.; ¹H NMR (CDCl₃) δ 8.56 (d, 1H, J=5.5 Hz), 7.97 (dd, 1H,J=1.1, 8.4 Hz), 7.72 (m, 1H), 7.62 (ddd, 1H, J=1.4, 7.0, 8.4 Hz), 7.41(m, 1H), 6.43 (d, 1H, J=5.5 Hz), 4.97 (br s, 1H, NH), 3.31 (m, 2H), 1.76(m, 2H), 1.46 (m, 2H), 1.39-1.27 (m, 12H), 0.88 (m, 3H); ¹³C NMR (CDCl₃)δ 152.2, 149.9, 149.6, 129.2, 128.2, 125.0, 122.7, 121.0, 102.4, 62.0,51.8, 32.6, 28.0, 25.7, 22.4, 14.0.

Example 89 N-(Dodecyl)quinolin-4-amine

A mixture of 4-chloroquinoline (3.25 g, 19.9 mmol), 1-dodecylamine (3.80g, 20.5 mmol), and tripropylamine (5.90 mL, 30.9 mmol) in 30 mL of1-pentanol was heated at reflux for 16.5 hr. Then, the volatilecomponents were evaporated in vacuo. The residue was partitioned betweenDCM (150, 100 mL) and a mixture of 1N NaOH and 5% Na₂CO₃ (20 mL each).The organic phases were dried over Na₂SO₄ and concentrated.Crystallization from ice-cold 10% EA/Hex, washing the collected solidwith ice-cold 20% Et₂O/Hex, gave 4.95 g colorless solid (mp 81.5-82.0°C.). LC/MS (230 nm) indicated the presence of 5-10% impurity. SPE (1%TEA/EA) separated an impurity with predominantly aryl hydrogens by NMR.The product was recrystallized from ice-cold 10% EA/Hex to give 4.70 gcolorless solid. Rf 0.12 (10% MeOH/DCM); mp 80.5-81.5° C.; ¹H NMR(CDCl₃) δ 8.56 (d, 1H, J=5.1 Hz), 7.97 (dd, 1H, J=1.1, 8.4 Hz), 7.72 (m,1H), 7.62 (ddd, 1H, J=1.5, 7.0, 8.5 Hz), 7.42 (ddd, 1H, J=1.5, 7.0, 8.5Hz), 6.42 (d, 1H, J=5.5 Hz), 4.98 (br s, 1H, NH), 3.31 (m, 2H), 1.76 (p,2H, J=7.3 Hz), 1.47 (m, 2H), 1.38-1.26 (m, 16H), 0.88 (t, 3H, J=6.8 Hz);¹³C NMR (CDCl₃) δ 151.3, 149.8, 148.7, 130.3, 129.1, 124.7, 119.3,118.9, 99.0, 43.5, 32.1, 29.8, 29.8, 29.8, 29.8, 29.6, 29.5, 29.2, 27.4,22.9, 14.3.

Example 90 N¹,N⁸-Di(quinolin-4-yl)octane-1,8-diamine

A mixture of 1,8-octanediamine and excess 4-chloroquinoline and DIEA inNMP was heated at 160° C. in a sealed tube for 3 days. The mixture wascooled and purified by SPE, washing with 1% MeOH/DCM and then elutingwith 7.5% MeOH/DCM+2% TEA to give the product as a solid. Rf 0.05 (EA+2%TEA); ¹H NMR (20% CD₃OD/CDCl₃) δ 8.32 (d, 2H, J=5.7 Hz), 7.85-7.80 (m,4), 7.58 (ddd, 2H, J=1.2, 6.9, 8.2 Hz), 7.38 (ddd, 2H, J=1.2, 6.9, 8.4Hz), 6.37 (d, 2H, J=5.7 Hz), 3.38-3.25 (m, 4H), 1.73-1.24 (m, 12H).

Example 91 N-[8-(Hexyloxy)octyl]quinolin-6-amine

8-(Hexyloxy)octanoic acid Approximately 6.0 mL of Jones reagent wasadded to a mixture of 8-(hexyloxy)octan-1-ol (2.1 g, 9.1 mmol) and 50 mLof DCM cooled by an ice bath, after which the green color of the mixturedid not persist. Then, the mixture was washed with H₂O and 0.1M HCl, andthe organic phase was dried over MgSO₄, diluted with 5 mL of MeOH,filtered through a pad of silica gel, washing the pad with 5% MeOH/DCM,and concentrated. FC (5% MeOH/DCM) gave 1.6 g of product. Rf 0.3 (5%MeOH/DCM); ¹H NMR (CDCl₃) δ 3.4 (t, 4H), 2.3 (m, 2H), 1.7-1.4 (m, 6H),1.4-1.2 (m, 12H), 0.9 (m, 3H).

8-(Hexyloxy)-N-(quinolin-6-yl)octanamide A mixture of 6-aminoquinoline(0.5 g, 3.5 mmol), 8-(hexyloxy)octanoic acid (847 mg, 3.47 mmol),1-hydroxybenzotriazole (469 mg, 3.47 mmol), 4-dimethylaminopyridine (42mg, 0.3 mmol), and EDC (663 mg, 3.47 mmol) in 20 mL of DCM was reacteduntil the starting material was consumed, as observed by TLC. Then, thevolatile components were evaporated, and the residue was partitionedbetween EA and H₂O, 5% Na₂CO₃, H₂O, and brine, and the organic phaseswere dried over Na₂SO₄ and concentrated. FC (50% EA/Hex) gave 225 mg ofthe product. Rf 0.4 (50% EA/Hex); ¹H NMR (CDCl₃) δ 8.8 (m, 1H), 8.4 (m,1H), 8.15 (m, 1H), 8.05 (m, 1H), 7.9 (br s, 1H, NH), 7.6 (m, 1H), 7.4(m, 1H), 3.4 (t, 4H), 2.4 (t, 2H), 1.7 (m, 2H), 1.6-1.4 (m, 4H), 1.4-1.2(m, 12H), 0.85 (m, 3H).

N-[8-(Hexyloxy)octyl]quinolin-6-amine A mixture of8-(hexyloxy)-N-(quinolin-6-yl)octanamide (171 mg, 0.46 mmol) and 20 mLof THF was cooled by an ice bath before 70 mg of lithium aluminumhydride was added. The mixture was allowed to warm slowly to roomtemperature overnight. Then, the mixture was recooled, and 0.7 mL ofH₂O, 0.7 mL of 15% NaOH, and 2.1 mL of H₂O were added cautiously. Themixture was filtered through a pad of Celite, washing with 5% MeOH/DCM,and the filtrate was concentrated. The residue was partitioned betweenEA and 5% Na₂CO₃ and brine, and the organic phase was dried over Na₂SO₄and concentrated. FC (50% EA/Hex) gave 100 mg of the product. Rf 0.3(50% EA/Hex); ¹H NMR (CDCl₃) δ 8.6 (m, 1H), 7.95-7.85 (m, 2H), 7.3 (m,1H), 7.1 (m, 1H), 7.7 (m, 1H), 3.4 (t, 4H), 3.2 (t, 2H), 1.8-1.2 (m,20H), 0.85 (t, 3H).

Example 92 N-[8-(Hexyloxy)octyl]quinolin-3-amine

N-[8-(Hexyloxy)octyl]quinolin-3-amine (66 mg) was prepared following themethod for N-[8-(hexyloxy)octyl]quinolin-6-amine starting with3-aminoquinoline (728 mg).

8-(Hexyloxy)-N-(quinolin-3-yl)octanamide: ¹H NMR (CDCl₃) δ 9.05 (br s,1H), 8.95 (br, s, 1H), 8.5 (br s, 1H, NH), 8.1 (d, 1H), 7.8 (d, 1H),7.7-7.5 (m, 2H), 3.4 (m, 4H), 2.5 (t, 2H), 1.8 (m, 2H), 1.7-1.2 (m,16H), 0.85 (t, 3H). 206-181 N-[8-(Hexyloxy)octyl]quinolin-3-amine ¹H NMR(CDCl₃) δ 8.6 (d, 1H), 8.0 (d, 1H), 7.6 (d, 1H), 7.5-7.3 (m, 2H), 7.0(m, 1H), 4.3 (br s, 1H, NH), 3.5-3.3 (m, 4H), 3.2 (m, 2H), 1.8-1.2 (m,20H), 0.9 (m, 3H).

Example 93 N-[8-(Hexyloxy)octyl]quinolin-8-amine

N-[8-(Hexyloxy)octyl]quinolin-8-amine (58 mg) was prepared following themethod for N-[8-(hexyloxy)octyl]quinolin-6-amine starting with8-aminoquinoline (472 mg).

8-(Hexyloxy)-N-(quinolin-8-yl)octanamide: Rf 0.7 (10% EA/Hex); ¹H NMR(CDCl₃) δ 9.8 (br s, 1H, NH), 8.85-8.75 (m, 2H), 8.2 (m, 1H), 7.6-7.4(m, 3H), 3.4 (m, 4H), 2.6 (t, 2H), 1.8 (m, 2H), 1.7-1.2 (m, 16H), 0.9(m, 3H).

N-[8-(Hexyloxy)octyl]quinolin-8-amine: Rf 0.6 (50% EA/Hex); ¹H NMR(CDCl₃) δ 8.7 (d, 1H), 8.1 (br s, 1H), 7.5-7.3 (m, 2H), 7.0 (d, 1H), 6.7(d, 1H), 3.5-3.3 (m, 4H), 3.3 (m, 2H), 1.8 (m, 2H), 1.7-1.2 (m, 18H),0.9 (m, 3H).

Example 94 N-[8-(Hexyloxy)octyl]-2-(trifluoromethyl)quinolin-4-amine

A mixture of 8-(hexyloxy)octan-1-amine (350 mg, 1.53 mmol),4-chloro-2-trifluoromethylquinoline (420 mg, 1.81 mmol) and TEA (0.32mL, 1.84 mmol) in 1 mL of NMP was heated at 150° C. for 16 hr. Themixture was cooled and partitioned between EA and 5% Na₂CO₃. The organicphases were washed with brine, dried over Na₂SO₄, and concentrated.Purification by preparative TLC gave the product. Rf 0.38 (20% EA/Hex);¹H NMR (CDCl₃) δ 8.01 (m, 1H), 7.75 (d, 1H, J=8.4 Hz), 7.62 (ddd, 1H,J=1.2, 6.9, 8.4 Hz), 7.42 (ddd, 1H, J=1.2, 7.0, 8.4 Hz), 6.65 (s, 1H),5.45 (m, 1H, NH), 3.38-3.34 (m, 4H), 3.27 (m, 2H), 1.76-1.18 (m, 20H),0.85 (m, 3H).

Example 95 7-Chloro-N-decylquinolin-4-amine

7-Chloro-N-decylquinolin-4-amine (8.10 g) was prepared following themethod for 7-chloro-N-dodecylquinolin-4-amine, starting with 5.18 g of1-decylamine and 6.53 g of 4,7-dichloroquinoline. Mp 102.5-103.0° C.(EA/Hex); ¹H NMR (CDCl₃) δ 88.5 (d, 1H, J=5.5 Hz), 7.9 (d, 1H, J=1.9Hz), 7.6 (d, 1H, J=8.8 Hz), 7.3 (m, 1H), 6.4 (d, 1H, J=5.5 Hz), 5.1 (brm, 1H, NH), 3.3 (m, 2H), 1.7 (m, 2H), 1.5-1.3 (m, 14H), 0.8 (m, 3H); ¹³CNMR (CDCl₃) δ 152.2, 149.9, 149.4, 134.9, 129.0, 125.4, 121.1, 117.3,99.2, 43.5, 32.1, 29.7, 29.7, 29.6, 29.5, 29.1, 27.3, 22.9, 14.3.

Example 96 7-Chloro-N-dodecylquinolin-4-amine

A mixture of 1-dodecylamine (4.57 g, 24.7 mmol), tripropylamine (9.4 mL,49 mmol), 4,7-dichloroquinoline (4.89 g, 24.7 mmol) and 50 mL of1-pentanol were heated at reflux for 22 hr. Then, the volatilecomponents were evaporated. The residue was partitioned between EA and5% Na₂CO₃ and brine, and the organic phase was dried over Na₂SO₄ andconcentrated. SPE (50% EA/Hex) gave the product as a yellow solid. Theproduct was taken up in DCM, washed with 5% Na₂CO₃, dried over Na₂SO₄,and concentrated. The product was crystallized from ice-cold 20% EA/Hexto give 7.50 g colorless solid. Rf 0.30 (50% EA/Hex); mp 95.0-97.0° C.;¹H NMR (CDCl₃) δ 8.5 (d, 1H, J=5.1 Hz), 7.9 (d, 1H, J=1.9 Hz), 7.6 (d,1H, J=8.8 Hz), 7.3 (m, 1H), 6.39 (d, 1H, J=5.5 Hz), 5.0 (br m, 1H, NH),3.3 (m, 2H), 1.8 (m, 2H), 1.5-1.2 (m, 20H, 0.9 (m, 3H); ¹³C NMR (CDCl₃)δ 152.3, 149.9, 149.4, 135.0, 129.1, 125.4, 121.0, 117.3, 99.3, 43.5,32.1, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 29.1, 27.3, 22.9, 14.3.

Example 97 N-(Decyl)quinazolin-4-amine

A mixture of 4-chloroquinazoline (6.90 g, 42.1 mmol), 1-decylamine (10.8mL, 54.3 mmol), and TEA (8.90 mL, 62.7 mmol) in 50 mL of IPA was heatedat reflux for 6 hr, then allowed to stand overnight. Then, the volatilecomponents were evaporated, and the residue was taken up in DCM andwashed with a mixture of 20 mL of 1N NaOH and 20 mL of 5% Na₂CO₃. Theorganic phase was dried over anhydrous Na₂SO₄ and filtered through a padof silica gel, washing with 5% MeOH/DCM. The filtrate was concentratedto give a solid. The solid was washed with 25 mL and 10 mL portions of20% Et₂O/Hex, then dried in vacuo to give 11.22 g of colorless solid. Rf0.41 (10% MeOH/DCM); mp 72.5-73.0° C.; ¹H NMR (CDCl₃) δ 8.66 (s, 1H),7.82 (dd, 1H, J=1.1, 8.8 Hz), 7.73-7.69 (m, 2H), 7.44 (m, 1H), 5.83 (brs, 1H, NH), 3.65 (m, 2H), 1.72 (m, 2H), 1.46-1.25 (m, 14H), 0.86 (t, 3H,J=7.0 Hz); ¹³C NMR (CDCl₃) δ 159.7, 155.7, 149.6, 132.7, 128.8, 126.1,120.6, 115.2, 41.6, 32.1, 29.8, 29.7, 29.6, 29.5, 27.6, 22.9, 14.3.

Example 98 N-Dodecylquinazolin-4-amine

1-Dodecylamine (4.20 g, 22.7 mmol) was taken up in 45 mL of IPA, and 10mL was removed by distillation. Then, the mixture was cooled slightly,and TEA (6.5 mL, 46 mmol) and 4-chloroquinazoline (3.72 g, 22.7 mmol)were added. The mixture was heated at reflux for 7 hr. Then, most of thevolatile components were removed by distillation. The residue waspartitioned between DCM (150, 100 mL) and a mixture of 1N NaOH and 5%Na₂CO₃ (20 mL each). The organic phases were dried over Na₂SO₄ andconcentrated. SPE (30, 50, and 60% EA/Hex step gradient) gaveproduct-containing fractions that were concentrated, taken up in DCM,washed with 5% Na₂CO₃, dried over Na₂SO₄, and concentrated to a syrup.Crystallization from ice-cold 30% EA/Hex gave 6.05 g colorless solid. Rf0.20 (50% EA/Hex); mp 74.0-75.0° C.; ¹H NMR (CDCl₃) δ 866 (s, 1H), 7.82(m, 1H), 7.74-7.69 (m, 2H), 7.45 (m, 1H), 5.76 (br s, 1H, NH), 3.65 (m,2H), 1.72 (m, 2H), 1.46-1.25 (m, 18H), 0.87 (m, 3H); ¹³C NMR (CDCl₃) δ159.6, 155.7, 149.6, 132.7, 128.9, 126.1, 120.6, 115.1, 41.6, 32.1,29.8, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 27.3, 22.9, 14.3.

Example 99 N-Decyl-7-fluoroquinazolin-4-amine

A mixture of 1-decylamine (1.2 mL, 6.0 mmol),4-chloro-7-fluoroquinazoline (1.1 g, 6.0 mmol), and TEA (1.3 mL, 9.3mmol) in 10 mL of IPA was heated at reflux for 6 hr. Then, the volatilecomponents were evaporated, and the residue was partitioned between DCM(400, 300 mL) and 5% Na₂CO₃ (400 mL). The organic phases were dried overanhydrous Na₂SO₄, filtered through a pad of silica gel, washing with 10%MeOH/DCM, and concentrated. The product was crystallized from EA/Hex.

Example 100 N-Dodecyl-7-fluoroquinazolin-4-amine

N-Dodecyl-7-fluoroquinazolin-4-amine was made from 1-dodecylamine (1.2mL, 5.2 mmol), 4-chloro-7-fluoroquinazoline (1.0 g, 5.5 mmol), and TEA(1.2 mL, 8.6 mmol) in 10 mL of IPA following the method for thepreparation of N-decyl-7-fluoroquinazolin-4-amine.

Example 101 7-Chloro-N-decylquinazolin-4-amine

7-Chloro-N-decylquinazolin-4-amine was made from 1-decylamine (1.5 mL,7.0 mmol), 4,7-dichloroquinazoline (1.4 g, 7.0 mmol), and TEA (2.0 mL,14 mmol) in 15 mL of IPA following the method for the preparation ofN-decyl-7-fluoroquinazolin-4-amine.

Example 102 7-Chloro-N-dodecylquinazolin-4-amine

7-Chloro-N-dodecylquinazolin-4-amine was made from 1-dodecylamine (1.3g, 7.0 mmol), 4,7-dichloroquinazoline (1.4 g, 7.0 mmol), and TEA (2.0mL, 14 mmol) in 15 mL of IPA following the method for the preparation ofN-decyl-7-fluoroquinazolin-4-amine.

Example 103 N-(6-Butoxyhexyl)quinazolin-4-amine

6-Butoxyhexan-1-amine (7.20 g, 41.1 mmol) was taken up in 200 mL, and 50mL was removed by distillation. The mixture was cooled slightly, and TEA(17.4 mL, 124 mmol) and 4-chloroquinazoline (11.11 g, 67.7 mmol) wereadded. The mixture was heated at reflux for 38 hr, then allowed to standat room temperature for 3 days. The volatile components were evaporated.The residue was partitioned between DCM (150, 2×50 mL) and a mixture of40 mL 1N NaOH and 40 mL of 5% Na₂CO₃. The organic phases were dried overanhydrous Na₂SO₄ and evaporated onto silica gel. SPE, washing with 30%EA/Hex and eluting with 60% EA/Hex, gave a yellow syrup thatcrystallized from 10% EA/Hex at −20° C. to give 4.64 g of colorlesssolid. Rf 0.25 (50% EA/Hex); mp 40-46° C.; ¹H NMR (CDCl₃) δ 8.64 (s,1H), 7.84 (d, 1H, J=8.4 Hz), 7.78-7.70 (m, 2H), 7.46 (ddd, 1H, J=1.4,7.3, 8.4 Hz), 6.12 (br s, 1H, NH), 3.66 (m, 2H), 3.41-3.37 (m, 4H), 1.74(m, 2H), 1.62-1.30 (m, 10H), 0.90 (t, 3H, J=7.3 Hz); ¹³C NMR (CDCl₃) δ159.8, 155.2, 148.6, 133.0, 128.1, 126.3, 120.9, 115.0, 70.9, 70.9,41.6, 32.0, 29.8, 29.4, 27.1, 26.2, 19.6, 14.1.

Example 104 N-[8-(Hexyloxy)octyl]quinazolin-4-amine

8-(Hexyloxy)octan-1-ol 1,8-Octanediol (201.4 g, 1.38 mol) was taken upin 1.3 L of IPA, and 250 mL of volatile material was removed bydistillation. The mixture was allowed to cool below boiling, and sodiummetal (6.9 g, 0.30 mol) was added in portions while maintaining ablanket of argon. After the addition was completed, the mixture wasboiled for one hour, and then it was allowed to stir at room temperatureovernight. 1-Bromohexane (32.2 mL, 0.23 mol) was added in a slow stream.After 25 hr, the mixture was warmed gently. Precipitate began to form.After 2 days of warming, the mixture was heated to distill 400 mL ofvolatile material. Then, heating was halted, and 16 g of NH₄Cl in 48 mLof H₂O was added. After 1 hr, the distillation was resumed and 450 mL ofdistillate was collected. Heating was halted, and 214 g of silica gelwas added to the hot mixture. The warm mixture was blended well andcooled. The excess diol was removed by SPE using 30% EA/Hex, whichafforded 25.9 g of light yellow oil containing the desired product. Rf0.19 (20% EA/Hex); ¹H NMR (CDCl₃) δ 3.63-3.58 (m, 2H), 3.37 (t, 4H,J=6.7 Hz), 1.66 (br s, 1H, OH), 1.57-1.50 (m, 6H), 1.30-1.28 (m, 14H),0.87 (t, 3H, J=6.6 Hz). 1,8-Octanediol was recovered by eluting with 5%MeOH/DCM, evaporation of solvent, and crystallization of three cropsfrom EA/Hex, which afforded 182.4 g of colorless solid.

8-(Hexyloxy)octyl methanesulfonate 8-(Hexyloxy)octan-1-ol was taken upin 250 mL of DCM and cooled using an ice bath. TEA (21.0 mL, 150 mmol)and methanesulfonyl chloride (10.5 mL, 134 mmol) were added in turn.After 1.25 hr, 20 g of ice chips were added. Most of the volatilematerial was evaporated. The residue was partitioned between 1:1 EA/Hex(3×300 mL) and H₂O, saturated NaHCO₃, H₂O, 1M HCl, H₂O, and brine (100mL each). The combined organic phases were dried over Na₂SO₄, filteredthrough a pad of silica gel, and concentrated. Rf 0.28 (20% EA/Hex); ¹HNMR (CDCl₃) δ 4.21 (t, 2H, J=6.6 Hz), 3.38 (t, 2H, J=6.4 Hz), 3.37 (t,2H, J=6.7 Hz), 2.98 (s, 3H), 1.72 (m, 2H), 1.61-1.46 (m, 4H), 1.40-1.24(m, 14H), 0.87 (t, 3H, J=6.8 Hz).

N-[8-(Hexyloxy)octyl]phthalimide Toluene (100 mL) was mixed with thecrude 8-(hexyloxy)octyl methanesulfonate and then was evaporated. Theresidue was taken up in 120 mL of DMF and 60 mL of NMP. Potassiumphthalimide (25.0 g, 135 mmol) was added. After mixing for 21.5 hr, 50mL of H₂O was added, and the volatile material was evaporated. Theresidue was partitioned between EA (3×300 mL) and H₂O (150 mL),saturated NaHCO₃ (150 mL), and brine (2×150 mL). The combined organicphases were dried over Na₂SO₄, filtered through a pad of silica gel, andconcentrated. Rf 0.50 (10% EA/Hex); ¹H NMR (CDCl₃) δ 7.81 and 7.68 (m,4H, AA′BB′), 3.65 (t, 2H, J=7.3 Hz), 3.36 (t, 2H, J=6.7 Hz), 3.35 (t,2H, J=6.7 Hz), 1.67-1.48 (m, 6H), 1.29-1.22 (m, 14H), 0.86 (t, 3H, J=6.8Hz).

8-(Hexyloxy)octan-1-amine IPA (100 mL) was mixed with the crudeN-[8-(hexyloxy)octyl]phthalimide and then was evaporated. The residuewas taken up in 450 mL of EtOH, hydrazine monohydrate (6.60 mL, 136mmol) was added, and the mixture was heated at reflux overnight. Themixture was concentrated by distillation of 300 mL of volatile material.

Heating was halted, 150 mL of 1M HCl was added to the hot mixture, andthe mixture was allowed to cool. The precipitate was removed byfiltration, and it was washed with 1:1 EtOH/H₂O (2×100 mL). The filtratewas concentrated to 100 mL, and the pH was adjusted to >10 using NaOHpellets. The mixture was extracted with DCM (3×250 mL), and the combinedorganic phases were dried over Na₂SO₄, filtered, and concentrated togive 27.6 g of cloudy liquid. ¹H NMR (CDCl₃) δ 3.36 (t, 4H, J=6.7 Hz),2.66 (t, 2H, J=6.9 Hz), 1.52 (m, 2H), 1.44-1.28 (m, 18H), 0.86 (m, 3H).

N-[8-(Hexyloxy)octyl]quinazolin-4-amine Crude 8-(hexyloxy)octan-1-aminewas taken up in 400 mL of IPA, and 250 mL of volatile material wasremoved by distillation. The mixture was cooled, and TEA (16.8 mL, 120mmol) and 4-chloroquinazoline (9.8 g, 60 mmol) were added. The mixturewas heated at reflux for 4 hr. TLC of an aliquot indicated a substantialquantity of ninhydrin (+) material remained. TEA (11.2 mL, 80 mmol) and4-chloroquinazoline (6.5 g, 38 mmol) were added. After 5 hr additionalheating the mixture was allowed to cool and stirred 12 hr. Then, thevolatile components were evaporated, and the residue was partitionedbetween DCM (300, 2×150 mL) and 1N NaOH and 5% Na₂CO₃ (100 mL each). Thecombined organic phases were dried over Na₂SO₄, filtered, andconcentrated. SPE, eluting with 20%, 30%, and 50% EA/Hex, gave productfractions that were combined and concentrated. The residue was taken upin 300 mL of EA, filtered, and concentrated. The resulting yellow solidwas recrystallized twice from 10% EA/Hex to give 30.3 g of pale yellowsolid. Rf 0.11 (40% EA/Hex); mp 67.0-67.5° C.; ¹H NMR (CDCl₃) δ 8.66 (s,1H), 7.83 (d, 1H, J=7.8 Hz), 7.75-7.70 (m, 2H), 7.46 (m, 1H), 5.81 (brs, 1H, NH), 3.65 (dt, 2H, J=5.5, 7.4 Hz), 3.38 (t, 4H), 1.73 (m, 2H),1.59-1.52 (m, 4H), 1.46-1.24 (m, 14H), 0.87 (t, 3H, J=6.9 Hz); ¹³C NMR(CDCl₃) δ 159.7, 155.6, 149.4, 132.8, 128.7, 126.2, 120.6, 115.1, 71.2,71.1, 41.7, 41.5, 31.9, 30.0, 29.6, 29.6, 29.5, 27.2, 26.4, 26.1, 22.8,14.3.

Example 105 N-[8-(4-Methoxyphenoxyl)octyl]quinazolin-4-amine

8-(4-Methoxyphenoxyl)octan-1-amine (4.03 g, 16.1 mm) was taken up in 125mL of IPA, and 50 mL of volatile components were removed bydistillation. The mixture was cooled slightly, and TEA (4.50 mL, 32.1mmol) and 4-chloroquinazoline (2.92 g, 17.7 mmol) were added. Heating atreflux was resumed. After 24 hr, the mixture was allowed to cool, and 15mL of 1N NaOH were added. The volatile components were evaporated. Theresidue was diluted with DCM, washed with 5% Na₂CO₃, dried overanhydrous Na₂SO₄, and concentrated onto silica gel. SPE, washing with50% EA/Hex and eluting with 40% EA/Hex+2% TEA, gave product-containingfractions, which were concentrated, taken up in DCM, washed with 5%Na₂CO₃, dried over anhydrous Na₂SO₄, and concentrated to give a yellowsolid. Recrystallization form EA/Hex gave 3.93 g of white solid. Rf 0.41(50% EA/Hex+2% TEA); mp 97.0-98.0° C.; ¹H NMR (CDCl₃) δ 8.66 (s, 1H),7.81 (dd, 1H, J=0.7, 8.4 Hz), 7.51 (m, 1H), 7.69 (ddd, 1H, J=1.5, 7.0,8.5 Hz), 7.41 (ddd, 1H, J=1.5, 7.0, 8.4 Hz), 6.83-6.78 (m, 4H, AA′BB′),6.09 (m, 1H, NH), 3.87 (t, 2H, J=6.6 Hz), 3.74 (s, 3H), 3.67 (m, 2H),1.76-1.66 (m, 4H), 1.46-1.33 (m, 8H); ¹³C NMR (CDCl₃) δ 159.7, 155.6,153.8, 153.4, 149.5, 132.6, 128.6, 126.0, 120.8, 115.6, 115.2, 114.8,68.7, 55.9, 41.5, 29.5, 29.4, 29.4, 27.1, 26.1.

Example 106 N-{2-[2-(Hexyloxy)phenoxyl]ethyl}quinazolin-4-amine

2-[2-(Hexyloxy)phenoxy]ethanamine (15.32 g, 64.6 mmol) was taken up in350 mL of IPA, and 50 mL was removed by distillation. The mixture wascooled slightly, and TEA (18.0 mL, 128 mmol) and 4-chloroquinazoline(11.0 g, 67.1 mmol) were added. The mixture was heated at reflux for 16hr. Then, the volatile components were evaporated and the residue waspartitioned between DCM and 5% Na₂CO₃ (500 mL of each). The organicphase was dried over Na₂SO₄ and concentrated. The solid wasrecrystallized from EA/Hex to give 16.0 g of solid. ¹H NMR (CDCl₃) δ 8.6(s, 1H), 7.9-7.7 (m, 3H), 7.4 (m, 1H), 7.0-6.8 (m, 4H), 6.6 (br s, 1H,NH), 4.3 (m, 2H), 4.1-4.0 (m, 4H), 1.8 (m, 2H), 1.4 (m, 2H), 1.3-1.2 (m,4H), 0.8 (m, 3H).

Example 107 N-{3-[2-(Hexyloxy)phenoxy]propyl}quinazolin-4-amine

2-(Hexyloxy)phenol A mixture of catechol (47.5 g, 432 mmol),1-bromohexane (71.2 g, 432 mmol), and K₂CO₃ (71.5 g, 518 mmol) in 120 mLof NMP and 240 mL of DMF was heated at 60° C. for 24 hr. Then, thevolatile components were evaporated, and the slurry was partitionedbetween EA (600, 2×250 mL) and H₂O, 5% Na₂CO₃ (2×), H₂O, 0.1M HCl, andbrine (150 mL each). The organic phases were dried over Na₂SO₄ andevaporated onto silica gel. SPE (10% EA/Hex) gave 75.5 g of a colorlessliquid that contained a 2.5:1 mole ratio of 2-(hexyloxy)phenol and1,2-bis(hexyloxy)benzene, as calculated from the NMR spectrum. Thereaction was repeated using catechol (71.68 g, 652 mmol), 1-bromohexane(91.0 mL, 651 mmol), and K₂CO₃ (108 g, 783 mmol) in 240 mL of DMF atroom temperature. The reaction gave 96.3 g pale yellow liquid thatcontained a 1:1 mole ratio of 2-(hexyloxy)phenol and1,2-bis(hexyloxy)benzene.

N-{3-[2-(Hexyloxy)phenoxy]propyl}phthalimide A 1:1 mixture of2-(hexyloxy)phenol and 1,2-bis(hexyloxy)benzene (47.2 g, 100 mmol ofphenol), K₂CO₃ (18.7 g, 136 mmol), and N-(3-bromopropyl)phthalimide(26.8 g, 100 mmol) in 100 mL of DMF was heated at 55° C. for 24 hr.Then, the mixture was cooled, and most of the volatile components wereevaporated. The residue was partitioned between EA (3×250 mL) and H₂O(3×200 mL), 0.05M HCl (2×150 mL), and brine (150 mL). The combinedorganic phases were dried over Na₂SO₄ and concentrated. SPE, washingwith 5% EA/Hex to elute residual starting materials and then eluting theproduct with 20% EA/Hex, gave 29.8 g of white solid. Rf 0.41 (20%EA/Hex).

3-[2-(Hexyloxy)phenoxy]propan-1-amine A mixture ofN-{3-[2-(hexyloxy)phenoxy]propyl}phthalimide (29.8 g, 78.2 mmol) andhydrazine monohydrate (4.80 mL, 101 mmol) in 300 mL of EtOH was heatedat reflux for 16 hr. Then, heating was stopped, and 50 mL of 2M HCl wasadded. The slurry was mixed for 2 hr, then filtered through a pad ofCelite, washing with 100 mL of 10% aqueous EtOH. The filtrate wasadjusted to pH 10 using NaOH pellets and concentrated. SPE, washing with3% MeOH/DCM and eluting with 8% MeOH/DCM+2% TEA, gave 15.5 g of yellowoil.

3-[2-(Hexyloxy)phenoxy]propan-1-amine (15.5 g, 61.8 mmol) was taken upin 250 mL of IPA, and 50 mL was removed by distillation. The mixture wascooled slightly, and TEA (10.5 mL, 74.8 mmol) and 4-chloroquinazoline(11.1 g, 67.6 mmol) were added. The mixture was heated at reflux for 16hr. Then, most of the volatile components were evaporated, and theresidue was partitioned between EA (300, 2×250 mL) and 5% Na₂CO₃ andbrine (150 mL each). The organic phases were dried over anhydrous Na₂SO₄and concentrated to a dark liquid. Trituration with two portions ofice-cold 50% Et₂O/Hex gave 14.9 g of light tan solid. Rf 0.20 (50%EA/Hex+2% TEA) 0.28 (5% MeOH/DCM+2% TEA); mp 67.0-67.5° C.; ¹H NMR(CDCl₃) δ 8.65 (s, 1H), 7.85-7.81 (m, 2H), 7.70 (ddd, 1H, J=1.5, 7.0,8.4 Hz), 7.38 (ddd, 1H, J=1.1, 6.9, 8.0 Hz), 7.11 (br s, 1H, NH),7.00-6.89 (m, 4H), 4.24 (m, 2H), 4.04 (m, 2H), 3.93 (m, 2H), 2.24 (m,2H), 1.71 (m, 2H), 1.37 (m, 2H), 1.23-1.17 (m, 4H), 0.81 (m, 3H); ¹³CNMR (CDCl₃) δ 159.7, 155.5, 149.5, 149.2, 148.6, 132.6, 128.3, 126.0,122.5, 121.6, 121.3, 115.5, 115.3, 113.8, 70.5, 69.2, 40.9, 31.6, 29.2,28.5, 25.8, 22.7, 14.1.

Example 108 N-{4-[2-(Hexyloxy)phenoxy]butyl}quinazolin-4-amine

4-[2-(Hexyloxy)phenoxy]butan-1-amine (13.82 g, 52.2 mmol) was taken upin 300 mL of IPA, and 50 mL was removed by distillation. Then, themixture was cooled slightly, and TEA (15 mL, 107 mmol) and4-chloroquinazoline (8.6 g, 52 mmol) were added. The mixture was heatedat reflux for 16 hr. Then, the volatile components were evaporated andthe residue was partitioned between DCM and 5% Na₂CO₃ (500 mL of each).The organic phase was dried over Na₂SO₄ and concentrated. The solid wasrecrystallized from EA/Hex to give 8.3 g of colorless solid.

Example 109 N-[8-(Quinazolin-4-ylamino)octyl]nicotinamide

N-(8-Aminooctyl)nicotinamide (2.60 g, 10.4 mmol) was taken up in 65 mLof IPA, and 30 mL of volatile components were removed by distillation.The mixture was cooled, and TEA (2.90 mL, 20.7 mmol) and4-chloroquinazoline (1.88 g, 11.5 mmol) were added. The mixture washeated at reflux for 6 hr. Then, the volatile components wereevaporated, and the residue was partitioned between DCM and a mixture of20 mL of 1N NaOH and 20 mL of 5% Na₂CO₃. The dark aqueous phase wasextracted with 40 mL of 1-butanol. The combined organic phases wereconcentrated. The residue was taken up in 10% MeOH/DCM+2% TEA andfiltered through a pad of silica gel. The filtrate was concentrated togive a dark solid. The solid was recrystallized from 10% aqueous MeOH,which removed some of the color. Recrystallization from EtOH gave twocrops of light tan solid with comparable ¹H NMR spectra; the crops werecombined to give 2.08 g with mp 173-176° C. and 67% purity by LC (230nm). FC (10% to 12% MeOH/DCM step gradient) and recrystallization fromIPA/H₂O gave 1.52 g of pale yellow solid, 89% purity by LC (230 nm).Trituration with ice-cold Et₂O and then 30% EA/Hex at room temperaturegave a solid with mp 172.5-176.0° C. and 90% purity by LC (230 nm). ¹HNMR (40° C., DMSO-d₆) δ 8.96 (d, 1H, J=1.5 Hz), 8.66 (d, 1H, J=3.3 Hz),8.56 (br s, 1H), 8.42 (s, 1H), 8.21-8.13 (m, 3H), 7.72 (m, 1H), 7.63 (m,1H), 7.48-7.44 (m, 2H), 3.51 (m, 2H), 3.23 (m, 2H), 1.62 (m, 2H), 1.51(m, 2H), 1.4-1.2 (m, 8H); ¹³C NMR (DMSO-d₆) δ 164.6, 159.3, 155.1,151.6, 149.0, 148.3, 134.8, 132.3, 130.1, 127.4, 125.4, 123.4, 122.6,114.9, 40.4, 39.2, 29.0, 28.8, 28.7, 28.5, 26.5, 26.4.

Example 110 N-[3-(Hexyloxy)benzyl]quinazolin-4-amine

[3-(Hexyloxy)phenyl]methanamine (18.5 g 89.3 mmol) was taken up in 300mL of IPA, and 100 mL of volatile material was removed by distillation.The mixture was cooled, and TEA (25.3 mL, 180 mmol) and4-chloroquinazoline (16.1 g, 98.3 mmol) were added. The mixture washeated at reflux for 5 hr, and then stirred at room temperatureovernight. Then, the volatile components were evaporated, and theresidue was taken up in DCM (200 mL) and washed with 1N NaOH (100 mL).The aqueous phase was extracted with DCM (100 mL). The combined organicphases were dried over Na₂SO₄, filtered, and concentrated to give ared-brown solid. SPE, eluting with 20%, 30%, and 50% EA/Hex, gaveproduct fractions that were combined and concentrated to yield a brownsolid. Recrystallization from EA/Hex gave 21.8 g of the product as acolorless solid. Rf 0.21 (50% EA/Hex); mp 106.0-107.0° C.; ¹H NMR(CDCl₃) δ 8.69 (s, 1H), 7.84 (d, 1H), 7.74-7.71 (m, 2H), 7.44 (m, 1H),7.25 (m, 1H), 6.96-6.93 (m, 2H), 6.83 (dd, 1H, J=2.2, 8.5 Hz), 6.18 (brs, 1H), 4.83 (m, 2H, AB), 3.92 (t, 2H, J=6.6 Hz), 1.75 (m, 2H), 1.42 (m,2H), 1.33-1.28 (m, 4H), 0.89 (m, 3H); ¹³C NMR (CDCl₃) δ 159.8, 159.5,155.8, 149.6, 139.7, 132.9, 130.1, 128.8, 126.3, 120.8, 120.2, 115.0,114.5, 113.8, 68.2, 45.5, 31.8, 29.4, 25.9, 22.8, 14.2.

Example 111 N-[3-(Decyloxy)benzyl]quinazolin-4-amine

(3-(Decyloxy)phenyl)methanol A mixture of 3-hydroxybenzyl alcohol (36.2g, 292 mmol), 1-bromodecane (55.5 mL, 269 mmol), and K₂CO₃ (44.3 g, 321mmol) in 60 mL of NMP and 120 mL of DMF was mixed at 60° C. for 2 dayswith the aid of a mechanical stirrer. Then, the volatile components wereremoved in vacuo. The resulting slurry was partitioned between 50%EA/Hex (300, 2×250 mL) and H₂O (400 mL), 0.2N NaOH (150 mL), H₂O (150mL), 2M HCl (150 mL), H₂O (150 mL), and brine (150 mL). The organicphases were dried over anhydrous Na₂SO₄, filtered through a pad ofsilica gel, and concentrated to 67.8 g of amber oil. The oil solidifiedexothermically. NMR indicated the presence of residual 1-bromodecane andEA. ¹H NMR (CDCl₃) δ 7.2 (m, 1H), 6.9 (m, 2H), 6.8 (m, 1H), 3.9 (br s,2H, AB), 3.9 (t, 2H, J=6.6 Hz), 2.6 (br s, 1H, OH), 1.8 (m, 2H), 1.5 (m,2H), 1.4-1.2 (m, 12H), 0.9 (m, 3H); ¹³C NMR (CDCl₃) δ 159.5, 142.7,129.6, 119.0, 113.8, 113.0, 68.1, 65.2, 32.0, 29.8, 29.7, 29.6, 29.5,29.4, 26.2, 22.8, 14.3.

1-(Chloromethyl)-3-(decyloxy)benzene A mixture of[3-(decyloxy)phenyl]methanol (58.4 g, 221 mmol) and 150 mL of toluenewas added dropwise to a mixture of thionyl chloride (19.4 mL, 266 mmol)and 50 mL of toluene. During the addition, gas evolution was observed.After 16 hr, the mixture was heated at reflux. After 1 hr, 150 mL ofvolatile material was removed by distillation. Then, the remainingvolatiles were evaporated in vacuo.

N-[3-(Decyloxy)benzyl]phthalimide The residue was taken up in 120 mL ofDMF and 60 mL of NMP, potassium phthalimide (49.2 g, 266 mmol) wasadded, and the mixture was heated at 60° C. for 24 hr. Then, the mixturewas cooled and partitioned between 50% EA/Hex and H₂O (2×), 0.1M HCl,and brine. The organic phases were dried over Na₂SO₄, filtered through apad of silica gel, and concentrated to 90.4 g of amber oil. ¹H NMR(CDCl₃) δ 7.8 and 7.7 (m, 4H, AA′BB′), 7.2 (m, 1H), 7.0 (m, 2H), 6.8 (m,1H), 4.8 (s, 2H), 3.9 (t, 2H, J=6.6 Hz), 1.7 (m, 2H), 1.4 (m, 2H),1.4-1.2 (m, 12H), 0.9 (m, 3H); ¹³C NMR (CDCl₃) δ 168.2, 159.6, 137.9,134.2, 132.3, 129.9, 123.6, 120.8, 114.8, 114.1, 68.2, 41.8, 32.1, 29.8,29.8, 29.6, 29.5, 29.5, 26.2, 22.9, 14.3.

[3-(Decyloxy)phenyl]methanamine IPA (50 mL) was mixed with the residueand then evaporated to remove residual EA. The residue was taken up in400 mL of EtOH, hydrazine monohydrate (14.5 mL, 299 mmol) was added, andthe mixture was heated at reflux. After 6 hr, the mixture was cooled,and 150 mL of 2M HCl was added. The solid precipitate was broken up toform a slurry, which was filtered and washed with 20% aqueous IPA. Thefiltrate was adjusted to pH 10 by adding NaOH pellets. Then, the mixturewas concentrated. The resulting liquid was partitioned between DCM and5% Na₂CO₃, and the organic phase was dried over anhydrous Na₂SO₄ andconcentrated.

N-[3-(Decyloxy)benzyl]quinazolin-4-amine Crude[3-(decyloxy)phenyl]methanamine was taken up in 400 mL of IPA, and 100mL of volatile components were removed by distillation. The mixture wasallowed to cool slightly. TEA (39 mL, 278 mmol) and 4-chloroquinazoline22.4 g, 136 mmol) were added. The mixture was heated at reflux for 20hr. Then, the mixture was allowed to cool, and the volatile componentswere evaporated. The mixture was partitioned between DCM (350, 2×100 mL)and 2N NaOH (150 mL). The organic phases were dried over anhydrousNa₂SO₄, 150 mL of MeOH were added, and the mixture was filtered througha pad of silica gel. The filtrate was concentrated to give a pink solid.The solid was recrystallized from EA/Hex to give a lightly coloredsolid. The solid was recrystallized from IPA to give 43.4 g of colorlesssolid. Rf 0.47 (10% MeOH/DCM); mp 93.0-95.5° C.; ¹H NMR (CDCl₃) δ 8.71(s, 1H), 7.86 (d, 1H, J=8.4 Hz), 7.76-7.68 (m, 2H), 7.46 (m, 1H), 7.27(m, 1H), 6.98-6.94 (m, 2H), 6.84 (m, 1H), 5.95 (br s, 1H, NH), 4.84 (m,2H, AB), 3.94 (t, 2H, J=6.6 Hz), 1.77 (m, 2H), 1.43 (m, 2H), 1.29-1.26(m, 12H), 0.87 (m, 3H); ¹³C NMR (CDCl₃) δ 159.8, 159.4, 155.6, 149.8,139.8, 132.9, 130.1, 128.9, 126.3, 120.7, 120.2, 115.0, 114.6, 113.8,68.3, 45.6, 32.1, 29.8, 29.8, 29.6, 29.5, 29.5, 26.3, 22.9, 14.3.

Example 112 N-(3-Phenoxybenzyl)quinazolin-4-amine

(3-Phenoxyphenyl)methanamine (1.55 g, 7.79 mmol) was taken up in 60 mLof IPA, and 15 mL of volatile material was removed by distillation. Themixture was cooled, and TEA (1.50 mL, 10.7 mmol) and 4-chloroquinazoline(1.20 g, 7.32 mmol) in 15 mL of IPA were added. The mixture was heatedat reflux for 5.5 hr, and then stirred at room temperature overnight.Then, the volatile components were evaporated, and the residue waspartitioned between DCM (3×70 mL) and 5% Na₂CO₃ (40 mL). The combinedorganic phases were dried over Na₂SO₄, filtered, and concentrated. SPE,eluting with 25% and then 55% EA/Hex, gave product fractions that werecombined and concentrated to yield an orange solid. Recrystallizationfrom EA/Hex gave a pink solid, and then from MeOH gave 1.29 g of a lightpink solid. Rf 0.19 (50% EA/Hex); mp 146.5-148.0° C.; ¹H NMR (CDCl₃) δ8.66 (s, 1H), 7.83 (d, 1H, J=8.5 Hz), 7.77 (d, 1H, J=8.1 Hz), 7.71 (m,1H), 7.42 (m, 1H), 7.30 (m, 3H), 7.10 (m, 2H), 7.04 (br s, 1H), 6.99 (m,2H), 6.90 (m, 1H), 6.44 (m, 1H, NH), 4.84 (m, 2H, AB); ¹³C NMR (CDCl₃) δ159.5, 157.9, 157.0, 155.5, 149.6, 140.4, 132.9, 130.3, 130.0, 128.7,126.3, 123.7, 122.6, 120.9, 119.2, 118.3, 117.9, 115.1, 45.1.

Example 113 N-[4-(Decyloxy)benzyl]quinazolin-4-amine

4-(Decyloxy)benzonitrile A mixture of 4-hydroxybenzonitrile (4.32 g,36.3 mmol), 1-bromodecane (6.80 mL, 32.9 mmol), and K₂CO₃ (6.61 g, 47.8mmol) in 20 mL of DMF was reacted for 2 days. The solvent was evaporatedin vacuo. The residue was partitioned between 50% EA/Hex (3×150 mL) and5% Na₂CO₃ (3×80 mL), H₂O (40 mL), 0.1M HCl (40 mL), and brine (80 mL).The organic phases were dried over anhydrous Na₂SO₄ and concentrated togive 8.30 g of colorless oil that solidified upon standing. ¹H NMR(CDCl₃) δ 7.54 and 6.90 (m, 4H, AA′BB′), 3.97 (t, 2H, J=6.6 Hz), 1.78(m, 2H), 1.42 (m, 2H), 1.34-1.25 (m, 12H), 0.86 (m, 3H); ¹³C NMR (CDCl₃)δ 162.6, 134.0, 119.4, 115.3, 103.7, 68.5, 32.0, 29.6, 29.4, 29.4, 29.1,26.0, 22.8, 14.2.

[4-(Decyloxy)phenyl]methanamine (7.61 g) was prepared as a colorlesssolid by the method for [4-(hexyloxy)phenyl]methanamine by treating4-(decyloxy)benzonitile with 2 g of LAH. ¹H NMR (CDCl₃) δ 7.2 (m, 2H),6.8 (m, 2H), 3.90 (t, 2H, J=6.6 Hz), 3.76 (s, 2H), 1.75 (m, 2H), 1.55(m, 2H), 1.43 (m, 2H), 1.4-1.2 (m, 10H), 0.87 (m, 3H); ¹³C NMR (CDCl₃) δ158.1, 135.4, 128.3, 114.5, 68.0, 46.0, 32.0, 29.6, 29.6, 29.5, 29.4,29.4, 28.1, 26.1, 22.7, 14.2.

N-[4-(Decyloxy)benzyl]quinazolin-4-amine (3.77 g) was prepared from[4-(decyloxy)phenyl]methanamine (3.04 g, 11.6 mmol), 4-chloroquinazoline(2.60 g, 15.8 mmol), TEA (3.40 mL, 24.2 mmol), and IPA (50 mL) using themethod for N-(3-phenoxybenzyl)quinazolin-4-amine. The product wasrecrystallized from 30% EA/Hex. Rf 0.24 (5% MeOH/DCM); mp 103.0-104.5°C.; ¹H NMR (CDCl₃) δ 8.71 (s, 1H), 7.85 (dd, 1H, J=0.7, 8.4 Hz), 7.74(dd, 1H, J=1.5, 6.9 Hz), 7.69 (m, 1H), 7.44 (ddd, 1H, J=1.1, 7.0, 8.1Hz), 7.31 (m, 2H), 6.88 (m, 2H), 5.90 (br s, 1H, NH), 4.78 (m, 2H, AB),3.95 (t, 2H, J=6.6 Hz), 1.77 (m, 2H), 1.45 (m, 2H), 1.4-1.2 (m, 12H),0.88 (m, 3H); ¹³C NMR (CDCl₃) δ 159.6, 159.1, 155.7, 149.7, 132.8,130.0, 129.7, 128.9, 126.2, 120.8, 115.0, 68.3, 45.2, 32.1, 29.8, 29.8,29.6, 29.5, 29.4, 26.2, 22.9, 14.3.

Example 114 N-[4-(Hexyloxy)benzyl]quinazolin-4-amine

N-[4-(Hexyloxy)benzyl]quinazolin-4-amine (31.9 g) was prepared from[4-(hexyloxy)phenyl]methanamine (32 g), 4-chloroquinazoline (19 g), TEA(32.5 mL), and IPA (250 mL) following the method for the preparation ofN-(3-phenoxybenzyl)quinazolin-4-amine. Mp 109.0-111.0° C. (from IPA); ¹HNMR (CDCl₃) δ 8.68 (s, 1H), 7.82 (m, 1H), 7.71 (m, 2H), 7.41 (m, 1H),7.29 (m, 2H, J=2.9, 4.8, 9.5 Hz, AA′BB′), 6.87 (m, 2H, J=2.9, 5.1, 9.5Hz, AA′BB′), 6.11 (br s, 1H, NH), 4.77 (m, 2H, AB), 3.93 (t, 2H, J=6.6Hz), 1.76 (m, 2H), 1.5 (m, 2H), 1.4-1.3 (m, 4H), 0.89 (m, 3H); ¹³C NMR(CDCl₃) δ 159.4, 150.0, 155.6, 149.6, 132.8, 130.0, 129.6, 128.7, 126.2,120.8, 115.0, 115.0, 68.3, 45.1, 31.8, 29.4, 25.9, 22.8, 14.2.

Example 1151-[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol

3-Nitroquinolin-4-ol 70% Aqueous nitric acid (6.1 mL) was added dropwiseto a mixture of 4-hydroxyquinoline (10 g, 69 mmol) and 100 mL of aceticacid heated at reflux. After 15 min, the mixture was allowed to cool toroom temperature. Dilution with EtOH resulted in the formation of aprecipitate, which was filtered and washed sequentially with EtOH, H₂O,and EtOH. Drying of the filtrate in vacuo gave 4.62 g of a light yellowpowder. ¹H NMR (DMSO-d₆) δ 9.2 (s, 1H), 8.3 (d, 1H), 7.9-7.7 (m, 2H),7.5 (m, 1H).

4-Chloro-3-nitroquinoline Phosphorus oxychloride (2.5 mL, 27 mmol) wasadded dropwise to a mixture of 3-nitroquinolin-4-ol (4.6 g, 24 mmol) and100 mL of DMF. The mixture was heated at 100° C. for 15 min, and thenpoured onto stirred ice. The slurry was neutralized with solid NaHCO₃,and the precipitate was filtered and washed with saturated NaHCO₃ andH₂O. The filtrate was taken up in DCM, dried over anhydrous Na₂SO₄, andconcentrated to give 2.3 g of solid.

2-Methyl-1-(3-nitroquinolin-4-yl)propan-2-ol A mixture of4-chloro-3-nitroquinoline (2.3 g, 11 mmol), 1-amino-2-methylpropan-2-ol(1.0 g, 11 mmol), TEA (9.3 mL), and 100 mL of DCM was heated at refluxuntil the starting material was consumed. The mixture was allowed tocool, washed with saturated NaHCO₃ and H₂O, dried over anhydrous Na₂SO₄,and concentrated to give 1.01 g of product. ¹H NMR (DMSO-d₆) δ 9.9 (brs, 1H, NH), 9.2 (s, 1H), 8.5 (d, 1H), 7.9-7.8 (m, 2H), 7.6 (m, 1H), 5.1(s, 1H, OH), 3.8 (m, 2H, ABX), 1.2 (s, 6H).

1-(3-Aminoquinolin-4-ylamino)-2-methylpropan-2-ol2-Methyl-1-(3-nitroquinolin-4-yl)propan-2-ol (1.01 g, mmol), 10% Pd-C(200 mg), and 20 mL of toluene were stirred under an atmosphere ofhydrogen until the starting material was consumed. The hydrogen wasreplaced by argon, and the mixture was filtered through a pad of Celiteand concentrated by evaporation to give 586 mg of product. ¹H NMR(CD₃OD) δ 8.3 (s, 1H), 8.1 (m, 1H), 7.8 (m, 1H), 7.5-7.4 (m, 2H),7.2-7.0 (m, 2H, ABX), 1.2 (s, 6H).

1-[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-olA mixture of 1-(3-aminoquinolin-4-ylamino)-2-methylpropan-2-ol (586 mg,2.54 mmol) and 0.4 mL of ethoxyacetic acid was heated at 130° C. for 3hr. The cooled mixture was poured into 5 mL of H₂O and made basic with6N NaOH. The resulting solid was collected by filtration, washed withH₂O, and dried in vacuo to give 655 mg of product. ¹H NMR (CDCl₃) δ 9.1(s, 1H), 8.3 (m, 1H), 8.1 (m, 1H), 7.7-7.5 (m, 2H), 4.9 (br s, 2H), 4.8(br s, 2H), 3.6 (q, 2H), 1.3 (s, 6H), 1.2 (t, 3H).

Example 116 1-(4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentylacetate

N-Isobutyl-3-nitroquinolin-4-amine 4-Chloro-3-nitroquinoline wasprepared from 3-nitroquinolin-4-ol (5.5 g, 28.8 mmol). Isobutylamine(3.2 mL, 32 mmol) was added slowly to a mixture of the4-chloro-3-nitroquinoline, TEA (24 mL, 170 mmol), and 40 mL of DCM. Themixture was heated at reflux for 30 min. Then, the volatile componentswere evaporated, and the residue was taken up in aqueous acid andfiltered. The filtrate was adjusted to pH 8-9 by adding concentratedNH₄OH, and the resulting solid was filtered and washed with H₂O. Dryingin vacuo gave 6.49 g of product. ¹H NMR (CDCl₃) δ 9.8 (br s, 1H, NH),9.3 (s, 1H), 8.3 (m, 1H), 8.0 (m, 1H), 7.8 (m, 1H), 7.4 (m, 1H), 3.8 (m,2H), 2.1 (m, 1H), 1.1 (d, 6H).

N⁴-Isobutylquinoline-3,4-diamine A mixture ofN-isobutyl-3-nitroquinolin-4-amine (19.0 g, 77.6 mmol) and 10% Pd-C (700mg) in 200 mL of EA was reacted under an atmosphere of hydrogen at 42psi until the starting material was consumed. Then, the hydrogen wasreplaced by argon, and the mixture was filtered through a pad of Celite.The filtrate was concentrated to give 15.2 g of product. ¹H NMR (CDCl₃)δ 8.4 (s, 1H), 7.9 (m, 1H), 7.8 (m, 1H), 7.5-7.4 (m, 2H), 3.9-3.6 (br m,3H, NH), 3.0 (d, 2H), 1.9 (m, 1H), 1.0 (d, 6H).

1-Isobutyl-1H-imidazo[4,5-c]quinoline A mixture ofN⁴-isobutylquinoline-3,4-diamine (2.33 g, 10.8 mmol) and 17 mL of formicacid was heated at 100° C. for 3 hr. The volatile components wereevaporated in vacuo. The residue was diluted with H₂O, made basic usingconcentrated NH₄OH, and extracted with DCM. The organic solvent wasreplaced with Et₂O, treated with activated charcoal, filtered through apad of Celite, and concentrated. NMR indicated the presence of startingmaterial. The crude was mixed with triethyl orthoformate, heated at 100°C. for 3 hr, and processed as before to give 1.4 g of product. ¹H NMR(CDCl₃) δ 9.3 (s, 1H), 8.3 (m, 1H), 8.1 (m, 1H), 7.9 (s, 1H), 7.7-7.5(m, 2H), 4.3 (d, 2H), 2.3 (m, 1H), 1.0 (d, 6H).

1-(1-Isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentan-1-ol n-Butyllithium(1.5M in hexanes, 3.6 mL) was added to a mixture of1-isobutyl-1H-imidazo[4,5-c]quinoline (1.4 g, 4.9 mmol) and 25 mL of THFcooled by a dry ice/IPA bath. After 15 min, valeraldehyde (0.80 mL, 7.5mmol) was added. The mixture was allowed to warm to room temperature.After 3 hr, H₂O and Et₂O were added, and the organic phase wasseparated, dried over anhydrous MgSO₄, and concentrated. FC, elutingwith EA, gave 990 mg of the product. ¹H NMR (CDCl₃) δ 9.2 (s, 1H), 8.1(m, 1H), 7.9 (m, 1H), 7.7-7.5 (m, 2H), 4.95 (m, 1H), 4.5 (m, 1H), 4.3(m, 1H), 2.3 (m, 2H), 1.6-1.3 (m, 4H), 1.1 (d, 3H), 1.0-0.8 (m, 6H).

1-(1-Isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentyl acetate Aceticanhydride (0.400 mL, 4.24 mmol) and TEA (0.510 mL, 3.64 mmol) were addedsequentially to a mixture of1-(1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentan-1-ol (818 mg, 2.75mmol) and 20 mL of DCM. After 16 hr, the mixture was diluted with 1volume of DCM and washed with H₂O and saturated NaHCO₃. The organicphase was dried over anhydrous MgSO₄ and concentrated to give 1.00 g ofproduct. ¹H NMR (CDCl₃) δ 9.3 (s, 1H), 8.25 (m, 1H), 8.1 (m, 1H),7.75-7.55 (m, 2H), 6.1 (m, 1H), 4.5 (m, 2H, ABX), 2.3 (m, 2H), 2.1 (s,3H), 1.5-1.3 (m, 4H), 1.1 (d, 3H), 1.0-0.8 (m, 6H).

2-(1-Acetoxypentyl)-1-isobutyl-1H-imidazo[4,5-c]quinoline 5-oxide Amixture of 1-(1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentyl acetate(980 mg, 2.91 mmol) and 32% peracetic acid (0.22 mL, 3.2 mmol) in 20 mLof EA was heated at reflux for 1 hr and stirred at room temperatureovernight. The volatile components were evaporated in vacuo, and theresidue was partitioned between DCM and saturated NaHCO₃ and H₂O. Theorganic phase was dried over anhydrous Na₂SO₄ and concentrated to give asolid. The solid was slurried with cold acetone, filtered, and dried togive 750 mg of product. ¹H NMR (CDCl₃) δ 9.3 (s, 1H), 9.0 (m, 1H), 8.5(br s, 2H, NH ₂), 8.15 (m, 1H), 7.85-7.75 (m, 2H), 6.0 (dd, 1H), 4.5 (m,2H, ABX), 2.3 (m, 2H), 2.1 (s, 3H), 1.5-1.3 (m, 4H), 1.1 (d, 3H), 0.95(d, 3H), 0.9 (m, 3H).

1-(4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentyl acetate Amixture of 4-toluenesulfonyl chloride (447 mg, 2.34 mmol) and 15 mL ofDCM was added slowly to a mixture of2-(1-acetoxypentyl)-1-isobutyl-1H-imidazo[4,5-c]quinoline 5-oxide (750mg, 2.13 mmol) and 8 mL of concentrated NH₄OH cooled by an ice bath. Themixture was allowed to warm to room temperature overnight. The mixturewas diluted with DCM and washed with saturated NaHCO₃, and the organicphase was dried over anhydrous Na₂SO₄ and concentrated to give 650 mg ofcolorless solid. ¹H NMR (CDCl₃) δ 7.9 (d, 1H), 7.7 (d, 1H), 7.5 (m, 1H),7.3 (m, 1H), 6.1 (dd, 1H), 5.5 (br s, 2H, NH ₂), 4.4 (m, 2H, ABX), 2.3(m, 2H), 2.15 (m, 1H), 2.1 (s, 3), 1.5-1.3 (m, 4H), 1.1 (d, 3H), 1.0-0.8(m, 6H).

Example 117 1-Isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-ol

2-Chloro-N-isobutyl-3-nitroquinolin-4-amine A mixture of isobutylamine(10.0 mL, 101 mmol) and TEA (15.6 mL, 111 mmol) in 10 mL of 1:1 DMF/DCMwas added slowly to 2,4-dichloro-3-nitroquinoline (26.94 g, 111 mmol) in100 mL of 4:1 DMF/DCM cooled with an ice bath. The mixture was allowedto warm to room temperature overnight. Then, the volatile componentswere evaporated, and the residue was partitioned between EA andsaturated NaHCO₃ and brine, dried over Na₂SO₄, and concentrated. FC (15%EA/Hex) gave the product as an orange solid. Recrystallization fromEA/Hex gave 3 crops of the product (17.97 g) as a light orange solid.

2-Chloro-N⁴-isobutylquinoline-3,4-diamine A mixture of2-chloro-N-isobutyl-3-nitroquinolin-4-amine (996 mg, 3.57 mmol) and 35mg of 5% Pt-C in 15 mL of MeOH was stirred under 2 atmospheres ofhydrogen for 90 min. Then, the mixture was blanketed with argon,filtered through a pad of Celite and concentrated to dryness.

4-Chloro-1-isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinoline A mixture ofthe crude 2-chloro-N⁴-isobutylquinoline-3,4-diamine and palmitic acid(3.66 g, 14.3 mmol) was heated at 180° C. for 4 hr. Then, the mixturewas partially cooled and, while mixing, diluted with 400 mL of EA and 10mL of 1M NaOH and 40 mL of 5% Na₂CO₃. The warm mixture was cooled withan ice bath, and a solid (presumably sodium palmitate) formed. Theliquid was decanted from the solid, the layers were separated, and theaqueous layer was extracted with EA (2×150 mL). The organic phases werewashed with 5% Na₂CO₃ (3×50 mL) and brine, dried over Na₂SO₄, andconcentrated. FC (4% MeOH/DCM) gave fractions that contained theproduct, observed by TLC. The fractions were concentrated, and two cropsof the product (1.14 g) were crystallized from DCM/Hex. Rf 0.27 (5%MeOH/DCM); ¹H NMR (CDCl₃) δ 7.8 (m, 2H), 7.4 (m, 1H), 7.3 (m, 1H), 4.2(d, 2H, ABX), 2.9 (m, 2H), 2.3 (m, 1H), 1.9 (m, 2H), 1.5-1.2 (m, 24H),1.0 (d, 6H), 0.85 (t, 3H).

1-Isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-ol A mixture of4-chloro-1-isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinoline (165 mg,0.35 mmol) in 5 mL of 50% concentrated NH₄OH/MeOH was heated at 160° C.for 72 hr. Then, the mixture was cooled and evaporated to a solid. Thesolid was washed with saturated NaHCO₃ and H₂O and dried in vacuo togive 160 mg light gray solid. Rf 0.29 (10% MeOH/DCM); ¹H NMR (CDCl₃) δ12.1 (br s, 1H, OH), 7.8 (m, 2H), 7.4 (m, 1H), 7.3 (m, 1H), 4.2 (d, 2H,ABX), 2.9 (m, 2H), 2.3 (m, 1H), 1.9 (m, 2H), 1.5-1.2 (m, 24H), 1.0 (d,6H), 0.85 (t, 3H).

Example 118 1-Octyl-1H-imidazo[4,5-c]quinoline

2,4-Dihydroxy-3-nitroquinoline Concentrated nitric acid (12.4 mL) wasadded to a mechanically-stirred mixture of 2,4-dihydroxyquinoline (20.2g, 125 mmol) in 160 mL of acetic acid at reflux. After 20 min, heatingwas stopped. After a further 15 min, 3 volumes of ice chips were added,and the mixture was stirred 30 min. The precipitate was filtered andwashed with four times with 1 volume of ice-cold H₂O. After drying invacuo, 23.0 g of orange solid was obtained.

2,4-Dichloro-3-nitroquinoline A mixture of2,4-dihydroxy-3-nitroquinoline (5.08 g, 24.7 mmol) and phenylphosphonicdichloride (13.9 mL, 98.4 mmol) was heated at 140° C. for 3 hr. Afterthe mixture had cooled somewhat, it was added to 18.5 g of NaHCO₃ in 150mL ice-cold H₂O. The pH was at least 6. The solid was filtered andwashed twice with H₂O. After drying in vacuo, 5.09 g of a tan solid wasobtained.

2-Chloro-3-nitro-N-octylquinolin-4-amine A mixture of2,4-dichloro-3-nitroquinoline (1.0 g, 4.1 mmol), 1-octylamine (0.75 mL),TEA (3.5 mL), and 20 mL of DCM were heated at reflux for 1 hr. Then, thevolatile material was evaporated, the residue was taken up in H₂O, andthe pH was adjusted to 8-9 with concentrated HCl and concentrated NH₄OH.The precipitate was collected and washed with H₂O. After drying invacuo, 1.65 g of a solid was obtained.

N⁴-Octylquinoline-3,4-diamine (515 mg) was obtained by treating2-chloro-3-nitro-N-octylquinolin-4-amine (1.33 g) with the conditionsused to prepare N-[8-(hexyloxy)octyl]pyrimidin-4-amine. ¹H NMR (CDCl₃) δ8.5 (s, 1H), 8.05 (d, 1H), 7.9 (d, 1H), 7.5 (m, 1H), 7.35 (m, 1H), 4.1(br s, 2H, NH ₂), 3.5 (m, 2H), 1.75 (m, 2H), 1.6-1.1 (m, 10H), 0.85 (m,3H).

1-Octyl-1H-imidazo[4,5-c]quinoline (400 mg) was obtained by treatingN⁴-octylquinoline-3,4-diamine (515 mg) with the conditions used toprepare 1-[8-(hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine. ¹H NMR (CDCl₃)δ 9.35 (s, 1H), 8.6 (m, 1H), 8.2 (d, 1H), 8.0 (s, 1H), 7.75 (m, 2H), 4.6(t, 2H), 2.0 (m, 2H), 1.5-1.1 (m, 10H), 0.9 (m, 3H).

Example 119 1-Hexadecyl-1H-imidazo[4,5-c]quinoline

2-Chloro-3-nitro-N-octylquinolin-4-amine A mixture of2,4-dichloro-3-nitroquinoline (1.0 g, 4.1 mmol), 1-octylamine (0.75 mL),TEA (3.5 mL), and 20 mL of DCM were heated at reflux for 1 hr. Then, thevolatile material was evaporated, the residue was taken up in H₂O, andthe pH was adjusted to 8-9 with concentrated HCl and concentrated NH₄OH.The precipitate was collected and washed with H₂O. After drying invacuo, 1.65 g of a solid was obtained.

N⁴-Octylquinoline-3,4-diamine (515 mg) was obtained by treating2-chloro-3-nitro-N-octylquinolin-4-amine (1.33 g) with the conditionsused to prepare N-[8-(hexyloxy)octyl]pyrimidin-4-amine. ¹H NMR (CDCl₃) δ8.5 (s, 1H), 8.05 (d, 1H), 7.9 (d, 1H), 7.5 (m, 1H), 7.35 (m, 1H), 4.1(br s, 2H, NH ₂), 3.5 (m, 2H), 1.75 (m, 2H), 1.6-1.1 (m, 10H), 0.85 (m,3H).

1-Octyl-1H-imidazo[4,5-c]quinoline (400 mg) was obtained by treatingN⁴-octylquinoline-3,4-diamine (515 mg) with the conditions used toprepare 1-[8-(hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine. ¹H NMR (CDCl₃)δ 9.35 (s, 1H), 8.6 (m, 1H), 8.2 (d, 1H), 8.0 (s, 1H), 7.75 (m, 2H), 4.6(t, 2H), 2.0 (m, 2H), 1.5-1.1 (m, 10H), 0.9 (m, 3H).

Example 120 1-Hexadecyl-1H-imidazo[4,5-c]quinolin-4-amine

1-Hexadecyl-1H-imidazo[4,5-c]quinolin-4-amine was made following themethod for the preparation of1-isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-ol, using2,4-dichloro-3-nitroquinoline (1.00 g), 1-hexadecylamine (1.00 g), 8 mLof triethyl orthoformate at reflux for imidazole ring formation, and asolution of 1 mL of anhydrous NH₃ in 8 mL of anhydrous IPA in the finalreaction. Final purification used FC (5% MeOH/DCM, Rf 0.17). ¹H NMR(CDCl₃) δ 7.9 (m, 1H), 7.8 (m, 1H), 7.75 (s, 1H), 7.5 (m, 1H), 7.3 (m,1H), 5.6 (br s, 1H, NH), 4.5 (t, 2H), 2.0 (m, 2H), 1.5-1.2 (m, 26H),0.85 (t, 3H).

Example 121 1-[2-(Dodecyloxy)ethyl]-1H-imidazo[4,5-c]quinoline

2-(Dodecyloxy)ethanol 60% Dispersion of sodium hydride in mineral oil(8.3 g, 208 mmol) was washed in Hex (2×). Then, a mixture of ethyleneglycol (17.4 mL, 312 mmol) in 250 mL of DMF and 25 mL of DCM was addedslowly while cooling with an ice bath. After 1 hr, 1-iodododecane (104mmol) was added. The mixture was allowed to warm to room temberature.After 24 hr, the volatile components were evaporated, and the residuewas partitioned between EA and 100 mL of 1M HCl, then 0.1M HCl and 5%Na₂S₂O₃, then 0.1M HCl, then brine, and the organic phases were driedover MgSO₄ and concentrated. SPE, washing with 5% EA/Hex and elutingwith 40% EA/Hex, gave 10.15 g of product. Rf 0.48 (40% EA/Hex); ¹H NMR(CDCl₃) δ 3.7 (m, 2H), 3.55-3.40 (m, 4H), 2.1 (br s, 1H, OH), 1.6 (m,2H), 1.4-1.2 (m, 18H), 0.85 (t, 3H).

2-(Dodecyloxy)ethyl methanesulfonate as a crude material was preparedfrom 2-(dodecyloxy)ethanol (10.15 g, 44.1 mmol), methanesulfonylchloride (4.3 mL, 53 mmol), and triethylamine (7.5 mL, 53 mmol) in 200mL of THF, and carried on. Rf 0.56 (40% EA/Hex).

1-(2-Iodoethoxy)dodecane (14.9 g) was prepared from 2-(dodecyloxy)ethylmethanesulfonate and 12.9 g of sodium iodide by the Finkelsteinreaction. Rf 0.94 (40% EA/Hex) 0.46 (5% EA/Hex); ¹H NMR (CDCl₃) δ 3.7(t, 2H), 3.45 (t, 2H), 3.25 (t, 2H), 1.6 (m, 2H), 1.4-1.2 (m, 18H), 0.85(t, 3H).

1-(2-Azidoethoxy)dodecane as a crude was prepared from1-(2-iodoethoxyl)dodecane (14.9 g, 43.8 mmol) and sodium azide (2.85 g,43.8 mmol) in 33 mL of DMF. Rf 0.28 (5% EA/Hex); ¹H NMR (CDCl₃) δ 3.6(t, 2H), 3.45 (t, 2H), 3.35 (t, 2H), 1.6 (m, 2H), 1.4-1.2 (m, 18H), 0.85(t, 3H).

2-(Dodecyloxy)ethanamine was prepared by the catalytic hydrogenation ofthe crude 1-(2-azidoethoxyl)dodecane using 1.5 g of 5% Pd-C in 150 mL ofMeOH. SPE, washing with 50% EA/Hex and eluting with 15% MeOH/DCM+2% TEA,gave 8.0 g of product.

1-[2-(Dodecyloxy)ethyl]-1H-imidazo[4,5-c]quinoline (103 mg) was preparedby the method for the preparation of1-hexadecyl-1H-imidazo[4,5-c]quinolin-4-amine starting with2-(dodecyloxy)ethanamine (2.73 g, 11.9 mmol) and2,4-dichloro-3-nitroquinoline (2.94 g, 12.1 mmol), using reduction ofboth nitro and aryl chloride by zinc/HCl, and formation of the imidazolering using 7 mL of triethyl orthoformate at reflux. Final purificationwas by FC (5% MeOH/DCM, Rf 0.10). ¹H NMR (CDCl₃) δ 9.3 (s, 1H), 8.2 (d,1H), 8.1 (d, 1H), 7.95 (s, 1H), 7.7-7.5 (m, 2H), 4.7 (m, 2H), 3.85 (m,2H), 3.3 (m, 2H), 1.4 (m, 2H), 1.3-1.1 (m, 18H), 0.8 (m, 3H).

Example 1221-[2-(Dodecyloxy)ethyl]-N,N-dimethyl-1H-imidazo[4,5-c]quinolin-4-amine

N⁴-[2-(Dodecyloxy)ethyl]-N²,N²-dimethyl-3-nitroquinoline-2,4-diamine Astoichiometric excess of 2-(dodecyloxy)ethanamine and2,4-dichloro-3-nitroquinoline (486 mg, 2.0 mmol) and DIEA (0.38 mL, 2.18mmol) in 10 ml of DMF and 10 mL of DCM was mixed at room temperature for2 days. No reaction was observed by TLC. The DCM was evaporated andreplaced by toluene, and the mixture was heated at reflux for 6 hr.Then, the reaction was cooled, partitioned between EA and saturatedNaHCO₃ and brine, and the organic phase was dried over Na₂SO₄ andconcentrated. FC (10% to 20% EA/Hex step gradient) gave 306 mg ofN⁴-[2-(Dodecyloxy)ethyl]-N²,N²-dimethyl-3-nitroquinoline-2,4-diamine asorange oil, as well as 376 mg ofN²,N⁴-bis[2-(dodecyloxy)ethyl]-3-nitroquinoline-2,4-diamine as orangeoil. ¹H NMR (CDCl₃) δ 7.9 (m, 2H), 7.6-7.55 (m, 2H), 7.1 (m, 1H), 3.8(m, 2H), 3.5-3.4 (m, 4H), 3.0 (s, 6H), 1.6 (m, 2H), 1.4-1.2 (m, 18H),0.85 (t, 3H).

1-[2-(Dodecyloxy)ethyl]-N,N-dimethyl-1H-imidazo[4,5-c]quinolin-4-amineThe nitro group ofN⁴-[2-(dodecyloxy)ethyl]-N²,N²-dimethyl-3-nitroquinoline-2,4-diamine(306 mg, 0.70 mmol) was reduced using zinc/HCl, and the ortho diaminewas reacted with triethyl orthoformate at reflux to give 197 mg of theproduct after FC (5% MeOH/DCM). Rf 0.15 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ7.9 (m, 2H), 7.8 (s, 1H), 7.45 (m, 1H), 7.2 (m, 1H), 4.6 (t, 2H), 3.85(t, 2H), 3.6 (s, 6H), 3.3 (t, 2H), 1.5 (m, 2H), 1.3-1.1 (m, 18H), 0.85(t, 3H).

Example 123 1-[6-(Octyloxy)hexyl]-1H-imidazo[4,5-c]quinoline

6-(Octyloxy)hexan-1-ol Sodium hydride (6.38 g, 266 mmol) was addedcautiously to a mixture of 1,6-hexanediol (47.2 g, 400 mmol) and 120 mLof DMF cooled by an ice bath. After 15 min, a mixture of 1-iodooctane(31.9 g, 133 mmol) in 120 mL of DCM was added. The mixture was allowedto warm to room temperature overnight. Then, the volatile componentswere evaporated, and the residue was partitioned between EA and 0.1MHCl, 5% Na₂S₂O₃, H₂O, and brine. The organic phases were dried overanhydrous MgSO₄ and concentrated. SPE, washing with 2% EA/Hex andeluting with 40% EA/Hex, gave 13.0 g of colorless oil. Rf 0.40 (50%EA/Hex); ¹H NMR (CDCl₃) δ 3.59 (t, 2H, J=6.7 Hz), 3.36 (t, 2H, J=6.7Hz), 3.35 (t, 2H, J=6.7 Hz), 2.02 (br s, 1H, OH), 1.56-1.47 (m, 6H),1.40-1.20 (m, 14H), 0.84 (m, 3H).

2-Chloro-3-nitro-N-[6-(octyloxy)hexyl]quinolin-4-amine TEA (8.40 mL,59.9 mmol) was added to a mixture of 6-(octyloxy)hexan-1-ol (7.60 g,33.0 mmol) and methanesulfonyl chloride (4.56 mL, 58.3 mmol) in 190 mLof DME cooled by an ice bath. The mixture was allowed to warm to roomtemperature. After 4 hr, 5 mL of H₂O were added and the volatilecomponents were evaporated. The residue was partitioned between EA(3×150 mL) and H₂O, saturated NaHCO₃, H₂O, 1M HCl, H₂O, and brine (100mL each). The organic phases were dried over MgSO₄ and concentrated to acolorless oil. The oil was taken up in 250 mL of acetone, sodium iodide(9.9 g, 66 mmol) was added, and the mixture was heated at reflux for 2hr. The volatile components were evaporated, and the residue waspartitioned between EA and H₂O, 5%

Na₂S₂O₃, H₂O, and brine. The organic phases were dried over MgSO₄ andconcentrated. SPE (5% EA/Hex) gave a purple oil. The oil was taken up in25 mL of DMF and 10 mL of toluene, potassium phthalimide (5.55 g, 30mmol) was added, and the mixture was heated at reflux for 4 hr. Then,the mixture was cooled and partitioned between EA and 0.1M HCl, 5%Na₂S₂O₃, H₂O, and brine. The organic phases were dried over MgSO₄ andconcentrated. SPE, washing with 5% EA/Hex and eluting with 7.5% EA/Hex,gave 10.05 g colorless oil. The oil was taken up in 500 mL of 5%IPA/EtOH, hydrazine monohydrate (2.0 mL, 41 mmol) was added, and themixture was heated at reflux for 4 hr. The mixture was cooled andconcentrated. The residue was partitioned between DCM and 5% Na₂CO₃. Theorganic phase was dried over anhydrous Na₂SO₄ and concentrated. SPE,washing with 50% EA/Hex and eluting with 15% MeOH/DCM+2% TEA, gave 1.91g of colorless oil. The oil was taken up in a mixture of 9 mL of DMA and9 mL of toluene, and 2,4-dichloro-3-nitroquinoline (2.16 g, 8.87 mmol)and DIEA (1.45 mL, 8.32 mmol) were added. The mixture was reacted atroom temperature for 88 hr and at reflux for 2 days. The mixture wascooled, the volatile components were evaporated, and the residue waspartitioned between EA and 5% Na₂CO₃ and brine. The organic phases weredried over Na₂SO₄ and concentrated. SPE (20% EA/Hex) gaveproduct-containing fractions with impurities. FC (20% EA/Hex) gave 2.06g of yellow oil that solidified upon standing. The solid wasrecrystallized from EA/Hex to give 1.70 g of yellow solid. Rf 0.22 (20%EA/Hex); ¹H NMR (CDCl₃) δ 7.84 (d, 1H, J=7.9 Hz), 7.76 (dd, 1H, J=1.2,8.4 Hz), 7.63 (ddd, 1H, J=1.2, 6.9, 8.1 Hz), 7.42 (ddd, 1H, J=1.3, 7.0,8.4 Hz), 5.98 (t, 1H, J=4.7 Hz, NH), 3.38-3.29 (m, 6H), 1.66 (m, 2H),1.56-1.42 (m, 4H), 1.36-1.34 (m, 4H), 1.2-1.1 (m, 10H), 0.8 (m, 3H).

1-[6-(Octyloxy)hexyl]-1H-imidazo[4,5-c]quinoline Four mL of a 1:3mixture of concentrated HCl and MeOH was added slowly to a mixture of2-chloro-3-nitro-N-[6-(octyloxy)hexyl]quinolin-4-amine (357 mg, 0.82mmol), zinc dust (320 mg), and 20 mL of DCM cooled by an ice bath. Themixture was allowed to warm to room temperature. After 16 hr, thevolatile components were evaporated, the residue was diluted with 75 mLof DCM, and the pH was adjusted to >8 using 5% Na₂CO₃. The organic phasewas separated, dried over anhydrous Na₂SO₄, and concentrated. Triethylorthoformate (5 mL) was added to the crude product, and the mixture washeated at 130° C. for 6 hr. Then, the mixture was cooled andconcentrated. The residue was partitioned between DCM and 5% Na₂CO₃. Theorganic phase was dried over Na₂SO₄ and concentrated. FC (3% and 5%MeOH/DCM step gradient) gave 101 mg of brown oil. Rf 0.21 (5% MeOH/DCM);¹H NMR (CDCl₃) δ 9.31 (s, 1H), 8.26 (m, 1H), 8.12 (m, 1H), 7.92 (s, 1H),7.70-7.58 (m, 2H), 4.54 (t, 2H, J=7.2 Hz), 3.34 (t, 2H, J=6.2 Hz), 3.33(t, 2H, J=6.7 Hz), 2.00 (m, 2H), 1.56-1.39 (m, 6H), 1.3-1.1 (m, 12H),0.83 (m, 3H).

Example 124 1-(8-Ethoxyoctyl)-1H-imidazo[4,5-c]quinoline

1-(8-Ethoxyoctyl)-1H-imidazo[4,5-c]quinoline was made by the method usedfor the preparation of 1-octyl-1H-imidazo[4,5-c]quinoline, substituting8-ethoxyoctan-1-amine for 1-octylamine. 8-Ethoxyoctan-1-amine was madeby the method used for the preparation of 8-(hexyloxy)octan-1-amine,using iodoethane and 1,8-octanediol as starting materials.

Example 125 1-(8-Methoxyoctyl)-1H-imidazo[4,5-c]quinoline

1-(8-Methoxyoctyl)-1H-imidazo[4,5-c]quinoline was made by the methodused for the preparation of 1-octyl-1H-imidazo[4,5-c]quinoline,substituting 8-methoxyoctan-1-amine for 1-octylamine.

Example 126 1-(8-Butoxyoctyl)-1H-imidazo[4,5-c]quinoline

1-(8-Butoxyoctyl)-1H-imidazo[4,5-c]quinoline was made by the method usedfor the preparation of 1-octyl-1H-imidazo[4,5-c]quinoline, substituting8-butoxyoctan-1-amine for 1-octylamine. 8-Butoxyoctan-1-amine was madeby the method used for the preparation of 10-(hexyloxy)decan-1-amine,using 1-bromobutane and 1,8-octanediol as starting materials.

Example 127 1-[9-(Hexyloxy)nonyl]-1H-imidazo[4,5-c]quinoline

9-(Benzyloxy)nonan-1-ol, as 8.79 g of colorless oil, was made by themethod used for the preparation of 8-(benzyloxy)octan-1-ol, using 27.1 gof 1,9-nonanediol, 7.85 mL of benzyl chloride in 20 mL of DME, 1.80 g ofsodium hydride, 60% dispersion in mineral oil, and 300 mL of DMF. Rf0.12 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.37-7.22 (m, 5H), 4.49 (s, 2H),3.61 (t, 2H, J=6.6 Hz), 3.45 (t, 2H, J=6.7 Hz), 1.65-1.49 (m, 4H),1.36-1.21 (m, 10H).

{[9-(Hexyloxy)nonyloxy]methyl}benzene Sodium hydride (920 mg, 38.3 mmol)was added to a mixture of 9-(benzyloxy)nonan-1-ol (8.79 g, 35.2 mmol)and 200 mL of DME. After 1 hr, 1-iodohexane (10.6 g, 50 mmol) was added.After 40 hr, analysis by TLC indicated little conversion. Anotherportion of sodium hydride was added. After 8 hr, another portion ofsodium hydride and 1-bromohexane (7.0 mL, 50 mmol) were added. Themixture was stirred 48 hr, then allowed to stand for several weeks.Then, 6 mL of concentrated NH₄OH were added cautiously. After 16 hr, thevolatile components were evaporated. The residue was partitioned betweenEA (3×250 mL) and H₂O (100 mL), 5% Na₂S₂O₃ (100 mL), H₂O (100 mL), 0.1MHCl (2×100 mL), and brine (100 mL). The organic phases were dried overanhydrous Na₂SO₄ and concentrated. SPE (5% EA/Hex) gave 8.47 g ofcolorless oil. Rf 0.75 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.34-7.23 (m, 5H),4.49 (s, 2H), 3.48-3.36 (m, 6H), 1.68-1.51 (m, 6H), 1.5-1.2 (m, 16H),0.88 (t, 3H, J+6.8 Hz).

1-(Hexyloxy)-9-iodononane A mixture of{[9-(hexyloxy)nonyloxy]methyl}benzene (8.47 g, 25.4 mmol),chlorotrimethylsilane (20 mL, 158 mmol), and sodium iodide (23.7 g, 158mmol) in 150 mL of DCM was heated at reflux for 60 hr, then mixed atroom temperature for 48 hr. Then, the volatile components wereevaporated. The residue was partitioned between EA (3×250 mL) andsaturated NaHCO₃ (100 mL), 5% Na₂S₂O₃ (100 mL), H₂O (100 mL), and brine(100 mL). The organic phases were dried over anhydrous MgSO₄ andconcentrated. Analysis by TLC suggested the presence of9-(hexyloxy)nonan-1-ol with low Rf. The mixture was taken up in 25 mL oftoluene and then concentrated. The purple oil was taken up in another 25mL of toluene, 5 mL of phosphorus oxychloride was added, and the mixturewas heated at reflux until the suspected alcohol was consumed, asobserved by TLC analysis. The mixture was cooled with an ice bath, andsaturated NaHCO₃ was added slowly, accompanied by gas evolution. Themixture was extracted with EA (3×250 mL), and the organic phases werewashed with H₂O, 0.1M HCl, and brine (100 mL each), dried over MgSO₄,and concentrated. SPE (2% EA/Hex), discarding early fractions thatcontained benzyl halides, gave 3.76 g of product as amber oil. Rf 0.53(5% EA/Hex); ¹H NMR (CDCl₃) δ 3.37 (t, 4H, J=6.7 Hz), 3.16 (m, 2H), 1.80(m, 2H), 1.57-1.49 (m, 4H), 1.4-1.2 (m, 16H), 0.87 (m, 3H).

N-[9-(Hexyloxy)nonyl]phthalimide A mixture of 1-(hexyloxy)-9-iodononane(3.80 g, 14.4 mmol), and potassium phthalimide (2.70 g, 14.6 mmol) in 8mL of DMF was heated at 100° C. for 5 hr. The mixture was cooled andpartitioned between EA (3×250 mL) and 5% Na₂CO₃, H₂O, 5% Na₂S₂O₃, H₂O,0.1M HCl, and brine (100 mL each). The organic phases were dried overanhydrous MgSO₄ and concentrated. SPE, washing with 5% EA/Hex andeluting with 7.5% EA/Hex, gave 3.30 g of product as a solid. Rf 0.26(10% EA/Hex); ¹H NMR (CDCl₃) δ 7.80 and 7.67 (m, 4H, AA′BB′), 3.64 (m,2H), 3.35 (t, 2H, J=6.7 Hz), 3.34 (t, 2H, J=6.7 Hz), 1.77-1.47 (m, 6H),1.28-1.22 (m, 16H), 0.86 (m, 3H).

9-(Hexyloxy)nonan-1-amine A mixture of N-[9-(hexyloxy)nonyl]phthalimide(3.05 g, 8.18 mmol) and hydrazine monohydrate (0.58 mL, 12 mmol) in 50mL of 5% IPA/EtOH was heated at reflux for 4 hr. The mixture was cooledand concentrated. The residue was partitioned between DCM and 5% Na₂CO₃.The organic phase was dried over anhydrous Na₂SO₄ and concentrated. SPE,washing with 50% EA/Hex and eluting with 15% MeOH/DCM+2% TEA, gave 1.08g of a mixture of 9-(hexyloxy)nonan-1-amine and phthalhydrazide. Rf 0.11(15% MeOH/DCM+2% TEA); ¹H NMR (CDCl₃) δ 4.6 (br s, 2H, NH ₂), 3.4-3.3(m, 4H), 2.7 (t, 2H), 1.7-1.1 (m, 22H), 0.8 (m, 3H).

2-Chloro-N-[9-(hexyloxy)nonyl]-3-nitroquinolin-4-amine The mixture of9-(hexyloxy)nonan-1-amine and phthalhydrazide was reacted with2,4-dichloro-3-nitroquinoline (1.11 g, 4.56 mmol) and TEA (0.63 mL, 4.49mmol) in 9 mL of DMF and 16 mL of toluene heated at reflux. After 24 hr,the mixture was cooled, partitioned between EA and H₂O, 5% Na₂CO₃, andbrine, dried over anhydrous Na₂SO₄, and concentrated. FC, eluting with15% and then 20% EA/Hex, gave 1.35 g of yellow product as an oil thatsolidified upon standing. Recrystallization from cold EA/Hex gave 650 mgof yellow solid. Rf 0.18 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.87 (d, 1H,J=8.6 Hz), 7.78 (dd, 1H, J=1.3, 9.5 Hz), 7.67.65 (m, 1H), 7.45 (m, 1H),5.99 (t, 1H, J=4.7 Hz, NH), 3.39-3.31 (m, 6H), 1.66 (m, 2H), 1.53-1.45(m, 4H), 1.4-1.1 (m, 16H), 0.82 (m, 3H).

1-[9-(Hexyloxy)nonyl]-1H-imidazo[4,5-c]quinoline Six mL of a 1:3 mixtureof concentrated HCl and MeOH was added slowly to a mixture of2-chloro-N-[9-(hexyloxy)nonyl]-3-nitroquinolin-4-amine (674 mg, 1.50mmol), zinc dust (585 mg), and 25 mL of DCM cooled by an ice bath. Themixture was allowed to warm to room temperature. After 1 hr, thevolatile components were evaporated, the residue was diluted with 75 mLof DCM, and the pH was adjusted to >8 using 5% Na₂CO₃. The organic phasewas separated, dried over anhydrous Na₂SO₄, and concentrated. Rf 0.41(15% MeOH/DCM) Triethyl orthoformate (4 mL) was added to the crudeproduct, and the mixture was heated at 130° C. for 6 hr. Then, themixture was cooled and concentrated. FC (3% and 5% MeOH/DCM stepgradient) gave 273 mg of brown oil. Rf 0.27 (5% MeOH/DCM); ¹H NMR(CDCl₃) δ 9.22 (s, 1H), 8.16 (m, 1H), 7.98 (m, 1H), 7.60-7.47 (m, 2H),4.38 (t, 2H, J=7.1 Hz), 3.27 (t, 2H, J=6.7 Hz), 3.26 (t, 2H, J=6.7 Hz),1.86 (m, 2H), 1.45-1.41 (m, 4H), 1.4-1.1 (m, 16H), 0.78 (m, 3H).

Example 128 1-(10-Butoxydecyl)-1H-imidazo[4,5-c]quinoline

1-(10-Butoxydecyl)-1H-imidazo[4,5-c]quinoline was made by the methodused for the preparation of 1-octyl-1H-imidazo[4,5-c]quinoline,substituting 10-butoxydecan-1-amine for 1-octylamine.10-Butoxydecan-1-amine was made by the method used for the preparationof 10-(hexyloxy)decan-1-amine, using 1-bromobutane and 1,10-decanediolas starting materials. Rf 0.23 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ 9.32 (s,1H), 8.27 (m, 1H), 8.12 (m, 1H), 7.93 (s, 1H), 7.66 (m, 2H), 4.54 (t,2H, J=7.2 Hz), 3.36 (t, 2H, J=6.5 Hz), 3.35 (t, 2H, J=6.5 Hz), 1.99 (m,2H), 1.57-1.13 (m, 18H), 0.88 (t, 3H, J=7.3 Hz).

Example 129 4-Amino-1-[8-(hexyloxy)octyl]pyridinium salts

A mixture of 8-(hexyloxy)octyl methanesulfonate (0.5 g, 1.62 mmol) and4-aminopyridine (450 mg) in 20 mL of THF was heated at reflux for 18 hr.The mixture was concentrated and purified by FC (5% MeOH/DCM) to give396 mg of an oily solid. Recrystallization from MeOH gave a solid. Mp108-110° C.; ¹H NMR (CDCl₃) δ 8.4 (br s, 1.4H), 7.8 (d, 2H), 7.2 (d,2H), 4.1 (m, 2H), 3.35 (m, 4H), 2.4 (br s, 4.5H), 1.8 (m, 2H), 1.6 (m,4H), 1.4-1.2 (m, 14H), 0.8 (m, 3H).

Example 130 4-(8-Methoxyoctylamino)-1-methylpyridinium iodide

A mixture of N-(8-methoxyoctyl)pyridin-4-amine (176 mg, 0.74 mmol) andiodomethane (0.5 mL, 8 mmol) in 4 mL of acetone was heated at 80° C. ina sealed tube for 1.5 hr, then allowed to stand at room temperature for2 days, during which a precipitate formed. The volatile components wereevaporated from the precipitated product. ¹H NMR (CDCl₃) δ 8.47 (m, 1H),7.99 (m, 2H), 7.57 (m, 1H), 6.59 (m, 1H), 4.04 (s, 3H), 3.35-3.21 (m,4H), 3.29 (s, 3H), 1.71 (m, 2H), 1.54-1.28 (m, 10H).

Example 131 1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine

N-[8-(Hexyloxy)octyl]-3-nitropyridin-4-amine A mixture of3-nitropyridin-4-ol (510 mg, 3.64 mol) in 1 mL of phenylphosphonicdichloride was heated at 170-140° C. for 3 hr. Then, the mixture wascooled and partitioned between EA and saturated NaHCO₃. The organicphase was washed with brine, dried over Na₂SO₄, filtered through a padof silica gel, and concentrated to give crude 4-chloro-3-nitropyridine.8-(Hexyloxy)octan-1-amine was taken up in 10 mL of pyridine, and 5 mL ofvolatile material was evaporated from the mixture. The mixture wascooled with an ice bath, TEA (0.44 mL, 3.14 mol) was added, and then amixture of the chloropyridine prepared above and 10 mL of DCM was added.The mixture was allowed to warm to room temperature overnight. Then, thereaction was concentrated by evaporation, and the residue waspartitioned between EA and saturated NaHCO₃. The organic phases werewashed with brine, dried over Na₂SO₄, and concentrated. Purification byFC (50% EA/Hex) gave 405 mg ofN-[8-(hexyloxy)octyl]-3-nitropyridin-4-amine as a yellow oil. Rf 0.28(50% EA/Hex); ¹H NMR (CDCl₃) δ 9.16 (s, 1H), 8.24 d, 1H, J=6.2 Hz), 8.12(br s, 1H), 6.66 (d, 1H, J=6.2 Hz), 3.38-3.25 (m, 6H), 1.70 (m, 2H),1.52-1.47 (m, 4H), 1.39-1.18 (m, 14H), 0.84 (t, 3H, J=6.7 Hz).

N⁴-[8-(Hexyloxy)octyl]pyridine-3,4-diamine A mixture ofN-[8-(hexyloxy)octyl]-3-nitropyridin-4-amine (405 mg, 1.15 mol) and 45mg of 10% Pd/C in 30 mL of MeOH was stirred under an atmosphere ofhydrogen for 5 hr. Then, the catalyst was removed by filtration throughCelite, and the filtrate was concentrated. Purification by SPE, washingwith 10% MeOH/DCM and then eluting with 15% MeOH/DCM+2% TEA, gave 216 mgof N⁴-[8-(hexyloxy)octyl]pyridine-3,4-diamine. Rf 0.05 (15% MeOH/DCM,ninhydrin (+)); ¹H NMR (CDCl₃) δ 7.86 (d, 1H, J=5.4 Hz), 7.79 (s, 1H),6.38 (d, 1H, J=5.4 Hz), 4.53 (br s, 1H), 3.62 (br s, 2H), 3.34 (t, 4H,J=6.7 Hz), 3.08 (m, 2H), 1.62-1.46 (m, 6H), 1.27-1.24 (m, 14H), 0.83 (t,3H, J=6.8 Hz).

1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine A mixture ofN⁴-[8-(hexyloxy)octyl]pyridine-3,4-diamine (216 mg, 0.67 mol) in 2 mL oftriethyl orthoformate was heated at reflux for 6 hr. Then, volatilematerial was removed by evaporation, and the residue was partitionedbetween EA and saturated NaHCO₃. The organic phases were washed withbrine, dried over Na₂SO₄, and concentrated. Purification by FC (7%MeOH/DCM) gave 217 mg of 1-[8-(hexyloxy)octyl]-1H-imidazo[4,5-c]pyridineas an amber oil. Rf 0.11 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ 9.02 (s, 1H),8.34 (d, 1H, J=5.7 Hz), 7.86 (s, 1H), 7.25 (m, 1H), 4.08 (t, 2H, J=7.0Hz), 3.30-3.25 (m, 4H), 1.78 (m, 2H), 1.45-1.43 (m, 4H), 1.22-1.19 (m,14H), 0.78 (t, 3H, J=6.7 Hz).

Example 132 1-Hexadecyl-1H-imidazo[4,5-c]pyridine

N-Hexadecyl-3-nitropyridin-4-amine 1-Hexadecylamine was taken up in 10mL of pyridine, and 6 mL of volatile components were removed bydistillation. The mixture was cooled, and a mixture of4-chloro-3-nitropyridine in 10 mL of DCM and 10 mL of DMF was added.Then, TEA (0.46 mL, 3.28 mmol) was added and the mixture was heated atgentle reflux. After 16 hr, the cooled mixture was taken up in EA andwashed with saturated NaHCO₃, H₂O, and brine. The organic phase wasdried over anhydrous Na₂SO₄ and concentrated. SPE, washing with 10%EA/Hex and eluting with 20% EA/Hex, gave 626 mg of solid. Rf 0.34 (50%EA/Hex); ¹H NMR (CDCl₃) δ 9.19 (s, 1H), 8.26 (d, 1H, J=6.1 Hz), 8.15 (brs, 1H, NH), 6.68 (d, 1H, J=6.2 Hz), 3.30 (m, 2H), 1.72 (m, 2H),1.42-1.17 (m, 26H), 0.86 (m, 3H).

1-Hexadecyl-1H-imidazo[4,5-c]pyridine A mixture ofN-hexadecyl-3-nitropyridin-4-amine (626 mg, 1.79 mmol) and 65 mg of 10%Pd-C in 25 mL of 1:1 EA/MeOH was stirred under a blanket of hydrogen for40 hr. The hydrogen atmosphere was replaced by argon, and the mixturewas filtered through a pad of Celite and concentrated. SPE, washing with10% MeOH/DCM and eluting with 10% MeOH/DCM+2% TEA, gave 540 mg ofcolorless solid. The solid was taken up in 8 mL of triethyl orthoformateand heated at reflux for 4 hr. Then, the volatile components wereevaporated. The residue was taken up in a fresh 8-mL portion of triethylorthoformate and heated at reflux for 6 hr. The volatile components wereevaporated. FC of the residue (5% MeOH/DCM) gave 375 mg of tan solid. Rf0.10 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ 9.06 (s, 1H), 8.39 (d, 1H, J=5.7Hz), 7.92 (s, 1H), 7.31 (dd, 1H, J=1.0, 5.7 Hz), 4.12 (m, 2H), 1.82 (m,2H), 1.26-1.18 (m, 26H), 0.81 (t, 3H, J=6.6 Hz).

Example 133 1-(10-Butoxydecyl)-1H-imidazo[4,5-c]pyridine

1-(10-Butoxydecyl)-1H-imidazo[4,5-c]pyridine (231 mg) as an amber oilwas prepared following the method for1-[8-(hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine, using 492 mg of4-hydroxy-3-nitropyridine and 535 mg of 10-butoxydecan-1-amine.

N-(10-Butoxydecyl)-3-nitropyridin-4-amine: Rf 0.30 (50% EA/Hex); ¹H NMR(CDCl₃) δ 9.18 (s, 1H), 8.25 (d, 1H, J=6.0 Hz), 8.14 (br s, 1H, NH),6.68 (d, 1H, J=6.2 Hz), 3.39-3.26 (m, 6H), 1.71 (m, 2H), 1.57-1.47 (m,4H), 1.40-1.27 (m, 14H), 0.88 (t, 3H, J=7.2 Hz).

N⁴-(10-Butoxydecyl)pyridine-3,4-diamine: Rf 0.08 (15% MeOH/DCM); ¹H NMR(CDCl₃) δ 7.89 (d, 1H, J=6.4 Hz), 7.83 (s, 1H), 6.41 (d, 1H, J=6.4 Hz),4.41 (br s, 1H, NH), 3.58 (br s, 2H, NH ₂), 3.39-3.33 (m, 4H), 3.11-3.10(br m, 2H), 1.66-1.47 (m, 6H), 1.40-1.26 (m, 14H), 0.88 (t, 3H, J=7.2Hz).

1-(10-Butoxydecyl)-1H-imidazo[4,5-c]pyridine: Rf 0.15 (5% MeOH/DCM); ¹HNMR (CDCl₃) δ 9.06 (s, 1H), 8.38 (d, 1H, J=5.7 Hz), 7.88 (d, 1H), 7.28(d, 1H, J=5.4 Hz), 4.12 (m, 2H), 3.35-3.29 (m, 4H), 1.82 (m, 2H),1.53-1.43 (m, 4H), 1.36-1.20 (m, 14H), 0.84 (m, 3H).

Example 134 N-(8-Methoxyoctyl)pyridin-4-amine

A mixture of 4-chloropyridine hydrochloride (1.50 g, 10.0 mmol),8-methoxyoctan-1-amine (894 mg, 5.62 mmol), TEA (1.80 mL, 10.4 mmol),and 4 mL of IPA was heated at 130-140° C. in a sealed tube for 48 hr.Then, the mixture was cooled and the volatile components wereevaporated. The residue was partitioned between DCM and 5% Na₂CO₃, andthe organic phase was dried over Na₂SO₄ and concentrated. FC (1% TEA+0%,2%, 3% MeOH/DCM step gradient) gave 176 mg of solid. Rf 0.13 (10%MeOH/DCM); ¹H NMR (CDCl₃) δ 8.6 (m, 1H), 7.8 (m, 2H), 6.9 (m, 2H), 3.3(m, 5H), 3.2 (m, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.4-1.2 (m, 8H).

Example 135 N-[8-(Hexyloxy)octyl]pyridin-3-amine

8-(Hexyloxy)octanal (1.12 g, 4.91 mmol), prepared by the Swern oxidationof 8-(hexyloxy)octan-1-ol, was mixed with 3-aminopyridine (500 mg, 5.32mmol) in 5 mL of acetontrile and 0.4 mL of 1M HCl. Then, 0.37 mL of 1Msodium cyanoborohydride in THF was added. After 20 hr, the mixture waspartitioned between EA and 5% Na₂CO₃ and brine, and the organic phasewas dried over Na₂SO₄ and concentrated. FC (70% EA/Hex) gave 160 mg ofthe product. ¹H NMR (CDCl₃) δ 8.0 (m, 1H), 7.9 (m, 1H), 7.1 (m, 1H), 6.9(m, 1H), 3.4 (t, 4H), 3.1 (t, 2H), 1.7-1.5 (m, 6H), 1.5-1.2 (m, 14H),0.85 (m, 3H).

Example 136 N-[8-(Hexyloxy)octyl]pyridin-2-amine

A mixture of 2-aminopyridine (458 mg, 4.8 mmol) and 8-(hexyloxy)octylmethanesulfonate (0.5 g, 1.6 mmol) in 20 mL of THF was heated at refluxfor 3 hr. Then, the reaction was cooled and worked up following theprocedure for N-[8-(hexyloxy)octyl]pyridin-3-amine to give 100 mg ofproduct. ¹H NMR (CDCl₃) δ 8.0 (m, 1H), 7.4 (m, 1H), 6.55 (m, 1H), 6.35(m, 1H), 4.6 (br s, 1H, NH), 3.4 (t, 4H), 3.2 (m, 2H), 1.7-1.5 (m, 6H),1.5-1.2 (m, 14H), 0.85 (m, 3H).

Example 137 N-[8-(Hexyloxy)octyl]pyrimidin-4-amine

6-Chloro-N-[8-(Hexyloxy)octyl]pyrimidin-4-amine8-(Hexyloxy)octan-1-amine (636 mg, 2.78 mmol) was taken up in 15 mL ofpyridine, and then 10 mL of volatile material was removed bydistillation. The mixture was cooled to room temperature, and 15 mL ofDCM, 4,6-dichloropyrimidine (621 mg, 4.17 mmol), and TEA (0.47 mL, 3.35mmol) were added sequentially. After being stirred overnight, TLCindicated the presence of the amine starting material, so a secondquantity of 4,6-dichloropyrimidine was added and the mixture was heatedat reflux for 3 hr. Then, the mixture was cooled, the volatile materialwas evaporated, and the residue was partitioned between EA and 5%Na₂CO₃. The organic phases were washed with brine, dried over Na₂SO₄,filtered through a pad of silica gel, and concentrated. Purification byFC (30% EA/Hex) gave 767 mg of6-chloro-N-[8-(hexyloxy)octyl]pyrimidin-4-amine as a tan solid. Rf 0.18(20% EA/Hex); ¹H NMR (CDCl₃) δ 8.30 (s, 1H), 6.30 (d, 1H, J=1.0 Hz),5.36 (br s, 1H, NH), 3.37 (t, 4H, J=6.9 Hz), 3.24 (m, 2H, AB), 1.6-1.5(m, 6H), 1.3-1.2 (m, 14H), 0.87 (m, 3H).

N-[8-(Hexyloxy)octyl]pyrimidin-4-amine A mixture of6-chloro-N-[8-(hexyloxy)octyl]pyrimidin-4-amine (767 mg, 2.25 mmol) in30 mL of DCM and 6.8 mL of 2M HCl/IPA was cooled using an ice bath.Then, 876 mg of zinc dust was added. After 45 min, the mixture wasallowed to warm to room temperature. After being stirred overnight, themixture was partitioned between DCM and 5% Na₂CO₃. The organic phase wasdried over Na₂SO₄ and concentrated. Purification by FC (5% MeOH/DCM)gave 229 mg of N-[8-(hexyloxy)octyl]pyrimidin-4-amine as a colorlesssolid. Rf 0.21 (5% MeOH/DCM); ¹H NMR (CDCl₃) δ 8.46 (s, 1H), 8.08 (d,1H, J=5.7 Hz), 6.25 (dd, 1H, J=1.2, 5.9 Hz), 5.59 (br s, 1H), 3.33 (t,4H, J=6.7 Hz), 3.21 (m, 2H, AB), 1.58-1.45 (m, 6H), 1.26-1.17 (m, 14H),0.83 (m, 3H).

Example 138 N-[8-Hexyloxy)octyl)pyrimidin-2-amine

A mixture of 2-chloropyrimidine (272 mg, 2.39 mmol),8-(hexyloxy)octan-1-amine (548 mg, 2.39 mmol), and TEA (0.34 mL, 2.42mmol) in 10 mL of DMF was heated at 80-90° C. for 2 hr. Then, themixture was partitioned between EA and 5% Na₂CO₃ (2×) and brine, and theorganic phase was dried over Na₂SO₄ and concentrated. FC (50% EA/Hex)gave 227 mg of product as a yellow solid. ¹H NMR (CDCl₃) δ 8.2 (d, 2H),6.4 (d, 2H), 5.6 (br s, 1H, NH), 3.3 (m, 4H), 1.6-1.4 (m, 6H), 1.4-1.2(m, 14H), 0.8 (m, 3H).

Example 139 1-[8-(Hexyloxy)octyl]-4-phenyl-1H-imidazole

4-Phenylimidazole (1.0 g, 6.9 mmol) was added to a mixture of sodiumtert-butoxide (7.9 mmol) in 20 mL of DMF cooled by an ice bath. After 30min, 8-(hexyloxy)octyl methanesulfonate (2.14 g, 6.95 mmol) was added,and the mixture was allowed to come to room temperature. After 6 hr,volatile components were evaporated. The residue was taken up in EA andwashed with saturated NaHCO₃, 0.1M HCl, and H₂O. The organic phase wasdried over anhydrous Na₂SO₄ and concentrated. FC (70% EA/Hex) gave 2.5 gof 1-[8-(hexyloxy)octyl]-4-phenyl-1H-imidazole. ¹H NMR (CDCl₃) δ 7.8 (m,2H), 7.6 (s, 1H), 7.4 (m, 2H), 7.2 (m, 2H), 3.9 (t, 2H), 3.4 (m, 4H),1.8 (m, 2H), 1.6-1.5 (m, 4H), 1.4-1.2 (m, 14H), 0.9 (m, 3H).

Example 140 N-[8-(Hexyloxy)octyl]isoquinolin-1-amine

1-Chloroisoquinoline (390 mg, 2.38 mmol), 8-(hexyloxy)octan-1-amine (360mg, 1.57 mmol), and triethylamine (0.22 mL, 1.57 mmol) in 2 mL of DMAwas heated at 80° C. for 24 hr. Then the mixture was cooled andpartitioned between EA and 5% Na₂CO₃ and brine, and the organic phasewas dried over Na₂SO₄ and concentrated. FC (20% EA/Hex) gave 87 mg ofthe product. Rf 0.25 (20% EA/Hex); ¹H NMR (CDCl₃) δ 7.97 (d, 1, J=6.0Hz), 7.76-7.73 (m, 1), 7.67-7.64 (m, 1), 7.59-7.53 (m, 1), 7.47-7.41 (m,1), 6.89 (d, 1, J=5.9 Hz), 5.25 (br s, 1), 3.62-3.55 (m, 2), 3.38 (t, 4,J=6.7 Hz), 1.77-1.67 (m, 2), 1.58-1.24 (m, 18), 0.89-0.84 (m, 4).

Example 141 N-[8-(Hexyloxy)octyl]isoquinolin-5-amine

N-[8-(Hexyloxy)octyl]isoquinolin-5-amine (123 mg) was prepared followingthe method for N-[8-(hexyloxy)octyl]quinolin-6-amine starting with8-(hexyloxy)octanoic acid (300 mg, 123 mmol) and 5-aminoisoquinoline(174 mg, 1.21 mmol). ¹H NMR (CDCl₃) δ 9.14 (d, 1, J=0.7 Hz), 8.44 (d, 1,J=6.1 Hz), 7.57-7.54 (m, 1), 7.45 (t, 1, J=7.9 Hz), 7.30-7.25 (m, 1),6.74 (dd, 1, J=0.7, 7.7 Hz), 4.35 (br s, 1), 3.41-3.35 (m, 4), 3.27-3.22(m, 2), 1.80-1.70 (m, 2), 1.57-1.21 (m, 18), 0.89-0.84 (m, 3).

Example 142 N-[8-(Hexyloxy)octyl]quinoxalin-2-amine

N-[8-(Hexyloxy)octyl]quinoxalin-2-amine (238 mg) was prepared followingthe method for N-[8-(hexyloxy)octyl]isoquinolin-1-amine starting with8-(hexyloxy)octan-1-amine (380 mg, 1.66 mmol) and 2-chloroquinoxaline(413 mg, 2.50 mmol), but the reaction proceeded at room temperature over4 days. Rf 0.20 (20% EA/Hex); ¹H NMR (CDCl₃) δ 8.14 (s, 1), 7.80 (dd, 1,J=1.2, 8.1 Hz), 7.64 (m, 1), 7.50 (m, 1), 7.29 (m, 1), 5.24 (br t, 1),3.46 (m, 2), 3.37-3.32 (m, 4), 1.66-1.47 (m, 6), 1.31-1.25 (m, 14), 0.84(m, 3).

Example 143 1-[8-(Hexyloxy)octyl]-1H-benzimidazole

8-(Hexyloxy)octyl methanesulfonate (9.4 g, 31 mmol) was added to amixture of benzimidazole (4.0 g, 31 mmol) and sodium tert-butoxide (31mmol) in 100 mL of DMF. After 6 hr, the volatile components wereevaporated, and the residue was partitioned between EA and saturatedNaHCO₃, 0.1M HCl, and H₂O, and the organic phases were dried over Na₂SO₄and concentrated. FC (70% EA/Hex) gave 7.4 g of the product. ¹H NMR(CDCl₃) δ 7.9 (s, 1H), 7.8 (m, 1H), 7.4 (m, 1H), 7.2 (m, 2H), 4.1 (t,2H), 3.3 (m, 4H), 1.9 (m, 2H), 1.7-1.5 (m, 4H), 1.4-1.2 (m, 14H), 0.9(m, 3H).

Example 144 N-[8-(Hexyloxy)octyl]pyrazin-2-amine

N-[8-(Hexyloxy)octyl]pyrazin-2-amine (102 mg) was prepared following themethod for N-[8-(hexyloxy)octyl]isoquinolin-1-amine starting with8-(hexyloxy)octan-1-amine (583 mg, 2.54 mmol) and 2-chloropyrazine (0.25mL, 2.81 mmol) and heating at 70° C. for 5 days. Rf 0.26 (40% EA/Hex);¹H NMR (CDCl₃) δ 7.9 (m, 1H), 7.8 (m, 1H), 7.7 (m, 1H), 4.8 (br s, 1H,NH), 3.4-3.2 (m, 6H), 1.6-1.4 (m, 6H), 1.4-1.2 (m, 14H), 0.8 (m, 3H).

Example 145 1-[8-(Hexyloxy)octyl]-1H-indole

1-[8-(Hexyloxy)octyl]-1H-indole (1.0 g) was prepared following themethod for 1-[8-(hexyloxy)octyl]-1H-benzimidazole starting with indole(836 mg, 7.1 mmol), 8-(hexyloxy)octyl methanesulfonate (1.1 g, 3.6mmol), and 7.1 mmol of sodium tert-butoxide. ¹H NMR (CDCl₃) δ 7.6 (d,1H), 7.3 (d, 1H), 7.2 (m, 1H), 7.1 (m, 2H), 6.5 (d, 1H), 4.1 (t, 2H),3.4 (m, 4H), 1.8 (m, 2H), 1.7-1.5 (m, 4H), 1.4-1.2 (m, 14H), 0.9 (m,3H).

Example 146 3-[8-(Hexyloxy)octyl]-3H-imidazo[4,5-b]pyridine

3-[8-(Hexyloxy)octyl]-3H-imidazo[4,5-b]pyridine was prepared followingthe method for 1-[8-(hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine startingfrom 2-chloro-3-nitropyridine (479 mg, 3.0 mmol) and8-(hexyloxy)octan-1-amine (0.69 g, 3.0 mmol). Since2-chloro-3-nitropyridine was commercially available, the first step inthe 1-[8-(hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine preparation(chlorination using phenylphosphonic dichloride) was not performed. Rf0.31 (5% MeOH/DCCM); ¹H NMR (CDCl₃) δ 8.21 (dd, 1, J=1.5, 4.7 Hz), 7.89(s, 1), 7.87 (m, 1), 7.02 (dd, 1, J=4.7, 7.9 Hz), 4.09 (m, 2), 3.21-3.15(m, 4), 1.74 (m, 2), 1.36-1.32 (m, 4), 1.14-1.10 (m, 14), 0.69 (m, 3).

Example 147 1-Dodecyl-1H-imidazo[4,5-c]quinoline

1-Dodecyl-1H-imidazo[4,5-c]quinoline (510 mg) was prepared following themethod for the preparation of 1-octyl-1H-imidazo[4,5-c]quinoline,starting with 2,4-dichloro-3-nitroquinoline (1.0 g, 4.1 mmol) and1-dodecylamine (1.0 g, 4.5 mmol). ¹H NMR (CDCl₃) δ 8.5 (s, 1H), 8.15 (d,1H), 8.05 (d, 1H), 7.5 (m, 1H), 7.3 (m, 1H), 3.7 (t, 2H), 1.8 (m, 2H),1.5-1.1 (m, 18H), 0.8 (m, 3H).

Example 148 1-[3-(Decyloxy)propyl]-1H-imidazo[4,5-c]quinoline

3-(Decyloxy)propan-1-amine (7.17 g of a solid) was prepared followingthe method for the preparation of 8-butoxyoctan-1-amine, starting from1,3-propanediol (26.3 mL, 363 mmol) and 1-iododecane (121 mmol) mixed in240 mL of 1:1 DCM/DMF.

1-[3-(Decyloxy)propyl]-1H-imidazo[4,5-c]quinoline (127 mg) was preparedfollowing the method for the preparation of1-octyl-1H-imidazo[4,5-c]quinoline, starting with2,4-dichloro-3-nitroquinoline (1.94 g, 7.99 mmol) and3-(decyloxy)propan-1-amine (1.72 g, 7.99 mmol). ¹H NMR (CDCl₃) δ 8.9.3(s, 1H), 8.3 (m, 2H), 7.95 (s, 1H), 7.7-7.5 (m 2H), 4.7 (t, 2H), 3.5-3.3(m, 4H), 2.2 (m, 2H), 1.6 (m, 2H), 1.4-1.2 (m, 14H), 0.8 (t, 3H).

Example 149 1-[4-(Decyloxy)butyl]-1H-imidazo[4,5-c]quinoline

4-(Decyloxy)butan-1-amine (2.42 g, 7.28 mmol) was prepared by lithiumaluminum hydride reduction of 4-(decyloxy)butyronitrile, which wasprepared in poor yield from the sodium alkoxide of 1-decanol and4-bromobutyronitrile.

1-[4-(Decyloxy)butyl]-1H-imidazo[4,5-c]quinoline (78 mg) was preparedfollowing the method for the preparation of1-octyl-1H-imidazo[4,5-c]quinoline, starting with2,4-dichloro-3-nitroquinoline (1.77 g, 7.28 mmol) and4-(decyloxy)butan-1-amine (2.42 g, 7.28 mmol). ¹H NMR (CDCl₃) δ 9.3 (s,1H), 8.25 (m, 1H), 8.15 (m, 1H), 7.95 (s, 1H), 7.7-7.5 (m, 2H), 4.6 (t,2H), 3.5-3.3 (m, 4H), 2.1 (m, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.4-1.1 (m,14H), 0.8 (t, 3H).

Example 150 1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]quinoline

1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]quinoline was made by the methodused for the preparation of 1-octyl-1H-imidazo[4,5-c]quinoline,substituting 8-(hexyloxy)octan-1-amine for 1-octylamine.

Example 151 1-{5-[3-(Hexyloxy)propoxy]pentyl}-1H-imidazo[4,5-c]quinoline

1-{5-[3-(Hexyloxy)propoxy]pentyl}-1H-imidazo[4,5-c]quinoline (2.75 g ofbrown oil) was made by the method used for the preparation of1-octyl-1H-imidazo[4,5-c]quinoline, starting with2,4-dichloro-3-nitroquinoline (5.35 g, 22 mmol) and5-[3-(hexyloxy)propoxy]pentan-1-amine (4.90 g, 20 mmol). ¹H NMR (CDCl₃)δ 9.3 (s, 1H), 8.25 (m, 1H), 8.1 (m, 1H), 7.9 (s, 1H), 7.7-7.5 (m, 2H),4.5 (t, 2H), 3.5-3.3 (m, 8H), 2.0 (m, 2H), 1.8 (m, 2H), 1.7-1.4 (m, 6H),1.4-1.2 (m, 6H), 0.8 (m, 3H).

Example 152 1-{3-[3-(Hexyloxy)phenoxy]propyl}-1H-imidazo[4,5-c]quinoline

1-{3-[3-(Hexyloxy)phenoxy]propyl}-1H-imidazo[4,5-c]quinoline (1.33 g ofbrown oil) was made by the method used for the preparation of1-octyl-1H-imidazo[4,5-c]quinoline, starting with2,4-dichloro-3-nitroquinoline (4.33 g, 17.8 mmol) and3-[2-(hexyloxy)phenoxy]propan-1-amine (4.37 g, 17.8 mmol). ¹H NMR(CDCl₃) δ 9.3 (s, 1H), 8.3-8.1 (m, 2H), 7.9 (s, 1H), 7.7-7.5 (m, 2H),7.1 (m, 1H), 6.6-6.4 (m, 3H), 4.7 (t, 2H), 3.95-3.80 (m, 4H), 2.4 (m,2H), 1.7 (m, 2H), 1.5-1.2 (m, 6H), 0.8 (m, 3H).

Biological Activity Examples Anti-Inflammatory Examples Example ASelective Killing of LPS-Activated Inflammatory Macrophages by CompoundAC

Summary: THP-1 is a human AML cell line that can be induced into amacrophage-like cell by treatment with 0.2 μM vitamin-D3 (vit-D3) for3-5 days. In the absence of an inflammatory activator (LPS; bacterialendotoxin), AC exerted little effect on cell viability in THP-1 cellsover a 6 hour period. Similarly, LPS in the absence of AC induced only alow level of cell death. In contrast, when both components, LPS and ACwere added to vit-D3 activated THP-1 cells, massive cytotoxicity wasobserved within 6 hours. These observations indicate that stimulatedmacrophages participating in an inflammatory reaction may bespecifically targeted for deactivation with AC.

Experiment Overview:

-   -   1. Vit-D3 activated THP-1 cells were transferred to the wells of        a 24-well dish    -   2. Compound AC, LPS from E. coli 0111:B4 or both components were        added    -   3. After 6 hours at 37 C the wells viable cell counts were        performed by FACS

Experimental Procedures

Cell Culture:

THP-1 cells (ATCC) treated with 0.2 μM vitamin-D3 (EMD Biosciences) for4 days prior to day 0 were transferred to the wells of 24-well dishes(1×10⁶ cells in 1 ml cRPMI [RPMI (ATCC)+10% ΔFBS (ATCC)]. LPS from E.coli 0111:B4 (Sigma-Aldrich) and compound AC were added to appropriatewells and the plates placed in a 37 C incubator. After 6 hours the wellswere processed for Annexin V apoptosis assay.

FACS Cell Count and Viability Assay:

After 6 hours, 500 μl of the cell suspension from each well wastransferred to 3 ml FACS tubes and 50 μl CountBright beads (Invitrogen)were added to each tube. Samples were vortexed, 2 μl propidium iodide(150 μM) (Sigma-Aldrich) added then acquired on the FACSCalibur.

Results:

As shown in Table 1, in the absence of a second pro-inflammatory signal(LPS), AC exerted little effect on cell viability in THP-1 cells over a6 hour period. Similarly, LPS in the absence of AC induced only a lowlevel of cell death. In marked contrast, when both LPS and AC were addedto vit-D3 activated THP-1 cells, massive cytotoxicity was observedwithin 6 hours. Cytotoxicity increased in a AC dose-dependent manner.

TABLE 1 Dose-dependent acute cell death in AC-treated THP-1 cells primedwith LPS (Viable cell percent change from 0 hours) Plus LPS Compound ACNo LPS (100 ng/ml) concentration Mean SE Mean SE 0 (0.1% 0.00 4.30−21.47 3.50 DMSO) 0.5 μM AC −8.75 5.92 −55.63 4.61 1.0 μM AC −2.43 4.24−65.93 3.13 2.0 μM AC −10.63 1.49 −77.43 3.44

As shown in Table 2, in the absence of a second signal (LPS), AC, in aconcentration range of 0.1 to 2 μM, exerted little effect on cellviability in THP-1 cells over a 6 hour period. Similarly, LPS in theabsence of AC induced a low level of cell death that increased in a dosedependent manner. In contrast, when both components, LPS and AC, wereadded to vit-D3 activated THP-1 cells, massive cytotoxicity was observedwithin 6 hours. Cytotoxicity appeared to have reached maximal level withthe lowest dose of LPS used (1 ng/ml).

TABLE 2 Titration of LPS in the THP-1 acute/5-hour AC + LPS-induced celldeath model (Viable cell percent change from 0 hours) THP-1 viable cell% from 0 hours 5 hours treatment LPS No AC 0.1 μM AC concentration MeanSE Mean SE  0 ng/ml 0.00 0.80 −13.24 0.73  1 ng/ml −23.36 1.77 −53.792.57  5 ng/ml −30.23 2.57 −53.64 1.73 10 ng/ml −31.25 1.45 −58.85 0.7920 ng/ml −40.17 1.38 −58.76 1.44

Conclusion:

AC selectively reduces viability of pro-inflammatory LPS-activatedmacrophages, with relative sparing of nonstimulated macrophages. A verylow dose of LPS (1 ng/ml) provided sufficient activation of macrophagesto make them susceptible to AC.

Example B Relative Potency of Compound AC and Chloroquine forInactivation of Inflammatory Macrophages

Background: THP-1 is a human AML cell line that can be induced into amacrophage-like cell with vitamin-D3 (vit-D3) then activated into aninflammatory state by stimulation with LPS (bacterial endotoxin). In themacrophage, LPS binding to toll-like receptor 4 (TLR-4) leads to NF-κBactivation and secretion of inflammatory cytokines which can lead totissue damage in inflammatory diseases.

Compounds of the invention inactivate inflammatory macrophages byaccumulating in acidic vacuoles and disrupting their structure andfunction, inhibiting release of vesicular inflammatory mediators andinducing cytosolic changes that trigger macrophage death or dysfunction,including inhibition of autophagy; autophagy is important fordifferentiation of monocytes into macrophages. The aim of this study wasto compare relative potency of a compound of the invention, AC, withchloroquine. Both AC and chloroquine are 4-aminoquinoline derivatives,and chloroquine is known to be useful for treatment of several clinicalinflammatory diseases.

In this experiment, cell viability was monitored and uptake andaccumulation of acridine orange, a lysosomotropic fluorescent dye, wasused to assess lysosomal acidification and integrity. JC-1 dye was usedto measure effects of test compounds on mitochondrial membrane potential(MMP); reduction of MMP is a feature of apoptotic cell death.

Experimental Procedures:

-   -   1. Vit-D3 activated THP-1 cells (0.5×10⁶ cells in 2 ml) were        transferred to the wells of a 24-well dish    -   2. Compound AC was added at a concentration of 0.5 μM, 1.0 μM or        5.0 μM    -   3. Chloroquine was added at a concentration of 25.0 μM, 50.0 μM        or 100.0 μM    -   4. LPS from E. coli 0111:B4 (1 ng/ml final concentration) was        added to some wells    -   5. After 5 hours viable cell count, Acridine Orange (A.O.)        uptake and JC-1 mitochondrial loading were determined by        fluorescence-activated cell sorting (FACS)

Cell Line Information:

THP-1: ATCC TIB-202 Organism: Human, male, one-year infant

Organ: Peripheral blood Disease: Acute Monocytic Leukemia (AML)

Cell type: Monocyte Growth properties: Suspension in RPMI plus 10% FBS

Test Compounds:

Batch Compound Conc. Supplier info. DMSO 100% Alfa Aesar E26X026 43998AC 10 mM N/A 073112DZ Chloroquine diphosphate 25 mM SIGMA C6628 100912JR(C.Q.) Bafilomycin A1 (Baf A1) 100 μM SIGMA B1793 040912JR Crude-LPS E.coli 0111:B4 100 μg/ml SIGMA L4391 111611JR Acridine Orange (A.O.) 50μg/ml Invitrogen 092311JR A3568 JC-1 200 μM Invitrogen 040611JR T3168CCCP 50 mM Invitrogen 818978 M34152 Sterile water N/A HyClone AXF39335SH30529.03 Sterile DPBS N/A HyClone AWJ21253 SH30529.03

Cell Culture:

THP-1 cells (p39) treated with 0.1 μM vit-D3 (100 μM) in DMSO] for 3days were counted, spun down, resuspended in serum-free RPMI (Lonza12-115F) and transferred to the wells of two 24-well dishes (0.5×10⁶cells in 2 ml). Compound AC was added (in triplicate) at 0.1 μM, 0.5 μMand 1.0 μM, Chloroquine diphosphate was added (in triplicate) at 10.0μM, 50.0 μM and 100.0 μM. Crude-LPS from E. coli 0111:B4 was added tosome wells (1 ng/ml final conc) and the plates placed in a 37 Cincubator. 1 μl of Baf A1 (50 nM final conc) was added to one well (noLPS) at T=4 hours to serve as a compensation control for Acridine Orangeloading. After 5 hours, 500 μl aliquots of cells were transferred toFACS tubes and viable cell counts, A.O. loading and JC-1 accumulationdetermined by FACS.

Acridine Orange (A.O.) uptake and viability cell count assay—5 hour timepoint:

Samples were vortexed, 2 μl of 50 μg/ml A.O. stock solution was added(200 ng/ml final) and the tubes incubated at 37 C for 15 minutes. Thetubes were washed twice in DPBS, resuspended in 500 μl DPBS and acquiredon the FACSCalibur. Acridine Orange exhibits strong fluorescence in bothFL-1 (green—RNA binding) and FL-3 (far red—acidic lysosomes).

Results:

As shown in Table 3 below, in the absence of LPS, low doses of AC hadlow direct cytotoxic effects that increased in a concentration dependentmanner at the acute/(5-hour) time point. Chloroquine followed a similartrend though this required 100-fold more drug versus AC; 100 μMChloroquine was approximately equivalent to 1 μM AC.

In the presence of a low dose of LPS (1 ng/ml), cytotoxicity wasincreased with addition of 0.1 μM (100 nM) AC. Addition of 10 μM, 50 μMor 100 μM Chloroquine had a smaller effect on LPS-induced cell deaththan did 1 μM AC, indicating approximately 100× higher potency of ACthan chloroquine for inactivating LPS-stimulated as well as basal THP-1cells.

Both AC and chloroquine reduced acridine orange fluorescence in THP-1cells primed with vitamin D3 and activated with 0.1 ng/ml LPS (Table 4),indicating deacidification or disruption of lysosomal integrity. AC wasapproximately 50× more potent than chloroquine for reducing acridineorange fluorescence.

AC treatment led to a dose-dependent reduction in mitochondrialdepolarization, resulting in a decrease mitochondrial accumulation ofred JC-1 dimers.

LPS alone (1 ng/ml) had no effect on mitochondrial integrity butpotentiated AC-induced mitochondrial depolarization. In contrastChloroquine had little or no direct effect on mitochondrial integrity atconcentrations up to 100 μM in the absence or presence of LPS.

TABLE 3 Effect of AC and chloroquine on cell viability after 5 hours +/−LPS in vit-D3 activated THP-1 cells THP-1 viable cell count/well percentchange from 0 hrs Test compound No LPS 1 ng/ml EPS concentration Mean ±SE Mean ± SE DMSO  0.00 ± 2.37 −10.20 ± 6.47 (Vehicle) 0.1 μM AC −17.46± 2.84 −32.77 ± 1.98 0.5 μM AC −17.01 ± 2.27 −40.99 ± 5.01 1.0 μM AC−31.20 ± 2.71 −49.63 ± 0.96 10.0 μM C.Q.  −7.34 ± 0.53 −17.38 ± 4.4450.0 μM C.Q. −17.11 ± 2.70 −30.13 ± 1.23 100.0 μM C.Q. −31.44 ± 1.37−43.98 ± 1.73

TABLE 4 Effect of AC and chloroquine on acridine orange fluorescenceafter 5 hours +/− vit-D3 activated THP-1 cells A.O. FL-3 fluorescence(MFI) percent change from DMSO no LPS No LPS 1 ng/ml LPS Treatment Mean± SE Mean ± SE DMSO  0.00 ± 3.89 −21.06 ± 0.45 0.1 μM AC −27.64 ± 9.68−54.72 ± 2.74 0.5 μM AC −54.59 ± 4.05 −68.24 ± 2.39 1.0 μM AC −69.52 ±2.05 −81.11 ± 2.65 10.0 μM C.Q. −49.37 ± 6.16 −64.76 ± 3.01 50.0 μM C.Q.−63.45 ± 2.36 −72.28 ± 0.78 100.0 μM C.Q. −91.25 ± 0.60 −88.28 ± 1.60

TABLE 5 Effect of AC and chloroquine on JC-1 accumulation inmitochondria after 5 hours +/− LPS in vit-D3 activated THP-1 cells JC-1Red cells (functional mitochondria) percent change from DMSO (no LPS) NoLPS 1 ng/ml LPS Treatment Mean ± SE Mean ± SE DMSO  0.00 ± 1.59 −0.33 ±0.69 0.1 μM AC  1.18 ± 0.91 −1.66 ± 0.96 0.5 μM AC −4.39 ± 1.40 −7.19 ±1.52 1.0 μM AC −10.40 ± 2.08  −16.41 ± 2.60  10.0 μM C.Q.  2.58 ± 0.81 4.39 ± 0.81 50.0 μM C.Q. −0.70 ± 1.24  2.21 ± 0.63 100.0 μM C.Q. −1.40± 0.67  1.07 ± 0.39

Conclusion:

AC displays selectivity for inactivating LPS-activated macrophagesversus unstimulated cells. AC also attenuated acridine orangeaccumulation in lysosomes, indicating that it caused lysosomaldisruption. AC was approximately 100 fold more potent than chloroquinefor inactivating macrophages, and about 50 times more potent thanchloroquine for disrupting lysosomal integrity as measured by acridineorange accumulation.

Example C Screen of Compounds of the Invention for Anti-InflammatoryActivity In Vitro

Background: THP-1 is a human acute myeloid leukemia (AML) cell line thatcan be induced into a macrophage-like cell with vitamin-D3 (vit-D3). Inthe macrophage, LPS (lipopolysaccharide; endotoxin) stimulation oftoll-like receptor 4 (TLR-4) leads to NF-κB activation and secretion ofinflammatory cytokines but also the priming of programmed death pathwaysthrough RIP and Caspase 8. The balance of this complex regulatorynetwork is dependent on highly specific kinases, enzymes that requireATP. Disruption of either cytosolic pH or ATP availability/energy leveluncouples this control network and the can macrophage shift away fromproduction of inflammatory cytokines towards a programmed death event,which has the net effect of limiting inflammatory damage.

Compounds of the invention have been shown to inactivate macrophagesrapidly (within 5 to 6 hours) when the macrophages have been put into apro-inflammatory state activated with LPS. More than 200 compounds ofthe invention were screened for anti-inflammatory activity in the THP-1system to assess their relative potency and activity in vitro.

Summary:

Addition of LPS to compound-treated macrophages resulted in acute/5-hourcell death; this activity increased in a concentration dependent manner.Treatment with test compounds alone exhibited only a low level of acutecytotoxicity.

The majority of compounds tested displayed significant ability toinactivate pro-inflammatory THP-1 cells in accord with the proposedmechanism of action involving lysosome disruption, which is notdependent upon binding to a specific protein target. Of the compoundstested, seven demonstrated higher activity than the active benchmarkcompound AC: CJ, AM, AG, CX, AF, BM and AH.

At the lowest concentration tested (0.1 μM), all seven tested compoundswere more active than AC in causing death of cells treated with LPS. Atconcentrations of 0.5 μM and above all compounds, including AC, reacheda maximum activity threshold.

Results:

Addition of LPS to test compound-treated macrophages resulted in massiveacute/5-hour cell death; this activity increased in a concentrationdependent manner (Table 6). Treatment with compounds alone withoutpro-inflammatory activation of the macrophages with LPS exhibited only alow level of acute cytotoxicity.

At the lowest concentration tested (0.1 μM), seven compounds were moreactive than AC in conditioning the cells for LPS-induced cell death. Atconcentrations of 0.5 μM and above, all eight compounds, including AC,reached a maximum activity threshold.

Compound CX was the most effective cytotoxic compound at theacute/5-hour time point, followed by a moderate activity group includingCJ, AF, 30006 and BM. AG and AM exerted the lowest effect on cytoplasmicconditioning, albeit still greater than that shown by AC.

TABLE 6 Compound screen: Reduction in viable THP-1 cell count (percentchange) from 0 hours after treatment with test compounds for 5 hoursCompound (0.1 μM) Compound (1.0 μM) Com- Plus LPS No LPS Plus LPS No LPSpound Mean ± SE Mean ± SE Mean ± SE Mean ± SE Vehicle  −7.42 ± 3.07 0.00 ± 4.71  −7.42 ± 3.07  0.00 ± 4.71 AC −15.14 ± 2.06 −7.48 ± 5.82−44.25 ± 2.53 −9.60 ± 1.96 CJ −30.15 ± 4.41 −5.53 ± 3.89 −41.62 ± 1.80−6.99 ± 1.55 AM −19.80 ± 1.96 −5.57 ± 2.67 −44.05 ± 1.38 −8.47 ± 3.31 AG−21.28 ± 1.52 −6.24 ± 0.69 −38.58 ± 0.73 −4.02 ± 2.83 CX −38.09 ± 0.41−8.00 ± 1.41 −49.57 ± 2.44 −9.20 ± 3.09 AF −27.32 ± 4.69 −8.99 ± 2.00−44.82 ± 2.46 −6.02 ± 2.31 BM −25.80 ± 3.26 −3.96 ± 0.82 −39.17 ± 2.18−4.18 ± 2.46 AH −26.55 ± 0.95 −9.66 ± 1.34 −35.51 ± 3.90 −7.87 ± 0.98

Example D Anti-Inflammatory Activity of Compounds of the Invention

Compounds of the invention have been shown to directly inhibit NF-κB,damage intracellular acidic lysosomes leading to proton leakage andacidification of the cytoplasm and also damage mitochondria reducing thecellular energy level. Together these actions result in direct celldeath in some vulnerable cell types, over a period of about 48 hours.Additionally in the macrophage, cytoplasmic acidification and energydepletion by compounds of the invention prime the cell for inactivationwhen exposed to low concentrations of LPS, leading to an acute (5-hour)cell death event through a combination of Caspase-driven apoptosis andRIP-driven necrosis.

Compounds of the invention were tested at 0.1 μM versus AC in theLPS-triggered THP-1 cell death assay. Both acute/5-hour andchronic/48-hour phases of cell death were assessed. Compounds werescreened in batches with DMSO as the negative control and AC as the highactivity control. Compounds were tested at the low concentration of 0.1μM with a view toward identifying agents more potent than the benchmarkagent AC; at higher concentrations, e.g. 1 μM, most compounds of theinvention are active in inducing cell death in this assay, which makesdifferentiation from AC less clear than at a 10 fold lower drugconcentration.

Results/Summary:

Seven of the compounds not only demonstrated equivalent activity to ACat the acute/5-hour time point (cell conditioning) but were also moreactive than AC at the chronic/48-hour time point (retention): CJ, AM,AG, CX, AF, BM and AH.

A further 15 tested compounds demonstrated equivalent activity to AC atboth the 5-hour and 48-hour time points: CI, CL, AL, AR, AN, AD, BH, CV,AJ, BD, BU, BK, EW, AK and AE.

The remaining 187 compounds exhibited lower anti-inflammatory activitythan AC at the tested concentration of 0.1 μM. However, this screen wasconducted at a suboptimal concentration to detect the most potentcompounds in the library; low activity at a concentration of 0.1 mM inthe context of this assay is still consistent with significant andpotent anti-inflammatory activity when compared to chloroquine or otherantimalarials.

SUMMARY TABLE 7 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −19.09 6.46 52.22 6.74 AC −34.96 3.83 27.70 4.12 CH−23.58 1.41 53.55 7.24 CI −33.19 2.15 28.46 1.27 CJ −39.08 0.63 15.444.55 CK −22.60 1.68 42.23 4.37 CL −33.77 2.31 29.43 0.86 CO −27.62 2.3743.95 1.27 AR −38.07 4.48 28.75 5.34 AN −38.87 4.25 31.66 1.43 AD −43.474.88 26.01 3.24 CX −39.48 1.53 8.50 4.04 BH −44.02 2.43 34.77 8.01 CV−39.94 1.23 23.02 5.00 AZ −24.00 1.47 50.12 1.11 CW −26.47 0.71 43.712.34 DA −25.97 2.71 43.55 6.40 DB −25.73 0.25 20.47 3.28 BA −20.15 1.0741.79 6.41 CY −29.18 1.70 47.86 2.06 CZ −29.41 1.34 53.70 1.63 CP −21.871.68 49.81 4.04 CR −24.54 2.32 40.02 10.49 BG −26.46 3.81 38.39 10.97

SUMMARY TABLE 8 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −15.79 2.35 81.91 10.05 AC −30.98 2.63 38.84 7.90CS −15.04 2.29 66.27 4.64 BT −15.61 1.14 66.98 2.63 DW −23.38 1.66 73.970.81 DX −13.66 2.36 59.95 3.73 DZ −12.39 0.38 73.5 1.3 EA −30.40 2.3473.48 17.34 EG −30.80 2.11 60.59 8.29 ED −29.12 1.27 81.40 4.16 DC−30.73 2.07 87.66 9.59 DI −32.79 1.21 82.24 3.39 DK −31.72 1.43 73.607.17 DL −35.64 1.88 61.01 4.54 DN −29.63 2.37 77.15 7.16 DS −14.93 2.0056.67 7.09 AF −33.78 3.20 13.79 3.87 BK −30.96 3.05 43.69 3.12 CG −24.244.35 54.66 1.13 BM −39.97 2.41 29.97 2.15 BN −17.24 0.92 60.91 2.81 AE−37.73 3.86 4.11 2.24 AB −20.14 0.71 56.56 5.96

SUMMARY TABLE 9 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −23.30 0.40 35.66 3.27 AC −34.70 1.94 14.24 1.47 AL−36.59 2.17 19.14 4.63 EI −16.40 1.18 39.53 5.09 BE −27.08 2.45 33.861.63 BF −31.22 2.14 31.64 4.04 BG −24.51 2.07 31.07 8.11 BJ −22.42 4.0718.03 3.64 BI −17.04 2.14 27.30 8.06 CT −15.13 3.87 34.36 2.98 CU −14.301.56 41.84 3.25 AI −22.65 2.45 28.60 12.70 DY −15.92 2.80 45.25 2.74 EE−17.77 1.15 24.32 3.49 EB −19.41 4.94 35.89 2.24 EC −13.74 0.73 47.408.60

SUMMARY TABLE 10 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −15.51 0.95 28.09 5.15 AC −28.61 0.31 11.13 3.65 AO−18.86 0.91 25.19 0.81 DP −10.67 2.78 42.36 6.73 AP −8.73 2.99 37.388.16 DD −22.24 4.26 44.34 4.25 DE −16.91 3.02 25.65 6.11 DF −14.22 3.0939.26 1.86 DJ −13.11 1.57 22.32 6.35 DM −13.85 3.09 34.67 10.04 DO−16.45 3.36 36.46 8.92 DR −30.11 7.00 27.12 5.64 DQ −14.50 6.72 32.314.28 BU −30.95 2.44 18.10 2.50 DV −15.76 0.16 24.69 2.29 BL −14.15 1.4232.33 5.20 DT −15.01 3.02 16.12 2.95 DU −19.46 3.16 17.10 2.36 FR −7.332.48 15.96 2.96 AV −12.93 2.26 38.76 3.70 AX −12.47 1.73 18.20 4.10

SUMMARY TABLE 11 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −19.10 0.94 −4.46 1.11 AC −28.75 2.33 −23.17 2.92BR −16.15 2.85 −5.72 1.19 CM −30.79 4.75 −6.80 3.16 BB −19.89 2.07 0.653.12 BC −18.89 1.94 6.40 11.50 BD −28.12 0.36 −17.21 4.61 BS −17.29 1.13−6.51 2.77

SUMMARY TABLE 12 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −38.16 2.40 −9.13 2.21 AC −46.72 3.21 −24.59 1.48FD −34.27 2.34 −3.68 4.14 FB −43.02 2.59 −10.18 3.14 FC −34.17 7.15−20.85 1.63 FH −29.93 1.60 −5.12 4.01 FF −25.50 0.78 −4.74 0.92 FE−28.83 3.01 −11.23 1.97 FY −35.57 2.74 −1.84 3.24 BP −26.04 1.33 −3.397.15 FG −24.92 3.17 1.15 3.75 FZ −23.87 1.56 −5.31 3.01

SUMMARY TABLE 13 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −24.88 2.82 26.90 5.17 AC −36.91 0.49 −9.22 3.97 GA−22.33 1.00 16.51 4.55 FI −23.79 2.33 12.70 1.85 GB −25.77 0.93 19.294.19 CD −28.27 0.57 7.55 2.55 CE −30.76 3.40 4.71 2.96 BQ −23.07 1.0713.70 1.17 FJ −31.23 2.21 27.44 2.43 FK −27.64 1.45 16.57 2.59 GC −27.623.64 19.30 7.07 CF −26.02 1.80 27.26 3.66 FO −20.14 1.51 20.18 2.47 FP−29.59 2.59 30.44 4.50 FQ −31.29 0.86 25.62 3.30 AU −29.50 3.48 16.863.41 FV −31.34 0.29 17.51 2.28 EK −22.83 2.09 15.50 2.40

SUMMARY TABLE 14 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Acute/5-hour Chronic/48-hour CompoundMean SE Mean SE DMSO −40.83 3.04 9.11 9.96 AC −43.44 2.32 −16.35 2.21 EL−32.95 1.57 −3.09 6.02 FS −28.46 1.15 −0.47 2.36 EM −35.35 1.22 −1.833.18 FT −27.22 1.21 3.59 3.14 FU −30.02 1.79 −2.75 1.97 CB −34.76 1.6910.62 5.40 CC −31.14 1.04 −1.09 0.38 FW −34.49 1.96 1.27 3.15 FX −31.282.66 −3.62 2.06 AS −32.02 3.71 3.86 1.52 EN −27.16 2.48 6.64 2.20 AY−36.14 1.27 7.71 4.95 CN −32.16 2.34 3.70 2.76 FN −27.54 2.71 3.54 4.49FM −46.22 2.64 9.74 2.98

SUMMARY TABLE 15 Compound screen: Viable cell percent change after 5 and48 hours in the THP-1 cell death assay (10 ng/ml LPS 0.1 μM testcompound) Cell death time point Chronic/48- Acute/5-hour hour CompoundMean SE Mean SE DMSO −28.93 2.75 40.68 6.03 AC −41.20 2.33 16.40 3.98 DG−25.02 0.28 37.90 7.88 DH −27.53 1.35 50.89 5.57 AQ −26.78 1.89 24.711.45 BV −27.24 2.50 42.14 2.90 BW −34.15 0.75 36.08 4.32 BX −34.84 1.6025.10 6.23 EH −29.46 3.65 32.85 4.45 BY −29.40 1.20 39.64 5.24 BZ −27.552.27 30.72 2.28 AT −32.45 1.49 30.34 2.30 BO −32.29 1.45 28.35 4.70 FL−30.26 2.85 38.59 1.87

Example E Anti-Inflammatory Properties of Compound AC in a Model of SkinInflammation

Objective: To evaluate the anti-inflammatory properties of compounds ofthe invention in a 12-O-tetradecanoylphorbol-13-acetate (TPA) inducedchronic skin inflammation mouse model. Topically applied phorbol esterssuch as TPA induce skin inflammation involving edema, macrophage and Tcell infiltration and epidermal hyperplasia (Alford et al., 1992), andthis system has been used as an animal model for dermatitis, mimickingaspects of human inflammatory skin disorders. TPA is also known as atumor promoter, so that agents which inhibit hyperproliferative orangiogenic actions of TPA may inhibit tumor promotion.

Methods

Drug formulations: Compound AC was dissolved in isopropylmyristate:propylene glycol (1:1)+0.9% DMSO at the indicatedconcentrations. TPA was dissolved in acetone:water (99:1). Dexamethasone(0.06%) was dissolved in normal saline.

Mice: HSD-ICR(CD-1R) female mice at 8-10 weeks of age were used in thisexperiment.

Experimental Design: Mice were placed into six groups of 10 mice each.20 μL of 0.01% TPA was administered to each ear on days 0, 2, 4, 7, 9,11, 13, 15, 18, 20, and 22. 20 μL of AC at various concentrations or 20μL of dexamethasone solution was applied to the ears daily beginning onday 7, after inflammatory changes in ear thickness were established. Earthickness was measured with calipers every three days.

Results

Compound AC treatment prevented inflammatory thickening of mouse earstreated with TPA. Histology indicated that both TPA-induced edema andepidermal hyperplasia were reduced by AC, as was angiogenesis. Thepotency of AC was comparable to that of dexamethasone, with significantactivity observed at the lowest dose of 12.5 micrograms of AC per earper day.

TABLE 16 Ear thickness of vehicle and compound-treated mice: day 22Treatment Ear thickness (mm) Vehicle 0.646 ± 0.1161 Dexamethasone, 0.05mg/ear 0.301 ± 0.0722 AC, 0.0125 mg/ear 0.362 ± 0.0394 AC, 0.025 mg/ear0.390 ± 0.0319 AC, 0.05 mg/ear 0.391 ± 0.0334 AC, 0.075 mg/ear 0.395 ±0.0438

REFERENCE

-   Alford J G, Stanley P L, Todderud G, Tramposch K M. (1992) Temporal    infiltration of leukocyte subsets into mouse skin inflamed with    phorbol ester. Agents Actions. 37(3-4):260-7

Example F Anti-Inflammatory Effects of Compounds of the Invention onPsoriasiform Dermatitis in Mice

Topical imiquimod (IMQ), a toll-like receptor agonist, has beenestablished as a model of Inflammatory skin diseases including psoriasisand atopic dermatitis. Dermal inflammatory changes and gene expressionin mice treated with topical imiquimod mimic human psoriasis anddermatitis (van der Fits et al., 2009; Swindell et al., 2011). Theeffect of a set of compounds of the invention were tested in a mousemodel of imiquimod-induced dermatitis, with topical tacrolimus anddexamethasone as comparators for assessing safety and efficacy relativeto standard agents used to treat dermatitis in humans.

Compounds to be tested for anti-inflammatory activity were individuallydissolved in ethanol at a concentration of 0.6% and then mixed with 9volumes of petrolatum (melted on a heated water bath at 50 degrees C.),yielding ointments containing 0.06% active drug. Dexamethasone ointmentwas prepared similarly, though at a final concentration of 0.03%,because 0.06% dexamethasone applied topically in preliminary experimentshad caused significant weight loss due to systemic absorption.Commercial 0.1% tacrolimus ointment (ProTopic™; Novartis) was also usedas an active comparator. Petrolatum containing 10% ethanol was used as acontrol treatment.

Female Balb/C mice (8 weeks old) were randomized and divided into groupsof 5 animals each. Polyethylene collars were affixed to the mice toprevent them from easily scratching their ears.

5% imiquimod was applied to both ears of each mouse (20 microliters perear) daily for 5 days, and then every other day for the full duration ofthe study. Inflammatory changes, including a doubling of ear thicknesswere apparent by day 5. On day 7 after initiation of imiquimod,treatment with topical agents was started. Both ears of each mouse weretreated with test ointments, with one compound per mouse.

Ear thickness and PASI assessments (Psoriasis Area and Severity Index, astandard psoriasis scoring system) were recorded twice per weekthroughout the study. The PASI score comprises the sum of evaluations ofswelling, erythema and scaling on scales from 0 to 4; the maximum PASIscore is 12, and the minimum, in unaffected skin, is 0).

Results

Imiquimod treatment resulted in significant inflammatory changes,including an increase in ear thickness and a change in PASI scores;control ears reached the maximum possible value in the PASI scoringsystem, with severe thickening, erythema and scaling. Compounds of theinvention, applied topically in an ointment base, reducedimiquimod-induced inflammatory damage to mouse ears, as assessed bycaliper measurements of thickness and PASI scoring of appearance. Thecomparator drugs tacrolimus and dexamethasone also reduced ear thicknessand PASI scores. Notably, AF was superior to the commercial clinicalform of topical 0.1% tacrolimus (Protopic ointment) in reducing earthickness and PASI score. The anti-inflammatory activity ofdexamethasone was accompanied by significant loss of body weight,indicating systemic toxicity due to dexamethasone absorption. Neithercompounds of the invention nor tacrolimus affected body weight. Inaddition to inducing inflammation of the ears imiquimod transfer fromthe ears to the scalps of mice resulted in loss of hair and psoriasiformdermatitis on the head, from between the ears, forward to the nose. Indexamethasone-treated mice, this area remained hairless after treatmentat the end of the experiment; in contrast, hair growth was maintained inthis area during daily treatment with AF, indicating that AF inhibitedpathologic inflammation without also impairing tissue normal tissuemaintenance. A known side effect of treatment with dexamethasone andother topical corticosteroids is thinning and weakening of the treatedareas; the lack of hair regrowth may reflect the clinical problem ofskin atrophy known as a side effect of topical dexamethasone. AF wasequally effective at 0.06% and 0.6% concentrations in the ointment base,indicating a wide therapeutic window. All of the tested compounds of theinvention reduced IMQ-induced changes in ear thickness, thusdemonstrating their anti-inflammatory activity in vivo.

TABLE 17 Ear thickness in mice with imiquimod-induced dermatitisTreatment Mean ± SEM Untreated (no IMQ) 0.220 ± 0.004  Control 1.355 ±0.004  AF 0.06% 0.355 ± 0.005 * AF 0.6% 0.390 ± 0.008 * AC 0.501 ±0.030 * BM 0.577 ± 0.019 * EF 0.613 ± 0.010 * DD 0.589 ± 0.018 * DU0.607 ± 0.027 * DE 0.593 ± 0.016 * AE 0.846 ± 0.023 * Dexamethasone0.305 ± 0.111 * Tacrolimus 0.1% 0.428 ± 0.007 * * = less than controlear thickness, p < .05

FIG. 18: PASI Scores in mice with imiquimod- induced psoriasiformdermatitis Treatment Mean ± SEM Untreated (no IMQ) 0.000 ± 0.000 Control 12.000 ± 0.000   AF 0.06% 3.575 ± 0.158 * AF 0.6% 4.875 ±0.155 * AC 7.150 ± 0.221 * BM 9.250 ± 0.183 * EF 7.275 ± 0.199 * DD7.450 ± 0.322 * DU 7.975 ± 0.621 * DE 7.250 ± 0.183 * AE 11.550 ±0.281   Dexamethasone 4.525 ± 0.375 * Tacrolimus 0.1%  6.075 ±0.0990 * * = less than control PASI score, p < .05

FIG. 19: Body weights of mice with imiquimod- induced psoriasiformdermatitis Body Weight (mean ± SEM) Treatment Initial (g) Final (g) D BW(g) Control 21.2 ± 0.8 21.9 ± 0.7 +0.7 AF 0.06% 20.5 ± 0.8 20.9 ± 0.6+0.4 AF 0.6% 20.8 ± 0.6 20.4 ± 0.6 −0.4 AC 21.1 ± 0.7 21.3 ± 0.6 +0.2 BM20.8 ± 0.7 20.9 ± 0.6 +0.1 EF 21.5 ± 0.6 21.3 ± 0.2 −0.2 DD 20.9 ± 0.820.7 ± 0.6 −0.2 DU 20.4 ± 0.7 20.9 ± 0.5 +0.5 DE 20.6 ± 0.5 20.5 ± 0.5−0.1 AE 20.9 ± 0.5 21.3 ± 0.4 +0.4 Dexamethasone 20.5 ± 0.6  18.1 ±0.5 *   −2.4 * Tacrolimus 0.1% 20.9 ± 0.7 20.4 ± 0.6 −0.5 * Less thaninitial body weight, P < .02

REFERENCES

-   Swindell W R, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X,    Nair R P, Voorhees J J, Elder J T, Wang X J, Sano S, Prens E P,    DiGiovanni J, Pittelkow M R, Ward N L, Gudjonsson J E. (2011)    Genome-wide expression profiling of five mouse models identifies    similarities and differences with human psoriasis. PLoS One.    6(4):e18266-   van der Fits L, Mourits S, Voerman J S, Kant M, Boon L, Laman J D,    Cornelissen F, Mus A M, Florencia E, Prens E P, Lubberts E. (2009)    Imiquimod-induced psoriasis-like skin inflammation in mice is    mediated via the IL-23/IL-17 axis. J Immunol. 182(9):5836-45

Example G Effects of Compounds of the Invention in a Mouse Model ofMultiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease mediated involvingdestruction by the immune system of myelin sheaths surrounding neuronaxons in the brain. An established animal model for this disease isExperimental Autoiimune Encephalitis (EAE), induced by immunization ofmice with proteins or peptides that induce an immune response tomyelin-specific proteins.

In this experiment, EAE was induced by immunization of mice with apeptide from proteolipid protein (PLP), a known antigenic target in MS.Several compounds of the invention were administered orally to assesstheir effect on the course of EAE, with quantitative evaluation ofdisease symptoms as an endpoint. Linomide, a small moleculeimmunomodulator with known activity in EAE models was used as acomparator drug.

Materials and Methods

41 mice received subcutaneous injections of 90 μg PLP139-151 in 200 μLof PBS on Day 0.

The PLP was prepared in incomplete Freund's adjuvant (IFA) by mixing 10mL IFA with 40 mg M. tuberculosis H37Ra (final concentration 4 mg/ml M.tuberculosis). The resulting mixture is complete Freund's adjuvant(CFA).

For injection, an emulsion of PLP139-151 and CFA was prepared by mixing1 mL of stock solution with 1 mL of CFA while vortexing for 15 minutesto form an emulsion.

Mice received vehicle or a test compound (60 μmol/kg; suspended in 1%aqueous hydroxypropylmethylcellulose) by oral gavage, three times perweek for 2 weeks followed by once daily treatment for 4 additionalweeks, beginning on Day 14. Vials with vehicle and with compounds werecoded by letters (A-E) in order to obtain blind readings of diseaseseverity.

Group 1 (n=7) VehicleGroup 2 (n=6): AZGroup 3 (n=7): CZGroup 4 (n=7): CPGroup 5 (n=7): CQGroup 6 (n=7) Linomide

Mice were monitored every other day for the development of clinicalsymptoms according to the grading system below.

Grading System for Clinical Assessment of EAE Score Clinical Signs 0Normal mouse, no overt signs of disease 1 Limp tail^(a) and hind limbweakness^(b), but not both 2 Limp tail^(a) and hind limb weakness^(b) 3Partial hind limb paralysis^(c) 4 Complete hind limb paralysis^(d) 5Moribund state; death by EAE; sacrifice for humane reasons ^(a)Limptail: complete flaccidity of the tail, and absence of curling at the tipof the tail when mouse is picked up. ^(b)Hind limb weakness: observed asa waddling gait, the objective sign being that, in walking, mouse's hindlimbs fall through the wire cage tops. ^(c)Partial hind limb paralysis:mouse can no longer use hind limbs to maintain rump posture or walk butcan still move one or both limbs to some extent. ^(d)Complete hind limbparalysis: total loss of movement in hind limbs; mouse drags itself onlyon its forelimbs. Mice at this stage are given food on the cage floor,long sipper tubes, and daily subcutaneous saline injections to preventdeath by dehydration.

Results:

Mice in all groups were displaying comparable mild EAE disease symptomsby day 14 after PLP injection, at which time oral treatment with thetest agents was initiated. At the termination of the study, on Day 46,Vehicle-treated mice displayed more severe disease symptom scores thandid the treatment groups. Compounds of the invention displayedprotective activity comparable to the positive control compoundlinomide.

TABLE 20 EAE Score on Day 14 Treatment (Before Treatment) EAE Score onDay 46 Vehicle 0.71 ± 0.18 3.57 ± 0.48 Linomide 0.93 ± 0.19 2.29 ± 0.48AZ 0.83 ± 0.41 2.50 ± 0.29 CZ 1.00 ± 0.00 2.29 ± 0.20 CP 0.86 ± 0.141.86 ± 0.34

Antifungal and Antiparasitic Examples Example H Anti-Candida Activity ofCompounds of the Invention

Reagents Manufacturer/Catalog # Lot # Candida albicans strain 3153 ATCC28367 61794 YPD Broth KD Medical YLF-3260 032111-03 Sabouraud DextroseAgar KD Medical #YPL-1050 C21-03 Sterile PBS, pH 7.4 Quality BiologicalInc; #114-058-131 DMSO Sigma; cat#D2650

Experiment Overview:

A single colony of Candida Albicans was grown in 50 ml YPD brothovernight (19 hr). The cells were washed with PBS and 3.5×10⁴ CFU/ml ofC. Albicans (144 μl/well) in YPD medium were plated in 96 well plates.Test compounds were then added to each well with concentration rangedfrom 5 to 40 μM as final concentrations. The plates were incubated at30° C. overnight (24 hrs) and OD at 600 nm was read at the end ofincubation as an index of yeast cell density.

Results:

Most of the compounds tested showed inhibition of Candida growth. Basedon inhibition curves, IC50 (50% inhibition of fungal growth) and MIC(99% of inhibition of fungal growth) values of compounds were calculatedusing XLfit and listed in the following table. The compounds with higherantifungal activity have the lower numerical values.

TABLE 21 50% Inhibition (IC50) and Maximum Inhibition Concentration(MIC) Value Compound IC50 (uM) MIC (uM) inactive compound AL 7.08 20.07BR AM 6.52 16.17 BS AG 8.92 16.01 BU AR 46.06 69.76 CB BH 18.05 30.12 CCAZ 10.40 21.10 AY BE 12.19 29.70 CD BF 14.19 26.95 CE BG 11.47 20.86 CFBJ 13.32 23.48 CG BI 17.48 27.76 BN BA 34.64 96.74 BV BB 50.92 99.69 BWBC 45.71 107.71 BX AJ 43.18 113.41 BY BD 37.45 133.84 BZ AI 18.29 56.38AO 34.70 84.94 AP 25.03 41.95 AA 10.97 27.31 AC 45.71 107.71 AF 45.5074.16 BK 11.17 19.03 BL 33.51 44.80 AU 16.28 30.95 AS 15.34 37.79 AV13.42 19.82 AW 13.30 24.81 AX 11.19 26.63 AT 14.50 51.21 BO 19.01 42.47BP 28.75 90.56 BQ 51.70 * AK 10.71 * BM 20.23 44.47 AE 7.82 * AH 5.2415.41 AB 10.98 33.00 AQ 41.20 * * The MIC cannot be calculated for thesecompounds due to insufficient data points.

Procedure:

Part-I: Preparation of Candida albicans Cells

-   1. One day prior to the inoculum preparation, pick a single colony    of Candida albicans strain 3153 (lot #61794) from the Sabouraud    Dextrose Agar plate using the inoculum loop and inoculate into a 250    mL flask containing 50 ml of YPD growth medium-   2. Incubate at 30° C. with shaking at 150 rpm for at least 18 hours    with loosened lid to allow air in and facilitate growth.-   3. Examine an aliquot of the culture under a microscope for Candida    cell morphology and lack of bacterial contamination; >95% of Candida    cells should be blastoconidia.-   4. Transfer 25 ml the overnight culture into a 50-ml plastic    disposable centrifuge tube, and centrifuge at 1000×g for 20 min.-   5. Discard the supernatant and wash the pellet with 4 ml of PBS at    three times. Vortex and centrifuge, 1000×g for 10 min.-   6. After the third wash, dispense the pellet with 2 ml PBS and    vortex.-   7. Make three 1:10 serial dilutions in sterile PBS (10⁻¹, 10⁻²,    10⁻³) from the 2 ml cell suspension using 15 ml culture tubes. The    final volume in each tube is 5 ml.-   8. Count the number of cells in cell suspension from the 10⁻³    dilution tube on the hemocytometer.    -   To calculate cell concentration per ml:

Average number of cells in one large square×dilution factor×10⁴10⁴=conversion factor to convert 10⁻⁴ml to 1 ml

-   -   The cell number in 50-fold dilution of 10⁻³ was: 14×10⁴ CFU/ml

-   9. Make a 1:4 dilution in YPD medium from the 50-fold dilution of    10⁻³ cell suspension for testing compounds.    -   The final C. albicans cell concentration for the test: 3.5×10⁴        CFU/ml

-   10. Plated 144 ul/well of the above dilution of cell on 96-well    plates.

Part-II: C. Albicans Growth Inhibition Testing with Compounds

-   1. From 10 mM DMSO stock solutions, make serial dilutions of    compounds to 0.13, 0.25, 0.40, 0.55, 0.75 and 1.0 mM solutions-   2. Add 6 ul each of diluted compound solutions per well in    duplicates. The final concentrations were 0, 5, 10, 16, 22, 30 and    40 micromolar.-   3. Incubated all plates at 30 C for overnight (˜24 hours).-   4. Read absorbance at OD600 for each plate.-   6. Calculate the % inhibition of each compound against the DMSO    treated cell.

Example I Evaluation of Activity of Compounds Against Saccharomycescerevisiae

Reagents Manufacturer/Catalog # Lot # Baker's yeast Red Star YPD BrothKD Medical YLF-3260 032111-03 Sabouraud Dextrose Agar KD Medical#YPL-1050 C21-03 Sterile PBS, pH 7.4 Quality Biological Inc;#114-058-131 DMSO Sigma; cat#D2650

Experiment Overview:

An overnight culture of S. cereviseae was dilution in YPD broth toconcentration of 40,000/ml and 150 μl/well was plated in 96 well plates.Compounds were then added to each well with concentration ranged from 4to 50 μM as final concentration. The plates were inoculated at 30° C.overnight with shaking at 220 rpm and absorbance at 600 nm was readafter 18 hour incubation.

Results:

Among all the effect compounds against S. cerevisiae, compounds AL, BG,and AW were the most effective ones. Compound AI generated lower IC₅₀from XLfit calculation, even though it could not reach near 100% kill athigh concentration like other compounds did. Chloroquine (C.Q.) did notshow any inhibition of yeast growth up to 50 uM. Following listed IC50(50% inhibition of fungal growth) and MIC (99% of inhibition of fungalgrowth) values of compounds (calculated using XLfit) based on inhibitioncurves.

TABLE 22 Anti-S. cerevisiae - 50% Inhibition (IC50) and MaximumInhibition Concentration (MIC) Value Compound IC50, uM MIC, uM inactivecompound AL 9.67 10.48 BA AM 13.41 18.88 BT AG 19.39 24.35 AC AN 19.1124.26 CA AZ 18.63 24.07 CB BE 19.23 24.13 Chloroquine BF 20.82 32.04 BG9.88 11.84 BJ 21.44 37.80 BI 28.58 47.08 AI 6.31 * AP 26.29 46.47 AC27.73 47.67 BK 21.40 29.38 AU 18.03 24.26 AS 38.47 48.91 AV 19.65 19.76AW 9.73 10.24 AX 19.61 19.92 AY 16.86 21.88 BP 35.56 50.81 AK 23.47 * BM30.57 50.45 BV 12.35 25.01 C12-Im 15.21 29.04 *The MIC cannot becalculated for these compounds due to insufficient data points.

Procedure:

Part-I: Preparation of Yeast Cells

-   1. One days prior to the inoculum preparation, pick a single colony    of S. cereviseae from the Sabouraud Dextrose Agar plate using the    inoculum loop and inoculate into a 50 mL tube containing 10 ml of    YPD growth medium-   2. Incubate at 30° C. with shaking at 220 rpm for 24 hours with    loosen lid to allow air in and facilitates growth.-   3. Examine an aliquot of the culture under a microscope for yeast    cell morphology and lack of bacterial contamination.-   4. Dilute the overnight culture with YPD medium at 1:30 dilution (70    ul to 2.1 ml) and count the number of cells as 4,230,000/ml.-   5. Mix 620 μl of 1:30 dilution and 64.4 ml YPD to make final    concentration of 40,000/ml cells-   6. Plated 144 μl/well in four 96-well plates.

Part-II: Yeast Growth Inhibition Testing

-   1. From 10 mM DMSO stock solutions, make serial dilutions of    compounds to 0.1, 0.2, 0.3, 0.63 and 1.25 mM solutions-   2. Add 6 μl each of diluted compound solutions per well in    duplicates. The final concentrations were 0, 4, 8, 12, 25 and 50    micromolar.-   3. Incubated all plates at 30 C for overnight (˜18 hours) with 220    rpm shaking.-   4. Read absorbance at OD600 for each plate on Spectra Max Plus plate    reader.-   5. Calculate the % inhibition of each compound against the DMSO    treated cell and plotted.

Example J Anti-Trichophyton Activity of Compounds of the Invention

Tricophyton rubrum is one of the primary fungi responsible forpersistent, treatment-resistant toenail infections.

Reagents Manufacturer/Catalog # Lot # Trichophyton rubrum ACTT, MYA-443859404737 PDB (potato dextrose broth) VWR 61000-102 0000130316 PDA(potato dextrose agar) VWR 90008-416 2214381 Sterile PBS, pH 7.4 QualityBiological Inc; #114-058-131 DMSO Sigma; cat#D2650 Transwell plate VWR29442-120 04709006 (Costar 3422, 24well with 8 μm)

Experiment Overview:

Trichophyton grown on two agar plates were collected by scraping into 10ml saline and filtered through 8 μm filters. The filtered solution wasdiluted (1:75) and plated in 96 well plates and treated with selectedcompounds of the invention.

Results:

This experiment included some active compounds from previous experimentand added several untested compounds. Culture treated by compounds AW,AX, AT, AE or AH showed no visible fungal grow with even the lowestconcentration (6 μM) tested, representing their strongest inhibitoryeffect against trichophyton growth. Most of rest compounds alsoinhibited fungal growth with higher concentration (12-18 μM). AO, AP,AF, BL, AQ and BO showed only partial or no inhibition on fungal growwith highest concentration (40 μM) tested. Following table listed themaximum inhibition concentration (MIC) based on scoring by eye.

TABLE 23 Com- Com- Com- pound MIC, μM pound MIC, μM pound MIC, μM AL 12AO >40 AX 6 AM 12 AP ~40 AT 6 AG 18 AC 18 BO >40 AN 18 AF >40 BP 12 AZ18 BL >40 AK 18 BE 12 AQ >40 BM 18 BF 18 AU 12 AE 6 BG 12 AS 25 AH 6 BJ18 AV 25 AB 18 BI 18 AW 6 C12-Im 18

Procedure:

Part-I: Preparation of Trichophyton rubrum Cells

Scrape frozen Trichophyton culture from ATCC vial and suspended in 100μl PDB, and then plate on a PDA plate. Incubate plate at 30 C for 4days.

The plate was covered almost full. Scrap colonies from two plates in 10ml saline and filter through 8 μm filter in a 24 well transwell plate(used 2 wells). Take OD of collected solution at 520 nm and 600 nm:

-   -   A 520 nm=0.13; A 600 nm=0.092 1× without dilution    -   A 520 nm=0.061; A 600 nm=0.037 1:2.5 dilution

Make 90 ml of 1:75 dilution in PDB broth from the filtered cellsuspension by mixing 1.2 ml of cell solution with 88.8 ml PDB andaliquot 144 μl/well in 5×96 well plates.

Part-II: Trichophyton Growth Inhibition Testing with Compounds

-   1. From 10 mM DMSO stock solutions, make serial dilutions of    compounds to 0.15, 0.3, 0.45, 0.63 and 1 mM solutions-   2. Add 6 μl each of diluted compound solutions per well in    triplicates. The final concentrations were 0, 6, 12, 18, 25 and 40    micromolar.-   3. Wrap the plates with parafilms and incubate all plates at 30° C.    for 6 days.    -   Take picture of the plates on KODAK imager with 17 captures of        1.5 sec/capture for total of 25.5 second exposure.

Example K Anti-Cryptococcus Activity of Compounds of the Invention

Reagents Manufacturer/Catalog # Lot # Cryptococcus neoformans ATCC 240674282211 Stain ID 52 YM Broth TEKNOVA #Y0731 Y073105J1101 SabouraudDextrose Agar KD Medical #YPL-1050 C21-03 Sterile PBS, pH 7.4 QualityBiological Inc; #114-058-131 DMSO Sigma; cat#D2650

Experiment Overview:

Cryptococcus neoformans (serotype D) were plated in 96 well plates with144 μl/well of 8×10e5

CFU/ml in YM growth medium. Diluted compounds were then added to eachwell with concentration ranged from 4 to 60 μM as final concentration induplicates. The plates were inoculated at 37° C. for total of 48 hours.Two readings of OD at 600 nm were measured after 30 and 48 hourtreatments.

Results:

Most compounds tested in this assay inhibited the growth ofCryptococcus, with compounds AL, AG, AW, AX, AA, AE, AH, AK, BM, and BNas the most effective ones. It is noteworthy that compounds AA and ACwere quite active against Cryptococcus, comparing with their relativeweak activities against Candida and S. cereviseae. Overall it seems thatCryptococcus is more susceptible to compounds of the invention than theother fungi tested. Chloroquine had very weak activity againstCryptococcus, with a maximum growth inhibition of 40% at a concentrationof 100 micromolar, so that its IC50 is greater than this concentration.IC₅₀ (concentration for 50% of inhibition) and MIC (concentration formaximum-99% of inhibition) were calculated using XLfit based on OD of 48hour reading are listed in the following table.

TABLE 24 compound IC50 MIC compound IC50 MIC AL 1.88 11.54 AS 1.46 26.81AM 3.32 13.32 AV 5.12 22.85 AG 1.78 17.55 AW 0.90 8.73 AD 3.98 45.20 AX1.06 10.56 AZ 2.01 15.83 AT 1.29 41.78 BE 3.45 13.15 BO 2.00 13.40 BG2.13 12.54 BP * * BJ 1.86 18.54 AK 0.85 24.62 BI 2.23 19.56 BM 0.7222.55 AA 3.34 40.55 BN 1.03 * AC 3.35 19.39 AE 0.53 6.99 AF 5.18 55.87AH 0.76 9.54 BK 2.44 16.51 AB 1.15 40.75 AU 1.63 14.36 C12-Im 1.81 20.54

Procedure:

Part-I: Preparation of Fungal Cells

-   1. Pick a single colony of Cryptococcus from the YM agar plate using    the inoculum loop and inoculate into a 125 ml flask containing 25 ml    of YM growth medium.-   2. Incubate at 37° C. with shaking at 220 rpm for 24 hours with    loosen lid to allow air in and facilitates growth.-   3. Examine an aliquot of the culture under a microscope for yeast    cell morphology and lack of bacterial contamination.-   4. Dilute the overnight culture with YM medium at 1:100 dilution and    count the number of cells as 1×10⁶ cfu/ml.-   5. Make a final concentration of cells suspension at 8×10⁵ cfu/ml in    YM medium.-   6. Plate 144 μl/well of 8×10⁵ cfu/ml cell suspension on 96-well    plates.

Part-II: Cryptococcus Growth Inhibition Testing with Compounds

-   1. From 10 mM DMSO stock solutions, make serial dilutions of    compounds to 0.1, 0.2, 0.3, 0.5, 1.0 and 1.5 mM solution-   2. Add 6 ul each of diluted compound solutions per well in    duplicates. The final concentrations were 0, 4, 8, 12, 20, 40 and 60    micromolar.-   3. Incubated all plates at 37° C. overnight (30 hours) with 150 rpm    shaking.-   4. Read absorbance at OD600 for each plate.-   5. Leave plates in 37° C. incubator for another day and read    absorbance at OD600 again at 48 hours to ensure the inhibitory    effect of the compounds.-   6. Calculated the % inhibition and IC50 of each compound against    untreated cells.

Example L Anti-Cryptococcus (Serotype A) Activity of Compounds of theInvention

Reagents Manufacturer/Catalog # Lot # Cryptococcus neoformans ATCCMYA-1017 58178990 serotype A YPD Broth KD Medical YLF-3260 090712-04Sabouraud Dextrose Agar KD Medical #YPL-1050 C21-03 Sterile PBS, pH 7.4Quality Biological Inc; #114-058-131 DMSO Sigma; cat#D2650

Experiment Overview:

Cryptococcus neoformans (serotype A) were plated in 96 well plates with144 μl/well of 5×10e5 CFU/ml in YPD growth medium. Diluted compoundswere then added to each well with concentration ranged from 0.05 to 10μM as final concentration in duplicates. The plates were inoculated at30° C. Two readings of OD at 600 nm were measured after 18 hr and 48hour treatments.

Results:

Most compounds tested in this assay inhibited the growth of Cryptococcus(serotype A), with AX, AK, BM, AE and AH as the most effective ones.C12-imidazol had relative weak activity against Cryptococcus serotype Aat low concentration. Data plotted was based on 26 hour reading because18 hour reading was too low. IC₅₀ (concentration for 50% of inhibition)and MIC (concentration for maximum—99% of inhibition) were calculatedusing XLfit based on OD of 26 hour reading are listed in the followingtable.

TABLE 25 50% Inhibition (IC50) and Maximum Inhibition Concentration(MIC) Value compound IC50, uM MIC, uM AL 3.01 10.47 AM 1.57 10.53 AG2.14 11.37 AC 1.15 12.56 AW 1.74 13.75 AX 0.91 17.29 AK 0.25 19.50 BM0.69 17.50 BN 3.73 56.10 AE 0.54 14.74 AH 0.39 12.00 C12-Im 3.67 10.83

It is worthy of note that C. neoformans (serotype A) is the mostsensitive fungus to the compounds compared to the other tested species,including C. Albicans, S. cerevisiae, Trichophyton rubrum, andCryptococcus serotype D

Procedure:

Part-I: Preparation of Fungal Cells

-   1. Pick a single colony of Cryptococcus from the Sabouraud Dextrose    agar plate using the inoculum loop and inoculate into a 125 ml flask    containing 25 ml of YPD growth medium-   2. Incubate at 30° C. with shaking at 220 rpm for 24 hours with    loosen lid to allow air in and facilitates growth.-   3. Examine an aliquot of the culture under a microscope for yeast    cell morphology and lack of bacterial contamination.-   4. Dilute the overnight culture with YPD medium at 1:100 dilution    and count the number of cells as 8×10⁶ cfu/ml.-   5. Make a final concentration of cells suspension at 5×10⁵ cfu/ml in    YPD medium after the stock culture had been stored at 4° C. for 3    days.-   6. Plate 144 μl/well of 5×10⁵ cfu/ml cell suspension on 96-well    plates.

Part-II: Cryptococcus Growth Inhibition Testing with Compounds

-   1. From 10 mM DMSO stock solutions, make serial dilutions of    compounds to 0.0013, 0.0025, 0.0125, 0.025, 0.05, 0.125 and 0.25 mM    solution-   2. Add 6 ul each of diluted compound solutions per well in    duplicates. The final concentrations were 0, 0.05, 0.1, 0.5, 1.0,    2.0, 5.0 and 10 micromolar.-   3. Incubated all plates at 30° C. overnight with 175 rpm shaking.-   4. Read absorbance at OD600 after 18 and 26 hours for each plate.-   5. Calculated the % inhibition and IC50 of each compound against the    untreated cell.

Example M Effects of Compounds of the Invention on THP-1-DerivedMacrophage Antifungal Activity; Development of a PhagocytosedCryptococcus neoformans Antifungal Screen

Background: In the preceding examples compounds have been shown topossess direct anti-fungal activity against Cryptococcus neoformans atconcentrations less than 5 μM. The compounds, being weak bases, arelysosomotropic, concentrating in the acidic lysosomal compartment ofmacrophages. Some pathogenic fungi, such as Cryptococcus neoformans,reside in acidic lysosomes of macrophages in an effort to avoid the hostimmune system (Srikanta et al., 2011.

Another lysosomotropic drug, chloroquine, which has some directanti-fungal activity at the much higher concentration of 100 μM in C.neoformans, has been shown to enhance anti-fungal activity ofmacrophages against C. neoformans when tested at only 10 μM. This effectwas shown to be due to the drug concentrating in lysosomes housing theyeast (Harrison et al., 2000) The potential therefore exists forcompounds of the invention to behave in a manner similar to chloroquinefor attacking Cryptococcus or other organisms residing in macrophages,but at much lower concentrations.

Results/Summary:

The compounds tested (AM, BM, AH and AC) all showed clear dose dependentinhibition of fungal growth after phagocytosis and lysis. AH showed thehighest potency with near 100% inhibition of the fungal growth at 2 μM.

The IC50 values after macrophage phagocytosis were comparable to theIC50 values for direct inhibition of fungal growth, in the absence ofmacrophages reported in an earlier study.

The compounds were capable of killing C. neoformans (serotype A) evenwhen the fungus was located within live macrophages.

REFERENCES

-   1: A sensitive high-throughput assay for evaluating host-pathogen    interactions in Cryptococcus neoformans infection Srikanta, D et    al (2011) PLoS ONE 6(7): e22773-   2: Conditional lethality of the diprotic weak bases Chloroquine and    Quinacrine against Cryptococcus neoformans Harrison, T. S et    al (2000) J Infect Disease 182: p283-289

Results:

Two concentrations of macrophages (1×10⁵ and 2×10⁵/well) and a highconcentration of C. neoformans (4×10⁶/well) (MOI values of 40 and 20respectively) were tested in this experiment.

All of the compounds tested showed clear dose dependent inhibition offungal growth after phagocytosis and lysis. Phagocytosis by macrophagesdid not protect the fungus cells from antifungal activity of compoundsof the invention.

The IC50 values after macrophage phagocytosis were comparable to theIC50 values for direct inhibition of fungal growth, in the absence ofmacrophages.

TABLE 26 IC50 for inhibition of fungal growth by compounds directly orafter macrophage phagocytosis IC50 value (μM) No 1 × 10⁵ 2 × 10⁵Compound macrophages macrophages macrophages AM 1.57 1.13 0.85 BM 0.691.80 1.31 AH 0.39 0.29 0.25 AC 1.15 1.29 1.35

Experimental Procedures:

Experiment Overview for Assay Development Plate #4:

THP-1 cells were adjusted to 5×10⁵/ml or 1×10⁶/ml in cRPMI+PMA

200 μl was transferred to a flat-bottomed 96-well dish (1×10⁵ and2×10⁵/well) (48 hrs at 37 C)

Media was removed and fresh cRPMI+PMA added (further 24 hrs at 37 C)

C. neoformans cells in DPBS were opsonized with human serum (60 mins at30 C)

The opsonized yeast was washed (DPBS) and resuspended at 1×10⁷/ml or2×10⁷/ml in cRPMI. 1000 added to macrophage plate (1×10⁶ and 2×10⁶/well)(4 hrs at 37 C) washed ×4 with DPBS 1000 of cRPMI was added to each well(18 hrs at 37 C) Compound AC was added to some wells. Media was removed,no wash, 25 μl 0.05% Triton X-100 added to lyse cells (3 mins RTrocking) 1250 YPD broth was added and the plate incubated (24 hrs at 30C then 24 hrs at 37 C) C. neoformans growth was determined on aSpectrophotometer (600 nm) after 24 and 48 hours

Cell Line Information:

THP-1:

ATCC TIB-202 Organism: Human, male, one-year old infant

Organ: Peripheral blood Disease: Acute Monocytic Leukemia (AML)

Cell type: Monocyte Growth properties: Suspension in RPMI plus 10% FBS

THP-1-derived macrophage differentiation protocol (PMA):

THP-1 cells (p15) grown in cRPMI [RPMI (Lonza 12-115F) plus 10% AFBS(Lonza DE14-701F)] were counted on a hemacytometer. Cells were spun at1,800 rpm, RT for 5 mins, supernatant aspirated, pellet disturbed thenadjusted to 5.0×10⁵/ml and 1.0×10⁶/ml in cRPMI supplemented with 0.2μg/ml phorbol 12-myristate 13-acetate (PMA) (1 mg/ml in DMSO SigmaP8139). 200 μl aliquots of each cell concentration were transferred to42 wells (half a plate) of a flat-bottomed 96-well dish (1×10⁵ and2×10⁵/well) and placed in a 37 C incubator for 48 hours, media was thenremoved and 200 μl of fresh cRPMI+PMA added. The plate was incubated foran additional 24 hours at 37 C then processed for yeast uptake.

Yeast Strain Information:

Cryptococcus neoformans:

ATCC MYA-1017 Designation: CDC21 Isolation: Derived from strain H99 frompatient with Hodgkin's disease, New York

Antigenic properties: Serotype-A Growth properties: Suspension in YEPDbroth 25 C Opsonization of Cryptococcus neoformans cells (human serumonly):

In parallel to macrophage preparation, C. neoformans cells were grownfrom a single colony in 20 ml YPD broth at 30 C overnight. Absorbance of1:10 dilution of the overnight (ON) culture gave 0.89 OD at 600 nm.Estimated concentration of this stock was 4×10⁸ cells/ml (2×10⁸ cells/mlgave an OD 600 nm of 0.426 in an earlier study Cryptococcus macrophagedevelopment plate 3 ML113012). The cells were washed with DPBS once andresuspended in 2 ml DPBS. 230 μl of this stock (˜60×10⁷ cells) wasbrought up to 500 μl with DPBS in an Eppendorf tube. For opsonization,500 μl of human serum (SIGMA 57023) was added and the tube incubated at30 C for 60 mins with orbital shaking. The opsonized fungal cells werewashed three times with 800 μl DPBS (1,100 g for 2 min) and resuspendedin 800 μl DPBS. A 1:200 dilution of cells was counted (4.25×10⁶/ml),equivalent to 8.5×10⁸/ml for the 1× stock. 470 μl of the 1× stock wasbrought up to 10 ml with cRPMI for a final concentration of 4×10⁷/ml.

Macrophage Mediated Anti-Fungal Activity Assay:

Media was aspirated from the prepared macrophage plate and 1000 of theopsonized fungal cell suspension added to the wells. Media without yeastwas added to triplicate wells for each macrophage concentration toprovide background readings. Three empty wells (no macrophages) wereseeded with fungus to serve as the wash control. The plates were thenincubated at 37 C for 4 hours then washed 4 times with DPBS (plates wereshakes briefly after addition of DPBS to increase wash efficiency). 144μl of cRPMI was added to each well and 60 of 12.5 μM, 25 μM and 50 μMstocks of compounds AM, BM, AH, and AC added in triplicate for finalconcentrations of 0.5 μM, 1 μM or 2 μM. The plate was incubated at 37 C,5% CO2 for 18 hours. Media was removed, 25 μl of 0.05% Triton X-100(SIGMA T-9284) in DPBS was added to each well and the plate rocked at RTfor 3 min, to lyse the cells. 125 μl YPD broth (KD Medical YLF-3260) wasthen added to each well and the plate placed in a 30 C incubator. C.neoformans cell growth was determined by measuring absorbance at 600 nmon a Spectrophotometer (Spectra Max Plus using program SoftMax Pro)after 30 hours.

Example N Antifungal Activity as Determined by Minimum Inhibitory andFungicidal Concentrations

Objective

The objective of this study was to determine the antifungal activity ofeight experimental compounds against a representative panel of fungalisolates, including Candida albicans, C. glabrata, Cryptococcusneoformans, Trichophyton rubrum, Aspergillus fumigatus, and Rhizopusspp. Antifungal activity was measured by minimum inhibitoryconcentration (MIC) and minimum fungicidal concentration (MFC).

Materials

Isolates

Three recent clinical strains of each species, taken from the culturecollection at the Center for Medical Mycology, Case Western University,were tested.

Antifungal Agents

Compounds in powder form were dissolved in DMSO. Serial dilutions ofeach compound were then prepared in RPMI-1640 in a range of 0.125-64μg/ml.

Methods

MIC testing was performed according to the CLSI M27-A3 and M38-A2standards for the susceptibility testing of yeasts and filamentousfungi, respectively (1, 2). Test isolates were subcultured from frozenslants onto potato dextrose agar plates (Trichophyton rubrum wassubcultured onto oatmeal plates for conidia production) and checked forpurity. Inocula were then prepared in RPMI-1640 (YNB for Cryptococcus)to a concentration of 0.5-2.5×10³ colony-forming units (CFU)/ml or0.4-5×10⁴ conidia/ml for yeast and filamentous fungi, respectively. MICendpoints were read at 50% and 100% inhibition, as compared to thegrowth control, at both 24 and 48 hrs (C. neoformans were incubated for72 hrs and T. rubrum strains were incubated for 96 hrs).

MFC determinations were performed according to the modificationspreviously described by Canton et al. and Ghannoum and Isham. (3, 4)Specifically, the total contents of each clear well from the MIC assaywere subcultured onto potato dextrose agar. To avoid antifungalcarryover, the aliquots were allowed to soak into the agar and then werestreaked for isolation once dry, thus removing the cells from the drugsource. Fungicidal activity was defined as a >99.9% reduction in thenumber of colony forming units (CFU)/ml from the starting inoculumcount, with compounds being determined as cidal if the MFC fell within 4dilutions of the MIC.

Results

The data shows that all eight compounds demonstrated antifungal activityagainst the strains tested, although MIC and MFC results were strainspecific. As can be seen in Table 27, compound AC showed the lowest MICvalues against the C. albicans strains at both the 50% and 100%inhibition at 24 hrs (<0.12-0.25 and <0.12-1 μg/ml, respectively) and 48hrs (<0.12-1 and 0.5-2 μg/ml, respectively). Importantly, compound ACwas cidal against 2 of the 3 C. albicans strains tested. Compound AGdemonstrated similar MIC and MFC values against the C. albicans strains.

Table 28 shows that compounds AG and AC were also the most activeagainst the C. glabrata strains tested. After 24 hrs, the MIC at 50% forcompound AG was 0.25-1 μg/ml and 0.5-2 at 100%. After 48 hrs, thecorresponding compound AG values were both 0.5-2 μg/ml. After 24 hrs,the MIC at 50% for compound AC was 0.5-1 μg/ml and 1-2 at 100%. After 48hrs, the corresponding compound AC values were 1-2 (50%) and 2-4 μg/ml(100%). Both compounds AG and AC were cidal against all of the C.glabrata strains tested.

As can be seen in Table 29, compounds AX and AH demonstrated thegreatest antifungal activity against the Cryptococcus neoformans strainstested. Compound AX had MIC values of 0.12-2 and 0.5-4 μg/ml at 50% and100% inhibition, respectively, while compound AH had correspondingvalues of 0.004-2 and 0.25-2 μg/ml. Both compounds were cidal againstall 3 neoformans isolates.

Table 30 shows the MIC and MFC values of the eight compounds against theAspergillus fumigatus strains. Compounds AE, AH, and AC showedequivalent inhibitory activity, with compound AE demonstrating MICvalues of <0.12-0.5 and <0.12-1 μg/ml at 50% and 100% inhibition,respectively, after 24 hrs. After 48 hrs, the corresponding values forcompound AE were 0.5-2 and 1-4 μg/ml. Compound AH demonstrated MICvalues of <0.12 and 0.25-0.5 μg/ml at 50% and 100% inhibition,respectively, after 24 hrs. After 48 hrs, the corresponding values forcompound AH were 0.25-1 and 0.25-4 μg/ml. For compound AC, the MICvalues at 24 hrs were <0.12 and 0.25-0.5 μg/ml for 50% and 100%inhibition, respectively, while the corresponding values at 48 hrs were0.5-1 and 1 μg/ml. However, only compounds AL, AM, and AG were cidalagainst one of the A. fumigatus strains (MRL 28397).

In Table 31, it can be seen that compounds AE, AH, and AC were the mostactive against the Rhizopus strains. At 24 hrs, compound AE showed MICvalues of <0.12 and 1-2 μg/ml for 50% and 100% inhibition, respectively,with corresponding 48 hr values of 1-2 and 1-4 μg/ml. Compound AH showedMIC values of 0.25-0.5 and 2 μg/ml for 50% and 100% inhibition,respectively, at 24 hrs and 2 μg/ml for both endpoint readings at 48hrs. At 24 hrs, compound AC showed MIC values of <0.12-0.25 and 0.5μg/ml for 50% and 100% inhibition, respectively, with corresponding 48hr values of 0.5 and 0.5-1 μg/ml. Generally, no cidal activity wasdemonstrated against the Rhizopus strains tested.

Finally, Table 32 shows the MIC and MFC values of the eight compoundagainst T. rubrum. At the 50% inhibition endpoint, compounds AG, AX, AE,AH, and AC showed equivalent activity (<0.12-4 μg/ml overall). At the100% inhibition endpoint, compounds AG, AH, and AC were equivalent(0.25-4 μg/ml overall), with compounds AX and AE ranging slightly higher(0.25-16 μg/ml). Within the definition of cidality (MFC within 4dilutions of the MIC) all compounds were considered cidal against the T.rubrum strains, though the MFC were high in some strains (8-16 μg/ml).

Overall, compounds AE, AH, and AC appeared to demonstrate the greatestinhibitory activity against the most fungal strains tested.

REFERENCES FOR EXAMPLE N

-   1. CLSI. Reference Method for Broth Dilution Antifungal    Susceptibility Testing of Yeasts; Approved Standard—Second Edition.    CLSI document M27-A2 (ISBN 1-56238-469-4). CLSI, 940 West Valley    Road, Suite 1400, Wayne, Pa. 19087-1898 USA, 2002.-   2. CLSI. Reference Method for Broth Dilution Antifungal    Susceptibility Testing of Filamentous Fungi; Approved    Standard—Second Edition. CLSI document M38-A2 [ISBN 1-56238-668-9].    CLSI, 940 West Valley Road, Suite 1400, Wayne, Pa. 19087-1898 USA,    2008.-   3. Canton E, Peman J, Viudes A, Quindos G, Gobernado M,    Espinel-Ingroff A. 2003. Minimum fungicidal concentrations of    amphotericin B for bloodstream Candida species. Diagn Microbiol    Infect Dis. 45:203-6.-   4. Ghannoum M A, Isham N. 2007. Voriconazole and Caspofungin    Cidality Against Non-Albicans Candida Species. Infectious Diseases    in Clinical Practice. 15(4):250-253.

TABLE 27 MIC and MFC ranges against Candida albicans strains (in μg/ml).Compound AL AM AG AW AX AE AH AC C. albicans Range 24 hr 48 hr 24 hr 48hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48hr MIC 0.5-2 2-4 0.5-2 0.5-4 0.25-0.5 0.5-2  1-4 4-8  0.12-0.5 1-40.12-1 2-4  <0.12-1 0.25-2   <0.12-0.25 <0.12-1 50% MIC  2-4 2-4  2-4 2-4 0.5-2  1-4 4-8 8 0.5-4  2-4  0.5-4 4 <0.12-4 1-4 <0.12-1    0.5-2100% MFC 4-8 4 2-4 8-32  4-32 8-64  4-32 2

TABLE 28 MIC and MFC ranges against Candida glabrata strains (in μg/ml).Compound AL AM AG AW AX AE AH AC C. glabrata Range 24 hr 48 hr 24 hr 48hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48hr MIC 2 2-4 1-2 2-4 0.25-1 0.5-2 4 8 2 8 4 4-8 2 4-8 0.5-1 1-2 50% MIC2 4 2-4 2-4  0.5-2 0.5-2 8  8-16 8 8 4 4-8 4-8 4-8   1-2 2-4 100% MFC 44-8 4 16-32 8-64 16-64  8-64 4-8

TABLE 29 MIC and MFC ranges against Cryptococcus neoformans strains (inμg/ml). Cr. neoformans Compound Range AL AM AG AW AX AE AH AC MIC 50%1-2 0.5-4 2-4  0.5-2 0.12-2 0.03-4 0.004-2  0.12-4 MIC 100% 2  2-4 4 2 0.5-4 0.25-4 0.25-2 0.25-4 MFC 2-4 8 8-16  2-8   4-8  >1-8   1-2 8

TABLE 30 MIC and MFC ranges against Aspergillus fumigatus strains (inμg/ml). Compound AL AM AG AW AX AE AH AC A. fumigatus Range 24 hr 48 hr24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr24 hr 48 hr MIC 2 2-4  0.5-1 2-4  0.5-1 1-2 2-4 8 0.12-0.25 1-4<0.12-0.5 0.5-2 <0.12 0.25-1 <0.12 0.5-1    50% MIC 2 4  1-2 4 1 1-2 4-816 0.5-1  4-8 <0.12-1   1-4 0.25-0.5 0.25-4 0.25-0.5 1 100% MFC 4-324-32  4->64 64->64 >64 >64 >64 16->64

TABLE 31 MIC and MFC ranges against Rhizopus strains (in μg/ml).Compound AL AM AG AW AX AE AH AC Rhizopus Range 24 hr 48 hr 24 hr 48 hr24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hrMIC 4 4-8  1-2 2-4  1-2 2-4 4 4-8  0.5-1 1 <0.12 1-2 0.25-0.5 2<0.12-0.25 0.5 50% MIC 4 8 2-4 4 2 2-4 4-8 8   1-2 1-2 1-2 1-4 2 2 0.50.5-1   100% MFC 64->64 8-32  4-16 64->64 >64 64 64 16-64

TABLE 32 MIC and MFC ranges against Trichophyton rubrum strains (inμg/ml). T. rubrum Compound Range AL AM AG AW AX AE AH AC MIC 50% 1-40.25-4 <0.12-2  1-8  <0.12-4  <0.12-4     <0.12-4  <0.12-2  MIC 100% 1-4 0.5-4 0.25-2 1-16 0.25-8 4-16 0.25-4 0.5-4 MFC 2-4   1-4  0.5-2 8-16  2-8 4-16  0.25-16 0.5-4

Anticancer Examples Example O Compounds of the Invention InhibitSyngeneic Breast Cancer Growth in Mice

Cancer models in mice generally either involve syngeneic murine tumorsin immunocompetent mice or xenografts of human tumors inimmunocompromised mice. An important aspect of using murine tumors inmice is that the tumor and host have much closer genetic similarity thando human xenografts in mice and therefore can be a very rigorous test ofselectivity of agents for inhibiting proliferation of cancer cellsversus normal tissues. 4T1 is breast cancer cell line commonly used as asyngeneic cancer model. Test compounds were chosen based upon theirability to selectively to kill 4T1 mouse mammary breast cancer cellsrelative to a normal mouse mammary cell line in vitro.

Female Balb/C mice were randomized into treatment groups and 10³ 4 T1cells were injected into into the mammary fat pad of each mouse in 0.1mL PBS on 4/28/10 (day 0). Mice received test compounds by oral gavagein 1% hydroxypropylmethylcellulose from day 2 until day 30. Tumor growthwas assessed by caliper measurements twice per week and tumor weightafter necropsy, and body weight was also monitored.

Treatment groups were:

-   -   1. Vehicle (1% hydroxypropylmethylcellulose; HPMC)    -   2. CI (120 μmol/kg/day)    -   3. BA (120 μmol/kg/day)    -   4. CP (120 μmol/kg/day)    -   5. CQ (120 μmol/kg/day)    -   6. AA (120 μmol/kg/day)    -   7. AC (120 μmol/kg/day)

TABLE 33 Results Final Tumor Initial Body Final Body Treatment Volume(mm³) Weight (g) Weight Δ BW % Vehicle 906 ± 316 22.2 ± 1.1 21.8 ± 0.7−1.7% CI 702 ± 244 21.8 ± 0.8 20.6 ± 0.6 −5.5% BA 641 ± 159 25.5 ± 1.524.8 ± 2.0 −2.7% CP 352 ± 114 24.1 ± 0.9 24.1 ± 1.3 −0.0% CQ 140 ± 60 24.9 ± 0.6 24.4 ± 0.9 −2.0% AA 563 ± 175 21.4 ± 1.0 20.3 ± 1.3 −5.1% AC723 ± 185 21.5 ± 1.0 19.7 ± 1.1 −8.4%

Compounds of the invention reduced tumor growth versus vehicle-treatedmice after daily oral administration at a dose of 120 μM/kg/day for 33days, with acceptable toxicity (less than 10% body weight loss). CQ wasthe most active of the compounds tested in this experiment in the 4T1breast cancer model. Compounds were chosen for in vivo testing basedupon their ability to selectively to kill 4T1 mouse mammary breastcancer cells relative to a normal mouse mammary cell line in vitro,indicating a correspondence between in vitro cancer cell linecytotoxicity in vivo anticancer activity of compounds of the invention.

Example P Effects of Compound AC in Mice Bearing Xenografts of HumanHormone-Independent Prostate Cancer

Experimental Procedure

Standard models for prostate cancer use subcutaneous xenografts of humanprostate cancer cell line. Local measurable tumors are produced at thesite of injection of the cells, and they metastasize to critical tissuessuch as the bones, lungs and liver. Mortality in this model is due tometastases impairing tissue function. Compounds of the invention wereassessed for inhibition of tumor growth and reduction or delay ofmortality in the PC-3 prostate cancer model, which mimics an advanced,androgen-independent stage of prostate cancer.

10 female nude mice (female Hsd:athymic nude-Foxn1^(nu)) received PC-3cells (5×10⁶ per mouse in 0.1 mL PBS) by subcutaneous injection into theright hind flank. After 8 days tumors were palpable and mice weredivided into two groups with approximately equal mean tumor sizes. Micereceived AC or vehicle (saline) via intraperitoneal (i.p.) injectiononce daily until day 79.

-   -   1. Vehicle (0.9% saline): Mean pretreatment tumor volume 55.7        mm³; body weight 26.6±0.9 g)    -   2. Compound AC: 120 μmol/kg/day. Mean pretreatment tumor volume        59.6 mm³; body weight 26.8±0.5 g)

Tumors were measured with calipers twice per week, and body weights andmortality were also monitored.

Results

All 5 vehicle-treated mice died by day 35 (Individual days of death 20,24, 24, 26, and 35). One mouse in the AC-treated group died on day 65and the remaining 4 survived until the study was terminated on day 79.

In the longest-surviving vehicle-treated mouse, the tumor volume was3007% larger at time of death on day 35 than at initiation of treatment;all other vehicle-treated animals died of metastatic disease withsmaller primary tumor sizes. Among mice treated with AC, tumors hadenlarged to an average of 949% of initial size at day 77; two of themice surviving to the end of the study had no detectable tumors at thattime and were deemed complete regressions, and one regressed more than50% from the initial tumor size. AC-treated mice had a mean body weightof 28.9±1.3 g at end of study; a weight gain rather than a weight lossfrom the initial group body weight of 26.8±0.5 g indicates that thetreatment was well tolerated. Daily injections of AC therefore markedlyimproved survival and decreased tumor size, including producing completeand partial regressions, in mice bearing hormone-independent prostatecancers.

Example Q Effects of Compounds of the Invention in a Mouse Model ofLiver Metastases of Human Colorectal Cancer

A major cause of morbidity and mortality in patients with colorectalcancer is metastasis of the tumor into the liver; colorectal cancer canoften be successfully resected from the primary site, but metastases tothe liver are much less accessible to surgical treatment. A mouse modelof colorectal cancer metastasis to the liver has been established, usingHCT-116 colon adenocarcinoma cells injected into the spleen of athymic(nude) mice. The HCT-116 cancer cells spontaneously spread from thespleen into the liver via the circulation, and they form tumors in theliver (Ishizu, K., Sunose, N., Yamazaki, K., Tsuruo, T., Sadahiro, S.,Makuuchi, H., and Yamori, T. Development and Characterization of a Modelof Liver Metastasis Using Human Colon Cancer HCT-116. Biol. Pharm. Bull.2007, 30(9):1779-1783).

Compounds CQ and AA were tested for antitumor activity in the HCT-116model of metastatic colorectal cancer.

Methods:

Mice (female Hsd:athymic nude-Foxn1^(nu)) were anesthetized withxylazine/ketamine intraperitoneal injection, followed by incisionapproximately 10 mm on the left subcostal region (area disinfected withethanol) to expose the peritoneum. The peritoneum was opened for about 8mm near the spleen, and 2.5×10⁶ cells in 50 μL PBS were injected intothe spleen using a 30 G needle. The spleen was repositioned, and thesurgical area was closed using sutures and clips.

N Treatment Dose (μmol/kg) Dose Volume (per mouse) 5♀ Vehicle N/A 0.4 mL5♀ CQ 240 0.4 mL 5♀ AA 240 0.4 mL

The day after receiving cells, mice were randomized into groups of fivebased upon body weight to provide groups with approximately equivalentmean body weight. Mice received a single, daily oral dose of testarticle or vehicle (1% hydroxypropylmethylcellulose) beginning 48 hoursfollowing cell injection into the spleen.

At study termination 28 days after HCT-116 cell injection, body weightswere recorded, and spleens and livers were removed, weighed and fixed in10% formalin. Livers were sectioned and stained; the relative areas ofnormal and tumor tissue were quantified in histology sections withquantitative planimetry software.

Results:

Tumors in the Vehicle control group occupied 14% of the liver asassessed by quantitative planimetry in histology sections. Bothcompounds CQ and AC markedly reduced the area of liver invaded bymetastatic cancer cells. The Vehicle group had a 12% higher liverweight/body weight ratio than the groups treated with either CQ or AC,corroborating the histology planimetry measurements indicating thattumors increased the total liver mass in the Vehicle group. Body weightswere not significantly different between groups of mice treated withvehicle-treated versus test compounds, indicating that the compounds ofthe invention were well tolerated at a dose of 240 μmol/kg/day for 28days.

TABLE 34 Tumor Area Tumor Area % Liver Weight Final Treat- % of Total ofVehicle % of Body Body Weight ment Liver Group Weight Grams Vehicle 14 ±5.6%  100%  6.1 ± 0.3% 27.4 ± 0.9    CQ 0.02 ± 0.01% * 0.15% * 5.3 ±0.1% 26.2 ± 0.9 NS AA  0.2 ± 0.26% *  1.5% * 5.3 ± 0.2% 28.2 ± 1.5 NS *= less than Vehicle group, P < .02

Example R Effects of Compounds of the Invention, Sorafenib, andCombinations in a Mouse Model of Human Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common and lethalcancers worldwide, generally developing as a consequence of chronicinfection with hepatitis B or C viruses. The tyrosine kinase inhibitorsorafenib is a multikinase inhibitor used for treatment of advanced HCC,and has both direct antitumor and antiangiogenic properties. Compoundsof the invention act via a different mechanism of action than doessorafenib or other kinase inhibitors; therefore it is possible thatcompounds of the invention, in addition to displaying single agentactivity, may also enhance the efficacy of sorafenib or other standardtreatments in HCC and other cancers.

The Hep3B hepatocellular carcinoma cell line is human in origin,contains genetic traces of hepatitis B virus, and can be injected intothe livers of athymic immunocompromised mice as a model of primary HCC.Oral sorafenib is active in this model and was used as both a positivecontrol treatment and as a partner for combination therapy with aselection of compounds of the invention. The test compounds were alladministered orally.

Methods:

The test compounds of the invention were suspended in 1%hydroxypropylmethylcellulose (HPMC) using a sonicator equipped with amicrotip to minimize particle size and maximize uniformity of thesuspension. Sorafenib was dissolved in a 1:1 mixture of Cremophor EL andethanol by heating to 60° C. for 1 minute and then sonicating for 10minutes to fully suspend.

Female nude mice (Hsd:athymic nude-Foxn1^(nu)) weighing approximately 25g were anesthetized with ketamine/xylazine, laid on their backs, and a1-cm transverse incision made through the skin and peritoneum of theleft upper abdomen. The mediant lobe of the liver was exposed byapplying gentle pressure on the abdomen. 1.5-2×10⁶ Hep3B cells in a 20μL volume of matrigel:EMEM serum free (1:1) were slowly implanted bysubserosal injection into the liver using a 27-gauge needle on aHamilton syringe. The liver was allowed to slip back into place, and theperitoneum was closed with sutures and wound clips.

Mice were divided into 8 groups of mice each following injection ofcells; the vehicle/vehicle group comprised 12 mice and the other groupscomprised 8 or 9. Mice began receiving oral testdrug treatments 48 hrpost cell injection.

TABLE 35 Group No. of No. Animals Treatment Daily Dose 1 12 1% HPMCvehicle; N/A cremophor vehicle 2 9 Sorafenib; 30 mg/kg/day 1% HPMCvehicle 3 8 AC; 180 μmol/kg/day cremophor vehicle 4 8 AC + sorafenib 180μmol/kg/day; 20 mg/kg/day 5 8 AK; 360 μmol/kg/day cremophor vehicle 6 9AK + sorafenib 360 μmol/kg/day; 20 mg/kg/day 7 8 AB; 360 μmol/kg/daycremophor vehicle 8 9 AB + sorafenib 360 μmol/kg/day; 20 mg/kg/day

The test compounds, sorafenib, and vehicles were administered by oralgavage. Sorafenib or its cremophor-containing vehicle were given in themorning and compounds of the invention or their HPMC vehicle wasadministered in the afternoon each day; all animals received two gavagetreatments of drugs or appropriate vehicles daily. In the group withsorafenib as the only active test agent, the daily dose was 30 mg/kg;when combined with compounds of the invention, the sorafenib dose wasreduced to 20 mg/kg because the tolerability of the combination wasunknown, and also because possible improved anticancer activity ofcompounds of the invention combined with a lower dose of sorafenib overa higher dose of sorafenib alone would more clearly demonstrateadvantageous activity of compounds of the invention.

Mice were sacrificed at day 35 after 2 of the initial 12 vehicle-treatedmice had died from tumor progression; livers were removed andphotographed, and tumors were dissected out for measurement andweighing.

Results

All vehicle-treated mice developed tumors, with a mean weight of about 2grams at the time of sacrifice. Sorafenib (30 mg/kg/day) as a singleagent reduced the tumor size by more than 50%. Compounds AC and AB alonealso reduced tumor size by more than 50%; AK alone produced anumerically but not statistically significant reduction in tumor sizeversus vehicle. Addition of sorafenib (20 mg/kg/day) to compounds of theinvention resulted in better inhibition of tumor growth than wasachieved with sorafenib alone at 30 mg/kg/day. The combinations of DD orAB with sorafenib produced more complete regressions (no viable tumordetected at necropsy) than single-agent treatments. All treatmentsincluding combinations were well-tolerated as indicated by maintenanceof body weight throughout the entire duration of the study.

TABLE 36 Effects of compounds of the invention alone and in combinationwith sorafenib on growth of hepatocellular carcinoma in nude mice TumorWeight Body Weight (g) (g) Complete Mean ± SEM Treatment N Mean ± SEMRegressions Initial Final Vehicle 10 2.03 ± 0.37  0 26.0 ± 0.4 26.4 ±0.5 Sorafenib 9 0.81 ± 0.20 * 1 25.9 ± 0.7 24.9 ± 0.4 AC 8 0.49 ± 0.17 *2 25.4 ± 0.5 25.6 ± 0.7 AC + 8  0.17 ± 0.07 *⁺ 4 24.9 ± 0.5 25.2 ± 0.9Sorafenib AK 8 1.56 ± 0.39  2 25.9 ± 0.7 24.9 ± 0.9 AK + 9 0.48 ± 0.22 *2 25.1 ± 0.7 25.1 ± 1.3 Sorafenib AB 8 0.88 ± 0.33 * 2 26.2 ± 0.7 26.0 ±0.9 AB + 9 0.38 ± 0.18 * 6 25.3 ± 0.7 25.7 ± 0.8 Sorafenib * = less thanVehicle group, P < .02 ⁺= less than Sorafenib group, p < .02

Example S In Vitro Screen for Anticancer Activity Against 4T1 MurineBreast Cancer and PC-3 Human Prostate Cancer

Compounds of the invention were screened for ability to kill or inhibitproliferation of cancer cell lines in vitro, as a complement to in vivostudies on subsets of compounds demonstrating anticancer efficacy invivo, at doses that were well tolerated after either oral orintraperitoneal administration.

Anticancer activity against 4T1 murine breast cancer cells cancer cellswas assessed in vitro by seeding 1×10⁴ cells/well in flat bottom cultureplates, then treating with selected 1 μM or 5 μM concentrations ofcompounds for 18 hr after plating. Then 10 μL of Wst1 dye reagent, atetrazolium dye indicator for cell death, was added/well and incubatedapproximately 2 hr before being assayed on the Biotek EL800 Universalmicroplate reader (450 nm, reference 630 nm).

Activity against PC3 human prostate cancer cells in vitro was assessedby a similar method. PC-3 prostate cancer cells were plated at 2×10⁴cells/well in 96 well flat bottom tissue culture plates, and incubatedfor approximately 20 hours with vehicle or test compounds atconcentrations of 0.4, 0.5 or 2.5 μM as indicated for specific compoundsin the right-hand column of Table 37. A 1/10^(th) volume of Wst1 dye wasadded/well and incubated for two hours in the cell culture incubator.Samples were analyzed in triplicate on an EL800 Universal MicroplateReader at 450 nm, reference wavelength 630 nm.

Numerical values in the Table 37 represent percent of cancer cellsurvival relative to vehicle treated cells at the indicatedconcentrations, with values under 100 indicating anticancer cytotoxicactivity at the drugs concentrations tested.

TABLE 37 Compound 4T1 1 μM 4T1 5 μM PC-3, [μM] Control (100%) (100%)(100%) 0 CH 45.2 27.2 102 0.4 μM CI 28.3 19.1 77.9 0.4 μM CJ 22.6 24.153.7 0.4 μM CK 62.5 45.3 51.4 0.5 μM CL 25.6 19.5 58.1 0.4 μM AL 16.618.3 61.6 0.4 μM AM 24.3 29.5 58.5 0.4 μM EI 95 45.8 31.2 2.5 μM AG 18.42.5 μM CO 28.4 55.6 77.1 0.4 μM AR 25.4 47 57 0.4 μM AN 26.6 50.3 75.90.4 μM AD 21.6 51.1 54.7 0.4 μM CX 25.1 20.7 45.9 0.4 μM BH 21 19.3 98.50.4 μM CV 25.7 16.9 73.8 0.5 μM AZ 52.2 29.1 95.4 0.4 μM CW 25.1 18.498.5 0.4 μM BE 23.1 18.7 99.1 0.4 μM BF 17.2 19 92.8 0.4 μM BG 17.4 17.899.1 0.4 μM DA 17.6 18.4 95.7 0.4 μM BJ 16.9 31.3 23.9 0.4 μM BI 30 17.3110.9 0.4 μM DB 20.1 22.2 24.7 0.4 μM BA 71.7 219.6 42.4 1.5 μM CY 24.529.1 40.5 0.4 μM CZ 50.6 28.3 96.7 0.4 μM CP 82.6 38 35.6 2.5 μM CQ 71.957.9 95.8 2.5 μM CR 109.9 31.8 53.2 2.5 μM CS 41.3 2.5 μM CT 34.5 2.5 μMCU 37.6 2.5 μM BR 105.5 122.4 CM 104.5 221.4 37.8  5 μM BB 59.6 41.116.3 2.5 μM BC 96.9 47.2 26 2.5 μM AJ 22.4 21.1 18.5 0.4 μM BD 25.5 27.729.3 0.4 μM BS 104.8 117.4 BT 119.2 120.9 DW 102.4 193.9 DX 112.2 104.8AI 16.2 17.9 36.4 0.4 μM DY 88.9 60.5 16.1  5 μM DZ 23.7 17.4 84.8 0.4μM EA 31.1 36.8 108 0.4 μM EE 24 18.1 34 0.4 μM EF 15.6 23.7 16.7 0.4 μMEG 34.7 27.7 92.2 0.4 μM EB 94.4 2.5 μM EC 94.6 2.5 μM DC 110.3 96.7 AO28.9 18.6 35 0.4 μM DI 107.5 126.1 DK 101.8 87.6 DL 70.9 21 43 2.5 μM DN103.5 56.7 31.7 2.5 μM DP 72.5 25.4 37.5 2.5 μM AP 109.7 246.1 DD 97.4104.1 DE 60.1 28.6 42 2.5 μM DF 27.1 20.8 101.9 0.4 μM DJ 89 66.9 85.92.5 μM DM 128.1 47.8 45.6 2.5 μM DO 116.2 35.2 59.2 2.5 μM DR 77.9 27.231.5 2.5 μM DQ 99.5 122.3 AA 69.1 31.2 82.6 1.5 μM AC 23.3 19.3 61.5 0.4μM DS 35.6 25.5 70 0.4 μM AF 24.7 25.6 19.1 0.4 μM BU 17.6 21.4 24 0.4μM BV 23.7 23.3 31.6 0.4 μM BK 29.2 0.4 μM BL 106.3 0.4 μM DG 105.2 94.7DH 96.6 112.3 AQ 94.8 92.7 BV 115 100.6 BW 122.6 235.7 BX 116.3 116 EH115.8 128 BY 107.4 209.4 96.6 2.5 μM BZ 122.2 259.8 CA 107.6 108.6 FO106.2 145.9 FP 116.2 116.2 FQ 110 98 AU 93 23.2 32.4 2.5 μM FV 104.1101.2 EK 116.4 114.2 EL 108 39.4 41.8 2.5 μM FS 121.5 107.3 EM 105.7 93FT 112.8 27.6 41.1 2.5 μM EW 21.2 18.9 14.1 0.4 μM FU 118.3 105.5 CB104.6 102.1 CC 109.5 99.5 FW 98.1  5 μM FX 111.6 96.6 AS 94.6 23.1 31.12.5 μM FR 100.9 2.5 μM AV 136.2 30 38.2 2.5 μM AW 44.2 18 38.2 0.4 μM AX24.3 18 31.2 0.4 μM EN 93.3 89.8 AY 131.3 34.5 50.4 2.5 μM CN 32.5 18.80.4 μM FN 92.9 79.4 FM AT 31.7 18.7 34.6 0.4 μM BO 20.7 18.6 13.4 0.4 μMFL 27.7 21.4 41.2 0.4 μM FD 106.2 111.7 112.1  5 μM FB 92.7 90 97.7 2.5μM FC 115.4 122.9 FH 100.9 102 89  5 μM FF 103.4 102.2 93  5 μM FE 107.531.7 34.2  5 μM FY 95.2 26.8 36 2.5 μM BP 33.6 23.3 50.5 0.5 μM FG 85.725.5 39.2 1.5 μM FZ 91.4 56.6 32.7  5 μM GA 97.1 35.5 41.3 1.5 μM FI26.5 26.7 35.2 0.5 μM GB 97 22.6 36.4 1.5 μM CD 16.6 2.5 μM CE 16.2 2.5μM BQ 21.4 2.5 μM FJ 38.1 24.5 38.6 0.5 μM FK 23.6 15.6 35.5 0.5 μM GC84.8 21.1 19.8 2.5 μM CF 96.7 28.6 126.4 2.5 μM GD 24.3 2.5 μM

Example T Effects of Compounds of the Invention of Resistance of HumanProstate Cancer Cells to Cytotoxic Chemotherapy Agents In Vitro

Cancer therapy is hindered by inherent or acquired resistance of tumorto single cytotoxic anticancer agents. One mechanism of cancer cellresistance to chemotherapy agents such as anthracylines, platinumcompounds, vinca alkaloids, taxanes, and some tyrosine kinaseinhibitors, is to sequester anticancer agents in lysosomes or relatedacidic vacuoles. Compounds of the invention were tested in vitro fortheir ability to increase sensitivity to several other classes ofanticancer agents to which PC-3 prostate cancer cells are relativelyresistant in vitro and in vivo.

PC-3 prostate cancer cells were plated at 2×10⁴ cells/well in 96 wellflat bottom tissue culture plates, and incubated approximately 20 hours.Cells were treated with an anticipated suboptimal concentration of testcompounds for cell killing as a single agent for approximately 30minutes. Chemotherapeutic agents (doxorubicin, oxaliplatin, paclitaxelor vincristine at concentrations suboptimal for PC-3 cell killing) wereadded and PC-3 cells were incubated for an additional 72 hours beforebeing assayed using Wst1 reagent. A 1/10^(th) volume of Wst1 dye wasadded/well and incubated for two hours in the cell culture incubator.Samples were analyzed in triplicate on an EL800 Universal MicroplateReader at 450 nm, reference wavelength 630 nm.

In Table 38, numerical values in the column headed “No Chemo” representpercent cell survival after exposure to the compounds of the inventionat concentrations indicated to the left of that column. In the columnsheaded by the names of the four chemotherapeutic agents, values lowerthan the corresponding “No Chemo” values indicate better anticanceractivity of the specific combination of the cytotoxic agent incombination with a compound of the invention than was obtained witheither class of compound alone. At the concentrations indicated, theminimal activity of the chemotherapy agents alone during 72 hours ofexposure was normalized to 100% for clarity in discerning synergistic oradditive effects of compounds of the invention. The results indicatethat, at the concentrations tested, a broad range of compounds of theinvention increase sensitivity of cancer cells to one or more of thetested cytotoxic chemotherapy agents doxorubicin, oxaliplatin,paclitaxel or vincristine.

TABLE 38 Cytotoxicity of suboptimal concentrations of compounds of theinvention alone and combined with cytotoxic chemotherapy agents Doxoru-Oxali- Pacli- Vincris- No bicin platin taxel tine Compound [μM] Chemo3.5 μM 100 μM 50 μM 100 nM Vehicle (100)   (100)   (100)   (100)  (100)   CH 0.4 μM 102   62.8 101.1  84.6 67.4 CI 0.4 μM 77.9 67.6 21.848.7 33.8 CJ 0.4 μM 53.7 18.9 19.7 51.7 16.9 CK 0.5 μM 51.4 111.6  143  64.2 138.2  CL 0.4 μM 58.1 22.6 23.2 50.3 27.7 AL 0.4 μM 61.6 21.9 21.951.8 28.1 AM 0.4 μM 58.5 24.7 25.4 54.8 26   EI 2.5 μM 31.2 66.1 75.150.1 69.5 AG 2.5 μM 18.4 21.1 27.1 21.8 17.1 CO 0.4 μM 77.1 28.4 29.251.6 32.8 AR 0.4 μM 57   22.4 24.1 54.1 24.2 AN 0.4 μM 75.9 28.2 24.745.8 67.3 AD 0.4 μM 54.7 23.9 23.1 46.1 46.7 CX 0.4 μM 45.9 21.7 22.248.2 38.1 BH 0.4 μM 98.5 35.7 30.6 61   71.6 CV 0.5 μM 73.8 36.2 30.621.4 36.1 AZ 0.4 μM 95.4 33.6 26.9 54.1 71.2 CW 0.4 μM 98.5 31.9 26.655.9 69.4 BE 0.4 μM 99.1 44.1 41.2 64   74.9 BF 0.4 μM 92.8 40.9 37.257.1 74.1 BG 0.4 μM 99.1 40.1 36.2 59.2 71.1 DA 0.4 μM 95.7 82.8 91.3100.8  19.1 BJ 0.4 μM 23.9 56.8 64.1 50.2 50.8 BI 0.4 μM 110.9  76.684.3 71.7 81.7 DB 0.4 μM 24.7 56   62.3 40.3 29.6 BA 1.5 μM 42.4 167.3 146.7  145.7  148.7  CY 0.4 μM 40.5 76.6 84.3 71.7 81.7 CZ 0.4 μM 96.789.1 91.1 101.9  90.3 CP 2.5 μM 35.6 72.4 76.5 74.5 48.2 CQ 2.5 μM 95.886.5 93.8 34.8 47.1 CR 2.5 μM 53.2 87.6 89.3 93.4 86.9 CS 2.5 μM 41.379   84.2 69.7 82.8 CT 2.5 μM 34.5 63.2 71.9 46.3 46.3 CU 2.5 μM 37.665   74.9 100.2  56.7 CM  5 μM 37.8 72.6 78.1 74.8 81.3 BB 2.5 μM 16.320.4 24.7 25   17.2 BC 2.5 μM 26   32.6 32.3 29.8 28.9 AJ 0.4 μM 18.533.1 22.5 20.8 20.1 BD 0.4 μM 29.3 66.1 61.3 28.4 33.3 AI 0.4 μM 36.480.8 89   96.1 64.9 DY  5 μM 16.1 21.2 20.6 23.3 18.3 DZ 0.4 μM 84.885.6 86.7 71.8 89   EA 0.4 μM 108   87.8 89   73.5 84.5 EE 0.4 μM 34  66.4 70.8 45.3 47.1 EF 0.4 μM 16.7 31.3 21.7 24.3 23.4 EG 0.4 μM 92.291.3 96.2 95.3 88.5 EB 2.5 μM 94.4 93.4 98.8 143.3  98.2 EC 2.5 μM 94.682.8 100.4  136.8  91.6 AO 0.4 μM 35   80.7 91   93.1 91.1 DL 2.5 μM43   193.5  172.6  164.8  164.9  DN 2.5 μM 31.7 64.1 78   64.7 72.3 DP2.5 μM 37.5 65.3 77.4 64.6 74.1 DE 2.5 μM 42   69.3 84.7 68.6 74   DF0.4 μM 101.9  88.7 96.5 89.4 95.4 DJ 2.5 μM 85.9 116.2  137.1  137.1 115.3  DM 2.5 μM 45.6 79.2 91.1 105.4  92.1 DO 2.5 μM 59.2 79.9 89.993.4 90.1 DR 2.5 μM 31.5 59.9 68.7 49.2 35.5 AA 1.5 μM 82.6 38.6 31  22.2 43   AC 0.4 μM 61.5 32.8 30   14   34.1 DS 0.4 μM 70   86.4 97  97.1 98.6 AF 0.4 μM 19.1 35   32.4 25.2 22.6 BU 0.4 μM 24   48.1 57.231   26.7 DV 0.4 μM 31.6 76.7 61.9 23.3 32.2 BK 0.4 μM 29.2 32.1 27.320.6 28.3 BL 0.4 μM 106.3  135.5  120   141.4  111.2  BY 2.5 μM 96.698.4 101.1  99.9 94.1 AU 2.5 μM 32.4 25.7 41.1 34.2 32   EL 2.5 μM 41.873.7 99.4 86.1 70.8 FT 2.5 μM 41.1 74.4 94.2 85.2 78.3 EW 0.4 μM 14.120   16.6 21.9 14.8 FW  5 μM 98.1 102.7  109.6  128.5  104.6  AS 2.5 μM31.1 51.1 55.5 36.8 30.8 FR 2.5 μM 100.9  93.2 102.5  102.5  99.1 AV 2.5μM 38.2 62.6 59.3 34.4 37.2 AW 0.4 μM 38.2 59.5 70   51.3 33.6 AX 0.4 μM31.2 57.9 49.5 26.7 31.5 AY 2.5 μM 50.4 78.9 92   90.1 78.7 AT 0.4 μM34.6 65.4 76.8 57.4 32.9 BO 0.4 μM 13.4 82.4 28.4 28.2 18.4 FL 0.4 μM41.2 81.3 87.9 92.8 69.7 FD  5 μM 112.1  101   85.3 95.6 98.7 FB 2.5 μM97.7 89.1 95.5 93.2 98.6 FH  5 μM 89   79.6 82.3 131.8  114.9  FF  5 μM93   90.7 95.2 136.1  110.1  FE  5 μM 34.2 46.8 67.6 113.7  37.3 FY 2.5μM 36   74.6 91.5 91   80.1 BP 0.5 μM 50.5 79.1 113.6  95.1 93   FG 1.5μM 39.2 65.7 85.5 47.2 41   FZ  5 μM 32.7 39.6 67.7 114.8  38.5 GA 1.5μM 41.3 82.2 91.8 109.2  84.2 FI 0.5 μM 35.2 79.8 91.4 84   73.7 GB 1.5μM 36.4 52.8 76.2 24   38.8 CD 2.5 μM 16.6 19.5 20.1 23.2 17.1 CE 2.5 μM16.2 44.3 18.8 23.5 15.6 BQ 2.5 μM 21.4 48.5 25.1 26.9 21.4 FJ 0.5 μM38.6 75.1 93   97.3 82.2 FK 0.5 μM 35.5 47.4 62   18   39   GC 2.5 μM19.8 59.5 63.2 30.3 26.4 CF 2.5 μM 126.4  68.8 83.5 70.3 75.3 GD 2.5 μM24.3 39.5 26.7 27   23.5

What is claimed is:
 1. A compound represented by Formula I or apharmaceutically acceptable salt thereof,G-NH-A-Q-X—Y—Z  I wherein G is a monocyclic, bicyclic, or tricyclicaromatic ring having one, two, or three ring nitrogen atoms, eitherunsubstituted or substituted at a ring carbon by amino, dimethylamino,hydroxy, halo, methyl, perfluoromethyl, or alkyl having from 1 to 16carbon atoms either unsubstituted or substituted by hydroxy or alkoxyhaving 1 to 12 carbon atoms or acetoxy; or at a ring nitrogen by alkylhaving from 1 to 16 carbon atoms either unsubstituted or substituted byhydroxy or alkoxy having from 1 to 8 carbon atoms; N is nitrogen, H ishydrogen, and NH is absent or present; A is absent or present and isalkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbonatom Q must be absent; Q is absent or present and is O, NHC(O), or NH,provided that if A is absent Q must be absent, and if both X and Y areabsent Q cannot be O or NH; X is absent or present and is alkyl havingfrom 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxyor phenoxy X must have more than 1 carbon atom; Y is absent or presentand is phenyl unsubstituted or substituted by halo, or is a monocyclicor bicyclic aromatic ring having one or two nitrogen atoms; Z is absentor present and is hydrogen, alkyl having from 1 to 12 carbon atomseither unsubstituted or substituted by one phenyl or phenoxy group,alkoxy having from 1 to 12 carbon atoms either unsubstituted orsubstituted by one phenyl or phenoxy group, phenyl, phenoxy, or NHC(O)R⁶or C(O)NHR⁶ or C(O)OR⁶ where R⁶ is alkyl having from 1 to 6 carbonatoms, provided that if all of A, Q, X, and Y are absent then Z must bealkyl having 6 to 12 carbon atoms.
 2. The compound or salt of claim 1,wherein G is selected from the group consisting of substituted orunsubstituted quinolyl, substituted or unsubstituted quinazolyl,unsubstituted isoquinolyl, unsubstituted quinoxalyl, unsubstitutedbenzimidazolyl, unsubstituted pyridyl, unsubstituted pyrazinyl,unsubstituted indolyl, substituted or unsubstituted imidazoquinolyl,substituted pyridinium, unsubstituted imidazopyridine, unsubstitutedpyrimidyl, and substituted imidazolyl.
 3. The compound or salt of claim1, wherein A-Q-X—Y—Z is selected from the group consisting ofalkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl, alkoxyalkyl,alkoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl,phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl,alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl,alkoxycarbonylphenyl, N-alkylcarbamoylphenyl, alkoxy(halophenyl),phenylalkyl, alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl,picolinamidoalkyl, nicotinamidoalkyl, isonicotinamidoalkyl,N-(quinolylamino)alkyl, N-(quinazolylamino)alkyl,phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl, phenylalkoxyphenyl,pyridylalkyl and hydroxyalkyl.
 4. The compound or salt of claim 2,wherein G is unsubstituted or substituted quinolyl.
 5. The compound orsalt of claim 4, wherein the compound is represented by Formula IA

wherein A is absent or present and is alkyl having from 1 to 12 carbonatoms, provided that if A has 1 carbon atom Q must be absent; Q isabsent or present and is O, NHC(O), or NH, provided that if A is absentQ must be absent, and if both X and Y are absent Q cannot be O or NH; Xis absent or present and is alkyl having from 1 to 5 carbon atoms,provided that if Y is absent and Z is alkoxy or phenoxy X must have morethan 1 carbon atom; Y is absent or present and is phenyl unsubstitutedor substituted by halo, or is a monocyclic or bicyclic aromatic ringhaving one or two nitrogen atoms; Z is absent or present and ishydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted orsubstituted by one phenyl or phenoxy group, alkoxy having from 1 to 12carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, phenyl, phenoxy, or NHC(O)R⁶ or C(O)NHR⁶ or C(O)OR⁶ whereR⁶ is alkyl having from 1 to 6 carbon atoms, provided that if all of A,Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms;and one of R¹ and R² is hydrogen and the other is selected from thegroup consisting of hydrogen, halo, methyl, and perfluoromethyl.
 6. Thecompound or salt of claim 5 where R¹ and R² are hydrogen.
 7. Thecompound or salt of claim 5 where R¹ is chloro.
 8. The compound or saltof claim 5 where R¹ is perfluoromethyl.
 9. The compound or salt of claim5 where R² is methyl.
 10. The compound or salt of claim 4, whereinA-Q-X—Y—Z is selected from the group consisting of alkoxyphenylalkyl,alkoxyphenyl, alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl,phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl,phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl,(halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl,N-alkylcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl,alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl,nicotinamidoalkyl, isonicotinamidoalkyl, phenylalkoxyphenoxyalkyl,alkylalkoxyphenyl, phenylalkoxyphenyl, pyridylalkyl andN-(quinolylamino)alkyl.
 11. The compound or salt of claim 4, wherein thecompound is represented by Formula IA1

wherein n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, provided thatif p is 1 then n must not be 0 or 1; p is 0 or 1; q is 0 or 1; one of R¹and R² is hydrogen and the other is selected from the group consistingof hydrogen, halo, methyl, and perfluoromethyl; R³ is selected from thegroup consisting of: alkyl having from 1 to 10 carbon atoms eitherunsubstituted or substituted by: a) a phenyl or monocyclic or bicyclicaromatic ring having one or two nitrogen atoms or phenoxy eitherunsubstituted or substituted by phenoxy or alkoxy having from 1 to 6carbon atoms, or b) alkoxy having from 1 to 6 carbon atoms, providedthat if R³ is alkyl substituted by alkoxy then alkyl must have more than1 carbon atom; and phenyl unsubstituted or substituted by halo andunsubstituted or substituted by: a) alkyl having from 1 to 6 carbonatoms unsubstituted or substituted by phenyl or phenoxy, b) alkoxyhaving from 1 to 10 carbon atoms unsubstituted or substituted by phenylor phenoxy, provided that when substituted by phenoxy the alkoxy musthave more than one carbon atom, c) phenyl, d) phenoxy, or e) C(O)OR⁶,C(O)NHR⁶, or NHC(O)R⁶, wherein R⁶ is alkyl having from 1 to 6 carbonatoms.
 12. The compound or salt of claim 11 wherein R¹ is hydrogen andR² is hydrogen.
 13. The compound of claim 12, wherein n is 2, 3, 4, 5,6, 7, 8, 9, or 10; P is 1; and R³ is alkyl having from 1 to 6 carbonatoms.
 14. The compound or salt of claim 13, wherein the compound isselected from the group consisting of:N-[8-(Hexyloxy)octyl]quinolin-4-amine,N-(8-Butoxyoctyl)quinolin-4-amine, N-(8-Methoxyoctyl)quinolin-4-amine,N-[6-(Hexyloxy)hexyl]quinolin-4-amine,N-(6-Butoxyhexyl)quinolin-4-amine,N-[10-(Hexyloxy)decyl]quinolin-4-amine,N-(10-Butoxydecyl)quinolin-4-amine, N-(5-Methoxypentyl)quinolin-4-amine.15. The compound or salt of claim 11, wherein n is 2, 3, 4, 5, 6, 7, 8,9, or 10; P is 1; one of R¹ and R² is hydrogen and the other is selectedfrom the group consisting of halo, methyl, and perfluoromethyl; and R³is alkyl having from 1 to 6 carbon atoms.
 16. The compound or salt ofclaim 15, wherein the compound is selected from the group consisting of:N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine,7-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine,8-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine,N-[8-(Hexyloxy)octyl]-7-(trifluoromethyl)quinolin-4-amine,N-[8-(Hexyloxy)octyl]-8-(trifluoromethyl)quinolin-4-amine.
 17. Thecompound or salt of claim 12, wherein n is 2, 3, 4, 5, 6, 7, 8, 9, or10; P is 1; R³ is alkyl having from 2 to 5 carbon atoms substituted byalkoxy having from 1 to 6 carbon atoms.
 18. The compound or salt ofclaim 17, wherein the compound is selected from the group consisting of:N-{5-[3-(Hexyloxy)propoxy]pentyl}quinolin-4-amine,N-{3-[5-(Hexyloxy)pentyloxy]propyl}quinolin-4-amine,N-[8-(3-Ethoxypropoxyl)octyl]quinolin-4-amine,N-[8-(2-Propoxyethoxyl)octyl]quinolin-4-amine.
 19. The compound or saltof claim 11, wherein the compound is represented by Formula IA1a

wherein n is 0, 1, 2, 3, 4, 5, 6, 7, or 8; p is 0 or 1, provided that ifp is 1 then n must not be 0 or 1; q is 0 or 1; one of R¹ and R² ishydrogen and the other is selected from the group consisting ofhydrogen, halo, methyl, and perfluoromethyl; R⁴ is hydrogen or halo; andR⁵ is selected from the group consisting of hydrogen; halo; unbranchedor branched alkyl having from 1 to 6 carbon atoms unsubstituted orsubstituted by phenyl or phenoxy; alkoxy having from 1 to 10 carbonatoms unsubstituted or substituted by phenyl or phenoxy, provided thatwhen substituted by phenoxy the alkoxy must have more than one carbonatom; phenyl; phenoxy; C(O)OR⁶; C(O)NHR⁶; or NHC(O)R⁶, wherein R⁶ isalkyl having from 1 to 6 carbon atoms.
 20. The compound or salt of claim19 wherein R¹ is hydrogen and R² is hydrogen.
 21. The compound or saltof claim 20, wherein p is 1 and R⁴ is hydrogen.
 22. The compound or saltof claim 21, wherein R⁵ is hydrogen.
 23. The compound or salt of claim22, selected from the group consisting of:N-[8-(Benzyloxy)octyl]quinolin-4-amine,N-(6-Phenoxyhexyl)quinolin-4-amine, N-(8-Phenoxyoctyl)quinolin-4-amine.24. The compound or salt of claim 21, wherein q is 0, and R⁵ is alkoxyhaving from 1 to 6 carbon atoms unsubstituted or substituted by phenyl.25. The compound or salt of claim 24, wherein R⁵ is in the orthoposition.
 26. The compound or salt of claim 25, wherein the compound isselected from the group consisting of:N-{2-[2-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine,N-{3-[2-(Hexyloxy)phenoxy]propyl}quinolin-4-amine,N-{4-[2-(Hexyloxy)phenoxy]butyl}quinolin-4-amine,N-[3-(2-Ethoxyphenoxyl)propyl]quinolin-4-amine,N-[3-(2-Methoxyphenoxyl)propyl]quinolin-4-amine,N-{3-[2-(Benyloxy)phenoxy]propyl}quinolin-4-amine.
 27. The compound orsalt of claim 24, wherein R⁵ is in the meta position.
 28. The compoundor salt of claim 27, wherein the compound is selected from the groupconsisting of: N-[8-(3-Methoxyphenoxyl)octyl]quinolin-4-amine,N-{4-[3-(Hexyloxy)phenoxy]butyl}quinolin-4-amine,N-{3-[3-(Hexyloxy)phenoxy]propyl}quinolin-4-amine,N-{2-[3-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine.
 29. The compound orsalt of claim 24, wherein R⁵ is in the para position.
 30. The compoundor salt of claim 29, wherein the compound is selected from the groupconsisting of: N-[8-(4-Methoxyphenoxyl)octyl]quinolin-4-amine,N-[6-(4-Methoxyphenoxyl)hexyl]quinolin-4-amine,N-{2-[4-(Hexyloxy)phenoxy]ethyl}quinolin-4-amine,N-{3-[4-(Hexyloxy)phenoxy]propyl}quinolin-4-amine,N-{4-[4-(Hexyloxy)phenoxy]butyl}quinolin-4-amine.
 31. The compound orsalt of claim 21, wherein R⁵ is unbranched or branched alkyl having from1 to 6 carbon atoms.
 32. The compound or salt of claim 31, wherein thecompound is selected from the group consisting of:N-[8-(m-Tolyloxy)octyl]quinolin-4-amine,N-[8-(p-Tolyloxy)octyl]quinolin-4-amine,N-[8-(o-Tolyloxy)octyl]quinolin-4-amine,N-[8-(4-tert-Butylphenoxy)octyl]quinolin-4-amine.
 33. The compound orsalt of claim 21, wherein R⁵ is fluoro.
 34. The compound or salt ofclaim 33, wherein the compound is selected from the group consisting of:N-[8-(4-Fluorophenoxyl)octyl]quinolin-4-amine,N-[8-(3-Fluorophenoxyl)octyl]quinolin-4-amine,N-[8-(2-Fluorophenoxyl)octyl]quinolin-4-amine.
 35. The compound or saltof claim 20, wherein p is
 0. 36. The compound or salt of claim 35wherein q is
 0. 37. The compound or salt of claim 36, wherein n is 0 38.The compound or salt of claim 37, wherein the compound is selected fromthe group consisting of: N-(Biphenyl-4-yl)quinolin-4-amine,N-(4-Hexylphenyl)quinolin-4-amine, Hexyl 4-(quinolin-4-ylamino)benzoate,N-(4-Phenoxyphenyl)quinolin-4-amine,N-(3-Phenoxyphenyl)quinolin-4-amine,N-(2-Phenoxyphenyl)quinolin-4-amine,N-[4-(Quinolin-4-ylamino)phenyl]hexanamide,N-[3-(Quinolin-4-ylamino)phenyl]hexanamide,N-Hexyl-4-(quinolin-4-ylamino)benzamide,N-Hexyl-3-(quinolin-4-ylamino)benzamide.
 39. The compound or salt ofclaim 37, wherein R⁵ is alkoxy having from 1 to 10 carbon atomsunsubstituted or substituted by phenyl.
 40. The compound or salt ofclaim 39, wherein the compound is selected from the group consisting of:N-(4-Methoxyphenyl)quinolin-4-amine,N-[4-(Benzyloxy)phenyl]quinolin-4-amine,N-(4-Butoxyphenyl)quinolin-4-amine,N-[4-(Hexyloxy)phenyl]quinolin-4-amine,N-[3-(Benzyloxy)phenyl]quinolin-4-amine,N-[3-(Hexyloxy)phenyl]quinolin-4-amine,N-[2-(Benzyloxy)phenyl]quinolin-4-amine,N-[2-(Hexyloxy)phenyl]quinolin-4-amine,N-[2-Fluoro-4-(hexyloxy)phenyl]quinolin-4-amine.
 41. The compound orsalt of claim 36, wherein n is 1 or
 2. 42. The compound or salt of claim41, wherein the compound is selected from the group consisting of:N-Benzylquinolin-4-amine, N-Phenethylquinolin-4-amine.
 43. The compoundor salt of claim 35, wherein q is
 1. 44. The compound or salt of claim43, wherein R⁵ is alkoxy having from 1 to 10 carbon atoms.
 45. Thecompound or salt of claim 44, wherein the compound is selected from thegroup consisting of: N-[4-(Hexyloxy)benzyl]quinolin-4-amine,N-[3-(Hexyloxy)benzyl]quinolin-4-amine,N-[2-(Hexyloxy)benzyl]quinolin-4-amine,N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4-amine,N-[4-(Decyloxy)benzyl]quinolin-4-amine,N-[3-(Decyloxy)benzyl]quinolin-4-amine.
 46. The compound or salt ofclaim 43, wherein R⁵ is phenoxy, or alkoxy having from 1 to 10 carbonatoms substituted by phenyl.
 47. The compound or salt of claim 46,wherein the compound is selected from the group consisting of:N-(3-Phenoxybenzyl)quinolin-4-amine,N-[3-(Benzyloxy)benzyl]quinolin-4-amine,N-(3-Phenethoxybenzyl)quinolin-4-amine.
 48. The compound or salt ofclaim 5 wherein the compound is represented by Formula IA2

wherein n is 2, 3, 4, 5, 6, 7, or 8; and R¹³ is phenyl unsubstituted orsubstituted by alkoxy having from 1 to 6 carbon atoms; or 2-, 3-, or4-pyridyl.
 49. The compound or salt of claim 48, wherein R¹³ isunsubstituted phenyl.
 50. The compound or salt of claim 49, wherein thecompound is selected from the group consisting of:N-[4-(Quinolin-4-ylamino)butyl]benzamide,N-[6-(Quinolin-4-ylamino)hexyl]benzamide,N-[8-(Quinolin-4-ylamino)octyl]benzamide.
 51. The compound or salt ofclaim 48, wherein R¹³ is phenyl substituted by alkoxy having from 1 to 6carbon atoms.
 52. The compound or salt of claim 51, wherein the compoundis selected from the group consisting of:3-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide,4-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide,2-(Hexyloxy)-N-[2-(quinolin-4-ylamino)ethyl]benzamide,2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide,2-(Hexyloxy)-N-[4-(quinolin-4-ylamino)butyl]benzamide.
 53. The compoundor salt of claim 48, wherein R¹³ is 2-pyridyl, 3-pyridyl, or 4-pyridyl.54. The compound or salt of claim 53, wherein the compound is selectedfrom the group consisting of:N-[8-(Quinolin-4-ylamino)octyl]picolinamide,N-[8-(Quinolin-4-ylamino)octyl]nicotinamide,N-[8-(Quinolin-4-ylamino)octyl]isonicotinamide.
 55. The compound or saltof claim 5, wherein the compound is selected from the group consistingof: N-(Pyridin-4-ylmethyl)quinolin-4-amine,N-(Pyridin-3-ylmethyl)quinolin-4-amine,N-(Pyridin-2-ylmethyl)quinolin-4-amine, N-Hexylquinolin-4-amine,N-(Decyl)quinolin-4-amine, N-(Dodecyl)quinolin-4-amine,N¹,N⁸-Di(quinolin-4-yl)octane-1,8-diamine.
 56. The compound or salt ofclaim 4, wherein the compound is selected from the group consisting of:N-[8-(Hexyloxy)octyl]quinolin-6-amine,N-[8-(Hexyloxy)octyl]quinolin-3-amine,N-[8-(Hexyloxy)octyl]quinolin-8-amine,N-[8-(Hexyloxy)octyl]-2-(trifluoromethyl)quinolin-4-amine,7-Chloro-N-decylquinolin-4-amine, 7-Chloro-N-dodecylquinolin-4-amine.57. The compound or salt of claim 2, wherein G is quinazolyl.
 58. Thecompound or salt of claim 57, wherein the compound is represented byFormula IB

wherein A is absent or present and is alkyl having from 1 to 12 carbonatoms, provided that if A has 1 carbon atom Q must be absent; Q isabsent or present and is O, NHC(O), or NH, provided that if A is absentQ must be absent, and if both X and Y are absent Q cannot be O or NH; Xis absent or present and is alkyl having from 1 to 5 carbon atoms,provided that if Y is absent and Z is alkoxy or phenoxy X must have morethan 1 carbon atom; Y is absent or present and is phenyl unsubstitutedor substituted by halo, or is a monocyclic or bicyclic aromatic ringhaving one or two nitrogen atoms; Z is absent or present and ishydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted orsubstituted by one phenyl or phenoxy group, alkoxy having from 1 to 12carbon atoms either unsubstituted or substituted by one phenyl orphenoxy group, phenyl, phenoxy, or NHC(O)R⁶ or C(O)NHR⁶ or C(O)OR⁶ whereR⁶ is alkyl having from 1 to 6 carbon atoms, provided that if all of A,Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms;and R¹ is selected from the group consisting of hydrogen, halo, methyl,and perfluoromethyl.
 59. The compound or salt of claim 58 where R¹ ishydrogen.
 60. The compound of claim 58, wherein A-Q-X—Y—Z is selectedfrom the group consisting of alkoxyphenylalkyl, alkoxyphenyl,alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, phenoxyphenyl,phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl,phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl,biphenyl, alkylphenyl, alkoxycarbonylphenyl, N-alkylcarbamoylphenyl,alkoxy(halophenyl), phenylalkyl, alkoxy(halophenyl)alkyl,(alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl,isonicotinamidoalkyl, phenylalkoxyphenoxyalkyl, alkylalkoxyphenyl,phenylalkoxyphenyl, pyridylalkyl, N-(quinazolylamino)alkyl, andN-(quinolylamino)alkyl.
 61. The compound or salt of claim 57, whereinthe compound is represented by Formula IB 1

wherein n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; Q is absent orpresent and is 0 or NHC(O), provided that if Q is present n cannot be 0or 1; R¹ is hydrogen or halo; and R⁷ is selected from the groupconsisting of: hydrogen, alkyl having from 1 to 6 carbon atoms; andphenyl or monocyclic aromatic ring having one nitrogen atom,unsubstituted or substituted by alkyl having from 1 to 6 carbon atoms oralkoxy having from 1 to 10 carbon atoms or phenyl or phenoxy; providedthat if Q is absent, then (CH₂)—R⁷ must have more than 5 carbon atoms.62. The compound or salt of claim 61, wherein Q is absent.
 63. Thecompound or salt of claim 62, wherein the compound is selected from thegroup consisting of: N-(Decyl)quinazolin-4-amine,N-Dodecylquinazolin-4-amine, N-Decyl-7-fluoroquinazolin-4-amine,N-Dodecyl-7-fluoroquinazolin-4-amine,7-Chloro-N-decylquinazolin-4-amine,7-Chloro-N-dodecylquinazolin-4-amine,
 64. The compound or salt of claim61, wherein Q is O or NHC(O).
 65. The compound or salt of claim 64,wherein the compound is selected from the group consisting of:N-(6-Butoxyhexyl)quinazolin-4-amine,N-[8-(Hexyloxy)octyl]quinazolin-4-amine,N-[8-(4-Methoxyphenoxyl)octyl]quinazolin-4-amine,N-{2-[2-(Hexyloxy)phenoxy]ethyl}quinazolin-4-amine,N-{3-[2-(Hexyloxy)phenoxy]propyl}quinazolin-4-amine,N-{4-[2-(Hexyloxy)phenoxy]butyl}quinazolin-4-amine,N-[8-(Quinazolin-4-ylamino)octyl]nicotinamide.
 66. The compound or saltof claim 61, wherein n is 1, Q is absent, and R⁷ is phenyl substitutedby alkoxy having from 1 to 10 carbon atoms or phenoxy.
 67. The compoundor salt of claim 66, wherein the compound is selected from the groupconsisting of: N-[3-(Hexyloxy)benzyl]quinazolin-4-amine,N-[3-(Decyloxy)benzyl]quinazolin-4-amine,N-(3-Phenoxybenzyl)quinazolin-4-amine,N-[4-(Decyloxy)benzyl]quinazolin-4-amine,N-[4-(Hexyloxy)benzyl]quinazolin-4-amine.
 68. The compound or salt ofclaim 2, wherein G is unsubstituted or substituted imidazoquinolyl. 69.The compound or salt of claim 68, wherein the compound is represented byFormula IC

wherein R¹ is hydrogen, OH, NH₂, or N(CH₃)₂; R² is selected from thegroup consisting of hydrogen, halo, methyl, and perfluoromethyl. R⁸ ishydrogen, or alkyl having from 1 to 15 carbon atoms unsubstituted orsubstituted by alkoxy having 1 or 2 carbon atoms or acetoxy; and R⁹ is abranched or unbranched alkyl having from 1 to 16 carbon atoms,unsubstituted or substituted by hydroxy, or alkoxy having from 1 to 12carbon atoms, provided that if substituted by hydroxy or alkoxy R⁹ musthave more than 1 carbon atom.
 70. The compound or salt of claim 69,wherein R² is hydrogen.
 71. The compound or salt of claim 70, whereinthe compound is selected from the group consisting of:1-[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol,1-(4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinolin-2-yl)pentyl acetate,1-Isobutyl-2-pentadecyl-1H-imidazo[4,5-c]quinolin-4-ol,1-Octyl-1H-imidazo[4,5-c]quinoline,1-Hexadecyl-1H-imidazo[4,5-c]quinoline,1-Hexadecyl-1H-imidazo[4,5-c]quinolin-4-amine,1-Dodecyl-1H-imidazo[4,5-c]quinoline,1-{5-[3-(Hexyloxy)propoxy]pentyl}-1H-imidazo[4,5-c]quinoline,1-{3-[3-(Hexyloxy)phenoxy]propyl}-1H-imidazo[4,5-c]quinoline.
 72. Thecompound or salt of claim 70, wherein R⁹ is an unbranched alkyl havingfrom 2 to 10 carbon atoms, substituted by alkoxy having from 1 to 12carbon atoms.
 73. The compound or salt of claim 72, wherein the compoundis selected from the group consisting of:1-[2-(Dodecyloxy)ethyl]-1H-imidazo[4,5-c]quinoline,1-[2-(Dodecyloxy)ethyl]-N,N-dimethyl-1H-imidazo[4,5-c]quinolin-4-amine,1-[6-(Octyloxy)hexyl]-1H-imidazo[4,5-c]quinoline,1-(8-Ethoxyoctyl)-1H-imidazo[4,5-c]quinoline,1-(8-Methoxyoctyl)-1H-imidazo[4,5-c]quinoline,1-(8-Butoxyoctyl)-1H-imidazo[4,5-c]quinoline,1-[9-(Hexyloxy)nonyl]-1H-imidazo[4,5-c]quinoline,1-(10-Butoxydecyl)-1H-imidazo[4,5-c]quinoline,1-[3-(Decyloxy)propyl]-1H-imidazo[4,5-c]quinoline,1-[4-(Decyloxy)butyl]-1H-imidazo[4,5-c]quinoline,1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]quinoline.
 74. The compound orsalt of claim 2, wherein G is substituted pyridinium.
 75. The compoundor salt of claim 74, represented by Formula ID

wherein R¹⁰ is alkyl having from 1 to 8 carbon atoms, unsubstituted orsubstituted by alkoxy having from 1 to 6 carbon atoms, provided that ifsubstituted by alkoxy R¹⁰ must have more than 1 carbon atom; R¹¹ ishydrogen, or alkyl having from 1 to 8 carbon atoms, unsubstituted orsubstituted by alkoxy having from 1 to 3 carbon atoms, provided that ifsubstituted by alkoxy R¹¹ must have more than 1 carbon atom; and X⁻ is acounterion.
 76. The compound or salt of claim 75, selected from thegroup consisting of: a 4-Amino-1-[8-(hexyloxy)octyl]pyridinium salt,4-(8-Methoxyoctylamino)-1-methylpyridinium iodide.
 77. The compound orsalt of claim 2, wherein G is 1H-imidazo[4,5-c]pyridine.
 78. Thecompound or salt of claim 77, wherein the compound is represented byFormula IE

wherein R¹² is alkyl having from 2 to 16 carbon atoms, unsubstituted orsubstituted by alkoxy having from 4 to 6 carbon atoms.
 79. The compoundor salt of claim 78, wherein the compound is selected from the groupconsisting of: 1-[8-(Hexyloxy)octyl]-1H-imidazo[4,5-c]pyridine,1-Hexadecyl-1H-imidazo[4,5-c]pyridine,1-(10-Butoxydecyl)-1H-imidazo[4,5-c]pyridine.
 80. The compound or saltof claim 2, wherein G is pyridyl.
 81. The compound or salt of claim 80,wherein the compound is selected from the group consisting of:N-(8-Methoxyoctyl)pyridin-4-amine, N-[8-(Hexyloxy)octyl]pyridin-3-amine,N-[8-(Hexyloxy)octyl]pyridin-2-amine.
 82. The compound or salt of claim2, wherein G is pyrimidyl.
 83. The compound or salt of claim 80, whereinthe compound is selected from the group consisting of:N-[8-(Hexyloxy)octyl]pyrimidin-4-amine,N-[8-Hexyloxy)octyl)pyrimidin-2-amine.
 84. The compound or salt of claim2, wherein G is 5-aryl 1H-imidazolyl.
 85. The compound or salt of claim84, wherein the compound is 1-[8-(Hexyloxy)octyl]-4-phenyl-1H-imidazole.86. The compound or salt of claim 2, wherein G is isoquinolyl.
 87. Thecompound or salt of claim 86, wherein the compound is selected from thegroup consisting of: N-[8-(Hexyloxy)octyl]isoquinolin-1-amine,N-[8-(Hexyloxy)octyl]isoquinolin-5-amine.
 88. The compound or salt ofclaim 2, wherein G is quinoxalyl.
 89. The compound or salt of claim 88,wherein the compound is N-[8-(Hexyloxy)octyl]quinoxalin-2-amine.
 90. Thecompound or salt of claim 2, wherein G is benzimidazolyl.
 91. Thecompound or salt of claim 90, wherein the compound is1-[8-(Hexyloxy)octyl]-1H-benzimidazole.
 92. The compound or salt ofclaim 2, wherein G is pyrazinyl.
 93. The compound or salt of claim 92,wherein the compound is N-[8-(Hexyloxy)octyl]pyrazin-2-amine.
 94. Thecompound or salt of claim 2, wherein G is indolyl.
 95. The compound orsalt of claim 94, wherein the compound is1-[8-(Hexyloxy)octyl]-1H-indole.
 96. The compound or salt of claim 2,wherein G is 3H-imidazo[4,5-b]pyridine.
 97. The compound or salt ofclaim 96, wherein the compound is3-[8-(Hexyloxy)octyl]-3H-imidazo[4,5-b]pyridine.
 98. A method fortreating or preventing a condition in a mammalian subject; the conditionbeing selected from the group consisting of an inflammatory disease, afungal infection, a unicellular parasitic infection, and a neoplasticdisease; comprising administering to the subject an effective amount ofthe compound or salt of any one of claims 1-97.
 99. The compound or saltof any one of claims 1-97 for use in treating or preventing a conditionin a mammalian subject; the condition being selected from the groupconsisting of an inflammatory disease, a fungal infection, a unicellularparasitic infection, and a neoplastic disease.
 100. Use of the compoundor salt of any one of claims 1-97 for treating or preventing a conditionin a mammalian subject; the condition being selected from the groupconsisting of an inflammatory disease, a fungal infection, a unicellularparasitic infection, and a neoplastic disease.
 101. Use of the compoundor salt of any one of claims 1-97 in the manufacture of a medicament fortreating or preventing a condition in a mammalian subject; the conditionbeing selected from the group consisting of an inflammatory disease, afungal infection, a unicellular parasitic infection, and a neoplasticdisease.
 102. A composition comprising the compound or salt of any oneof claims 1-97 for use in treating or preventing a condition in amammalian subject; the condition being selected from the groupconsisting of an inflammatory disease, a fungal infection, a unicellularparasitic infection, and a neoplastic disease.
 103. The method, compoundfor use, use, or composition of any one of claims 98-102, wherein themammalian subject is a human subject.
 104. The method, compound for use,use, or composition of any one of claims 98-102, wherein the conditionis an inflammatory disease.
 105. The method, compound for use, use, orcomposition of claim 104, wherein the inflammatory disease is aninflammatory skin condition.
 106. The method, compound for use, use, orcomposition of claim 105, wherein the inflammatory skin condition isselected from the group consisting of psoriasis, psoriatic dermatitis,eczema, atopic dermatitis, and impetigo.
 107. The method, compound foruse, use, or composition of claim 104, wherein the inflammatory diseaseis a systemic autoimmune disorder.
 108. The method, compound for use,use, or composition of claim 107, wherein the systemic autoimmunedisorder is selected from the group consisting of rheumatoid arthritis,systemic and discoid lupus erythematosis, psoriatic arthritis,vasculitis, Sjogrens syndrome, scleroderma, autoimmune hepatitis, andmultiple sclerosis.
 109. The method, compound for use, use, orcomposition of any one of claims 98-102, wherein the condition is afungal infection.
 110. The method, compound for use, use, or compositionof claim 109, wherein the fungus is selected from the group consistingof Candida, Saccharomyces, Trichophyton, Cryptococcus, Aspergillus, andRhizopus.
 111. The method, compound for use, use, or composition ofclaim 110, wherein the Candida is Candida albicans or Candida glabrata.112. The method, compound for use, use, or composition of claim 110,wherein the Saccharomyces is Saccharomyces cerevisiae.
 113. The method,compound for use, use, or composition of claim 110, wherein theTrichophyton is Trichophyton rubrum.
 114. The method, compound for use,use, or composition of claim 110, wherein the Cryptococcus isCryptococcus neoformans.
 115. The method, use, or composition of claim114, wherein the Cryptococcus neoformans is Cryptococcus neoformansserotype D or Cryptococcus neoformans serotype A.
 116. The method,compound for use, use, or composition of claim 110, wherein theAspergillus is Aspergillus fumigatus.
 117. The method, compound for use,use, or composition of any one of claims 98-102, wherein the conditionis infection with a unicellular parasitic microorganism.
 118. Themethod, compound for use, use, or composition of claim 117, wherein theparasitic infection is infection with a parasitic microorganism thatresides within acidic vacuoles in cells of the subject.
 119. The method,compound for use, use, or composition of claim 117, wherein theparasitic microorganism is selected from the group consisting ofmycobacteria, gram positive bacteria, amoebae, and gram negativebacteria.
 120. The method, compound for use, use, or composition ofclaim 117, wherein the parasitic microorganism is selected from thegroup consisting of tuberculosis, listeria, leishmania, a trypanosome,Coxiella burnetii, and a Plasmodium.
 121. The method, compound for use,use, or composition of any one of claims 98-102, wherein the conditionis a neoplastic disease.
 122. The method, compound for use, use, orcomposition of claim 121, wherein the neoplastic disease is ahematologic cancer.
 123. The method, compound for use, use, orcomposition of claim 121, wherein the neoplastic disease is a solidtumor.
 124. The composition of claim 102, further comprising apharmaceutically acceptable carrier.
 125. The method, compound for use,use, or composition of any one of claims 98-102, wherein the compound orcomposition is administered topically to the subject.
 126. The method,compound for use, use, or composition of any one of claims 98-102,wherein the compound or composition is administered systemically to thesubject.
 127. The method, compound for use, use, or composition of claim126, wherein the compound or composition is administered orally,rectally, parenterally, or nasally.
 128. A method of inhibiting a fungusex vivo, comprising contacting a surface or the fungus with the compoundor salt of any one of claims 1-97.
 129. The method, compound for use,use, or composition of claim 128, wherein the fungus is selected fromthe group consisting of Candida, Saccharomyces, Trichophyton,Cryptococcus, Aspergillus, and Rhizopus.
 130. The method, compound foruse, use, or composition of claim 129, wherein the Candida is Candidaalbicans or Candida glabrata.
 131. The method, compound for use, use, orcomposition of claim 129, wherein the Saccharomyces is Saccharomycescerevisiae.
 132. The method, compound for use, use, or composition ofclaim 129, wherein the Trichophyton is Trichophyton rubrum.
 133. Themethod, compound for use, use, or composition of claim 129, wherein theCryptococcus is Cryptococcus neoformans.
 134. The method, use, orcomposition of claim 133, wherein the Cryptococcus neoformans isCryptococcus neoformans serotype D or Cryptococcus neoformans serotypeA.
 135. The method, compound for use, use, or composition of claim 129,wherein the Aspergillus is Aspergillus fumigatus.